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ABSTRACT 
 
Background 
People with intellectual disability (ID) are believed to have higher prevalence of type 
2 diabetes (T2DM) and cardiovascular disease (CVD). There is limited research on 
prevalence and prevention in this population. 
 
Objectives 
The objectives for this programme of work were to: 
x establish a programme of research conducted in a population with ID that 
significantly enhances the knowledge and understanding of impaired glucose 
regulation (IGR) and T2DM in people with ID; 
x test strategies for early identification of IGR and T2DM in people with ID; 
x develop a lifestyle education programme and educator training protocol to 
promote behaviour change in a population with ID and IGR (or high risk of 
T2DM/CVD). 
 
Setting 
Leicestershire, UK. 
 
Participants 
Adults with ID were recruited from community settings, including residential homes 
and family homes. Adults with mild to moderate ID with elevated body mass index 
(BMI 25) and/or IGR were invited to take part in the education programme. 
 
Main outcome measures 
The primary outcome for the screening programme was prevalence of screen-
detected T2DM and IGR. Uptake, feasibility and acceptability of the intervention 
were assessed. 
 
Data sources 
Participants were recruited from general practices, specialist ID services, clinics and 
through direct contact. 
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Results 
A total of 930 people with ID were recruited to the screening programme: 58% were 
male, 80% white and 68% overweight or obese. Mean age was 43.3 years (SD 
14.2). Bloods were obtained for 675 participants (73%). Prevalence of previously 
undiagnosed T2DM was 1.3% (95% CI 0.5 to 2%) and IGR was 5% (95% CI 4% to 
7%). Abnormal IGR was more common in those of non-white ethnicity, with a first 
degree family history of diabetes, with increasing weight, waist circumference, BMI, 
diastolic BP, triglycerides, and lower high density lipoprotein cholesterol.  
 
We developed a lifestyle educational programme for people with ID, informed by 
findings from qualitative stakeholder interviews (healthcare professionals, n=14; 
people with ID, n=7) and evidence reviews. Subsequently, 11 people with ID (and 
carers) participated in pilot education sessions (2 groups) and 5 people attended 
education for the feasibility stage (1 group). We found it was feasible to collect 
primary outcome measures physical activity and sedentary behaviour using wrist-
worn accelerometers. We found the programme was relatively costly, meaning that 
large changes in activity or diet (or a reduction in programme costs) were necessary 
for the programme to be cost effective. We also developed a quality development 
process for assessing intervention fidelity. 
 
Limitations 
We were only able to screen around 30% of the population and only involved a small 
number in the piloting and feasibility work. 
 
Conclusions 
Results from this programme of work have significantly enhanced existing 
knowledge and understanding of T2DM and IGR in people with ID. We have 
developed a lifestyle education programme and educator training protocol to 
promote behaviour change in this population. 
 
Future work: Further work is needed to evaluate the STOP Diabetes intervention to 
identify cost-effective strategies for its implementation. 
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SCIENTIFIC SUMMARY 
 
 
Background 
 
Type 2 diabetes (T2DM) is a serious chronic condition that is associated with an 
increased risk of cardiovascular disease and affects approximately 6% of the UK 
adult population. Impaired glucose regulation (IGR), whereby blood glucose is 
elevated above the normal range, is a pre-cursor to T2DM and affects approximately 
12% of the UK adult population. T2DM can be prevented through changes to 
lifestyle, and lifestyle education interventions have been shown to be cost-effective in 
delaying or preventing the transition to T2DM in people with IGR in the general 
population. 
 
Intellectual disability (ID), also known as learning disability, is a life-long condition 
with onset before adulthood, characterised by a reduced ability to understand new or 
complex information, to learn new skills and a reduced ability to cope independently. 
People with ID are believed to have higher prevalence of T2DM owing to increased 
prevalence of a number of risk factors, including obesity and lack of exercise. 
However, there has been very little research in this area, and the evidence base for 
detection and prevention of T2DM has not yet been applied in a population with ID.  
 
The focus of this research programme was to conduct a diabetes screening 
programme among people with ID and to develop a lifestyle multi-component 
education programme for the prevention of T2DM and cardiovascular disease 
(CVD), suitable for use in this population. 
 
Objectives 
 
The objectives of the programme were to: 
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x establish a programme of research conducted in a population with ID that 
significantly enhances the knowledge and understanding of IGR and T2DM in 
people with ID; 
x test strategies for early identification of IGR and T2DM in people with ID; 
x develop a lifestyle education programme and educator training protocol to 
promote behaviour change in a population with ID and IGR (or high risk of 
T2DM/CVD based on elevated body mass index (BMI)). 
 
To achieve these objectives, three distinct work packages (WP) were developed. 
 
WP1: development and assessment of the feasibility of a structured screening 
programme to determine the prevalence and demographic risk factors for T2DM and 
IGR in people with ID. This work package also included the validation of the 
Leicester Self-Assessment diabetes risk score in people with ID, cost-effectiveness 
analysis and establishment of data linkage mechanisms. 
WP2: development of a lifestyle education programme for people with ID and IGR (or 
high risk of T2DM/CVD based on elevated BMI). 
WP3: development of an intervention fidelity process for the assessment of 
educators delivering the intervention. 
 
Service user involvement 
 
Service users were integral to the research programme. People with ID helped to 
promote the programme, develop study documentation and research processes, 
recruit and train staff, test procedures and to disseminate the findings. 
 
Methods 
 
WP1: Screening programme 
 
We recruited adults with ID from community settings, including residential homes 
and family homes. Potential participants were approached through general practices, 
specialist ID services (using the Leicestershire Learning Disability Register), 
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specialist ID clinics and through direct contact with the research team. We collected 
information on demographics, medical and family history, depression, behaviour 
problems, lifestyle factors and activity levels. We also collected biomedical measures 
(plasma glucose, glycated haemoglobin (HbA1c), lipids, urea and electrolytes, liver 
function tests, thyroid function, albumin), anthropometric measures (height, weight, 
BMI, waist and hip circumference) and blood pressure. 
 
WP1: Physical activity sub-study 
 
Adults who consented to take part in the screening programme and who were able to 
walk unassisted were asked if they would be willing to wear the ActiGraph waist-
worn accelerometer or GENEActiv wrist-worn accelerometer to assess physical 
activity and sedentary behaviour. 
 
WP1: Validation of the Leicester Self-Assessment risk score 
 
The Leicester Self-Assessment risk score for detecting those at risk of undiagnosed 
IGR/T2DM was validated using the data from the screening programme. Sensitivity, 
specificity, positive predictive value and negative predictive value were calculated 
with 95% confidence interval (CI) for a cut point of greater than or equal to 16 points.  
 
WP1: Cost-effectiveness study 
 
Economic work was undertaken to estimate the cost-effectiveness of the STOP 
Diabetes lifestyle education programme (see WP2) compared with current routine 
care in reducing cardio-metabolic co-morbidities among individuals with ID. 
 
WP2: Lifestyle education programme 
 
Adults with mild to moderate ID with BMI 25 and/or IGR were invited to take part in 
the STOP Diabetes lifestyle education programme. This involved initial intervention 
and curriculum development, two cycles of testing and evaluation and a final 
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refinement of the programme, and included interviews with adults with ID, carers and 
health professionals. 
 
Feasibility was assessed by collecting primary outcomes physical activity and 
sedentary behaviour, and secondary outcomes weight, height, BMI, waist 
circumference, blood pressure and dietary intake before delivering the education 
programme and three months after delivering the education programme.  
 
WP3: Intervention fidelity 
 
We conducted preliminary work towards developing an intervention fidelity process 
and tool specifically tailored to people with ID. 
 
Results 
 
WP1: Screening programme 
 
In total, 930 (29% of those originally approached) took part in the screening 
programme. Their mean age was 43.3 years. Fifty-eight per cent were men, 80% 
were white and most were overweight (31%) or obese (37%). Anthropometric 
measures were available for at least 86% of participants. Bloods were available for 
675 participants (73%) to assess the prevalence of IGR/T2DM. 
 
The overall prevalence of screen-detected (undiagnosed) T2DM was 1.3% (95% CI 
0.5 to 2%) and IGR was 5% (95% CI 4% to 7%) among people with ID. Abnormal 
glucose regulation was almost four times more common in those from non-white 
ethnic groups (OR=3.93; 95% CI 2.10 to 7.33) and more than three times more 
common among those with first degree history of diabetes (OR=3.35; 95% CI 1.64 to 
6.86). Similarly, increasing weight, waist circumference, BMI, diastolic blood 
pressure, triglycerides and decreasing high density lipoprotein cholesterol, were 
associated with an increased risk of abnormal glucose regulation. 
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WP1: Physical activity sub-study 
 
Of 203 people approached, 97 (48%) agreed to wear the waist-worn accelerometer. 
Valid data ( KRXUVGD\ IRU  GD\V were obtained for 55 participants (57%).  
Similarly, of 76 people approached, 47 (62%) agreed to wear the wrist-worn 
accelerometer. Valid data were obtained for 39 of these participants (83%). Thus, 
compliance could be improved by wearing wrist-worn accelerometers. 
 
WP1: Validation of the Leicester Self-Assessment risk score 
 
Of 88% of adults with data available, 82% of people with abnormal glucose 
regulation were correctly identified as being at high or very high risk (sensitivity). 
Ninety-eight per cent of participants with low/medium risk scores were correctly 
identified as being at low risk. 
 
WP1: Cost-effectiveness 
 
Findings from the health economic component of the analysis showed that, in its 
current form, the STOP Diabetes education programme we developed in WP2 would 
not be cost-effective at £20,000 cost per quality-adjusted life year (QALY) threshold. 
However, there were scenarios in which the intervention may be effective if 
commissioners/payers were willing to fund the intervention up to a threshold of 
£30,000 per QALY. 
 
WP2: Lifestyle education programme 
 
Interviews carried out at initial curriculum development revealed that people with ID 
liked to use visual aids to help them to learn. Health professionals also highlighted 
the importance of allowing for the diverse ability levels of people with ID, such as 
different attention span and ability levels. Important considerations included the need 
to use recall and repetition to support learning, ensuring familiarity and consistency 
and allowing generalised behaviour change goals to allow for different levels of 
physical ability. For the testing cycles, we found that learning was facilitated by the 
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group dynamic, recapping main messages, using concrete examples and walking 
exercises. However, conceptual exercises, abstract examples and giving too many 
messages did not work so well. 
 
Preliminary findings suggest that it was both acceptable and feasible to collect 
outcome measures, including physical activity and sedentary behaviour, at baseline 
and 3-months post intervention delivery for this study. In this small sample (n=5), all 
anthropometric outcome measures, 80% of blood pressure and 60% (3 out of 4 who 
agreed at baseline) of accelerometer data were available at three months follow up. 
 
WP3: Intervention fidelity 
 
We completed the first step in developing a tool for assessing intervention fidelity of 
the education programme. Preliminary findings suggest some variance between 
educators. The new tool involved focusing on educators’ teaching at the group’s 
pace and avoiding abstract concepts, abbreviations and jargon and engaging the 
learners without asking them to summarise key messages. 
 
Conclusions 
 
This programme of work has significantly enhanced existing knowledge and 
understanding of T2DM and IGR in people with ID. It has also allowed us to test 
strategies for early identification of IGR and T2DM in this population. Further work is 
needed to evaluate the intervention we have developed and to identify cost-effective 
strategies for its implementation. 
 
 
Word Count: 1422 
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PLAIN ENGLISH SUMMARY 
 
Adults with intellectual disabilities (ID) have more health problems than the general 
population. They are less likely to access help, and more likely to be overweight and 
not get enough exercise. This may increase their chance of getting diabetes. 
 
Type 2 diabetes (T2DM) is a long-term condition, which can cause damage to blood 
vessels and nerves. Impaired glucose regulation (IGR) happens when blood sugar 
levels are higher than normal but not high enough to be T2DM. People with IGR are 
more likely to develop T2DM, heart disease and strokes, but can make changes to 
their lifestyle to prevent this. 
 
Our research aimed to: 
1) Screen people with ID for T2DM and IGR. 
2) Develop a lifestyle education programme to help people with ID stay healthy. 
 
We recruited 930 people, and collected blood samples from 675 to test for diabetes. 
We found about 1 in 100 people had undiagnosed T2DM and 5 in 100 had IGR. 
More than two-thirds (68%) were overweight or obese.  
 
We developed a lifestyle education programme. We asked a few small groups of 
people with ID (and carers) to come to the 8 week programme. Attendance at the 
education sessions was good. Overall, people felt positive about the education. 
 
To conclude, less people had T2DM or IGR than we expected. However, we found 
that many people with ID were overweight or obese. We succeeded in developing a 
lifestyle education programme to help people do more physical activity, eat healthier 
and lose weight. 
 
Word Count: 245 
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EASY READ SUMMARY 
 
   
   
   
 
 
We want to tell you about the STOP 
Diabetes Research Study. 
 
A research study is a way we try to find out 
about the answers to questions. 
 
         Our research study was about diabetes. 
 
We want to tell you what we found out. 
 
 
What is diabetes? 
 
        
 
Diabetes is an illness. 
         
 
 
           
 
People with diabetes have too much sugar 
(glucose) in their blood. 
 
 
Their body cannot use sugar properly. 
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People with diabetes may feel: 
 
      
 
x Tired and ill 
      
 
x Thirsty 
    
 
x And need to go to the toilet a lot. 
 
 
 
Why did we do this research study? 
     
 
We want people with learning disabilities to 
be healthy. 
    
        
 
We wanted to know if people with learning 
disabilities have diabetes. 
 
We wanted to know if people with learning 
disabilities could get diabetes in the future. 
 
 
 
We wanted to know the best way to stop 
(prevent) diabetes. 
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Who did the research study? 
      
 
Professor Khunti 
      
 
Professor Bhaumik 
     
 
And a research study team to help them. 
   
 
x Nurse 
    
 
x Secretary 
   
 
x Researcher 
 
  
 xxxviii 
 
 
 
 
How did we do the research study? 
    
 
We asked people with learning disabilities 
and their carers about their health. 
 
 
      
 
       
    
 
We checked: 
 
x How tall they were. 
 
 
x How much they weighed. 
 
 
x What was their blood pressure. 
      
 
We tested their urine (wee). 
   
 
We tested their blood. 
 
    
 
 
We invited some people and their carers to 
be part of a small group. 
 
This group learned about staying healthy. 
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What did we find out? 
 
More than 900 people with learning 
disabilities took part in our research study. 
 
 
 
x Slightly more men than women 
took part. 
 
 
x 9 people had diabetes. 
 
 
x 35 people had too much sugar in their 
blood. 
 
The good news is that not many people 
had diabetes! 
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But 
 
We found a lot of people weighed too 
much. 
529 people weighed too much 
 
 
And others were not very active. 
 
 
 
Some of these people learned about 
staying healthy. 
 
We want to teach more people about 
staying healthy in the future. 
 
 
    
 
We want to thank everyone who has 
helped us! 
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CHAPTER 1.   INTRODUCTION 
 
 
1.1 Rationale 
 
The focus of this research programme was to estimate the prevalence of type 2 
diabetes (T2DM) and impaired glucose regulation (IGR), among people with 
intellectual disabilities (ID), and to develop and test a lifestyle education programme 
for the prevention of T2DM, suitable for use in this population. 
 
This research programme was developed to address gaps in the evidence base with 
regard to determining the prevalence of T2DM and IGR in adults with ID, and lack of 
suitable prevention programmes specially tailored for people with ID. Since 
beginning this research, priorities set out in the 2015-2016 National Health Service 
(NHS) England Business Plan1 have highlighted the need to improve services for 
people with ID and to establish a national ID Mortality Review, with both diabetes 
and obesity identified as health priorities.2 An additional health priority identified for 
all patients is the prevention of obesity and T2DM via a national “evidence-based 
lifestyle management programme”, to support people to make healthy lifestyle 
changes.1 
The current evidence-base for screening and successfully managing those at risk of 
diabetes through diet, exercise and behaviour therapy relates to the general 
population. It is not currently known whether screening for T2DM and IGR or 
prevention strategies through lifestyle education can be successful in people with ID. 
 
1.2 Aims and objectives 
 
The aims of the programme were to: 
x establish a programme of research conducted in a population with ID that 
significantly enhances the knowledge and understanding of IGR and T2DM in 
people with ID; 
x test strategies for early identification of IGR and T2DM in people with ID; 
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x develop a lifestyle education programme and educator training protocol to 
promote behaviour change in a population with ID and IGR (or high risk of 
T2DM/CVD based on elevated body mass index (BMI)). 
 
1.3 Overview of the programme of research 
 
To achieve these aims, three distinct work packages were developed (Figure 1). 
 
Work package 1 (WP1): 
x to develop and assess the feasibility of a diabetes screening programme in a 
community setting for adults with ID (Chapters 5 and 6); 
x to determine the prevalence and demographic risk factors for T2DM and IGR 
in people with mild to profound ID (Chapters 5 and 6); 
x to validate the Leicester Self-Assessment diabetes risk score in people with 
ID (Chapters 5 and 6); 
x to determine the cost-effectiveness of lifestyle intervention (see WP2) 
compared to current care (Chapter 12); 
x to establish data linkage to Hospital Episode Statistics and the Office for 
National Statistics (Chapters 5 and 6). 
 
Work package 2 (WP2): 
x to develop a lifestyle education programme for people with ID and IGR (or 
high risk of T2DM/CVD based on elevated BMI), (Chapters 8 and 9); 
x to assess the feasibility of collecting outcome measures before and 3-months 
after attendance at lifestyle education (Chapter 10). 
 
Work package 3 (WP3): 
x to develop a quality assurance (“intervention fidelity”) process for the 
assessment of educators delivering the education (Chapter 11). 
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Figure 1: Flow chart programme of work 
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1.4 Scope of the report 
 
The remainder of this chapter provides a brief overview of the ethics and governance 
arrangements, and provides the detailed background for this research programme. 
 
Subsequent chapters contain individual summaries, but briefly comprise: 
x a systematic review of prevalence/incidence of T2DM in people with ID 
(Chapter 2); 
x a systematic review of multi-component behaviour change interventions in 
people with ID (Chapter 3); 
x details of the involvement of people with ID throughout the programme of 
research (Chapter 4); 
x methods for the screening programme (Chapter 5); 
x results from the screening programme (Chapter 6); 
x methods and results from a physical activity sub-study (Chapter 7); 
x details of the development of the lifestyle education programme (Chapters 8 
and 9); 
x methods and findings from a feasibility phase collecting pre and post 
intervention outcome measures (Chapter 10); 
x details of the development of the intervention fidelity process (Chapter 11); 
x methods and results for the economic analysis undertaken (Chapter 12); 
x discussion of findings and conclusions (Chapter 13). 
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1.5 Ethics and governance 
 
1.5.1 Approvals 
 
The University of Leicester acted as sponsor for the programme of research. NHS 
research ethics approval was obtained from the East of England - Cambridge 
Central Research Ethics Committee (reference: 12/EE/0340). Research and 
development approval was obtained for the research sites from: Leicestershire 
Partnership NHS Trust; Leicester City Clinical Commissioning Group (CCG), East 
Leicestershire & Rutland CCG, and West Leicestershire CCG; and University 
Hospitals of Leicester NHS Trust. 
 
1.5.2 Adherence to mental capacity legislation  
 
Obtaining consent was the largest ethical consideration for this programme. Strict 
standard operating procedures needed to be established to ensure that valid consent 
was obtained in accordance with English capacity legislation,3 whilst taking into 
account the heterogeneity in capacity of individuals. More details on assessment of 
capacity and taking consent are contained in the methodology section for the 
screening programme (see Chapter 4). This included providing people with all 
information relevant to making the decision on whether to participate in the research, 
and communicating this in a way that was appropriate to them (such as using simple 
language and visual aids). 
 
The process for those who lacked capacity involved talking to a ‘consultee’, whose 
role was to consider the study from the participant’s perspective (see Appendix 1, 
Figure 26). Regardless of whether the person with ID had capacity to decide on 
participation, the research was discussed with them to help them to understand the 
project as far as they had the capacity to do so, and to indicate any opinion they had 
on participation. For example, if a person without decision-making capacity appeared 
even slightly anxious or reluctant to take part, this would be respected, and they 
would not be recruited in the study.  
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1.5.3 Programme steering group 
 
Strategic oversight and direction of the research programme was provided by the 
programme steering group (see Figure 2), which comprised the chief investigator 
(KK), the lead researcher/project manager (AD), and co-applicants listed in the 
application, with ad hoc attendance from service users. The meetings were held four 
times per year and were independently chaired by Dr Colin Greaves, University of 
Exeter (see Figure 2). The meetings involved discussion of contractual issues, 
staffing, protocol and ethical amendments, public involvement (a rolling agenda 
item), recruitment progress, economic analysis, education development, anticipated 
timelines and progress against project aims. 
 
1.5.4 Operational groups 
 
The research team, (researchers, ID research nurses, research administrator) met 
frequently throughout the programme to plan individual components of the 
programme and to discuss progress. Details from these meetings were fed back to 
the steering group. 
 
The education development team, (a multi-disciplinary team of healthcare 
professionals and researchers, with expertise both in the field of ID and in 
developing diabetes and CVD prevention programmes) met regularly to oversee and 
facilitate development of the lifestyle education programme (work package 3).  
Progress and key decisions were fed back at steering group meetings. 
 
1.5.5 Service user groups 
 
A number of service users were involved in the research programme, but two service 
user self-advocacy groups were particularly influential. The groups met regularly, 
facilitated by an experienced supporter, and their comments were fed back to the 
steering group. More information about these and other service users’ involvement is 
detailed in the fourth chapter of this report. 
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Figure 2: Governance structure of STOP Diabetes programme 
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1.5.6 Data protection 
 
A six-digit study code was used to identify all study participants. This code was used 
for all hard and electronic copies of data collected for this programme (including 
questionnaires, anthropometric data and blood samples), which were retained in a 
secure setting. 
 
Leicester Clinical Trials Unit (UK Clinical Research Collaboration registration number 
43) were responsible for the development of a secure database for the data collected 
as part of this research programme. 
  
 9 
 
1.6 Background  
 
1.6.1 Definition of intellectual disability and case identification 
 
ID, also known as learning disability, is a life-long condition with onset before 
adulthood, characterised by a reduced ability to understand new or complex 
information, to learn new skills and a reduced ability to cope independently.4 Severity 
levels for ID are typically categorised by broad intelligence quotient (IQ), alongside 
the required deficits in independent living skills, into: mild (IQ 50-69), moderate (IQ 
35-49), severe (IQ 20-34) and profound (IQ<20) ID.5 Acknowledging the wide 
variation that exists between individuals with ID, typical abilities suggested for each 
category are outlined in Table 1 (based on World Health Organisation (WHO) ICD-
10).5 More recently in the UK, the Learning Disabilities Public Health Observatory 
has offered a “working definition” which includes brief practical guidance to improve 
recognition of ID and assist agencies to target services.6  
 
The aetiology of ID can be broadly divided into problems which occur in the 
antenatal, perinatal or postnatal period, or due to multiple factors. Common causes 
of ID include: genetic and chromosomal disorders, both non-inherited (e.g. Down’s)7 
and inherited (e.g. Fragile X); and non-genetic factors such as infection and 
environmental factors. However, in the majority of cases no specific cause is found.8 
 
A recent meta-analysis of population based studies suggests that overall around 1% 
of people worldwide have ID, with wide variation dependant on age-group and 
income of the country (lower, middle and higher); for adults the proportion is around 
0.5%.9 Evidence from existing ID registers and general practice lists in England 
suggests that the prevalence of ID is approximately 3–5 per 1000 individuals.10, 11 
However, it is thought that the true prevalence could be as high as 2% of the adult 
population, as people with mild ID are generally under-represented.11 
 
For the current research programme, cases were identified via: 1) records held on 
adults with ID in general practices; and 2) a register of adults attending ID services 
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owned by the local mental health trust (Leicestershire Partnership NHS Trust), the 
Leicestershire Learning Disability Register (see section below).  
 
General practices in the UK are now incentivised to maintain a register of people 
with ID.12, 13 Locally, for practices within Leicester City, East Leicestershire and 
Rutland, and West Leicestershire CCGs, the total number of adults (aged 18 and 
over) on general practice registers with an identified ID is estimated to be around 
4,300 (based on figures provided by Leicestershire Partnership NHS Trust). 
 
The Leicestershire Learning Disability Register includes adults with ID (aged 19 
years and over) who live in the unitary authorities of Leicester City, Leicestershire 
and Rutland.14 The Register was established in 1987 to help facilitate the provision 
and monitoring of services, and enable the collection of public health data. It is 
currently a joint venture between Leicestershire Partnership NHS Trust and Leicester 
City CCG. Enrolment is via a large network of service providers including specialist 
ID services, social services and primary care. Currently, there are ~3900 people with 
mild to profound ID on the register. However, as the Leicestershire Learning 
Disability Register is based on service use, some adults, particularly those with mild 
ID who have little or no support from services, may not currently be identified. This 
potentially accounts for some of the differences between the number of people 
identified on this register and on local general practice registers. 
 
 
 
 
 
 
  
 11 
 
 
Table 1: Intellectual disability categories and suggested abilities 
 
Severity of  
ID 
Suggested abilities and skills  
IQ 
level 
 
Mild  x Good verbal communication, and basic reading and 
writing skills 
x Usually independent in self-care and practical 
domestic tasks 
x Often able to form/maintain good social relationships 
x May have employment 
Moderate x Limited language 
x Able to achieve some independence with support, but 
requirements for support will vary 
x Usually fully mobile 
Severe x Uses some words and gestures 
x Activities need to be supervised and ongoing support 
necessary 
x May have problems with movement 
Profound x Communication very limited 
x Support needed for all daily living activities  
x Mobility usually severely impaired 
 
 
 
 
 
 
 
 
 
 12 
 
 
1.6.2 Type 2 diabetes and impaired glucose regulation 
 
T2DM is a serious chronic disease, characterised by prolonged hyperglycaemia.15 Its 
symptoms can reduce quality of life and lead to serious health complications, 
including blindness, renal failure and amputation; 50% of new cases have 
demonstrable atherosclerosis at diagnosis.15-17 The prevalence of diabetes in 
England is estimated to be 6.2%,18 rising to 8.0% (95% CI 5.7% -11.7%) when 
including undiagnosed cases.19 T2DM accounts for around 85-90% of diabetes 
cases; it creates a huge economic burden on NHS resources, at a cost of £8.8 billion 
annually (~10% of total NHS expenditure).20 
 
IGR is a condition where blood glucose concentrations are elevated above the 
normal range but do not satisfy the criteria for T2DM.21, 22 Approximately 12% of the 
UK adult population have IGR, of which an estimated 5–12% go on to develop T2DM 
each year. Observational studies show a consistent and continuous association 
between glycaemia and CVD risk whereby people with IGR have a significantly 
elevated risk of CVD.23-25 Given the economic burden associated with this condition 
and its related co-morbidities, this group represents an important target for 
preventative strategies.26 Other commonly used terms to describe IGR include pre-
diabetes, non-diabetic hyperglycaemia or high risk of diabetes; throughout the report, 
this high risk group will be referred to as IGR.  
 
Previously in clinical practice, T2DM and IGR were identified using the “gold 
standard” oral glucose tolerance test (OGTT).22 However, since the publication of 
updated WHO guidance in 2011 and subsequent National Institute for Health and 
Care Excellence (NICE) guidance in 2012, there has been a shift away from the use 
of the OGTT to glycated haemoglobin (HbA1C).27, 28  Potential benefits of HbA1c 
include it being a non-fasting blood test, less inter-test variability, and the ability to 
provide an indication of longer term hyperglycaemia (over 6-8 weeks).29  An HbA1c 
of  mmol/l (6.5%) is suggestive of T2DM and 42-47 mmol/l (6.0-6.4%) of IGR or 
high risk.27 Further details on the methods used to identify T2DM and IGR for this 
programme of research are provided in Chapter 5 (see Section 5.7 and Figure 15 ). 
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1.6.3 Risk factors for type 2 diabetes and cardiovascular disease in 
people with intellectual disabilities 
 
In the general population, increasing levels of obesity and sedentary lifestyles have 
been associated with a rise in non-communicable diseases, including T2DM and 
cardiovascular disease (CVD).30-33 
 
Chronic conditions are becoming increasingly important for people with ID as their 
life expectancy increases.34 There are a number of risk factors for T2DM that are 
known to be highly prevalent in people with ID, suggesting that T2DM and CVD may 
be more prevalent in this group. These include: 
x sedentary behaviour;35-38 
x high prevalence of obesity;32-34, 39 
x increased antipsychotic drug use for the management of challenging 
behaviour40, 41 and psychosis,42 which are associated with weight gain, 
hyperglycaemia and worsening of other metabolic CVD risk factors;43-45 
x genetic conditions associated with obesity (e.g. Prada-Willi syndrome).46 
 
Physical inactivity and sedentary behaviour are both common among people with ID, 
with only a minority (18-33%) achieving the recommended 30 minutes of 
moderate/vigorous physical activity daily47, 48 and less than 15% of people with ID 
complete the recommended 10,000 steps per day.49  Furthermore, less than 10% of 
adults with ID who live in supported accommodation have an intake of fruit and 
vegetables sufficient for a balanced diet.50 Evidence suggests that paid carers know 
little about public health recommendations on dietary intake.50 
 
However, little is known about T2DM, CVD and associated risk factors in the ID 
population. UK-based data on the prevalence of T2DM are currently unclear.32 
Current estimates for diabetes prevalence in the UK are based on routinely reported 
data, rather than population based studies. The suggested prevalence of diagnosed 
diabetes in people with ID in England is around 6-7% but estimates are unable to 
distinguish between T2DM and other forms of diabetes.13, 51 Similarly, the prevalence 
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of CVD among people with ID is reported to be greater than the general population, 
but the overall prevalence is unclear.52 
 
Further information on the current prevalence of T2DM, CVD and related risks 
factors in the ID population, is presented in the systematic review in the second 
chapter of this report.  
 
1.6.4 Diabetes screening 
 
Given the increasing prevalence of diabetes, and the conferred risk of developing 
cardiovascular disease, early identification and intervention through screening has 
been shown to be a useful approach in the general population.53, 54 The value of 
screening for IGR has also been demonstrated.  
 
It is currently unknown whether screening for asymptomatic glucose disorders is 
viable within UK populations with ID; there is a lack of evidence on feasibility, 
acceptability, outcomes and benefits. People with ID have been recommended by 
NICE as being an important group to consider in terms of diabetes prevention 
strategies, given their supposed high risk of developing diabetes.27  
 
General practitioners (GPs) in England have been incentivised to provide annual 
KHDOWKFKHFNVWRDGXOWVZLWK,'VLQFHDJHG\HDUVVLQFH5HFHQW
data suggest that nationally uptake of checks is around 44%.55 However, the 
proportion who additionally have bloods taken as part of the health check, including 
HbA1c (7%) and cholesterol (30%), is extremely low.13 
 
1.6.5 Risk scores for the early identification of impaired glucose 
regulation and type 2 diabetes 
 
NICE recommend a staged approach to screening for those at risk of diabetes in the 
general population.56 This involves using a risk score to pre-screen for individuals at 
the greatest risk of T2DM followed by a blood test in those at the highest risk. 
However, this approach has not been tried with populations with ID. 
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Risk scores are a non-invasive way of stratifying a population for targeted screening. 
They use information data from non-invasive risk factors to calculate an individual’s 
score; a higher score reflects a higher risk. Risk scores can be applied to: 1) an 
individual as a questionnaire, (these scores generally only require data from non-
invasive risk factors which would be known by members of the public); or 2) a 
population (for example in primary care, where software is used to calculate the 
score using routine data from electronic medical records) and screening invitations 
can then be sent to those at highest risk. A number of diabetes risk scores have 
been developed and validated for use in the UK general population.56-60 One such 
score is the Leicester Self-Assessment Risk Score (see Appendix 2), which allows 
people to easily assess their own risk of having undiagnosed IGR or T2DM and then 
self-refer for screening with a healthcare professional.58  The score contains seven 
questions, which ask about age, sex, ethnicity, body mass index (BMI), waist 
circumference, family history of diabetes, and high blood pressure (BP). The score 
has been validated for use in a multi-ethnic UK population58, 61 and is specifically 
recommended for identifying people at risk opportunistically by NICE.56  
 
To date, we are not aware of any risk scores that have been specifically assessed 
for use in ID populations. However, it cannot be assumed that a risk score developed 
for a specific population will work well in another;62 for people with ID, there may be 
different risk factors or weightings for specific risk factors may change, when 
compared to the general population. Therefore, this programme of work will seek to 
validate the Leicester Self-Assessment Risk Score in a population with ID (this work 
is presented as part of the screening study, Chapters 5 and 6). 
 
1.6.6 Diabetes prevention in adults with intellectual disabilities 
 
People with ID experience a disproportionate burden of health inequalities compared 
with the general population, including poorer mental and physical health and higher 
rates of mortality.63-66 Despite their increased health needs, they often find it difficult 
to access primary care services and participate in health promotion activities.67-69 
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Given the health inequalities among people with ID and possible increased risk of 
developing diabetes, people with ID have the potential to benefit from lifestyle 
changes (with appropriate support) that are addressed in lifestyle education 
programmes. However, the evidence base for diabetes prevention relates to the 
general adult population; literature focusing on ID is scarce. Details of the key 
literature on lifestyle behaviour change interventions aimed at modifying risk factors 
for T2DM and CVD in people with ID, are presented in the systematic review in 
Chapter three of this report. 
 
Current evidence from studies conducted in the general population suggest that 
intensive multi-component lifestyle interventions aimed at weight loss, a healthy diet 
and increased physical activity can successfully reduce the risk of diabetes by 30–
60% in those with IGR, and are likely to be cost-effective in the long term.54, 70  
 
Increasing physical activity is fundamental to diabetes prevention initiatives as 
research suggests that inactivity may have more impact than increased body weight 
in the development of insulin resistance.71 
 
NICE recommends that, for both obesity management72 and prevention of T2DM,27 
lifestyle interventions should be multi-component, involving both dietary and physical 
activity advice and incorporating behaviour change techniques. However, currently 
there are no national prevention programmes suitable for people with ID, despite 
ongoing recommendations to make ‘reasonable adjustments’ to healthcare services 
to address inequities in provision.73 
 
Education, exercise and leisure pursuits are often determined or influenced by carers 
(paid or family carers) who may have a range of competing time demands and a 
number of people to provide support for. For people with limited carer support, 
difficulties in understanding health risks could also influence motivation to change 
lifestyles. Therefore, there is the potential for this group to benefit from the 
development of a lifestyle education programme that is targeted at both people with 
ID and their carers, in order to encourage changes in lifestyle behaviours that could 
reduce the long-term chances of this high-risk group developing diabetes. 
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1.7 Concluding remarks 
 
This chapter has provided the rationale and aims for the research programme, and 
an overview of the programme of work undertaken. The following chapter presents a 
systematic review conducted to consolidate the evidence on rates of T2DM, CVD 
and associated risk factors in adults with ID. 
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CHAPTER 2.   SYSTEMATIC REVIEW AND META-ANALYSIS: 
RATES OF TYPE 2 DIABETES, CARDIOVASCULAR DISEASE 
AND ASSOCIATED RISK FACTORS IN INTELLECTUAL 
DISABILITY POPULATIONS 
 
2.1 Overview 
 
In this chapter, we describe the first of two systematic reviews carried out for the 
research programme. We present the existing evidence in relation to the prevalence 
of T2DM, CVD and associated risk factors among people with ID. We have used the 
PRISMA (preferred reporting items for systematic reviews and meta-analyses) 
checklist74 as a guide to reporting the methods and findings from the review. 
 
2.2 Rationale 
 
It is recognised in the literature that ID populations may be at increased risk of 
developing T2DM and subsequent CVD through increased risk factors such as 
obesity. The global increase in the prevalence of obesity, CVD and T2DM and 
current discrepancies between studies focusing on prevalence of such conditions in 
those with ID suggested a need for a systematic review of literature in this area.  
 
Two recent reviews have been conducted that have focused on diabetes prevalence 
among people with ID.75, 76 The reviews were unable to distinguish between T2DM 
and other types of diabetes. Similarly, the prevalence of CVD among people with ID 
is reported to be greater than the general population, but the overall prevalence is 
unclear.52 
 
The overall aim of this component of the research programme was to consolidate the 
evidence for current rates of T2DM, CVD, and associated risk factors, restricting to 
population-based studies of adults with ID. If sufficient data were available, we also 
intended to conduct a meta-analysis. A secondary aim was to compare these data 
with the general population, where possible. 
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2.3 Objectives 
 
The objectives of this review were: 
• to establish the prevalence of T2DM in the ID population; 
• to establish the prevalence of CVD in the ID population; 
•  to establish the prevalence of risk factors for T2DM and/or CVD (obesity, 
adverse lipid profiles, IGR and hypertension) in the ID population. 
 
2.4 Methods 
 
2.4.1 Protocol and registration 
 
This systematic review was registered with the international register of prospective 
systematic reviews (PROSPERO: CRD42015019048).77 
 
2.4.2 Eligibility criteria 
 
The review was guided by the PICOS (population, intervention, comparison, 
outcome, study designs) model.78 :HGHILQHG WKHSRSXODWLRQDVDGXOWV \HDUV
with ID (whole study population or a defined sub-sample). The items of interest were 
defined as T2DM, CVD and their associated risk factors. Context was defined as 
population-based studies. We defined the outcomes as prevalence and/or incidence 
rates (or data to enable this calculation). Study designs included cross-sectional, 
retrospective and prospective cohort studies (Table 2). 
 
All studies published since 1 January 2000 (until 21 April 2015) and in English 
language were eligible. We contacted lead authors for further information where 
inclusion/exclusion could not be determined. 
  
 20 
 
Table 2: Inclusion and exclusion criteria for systematic review of prevalence 
and risk factors 
 Inclusion Criteria Exclusion criteria 
Population 
Whole study population or 
defined sub-sample of 
DGXOWV\HDUV* 
Restrictively selected 
cohort based on outcome 
(e.g. all participants obese 
at time of data collection) 
Items of interest 
T2DM / Diabetes 
CVD (atherosclerotic) 
Overweight/Obesity 
Hypertension 
Hyperlipidaemia 
Elevated glucose/IGR 
Metabolic syndrome 
 
Context Population-based studies  
Outcomes 
Prevalence 
Incidence 
 
Study designs 
Cross-sectional 
Retrospective cohort 
Prospective cohort 
 
* Because the focus of the review was to obtain prevalence rates generalisable to the adult 
ID population as a whole, studies with >20% aged under 18 years, >20% disability other 
than ID and >25% with specific ID were excluded. 
 
We chose to limit studies to those published from the year 2000 so that the current 
prevalence of T2DM and CVD could be estimated accurately; it is known that the 
prevalence of both these conditions has increased substantially in recent decades. 
 
2.4.3 Information sources 
 
For this review, we searched databases EMBASE, MEDLINE, and PsychINFO. The 
last date of the search was 21 April 2015. We also searched the reference lists of 
relevant articles for possible additional studies. 
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2.4.4 Search 
 
We combined medical subject headings (MeSH) terms and key words for T2DM, 
CVD, overweight/obesity, hypertension, hyperlipidaemia, elevated glucose / impaired 
glucose tolerance (IGT), metabolic syndrome and ID (see Table 3 for MEDLINE 
search strategy).  The search was limited to English language studies with cohorts of 
DGXOWV\HDUVRIDJHGHSHQGLQJRQWKHGDWDEDVH 
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Table 3: Search strategy for MEDLINE electronic database 
1. Exp Diabetes Mellitus, Type 2/  
2. (diabet* adj3 type adj “2”).ti,ab.  
3. T2DM.ti,ab.  
4. (diabet* adj3 type adj ii).ti,ab.  
5. niddm.ti,ab.  
6. (non-insulin-dependent adj2 diabet*).ti,ab.  
7. (adult-onset adj2 diabet*).ti,ab.  
8. Or/1-7  
9. Exp Hypertension/  
10. hypertens*.ti,ab.  
11. (blood adj pressure adj3 (high or elevated or increased or raised)).ti,ab.  
12. Or/9-11  
13. Exp Metabolic syndrome x/  
14. (metabolic adj syndrome).ti,ab.  
15. (cardiometabolic adj syndrome).ti,ab.  
16. (Insulin adj resistance adj syndrome).ti,ab.  
17. MetSyn.ti,ab.  
18. MetS.ti,ab.  
19. Or/13-18  
20. Exp. Hyperlipidemias/  
21. Hyperlipid*.ti,ab.  
22. dyslipid*.ti,ab.  
23. hypercholes*.ti,ab.  
24. hypertriglycer*.ti,ab.  
25. (cholesterol* adj2(high or elevated or raised or increased)).ti,ab.  
26. (triglcerid* adj2(high or elevated or raised or increased)).ti,ab.  
27. (lipid adj profile adj2(adverse or abnormal)).ti,ab.  
28. Or/20-27  
29. Exp. Glucose intolerance/  
30. (impaired adj glucose adj(tolerance or regulation)).ti,ab.  
31. (impaired adj fasting adj glucose).ti,ab.  
32. IGT.ti,ab.  
33. IFG.ti,ab.  
34. IGR.ti,ab.  
35. Exp Prediabetic state/  
36. prediabet*.ti,ab.  
37. pre-diabet*.ti,ab.  
38. Or/29-37  
39. (cardiovascular adj diseas*).ti,ab.  
40. CVD.ti,ab.  
41. CHD.ti,ab.  
42. Exp. Myocardial infarction/  
43. (infarct* adj2 myocardial).ti,ab.  
44. Exp Coronary disease/  
45. (coronary adj2 diseas*).ti,ab.  
46. (acute adj coronary adj syndrom*).ti,ab.  
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47. Exp angina pectoris/  
48. angina.ti,ab.  
49. Exp myocardial ischemia/  
50. (isch* adj2 heart adj2 diseas*).ti,ab.  
51. (Myocardial adj2 isch*).ti,ab.  
52. Exp. Stroke/  
53. strok*.ti,ab.  
54. (cerebrovascular adj2 diseas*).ti,ab.  
55. (cerebrovascular adj2 accident*).ti,ab.  
56. (cerebral adj2 diseas*).ti,ab.  
57. (cerebral adj2 accident*).ti,ab.  
58. CVA.ti,ab.  
59. TIA.ti,ab.  
60. (brain adj1 infarc*).ti,ab.  
61. (brainstem adj1 infarc*).ti,ab.  
62. Exp ischemic attack, transient/  
63. (isch* adj2 attac* adj2 transient).ti,ab.  
64. Exp Atherosclerosis/  
65. atheroscle*.ti,ab.  
66. (arteriosclerotic adj vascular adj diseas*).ti,ab.  
67. exp Peripheral Arterial Disease/ or exp Peripheral Vascular Diseases/  
68. (peripheral adj2 arter* adj2 diseas*).ti,ab.  
69. (peripheral adj2 vascular adj2 diseas*).ti,ab.  
70. (peripheral adj1 angiopath*).ti,ab.  
71. or/39-70  
72. exp obesity/  
73. obes*.ti,ab.  
74. overweight.ti,ab.  
75. (body adj weight adj2 (high or elevated or increase*)).ti,ab.  
76. (bodyweight adj2 (high or elevated or increase*)).ti,ab.  
77. (body adj mass adj3 (high or elevated or increase*)).ti,ab.  
78. (waist adj2 (large or elevated or increas*)).ti,ab.  
79. Exp body mass index  
80. (BMI adj2 (high or elevated or increase*)).ti,ab.  
81. or/72-80  
82. exp Intellectual disability/  
83. (learning adj1 disabilit*).ti,ab.  
84. (developmental adj1 disabilit*).ti,ab.  
85. (intellectual adj1 disabilit*).ti,ab.  
86. (impair* adj2 intellectual adj2 function*).ti,ab.  
87. (mental* adj1 impair*).ti,ab.  
88. (mental* adj1 handicap*).ti,ab 
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2.4.6 Study selection 
 
Full texts were identified after titles and abstracts were read separately by two 
investigators (TC and AD) who discussed discrepancies in selection at a later 
meeting. Only full length articles were included; review articles were removed after 
being examined for references. Once we had retrieved the full-text of the articles, 
they were examined separately (by TC and AD) to check suitability for inclusion. 
 
2.4.7 Data collection process 
 
We designed a data extraction form specifically for this review. Data were extracted 
by one investigator (TC) and verified for accuracy by another investigator (AD).  
 
2.4.8 Data items 
 
For each study, the first author’s name, title of the paper, year of publication, country 
of the cohort, study type, sampling method, dates of data collection, and 
inclusion/exclusion criteria were extracted. We also extracted total sample size or 
sub-population size, mean ages, proportion of male/female, severity of ID and 
ethnicity. For each of the outcomes, we also extracted how they were defined, how 
they were measured and the total number and proportion of people for whom they 
were measured. We extracted data separately for males and females, where 
reported. When framing the research question and designing the search strategy, we 
did not consider physical activity/sedentary behaviour, dietary factors or smoking; 
however, we extracted this information for studies that reported them. We also 
extracted information on general population data. 
 
2.4.9 Risk of bias in individual studies 
 
We used funnel plots79 and the Egger’s test80 to examine potential publication bias in 
the literature for the outcomes T2DM, ischaemic heart disease, obesity, hypertension 
and undefined CVD.  
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2.4.10 Summary measures 
 
The main outcome measures for the meta-analysis were the prevalence of T2DM 
and CVD. Secondary outcome measures were prevalence of: 
x overweight/obesity; 
x hypertension; 
x hyperlipidaemia; 
x elevated glucose/IGT; 
x metabolic syndrome. 
 
2.4.11  Synthesis of results 
 
Owing to the variation in reporting of outcomes, we extracted descriptions and 
definitions of each outcome for analytic purposes and sub-categorised for meta-
analyses. We sub-categorised circulatory disease outcomes as ischaemic heart 
disease, cerebrovascular disease, and undefined CVD. We sub-categorised diabetes 
outcomes as T2DM and pooled diabetes. BMI outcomes were labelled as obese 
(BMI>30) and overweight (BMI 25-29.9). In some articles, overweight and above (BMI 
>25) was used as an outcome. We combined papers reporting both obese and 
overweight data to create an overweight and above outcome. Outcome definitions 
can be seen in Appendix 3 (Table 64). 
 
Owing to the large amount of variability between studies, we used a random effects 
model to pool the point prevalence for each outcome. We conducted a secondary 
meta-analysis including data from a sub-set of 10 papers,81-90 which additionally 
reported general population comparison data (from the same population and time 
period). We assessed heterogeneity using the I2 test.80 
 
2.4.12  Additional analysis 
 
After the meta-analysis, meta-regression was used to determine if study 
characteristics could explain heterogeneity (as measured using the I2 test). These 
study characteristics were severity of ID, mean age, and method of data collection 
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(self/carer reported, researcher collected, retrospective records/database). We 
conducted all analyses using Stata statistical software, version 14 (StataCorp.). 
Significance was set at the 5% level (p<0.05) and 95% confidence intervals (CIs) are 
presented throughout. 
 
2.5 Results 
 
2.5.1 Study selection 
 
In total, we identified 4513 articles via the literature searches. After duplicates were 
removed, 3645 articles remained to be screened. We reviewed the full-text of 158 
articles once 7 articles from other sources had been added (Figure 3). The authors 
of seven studies were contacted for information regarding their studies;91-97 five 
authors replied and two studies were deemed suitable to be included in the 
systematic review and meta-analysis.94, 95 We also included a study from one of the 
authors who did not reply after re-reading and discussing the article collectively in 
more depth.93 
 
After review, 62 articles50, 81-90, 93-95, 98-145 were included. Four of these articles 
reported findings from the same study90, 102-104 and a further two articles reported 
findings from the same study,109, 125 leaving 58 studies remaining for the final 
systematic review and meta-analysis.  
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Figure 3: Flow diagram of study selection 
 
 
2.5.2 Study characteristics 
 
The 58 studies included in the quantitative synthesis presented data on more than 
47,000 individuals. The characteristics of each of the studies are presented in Table 
4. 
 
Ten of the studies included in the systematic review also presented general 
population comparison data for inclusion in the secondary meta-analysis.  
 
The studies represented 23 countries on five continents. One study covered 14 
European countries. Most studies were conducted in the USA/Canada (n = 17). The 
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remaining studies were conducted in Europe (Netherlands (n = 7); UK (n = 9); 
France (n = 2); Norway (n = 1); and Ireland (n = 2)), Asia (n = 11), Australia/New 
Zealand (n = 6) and South Africa (n = 2). Primarily, included studies presented 
researcher collected data (n = 25). The remaining studies used retrospective 
database or medical records data (n = 19); self/carer reported questionnaire data (n 
= 11). Three studies used a combination of the above methods.  
 
All studies were published in the years 2000–2015. The average mean age was 42.8 
years, with an average mean range of 23.3-65.5 years old. The average mean 
percentage of male participants was 52.4%. The number of people included in the 
studies ranged from 25 to 8911, with a mean of 824. 
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Table 4: Studies included in the systematic review of prevalence and risk factors 
Author/year Country ID severity 
Data Source/collection 
method (year collected 
if retrospective) 
Total 
N 
Male 
% 
Mean age 
 
Outcomes reported Study design 
Molteno 
(2000)131 South Africa 
MILD 0.3% MOD 18.7% 
SEV 37.7% PROF 
33.5% 
MISSING DATA 
Researcher collected 
data (CFS) 615 51 NR Overweight, Obese 
Cross-sectional 
observational 
Robertson 
(2000)50 UK NR 
Questionnaire/interview 
(CFS) 500 60.3 44.4 Overweight, Obese  
Cross-sectional 
observational 
Janicki 
(2002)114 USA 
MILD 1.3% MOD 50.3% 
SEV/PROF 47% 
Health questionnaire 
data (CFS) 1373 53.0 53.5 
CVD 
Undiagnosed diabetes 
Overweight, Obese 
Hypertension 
Hyperlipidaemia 
Cross-sectional 
observational 
Lewis 
(2002)119 USA 
MILD 37.1% MOD 16.4% 
SEV 14.7% PROF 15.3% 
Medical 
records/information from 
carers/physical exam by 
nurse (1997) 
353 49.9 35.8 
Overweight, Obese 
Hypertension 
Hypercholesterolaemia 
Cross-sectional 
retrospective 
Marshall 
(2003)124 UK NR 
Health check 
questionnaire (CFS) 728 NR NR 
Overweight, Obese 
Hypertension 
Hypercholesterolaemia 
Cross-sectional 
observational 
 
Havercamp 
(2004)83 USA 
MILD 39.4% MOD 26.6% 
SEV 14.7% PROF 10.6% 
Health survey interview 
data 
477 56.1 NR 
CVD 
Undefined diabetes 
Cross-sectional 
Retrospective 
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Levy 
(2006)117  USA 
MILD 47.6% MOD 31.1% 
SEV 14.6% PROF 6.8% 
Medical record review 
(NR) 103 52.4 38.2 
Hypertension 
Hypercholesterolaemia 
Cross-sectional 
retrospective 
(2001-2002) Overweight, Obese  
Hypertension 
Hove 
(2004)111 Norway 
MILD 39.2% MOD 42.1% 
SEV 15.5% 
Health questionnaire 
data (CFS) 274 52.0 NR Overweight, Obese 
Cross-sectional 
observational 
Merrick 
(2004)129 Israel NR 
Health questionnaire 
data (CFS) 2282 51 49.8 
Heart disease 
T2DM 
Overweight+ 
Hypertension 
Hyperlipidaemia 
Cross-sectional 
observational 
Moore 
(2004)132 Australia NR 
Researcher collected 
data (CFS) 93 NR 32.5 Overweight, Obese 
Cross-sectional 
observational 
Emerson 
(2005)105  UK NR 
Audit review of the 
quality of supported 
accommodation 
(2000-2002) 
1304 54.0 49.3 Overweight, Obese 
Cross-sectional 
observational 
Yen 
(2005)144 Taiwan 
MILD 22.2% MOD 34.9% 
SEV 28.1% PROF 14.8% 
Postal questionnaire 
data (2001) 516 NR NR Overweight, Obese 
Cross-sectional 
retrospective 
Ito (2006)89 Japan NR 
Care home periodic 
medical evaluation data 
(2002) 
526 NR NR Overweight, Obese 
Cross-sectional 
retrospective 
Lennox 
(2006)116 Australia NR 
Medical history chart/GP 
examination (CFS) 25 NR 45.0 
Overweight, Obese 
Hypertension 
Cross-sectional 
observational 
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Overweight, Obese 
Undefined diabetes 
McDermott 
(2006)86 USA NR 
Electronic medical 
records (1990-2003) 618 NR NR 
Ischaemic heart 
disease 
Cerebrovascular 
disease 
Hypertension 
Obese 
T1&T2DM 
Cross-sectional 
retrospective 
Rurangirwa 
(2006)93 USA NR 
Study questionnaire data 
(2004) 173 58.0 23.3 Overweight+ 
Cross-sectional 
retrospective 
Shah 
(2006)135 UK NR Mail questionnaire (CFS) 119 NR NR Undefined diabetes 
Cross-sectional 
observational 
Van Den 
Akker 
(2006)140 
Netherlands 
MILD 11% MOD 53% 
SEV 28% PROF 8% 
Electronic health service 
provider database (NR) 436 52 NR 
Ischaemic heart 
disease 
Cerebrovascular 
disease 
Hypertension 
Cross-sectional 
retrospective 
Levy 
(2007)118 USA 
SEV 65.4% PROF 
34.6% 
Medical record 
review/retrospective 
medical billing data 
(2006-2007) 
52 52.0 NR 
Overweight+ 
Hypercholesterolaemia 
Hypertension 
Undefined diabetes 
Cross-sectional 
retrospective 
 
McDermott 
(2007)87 USA NR 
Electronic medical 
records (1990-2003) 585 NR NR Undefined diabetes 
Cross-sectional 
retrospective 
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McGuire 
(2007)127 Ireland 
MILD 14.1% MOD 
63.5% 
SEV 12.8% PROF 9% 
Postal questionnaire 
(CFS) 155 53.5 37.0 Overweight, Obese 
Cross-sectional 
observational 
Wang 
(2007)142 Taiwan NR 
Health questionnaire 
data (CFS) 1128 57.6 NR 
Heart disease 
Overweight+ 
Cross-sectional 
observational 
Bhaumik 
(2008)99 UK NR 
Questionnaire data 
register (1998-2001) 1119 59.0 NR 
Overweight, Obese 
Heart disease 
Cross-sectional 
retrospective 
Henderson 
(2008)84 USA NR 
Medical chart data 
(2005) 100  NR 
T2DM 
Overweight, Obese 
Hypertension 
Dyslipidaemia 
Cross-sectional 
Retrospective 
Melville 
(2008)128 UK 
MILD 40.9% MOD 
25.1% 
SEV 18.2% PROF 
15.8% 
Face to face 
interview/physical 
examination by nurse 
(CFS) 
945 55.6 NR Overweight, Obese 
Cross-sectional 
observational 
Wallace 
(2008)141 Australia NR 
Medical chart data from 
GP physical examination 
(2002-2005) 
155 52 NR 
CVD 
Elevated glucose 
T1&T2DM 
Overweight, Obese 
Hypertension 
Hypercholesterolaemia 
Cross-sectional 
retrospective 
 
 
De Winter  
(2009)81 Netherlands 
MILD 12.1% MOD 33.2% 
SEV 34.3% PROF 20.4% 
GP screened/medical 
chart/structured 
470 NR NR 
Myocardial infarction 
Cerebrovascular 
Cross-sectional 
observational 
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interview (CFS) disease 
Hypertension 
Diabetes 
Elevated glucose 
Obese 
Hypercholesterolaemia 
Gale 
(2009)107 UK NR 
GP survey data collected 
for study 
(2007-2009) 
1097 58.0 NR Overweight, Obese 
Cross-sectional 
observational 
Henderson 
(2009)110 USA 
MILD/MOD 53% 
SEV/PROF47% 
Health questionnaire 
data (CFS) 1196 53.0 NR Overweight+ 
Cross-sectional 
observational 
Maaskant 
(2009)123 Netherlands NR 
Database data from a 
service care provider 
(2002-2007) 
336 55.1 NR Overweight, Obese 
Cross-sectional 
retrospective 
Moss 
(2009)134 South Africa NR 
Questionnaire/physical 
examination by nurse 
(CFS) 
100 47 NR 
Elevated glucose 
Overweight+ 
Hypertension 
Hypercholesterolaemia 
Cross-sectional 
observational 
Sohler 
(2009)136 USA NR 
Medical chart data 
(2001-2005) 5930 NR NR 
Undefined diabetes 
Overweight, Obese 
Hypertension 
Hypercholesterolaemia 
Cross-sectional 
retrospective 
 
Van de 
Louw 
Netherlands 
MILD 10% MOD 38% 
SEV/PROF 52% 
Researcher collected 
data (CFS) 258 51.6 47 Hypertension 
Cross-sectional 
observational 
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(2009)139 
Shireman 
(2010)95 USA NR 
Medical care database 
data (2005-2006) 291 52.6 NR 
Undefined diabetes 
 
Cross-sectional 
retrospective 
Stedman 
(2010)138 New Zealand NR 
Service user database 
data collected by 
doctor/healthy lifestyles 
coordinator (6 months 
prior to study) 
98 NR 43 Overweight, Obese 
Cross-sectional 
observational 
Tyler  
(2010)88 USA NR 
Electronic medical care 
database (2005-2008) 1267 53.8 38.8 
Ischaemic heart 
disease 
Undiagnosed diabetes 
Obese 
Hypertension 
Hyperlipidaemia 
Cross-sectional 
retrospective 
Chen 
(2011)101 China NR Physical exam (2008) 117 NR NR 
Heart disease 
Diabetes 
Hypertension 
Elevated glucose 
Hypercholesterolaemia 
Cross-sectional 
observational 
Frighi 
(2011)106 UK 
MILD 48% MOD 30.2% 
SEV/PROF 21.8% 
Care home visitation 
questionnaire data 
(CFS) 
202 52.0 42.1 
Overweight+ 
T2DM 
Cross-sectional 
observational 
 
Haveman 
(2011) 
14  
European 
MILD 22.7% MOD 28.2% 
SEV 20.7% PROF 11.8% 
Interview survey data 
(CFS) 1253 51.0 41.0 
Undefined diabetes 
Hypertension 
Cross-sectional 
observational 
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POMONA II 
study109 
countries Myocardial infarction 
Cerebrovascular 
disease 
Lee 
(2011)115 Australia 
MILD 33% MOD 22% 
SEV 23% PROF 21% 
ID database with 
medical data (2006-
2011) 
162 52.0 44.0 
Ischaemic Heart 
Disease 
Overweight, Obese 
Undefined diabetes 
Hypertension 
Cross-sectional 
retrospective 
Martinez-
Leal (2011) 
POMONA II 
study125 
14  
European 
countries 
MILD 21.8% MOD 27.7% 
SEV 19.7% PROF 11.4% 
Interview survey data 
(CFS) 1257 50.5 41.4 Overweight, Obese 
Cross-sectional 
observational 
Stancliffe 
(2011)137 USA NR 
Consumer survey 
interview (2008-2009) 8911 NR 43.5 
Overweight, Obese 
Overweight+ 
Cross-sectional 
retrospective 
Wong 
(2011)143 Hong Kong 
MILD 4.9% MOD 41.8% 
SEV/PROF 51.9% 
Survey questionnaire 
delivered by health 
professional (CFS) 
811 53.3 44 
Heart disease 
Cerebrovascular 
disease 
Undefined diabetes 
Overweight+ 
Hypertension 
Hypercholesterolaemia 
Cross-sectional 
observational 
 
Chang 
(2012)100 Taiwan 
MILD 65% MOD 16% 
SEV 9% PROF 10% 
Annual health check 
database (NR) 129 56.6 33.0 
Overweight, Obese 
Heart disease 
Elevated glucose 
Cross-sectional 
observational 
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Hypercholesterolaemia 
Metabolic syndrome 
De Winter 
(2012)_1 
HA-ID 
study103 
Netherlands 
MILD 24.8% MOD 48% 
SEV 16% PROF 8.9% 
Medical records/Physical 
examination (CFS) 945 51.0 61.5 Overweight, Obese 
Cross-sectional 
observational 
De Winter 
 (2012)_2 
HA-ID 
study102 
Netherlands 
MILD 24.5% MOD 48.6% 
SEV 16%  PROF 8.7% 
Medical records/Physical 
examination (CFS) 980 51.3 61.5 
Hypertension 
Hypercholesterolaemia 
Metabolic syndrome 
Diabetes 
Cross-sectional 
observational 
Gazizova 
(2012)82 UK 
MILD 61% MOD 24% 
SEV 15% 
Routine health 
assessment of people 
within a service (2009) 
100 67.0 NR Overweight, Obese 
Cross-sectional 
observational 
Hsu 
(2012)113 Taiwan 
MILD/MOD 47% 
SEV/PROF 53% 
Health examination 
charts (2009) 164 NR 33.0 
Overweight+ 
Metabolic syndrome 
Cross-sectional 
retrospective 
Lin, L.P. 
(2012)122 Taiwan NR 
Annual health 
examination chart (2010) 184 62.5 NR Hypertension 
Cross-sectional 
retrospective 
Morin 
(2012)133 Canada 
MILD 32.9% MOD 
46.4% 
SEV 11.2% PROF 5.2% 
Mail questionnaire data 
(CFS) 789 NR NR 
Heart disease 
Undefined diabetes 
Cross-sectional 
observational 
 
 
Begarie France NR Questionnaire data 255 NR NR Overweight, Obese Cross-sectional 
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(2013)98 (CFS) observational 
De Winter 
(2013)104 
HA-ID study 
Netherlands 
MILD 24.9% MOD 53% 
SEV 13.4% PROF 4.6% 
Medical records/Physical 
examination (CFS) 629 53.6 61.5 Peripheral arterial disease 
Cross-sectional 
observational 
Haider 
(2013)108 Australia NR 
Telephone questionnaire 
(2008-2009) 897 NR 38.4 
Heart disease 
Cerebrovascular disease 
T2DM 
Overweight, Obese 
Cross-sectional 
retrospective 
Jansen 
(2013)85 Netherlands 
MILD 6.9% MOD 37.8% 
SEV 29% PROF 26.3% 
Medical file data (2007) 510 55.7 65.5 Myocardial infarction 
Cerebrovascular disease 
Cross-sectional 
retrospective 
Lin, J.D. 
(2013)120 Taiwan NR 
Annual health 
examination chart (2010-
2012) 
215 NR NR 
Hypercholesterolaemia 
Hypertension 
Elevated glucose 
Cross-sectional 
retrospective 
McCarron 
(2013)126 Ireland NR 
Face to face 
questionnaire – first 
wave data for a 
longitudinal study (CFS) 
753 45.0 54.8 
Ischaemic heart disease 
Cerebrovascular disease 
Hypertension 
Cross-sectional 
observational 
Vacek 
(2013)94 USA NR 
Medical care database 
data (2006-2007) 3079 NR NR Hypertension 
Cross-sectional 
retrospective 
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Hsieh 
(2014)112 USA 
MILD 44.9% MOD 23.7% 
SEV/PROF 8.4% 
Longitudinal study 
baseline data (2012) 
questionnaire data 
(CFS) 
1450 55.2 37.1 Overweight, Obese 
Cross-sectional 
observational 
Mikulovic 
(2014)130 France NR 
Face to face interview 
questionnaire (2007) 570 NR 38.1 Overweight, Obese 
Cross-sectional 
retrospective 
De Winter 
(2015)90 Netherlands 
MILD 21.3% MOD 47.6% 
SEV 16.7% PROF 9.0% 
Medical records/Physical 
examination (CFS) 990 51.3 61.1 
Hypertension 
Hypercholesterolaemia 
T1DM 
T2DM 
Diabetes 
Peripheral arterial disease 
Elevated glucose 
Obese 
Metabolic syndrome 
Cross-sectional 
observational 
Lin, L.P. 
(2015)121 Taiwan 
MILD 6.5% MOD 32.6% 
SEV 34.8% PROF 26.1% 
NR (CFS) 67 NR NR Overweight, Obese Cross-sectional 
observational 
Zaal-
Schuller 
(2015)145 
Netherlands MILD/MOD 51.1% 
SEV/PROF 48.9% 
Researcher screened 
(CFS) 
407 NR NR Peripheral Arterial disease Cross-sectional 
observational 
ID (intellectual disability); MILD (mild intellectual disability); MOD (moderate intellectual disability); SEV (severe intellectual disability; PROF (profound 
intellectual disability); NR (not reported); CFS (collected for study); CVD (cardiovascular disease); T2DM (Type 2 diabetes mellitus); T1&T2DM (Type 1 and 
Type 2 diabetes combined) 
Greyed out boxes indicate articles which report findings from the same study 
 39 
 
2.5.3 Risk of bias within studies 
 
The funnel plots did not show any obvious asymmetry and Egger’s test was not 
statistically significant for any of the outcome measures (specifically T2DM: t=-0.22; 
p=0.84; ischaemic heart disease: t=-0.13; p=0.91; cerebrovascular disease: t=0.35; 
p=0.58) (see Appendix 4 and 5 and 6 (Figure 27; Figure 28; Figure 29) for funnel 
plots). 
 
2.5.4 Results of individual studies and synthesis of results 
 
2.5.4.1 Prevalence of type 2 diabetes 
 
Figure 4 shows the individual studies reporting on the prevalence of T2DM and 
overall pooled prevalence. Prevalence estimates ranged from 2%84 to 13%.90 The 
pooled prevalence of T2DM was 7.6%. The prevalence of any diabetes was 8.7%; 
this ranged from 2%84 to 11%95, 102, 117 (data not presented). 
 
Figure 4: Individual studies and pooled prevalence of type 2 diabetes 
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2.5.4.2 Prevalence of cardiovascular disease 
 
Figure 5 shows the individual studies reporting on the prevalence of ischaemic heart 
disease. Prevalence estimates for ischaemic heart disease ranged from 0%140 to 
12%.126 The pooled prevalence of ischaemic heart disease was 3.7%. 
 
 
Figure 5: Individual studies and pooled prevalence of ischaemic heart disease 
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Similarly, Figure 6 shows the individual studies reporting on the prevalence of 
cerebrovascular disease. Estimates were fairly consistent in the <1%–4% range. The 
pooled prevalence of cerebrovascular disease was 2.2%. The pooled prevalence for 
undefined CVD was 10.6%, but ranged by individual study from 4%143 to 22%,114 
reflecting the diverse case definitions. 
 
 
 
 
Figure 6: Individual studies and pooled prevalence of cerebrovascular disease 
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2.5.4.3 Prevalence of other risk factors 
 
Table 5 summarises the findings from the individual meta-analyses. The overall 
estimated prevalence of hypertension was 18.5%. The estimated prevalence of 
overweight was 29.2%, obesity was 27.3%, and the prevalence of %0,  NJP2 
was 53.4%.  
 
Table 5: Point prevalence for outcome measures in the intellectual disability 
population 
Outcome 
Study 
n 
Total n 
Total n with 
outcome 
Pooled estimate 
(95% CI) I
2
 
Ischaemic heart disease 9 5586 200 0.04 (0.01, 0.06) 0% 
Cerebrovascular 
disease 
8 5748 114 0.02 (0.00, 0.05) 0% 
Undefined CVD 8 7773 881 0.10 (0.05, 0.15) 77.5% 
T2DM 5 4183 317 0.08 (0.05, 0.11) 0% 
Any diabetes 23 19133 1636 0.09 (0.07, 0.10) 0% 
Hypertension 28 17161 3008 0.19 (0.13, 0.24) 93.2% 
Overweight 32 24923 7434 0.29 (0.26, 0.33) 89.5% 
Obese 35 27274 7741 0.27 (0.23, 0.32) 93.6% 
Overweight and above 41 31172 16525 0.53 (0.49, 0.58) 96.4% 
Hypercholesterolemia 9 3892 491 0.17 (0.08, 0.26) 86.9% 
Metabolic syndrome 3 821 287 0.23 (0.00, 0.50) 91.7% 
Negative confidence intervals (CIs) have been rounded up to 0.00 
 
On making comparisons with the general population, we found that the ID population 
had decreased odds of having ischaemic heart disease (OR 0.44 (95% CI 0.34 to 
0.58; p<0.01)). No other statistically significant results were found, but we observed 
high heterogeneity for the other outcomes (see Table 6). 
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Table 6: Findings from the general population comparison meta-analysis 
Outcomes 
Study 
n 
ID 
total 
n 
ID total n 
with 
outcome 
GP 
total n 
GP total n 
with 
outcome 
Odds ratio 
(95% CI) I
2
 
Ischaemic 
heart disease 
3 2395 67 5441 335 
0.44 (0.34, 
0.58)* 0% 
Any diabetes 6 4014 411 13404 1371 
0.96 (0.61, 
1.5) 92.2% 
Hypertension 6 3588 1097 14262 4598 
0.76 (0.58, 
0.99) 86.9% 
Overweight 4 1487 477 17819 5986 
1.31 (0.47, 
3.66) 96.5% 
Obese 7 3838 1004 23230 6824 
1.09 (0.65, 
1.82) 95.3% 
*p<0.01 
 
 
2.5.5 Risk of bias across studies 
 
We found high heterogeneity in a number of outcomes when prevalence was pooled 
(Table 5) as well as in a number of outcomes for the general population comparison 
(Table 6). We further explored heterogeneity using meta-regression (see below). 
 
2.5.6 Additional analyses 
 
Meta-regression was used to investigate the effects of mean age, severity of ID and 
data collection method (researcher collected data, self/carer reported data, or 
retrospective records data) for prevalence of outcomes (Table 7). Mean age was 
found to affect hypertension only (one unit increase in mean age led to 1% increase 
in prevalence). Severity of ID had no significant effects on prevalence. Data 
collection method was found to have an effect on any diabetes when database 
collected data was compared to self/carer reported data (i.e. database studies 
tended to report lower prevalence of diabetes). It was also found to have an effect on 
obesity prevalence when database collected data was compared to researcher 
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collected data (i.e. database studies tended to report lower prevalence), see Table 7. 
Owing to the small amount of studies and insufficient data, no meta-regression was 
performed for general population comparison analyses. 
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Table 7: Results of meta-regression effects analyses for point prevalence 
 
 
Variable No. obs Effect (95% CI) P-value 
Ischaemic heart disease 
Database vs self/carer reported data 9 0.06 (-0.02, 0.14) 0.14 
Database vs researcher collected data 9 0.0009 (-0.08, 0.08) 0.98 
Mean age 5 0.0001 (-0.01, 0.01) 0.66 
% mild/moderate ID 5 0.0005 (-0.01, 0.01) 0.88 
Type 2 diabetes 
Database vs self/carer reported data 5 0.05 (-0.21, 0.12) 0.35 
Database vs researcher collected data 5 0.06 (-0.39, 0.26) 0.49 
Mean age 3 -0.00005 (-0.04, 0.04) 0.99 
% mild/moderate ID Insufficient observations 
Any diabetes 
Database vs self/carer reported data 21 -0.05 (-0.08, -0.05) 0.01* 
Database vs researcher collected data 21 -0.04 (-0.11, 0.04) 0.33 
Mean age 10 0.0006 (0.00, 0.01) 0.70 
% mild/moderate ID 11 0.001 (0.00, 0.00) 0.23 
Obesity 
Database vs self/carer reported data 35 -0.05 (-0.19, 0.08) 0.44 
Database vs researcher collected data 35 -0.12 (-0.21, -0.02) 0.02* 
Mean age 18 -0.0009 (-0.01, 0.01) 0.77 
% mild/moderate ID 17 0.002 (0.00, 0.01) 0.07 
Overweight 
Database vs self/carer reported data 32 0.06 (-0.05, 0.17) 0.26 
Database vs researcher collected data 32 0.01 (-0.07, 0.1) 0.8 
Mean age 17 0.01 (0.00, 0.01) 0.16 
% mild/moderate ID 16 0.002 (-0.00, 0.01) 0.27 
Hypertension 
Database vs self/carer reported data 28 -0.08 (-0.21, 0.04) 0.17 
Database vs researcher collected data 28 -0.01 (-0.12, 0.11) 0.89 
Mean age 13 0.01 (0.00, 0.02) 0.05* 
% mild/moderate ID 13 0.0008 (-0.01, 0.01) 0.74 
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2.6 Discussion 
 
 
2.6.1 Summary of evidence 
 
In this systematic review, we found that the prevalence of T2DM was 8% and any 
diabetes was 9%. For CVD, the prevalence of ischaemic heart disease, 
cerebrovascular disease and undefined CVD was 4%, 2% and 10% respectively.  
 
The current prevalence of T2DM, CVD and associated risk factors in the ID 
population was found to be similar to that in the general population. However, we 
found that ischaemic heart disease was significantly lower in the ID population. The 
meta-regression showed that the method of data collection had minor effects on 
pooled diabetes and obesity. Mean age had minor effects on hypertension.  
 
2.6.2 Strengths and limitations 
 
A particular strength of this review is that we used robust methods. We wrote to 
authors to clarify and obtain additional data rather than excluding the articles. To our 
knowledge, this is the first systematic review and meta-analysis of prevalence of 
T2DM, CVD and associated risk factors in adults with ID. In addition, it is the first 
review of its kind to make comparisons with the general population.  
 
However, we had limited data to separate T2DM from other diabetes and were 
sometimes restricted to unclear or poorly defined outcome measure definitions. 
There was also limited data available to make comparisons with the general 
population.  We would have benefited from additional general population data 
alongside ID population data to make more valid, generalisable comparisons.  
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2.6.4 Findings in relation to other studies 
 
Two recent reviews have been conducted that have focused on diabetes prevalence 
among people with ID.75, 76 The reviews found a mean prevalence of 8.7%75 and 
8.3%76 for combined gestational, type 1 diabetes (T1DM) and T2DM, but the reviews 
were unable to report on specific types of diabetes. The overall prevalence of CVD 
among people with ID is unclear.52 However, our finding that ischaemic heart 
disease was significantly lower in the ID population differs somewhat from the 
literature which suggests that the prevalence of CVD among people with ID is 
greater than the general population.52 
 
2.6.5 Conclusions 
 
Findings from the systematic review and meta-analysis presented in this chapter 
suggest that T2DM is at least as common in people with ID as in the general 
population. The findings also identify a gap in knowledge in relation to the 
prevalence of T2DM as many studies did not report this separately. In addition, none 
of the studies in our review reported on screen-detected T2DM in the ID population. 
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CHAPTER 3.   SYSTEMATIC REVIEW OF THE EFFECTIVENESS 
OF MULTI-COMPONENT BEHAVIOUR CHANGE 
INTERVENTIONS AIMED AT REDUCING MODIFIABLE RISK 
FACTORS 
 
3.1 Overview 
 
In this chapter, we describe the second of two systematic reviews conducted as part 
of the research programme. We present the existing evidence in relation to multi-
component behaviour change interventions that modify risk factors for T2DM and 
CVD in people with ID. The PRISMA checklist74 has been used to guide the reporting 
of this systematic review.  
 
3.2 Rationale 
 
Non-communicable diseases are on the rise globally and there is increasing demand 
for lifestyle behaviour change interventions to reduce morbidity, mortality and rising 
health costs.146 The suggested mechanisms for this rise are increased availability of 
energy rich foods and more sedentary lifestyles.147 T2DM and CVD, and shared 
associated risk factors are major contributors to morbidity and mortality.148 
 
Conditions such as CVD and T2DM share similar risk factors, including 
dyslipidaemia, hypertension, obesity, and IGR. In the general population, these risk 
factors can be effectively lowered through interventions focusing on changes in 
nutrition and physical activity.149-151 With a suggested increased risk of non-
communicable diseases within ID populations, special attention needs to be paid to 
the efficacy and effectiveness of multi-component behaviour change interventions to 
reduce this disparity. However, there is a lack of quality evidence on the health and 
healthcare of people with ID, including effectiveness of health interventions.152 
Previous systematic reviews of lifestyle behaviour change interventions in ID153-155 
have generally been unable to make specific recommendations due to inadequacies 
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in study design, conduct, lack of theory basis for intervention and/or unclear 
reporting. 
 
For the current review, we aimed to consolidate the evidence for the reduction of risk 
of T2DM and/or CVD through the delivery of multi-component behaviour change 
interventions in the ID population. 
 
3.3 Objectives 
 
The objectives were: 
x to establish the effectiveness of multi-component behaviour change 
interventions in promoting weight loss in the ID population; 
x to establish the effectiveness of multi-component behaviour change 
interventions in reducing other modifiable risk factors for T2DM and/or CVD in 
the ID population; 
x to establish the effectiveness of multi-component behaviour change 
interventions aimed  at primary prevention of T2DM or CVD, or reducing 
associated risk factors in the ID population. 
 
3.4 Methods 
 
3.4.1 Protocol and registration 
 
The systematic review was registered with the international register of prospective 
systematic reviews, PROSPERO 2015:CRD42015020758.156 
 
3.4.2 Eligibility criteria 
 
The review was guided by the PICOS (population, intervention, comparison, 
outcome, study designs) model.78 We defined the population as adults (18 years) 
with ID (whole study population or a defined sub-sample). We defined the 
intervention as any multi-component lifestyle behaviour change intervention aimed at 
primary prevention of T2DM or CVD, or a reduction in associated risk factors for 
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people with ID and/or their carers. We included studies with and without comparison 
groups. We defined outcome measures as changes in anthropometric measures 
(weight, BMI, waist circumference), BP, lipid levels, glucose levels, physical activity 
levels, sedentary behaviour and dietary habits. The study design was defined as an 
experimental study (before and after study, randomised controlled trial or non-
randomised controlled trial) with a follow-up period of at least 24 weeks or 6-months 
from baseline (to allow for the initiation and maintenance of medium and longer term 
behaviour change),157 see Table 8. 
 
All studies published since 1 January 2000 (until 21 April 2015) and in English 
language were eligible. Studies were limited to those published from the year 2000 
when most large diabetes prevention trials were first published in the general 
population.70 
 
We contacted lead authors for further information where inclusion/exclusion could 
not be determined. 
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Table 8: Inclusion and exclusion criteria of studies included in the systematic 
review of multi-component lifestyle behaviour change interventions  
 
 Inclusion Criteria Exclusion criteria 
Population 
Whole study population or defined 
sub-sample of 
DGXOWV\HDUV* 
 
Intervention 
Multi-component lifestyle behaviour 
change intervention aimed at 
primary prevention of T2DM or CVD 
or a reduction in associated risk 
factors (weight management, 
increasing physical activity/reducing 
sedentary behaviour, dietary 
improvement) 
Interventions involving meal 
replacements, or were aimed 
at increasing physical fitness 
(in isolation) as opposed to 
changes in levels of physical 
activity 
Comparison 
Studies without comparison groups 
were included 
 
Outcomes 
Changes in anthropometric 
measures (e.g. weight ,BMI, body 
fat, waist circumference) 
Blood pressure 
Lipid levels 
Physical activity 
Sedentary behaviour 
Dietary habits 
 
Study designs 
Before and after study 
Randomised controlled trial 
Non-randomised controlled trial 
Follow-up period <24 
weeks/<6 months from 
baseline 
* For generalisability to the adult ID population as a whole, studies with >20% aged under 18 
years, >20% disability other than ID and >25% with specific ID were excluded. 
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3.4.3 Information sources 
 
We searched the electronic databases EMBASE, MEDLINE, CINAHL, CENTRAL 
and PsychINFO for this systematic review. The last date of the search was 21 April 
2015. We searched the references lists of relevant systematic reviews and included 
papers within those for additional studies. 
 
3.4.4 Search 
 
We combined MeSH terms and key words for multi-component lifestyle interventions 
and outcome measures and ID.  The search was limited to English language studies 
ZLWKFRKRUWVRIDGXOWV\HDUVRIDJHGHSHQGLQJRQWKHGDWDEDVHVHHTable 9 for 
MEDLINE search strategy). 
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Table 9: Search strategy for MEDLINE electronic database 
1. (Behav* adj1 (Modif* or therap*)).ti,ab. 
2. Cognitive* therap*.ti,ab. 
3. (Health* adj2 (Educat* or promot* or behav*)).ti,ab. 
4. Educat* adj2 program*.ti,ab. 
5. (Diet* adj2 (Intervention* or modif* or therap*)).ti,ab. 
6. (Health* adj2 Eating).ti,ab. 
7. (Nutrition* adj2 (intervention* or modif* or counsel* or therap*)).ti,ab. 
8. (Exercis* adj2 (intervention* or therap*)).ti,ab. 
9. (Physical adj (education or fitness or activit* or training or exercise)).ti,ab. 
10. (Lifestyle adj2 (advice or guidance or modif* program* or interven*)).ti,ab. 
11. (Weight adj2 (control* or los* or reduc* or maintenance or management)).ti,ab. 
12. Weight adj loss adj program*.ti,ab. 
13. Exercise*.ti,ab. 
14. Sport*.ti,ab. 
15. exp Health Promotion/ 
16. exp Nutrition Therapy/ 
17. exp Exercise Therapy/ 
18. (Sedentary adj (behav* or lifestyle* or individual* or population*)).ti,ab. 
19. or/1-18 
20. exp Intellectual disability/ 
21. ((learning or development* or intellectua* or mental*) adj1 disabilit*).ti,ab. 
22. (impair* adj2 intellectual adj2 function*).ti,ab. 
23. (mental* adj1 (impair* or handicap*)).ti,ab. 
24. Exp mentally disabled persons/ 
25. (mental* adj2 retard*).ti,ab. 
26. Or/20-25 
27. 19 and 26 
28. animal/ not (animal/ and human/) 
29. 27 not 28 
30. limit 29 to english language 
31. limit 30 to yr=2000-current 
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3.4.5 Study selection 
 
Full texts were identified after titles and abstracts were read separately by two 
investigators (TC, AD) who discussed discrepancies in selection at a later meeting.  
On retrieving the full-text articles, papers were again examined separately by two 
investigators (TC, AD) to check for suitability for inclusion.  
 
3.4.6 Data collection process 
 
We created a data extraction form for this review. Data were extracted by one 
investigator (TC) and verified for accuracy by another investigator (AD).   
 
3.4.7 Data items 
 
For each study, we collected the first author’s name, title of paper, year of 
publication, country of the cohort, study design, sampling method, intervention 
details, and dates of data collection and the intended recipient of the intervention. 
For the whole study population (and for each group, if applicable), we extracted data 
on total sample size or sub-population size, mean ages, proportion of males/females, 
severity of ID, ethnicity, and withdrawals.  
 
For each reported outcome, we extracted information on how outcomes were 
defined and measured, the total number measured for each outcome, length of 
follow up, mean baseline and post intervention value, mean between-group change 
and/or change baseline to follow up along with a measure of variability (SD, SE etc.). 
We extracted data separately for males and females, where reported.  
 
3.4.8 Quality assessment 
 
The NICE quality appraisal checklist for quantitative intervention studies158 was used 
to assess the quality of the selected studies. The checklist included criteria for 
assessing the internal and external validity of experimental and observational 
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quantitative studies (randomised controlled trials (RCTs), non-randomised controlled 
trials, before and after studies) and allowed assignment of an overall quality grade 
(categories ++, + or -). Studies were assessed by one reviewer (TC) and verified for 
accuracy by a second reviewer (RS). 
 
3.4.9 Risk of bias in individual studies 
 
Prior to carrying out this systematic review, we anticipated using funnel plots79 and 
the Egger’s test80 to examine potential publication bias in the literature for the 
collected outcomes. However, owing to the small number of studies included in this 
review resulting in low power to detect bias, these methods were not used. 
 
3.4.10 Data synthesis 
 
Data synthesis for this review involved describing the study characteristics (country, 
population size, age, %male, ethnicity, severity of ID, eligibility criteria, outcomes 
report and follow-up period) of included articles. We then described the details and 
behavioural strategies of each of the multi-component lifestyle behaviour change 
interventions, including their structure and delivery and the underlying theory behind 
each of the interventions. Finally, we described the outcome measures and study 
findings. Given the low number of studies included, a formal evidence synthesis was 
not undertaken.  
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3.6 Results 
 
3.6.1 Study selection 
 
The literature searches yielded 3508 articles. After duplicates were removed, 3167 
articles remained to be screened. We retrieved and reviewed the full-text of 39 
articles for 32 studies (Figure 7). Most potentially relevant studies were noted for 
their small sample size, short follow up, high attrition rates and/or incomplete data for 
key outcomes. We contacted the authors of four study protocols for further 
information.159-162 One of the authors did not reply, and we were informed that the 
remaining three protocols were still awaiting publication and could not be included in 
the review. In total, we identified only four studies for inclusion in this review. 
 
 
Figure 7: Flow diagram of study selection 
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3.6.2 Study characteristics 
 
The four studies included in the systematic review presented data on 700 individuals. 
The characteristics of each of the studies are presented in Table 10. 
 
The studies covered three countries (USA, UK and Sweden).  Two studies were 
single arm, and two studies had a control group. All four studies reported data for 
physical activity and/or sedentary behaviour. 
 
The average mean age was 42.2 years and the average percentage of male 
participants was 42.9%. The mean average group size was 174 before drop-out and 
104 after drop-out. Group sizes ranged from 54 to 443 before drop-out and from 44 
to 196 after drop-out. The majority of participants were white (68% where known); 
approximately one-quarter (26%) were black and the remaining 7% were from other 
ethnic groups. Only one study provided information on severity of ID, but based on 
eligibility criteria, the remaining studies were likely to comprise adults in the mild to 
moderate ID range. Other descriptive information for each study is presented in 
Table 10. 
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Table 10: Studies included in the systematic review of multi-component behaviour change interventions  
Author & 
year Country 
N (n 
after 
drop
out) 
Mean age 
(SD) 
% 
Male 
Ethnic 
Group 
Mean 
BMI 
Eligibility criteria 
 
Severity of 
ID 
Key outcomes 
reported 
Follow-
up 
period 
Bazzano 
(2009)163 
 
“Healthy 
Lifestyle 
Change 
Program 
(HLCP)” 
USA 68 
(44) 
 
44.0 38.6% White (64%) 
Black African 
(21%) 
Other (16%) 
33.3 - Age 18–65 
- High-functioning ID 
- %0, 
- Diabetes or risk factors for 
diabetes (incl.hypertension, 
hyperlipidaemia, family history, 
hyperglycaemia, ethnicity 
(non-white), age >45 years) 
NR 
 
BMI, Weight 
Waist 
circumference 
Physical activity 
(frequency and 
duration) 
7 
months 
Melville 
(2011)164 
 
“TAKE-5 
STUDY” 
UK 54 
(47)  
48.3 40.7% White (97%) 
Pakistani 
(2%) 
Other Asian 
(2%) 
40.0 - \HDUVROG 
- %0, 
- Ambulatory 
Excluded 
- Prada-Willi syndrome 
MILD 31.5% 
MOD 31.5% 
SEV 35.2% 
PROF 1.9% 
BMI, Weight 
Waist 
circumference 
Sedentary & 
Physical activity 
(mins/day 
accelerometer) 
24 
weeks 
McDermott 
(2012)165 
 
“Steps To 
Your 
Health 
(STYH)” 
USA 443 
(196) 
38.8 49.2% White (42%) 
Black (57%) 
Hispanic 
(1%) 
Other (1%) 
32.4 - Age 18–65 
- Voluntary participation 
- Ambulatory and 
communicative 
- Mild to moderate ID 
- Residence in independent or 
supported settings. 
Excluded 
- Underweight (BMI<18.5) 
NR 
 
BMI 
Moderate to 
vigorous physical 
activity 
(accelerometer) 
 
12 
months 
Bergstrom 
(2013)166 
 
 
Sweden 130 
(129)  
Int.  
36.2(10.1) 
Control  
39.4(11.3) 
43.1% NR Int. 
30.0  
Control 
28.5 
- Adults 
- Mild to moderate ID 
- UHVLGHQWV 
NR BMI, Weight 
Waist 
circumference 
Physical activity 
(steps/day 
pedometer) 
12–16 
months 
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3.6.3 Study quality 
 
A breakdown of study quality is presented in Table 11. The studies were generally of 
high quality; in particular, all of them achieved at least a good quality rating for 
internal and external validity. However, two of the four studies failed to account for all 
of the participants when concluding the study, and three of the four studies did not 
report on whether the studies were sufficiently powered to detect differences. 
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Table 11: Quality assessment of articles included in the systematic review 
 
 Bazzano163 Melville164 McDermott165 Bergstrom166 
SECTION 1 – POPULATION 
Source population/area well-described? + ++ ++ ++ 
Eligible population/area representative of source population/area? ++ + ++ ++ 
Selected participants/areas represent eligible population? + ++ ++ + 
SECTION 2 – METHOD OF ALLOCATION TO INTERVENTION (OR COMPARISON) 
Allocation to intervention (or comparison). Was selection bias minimised? NA NA ++ ++ 
Interventions (and comparisons) well described and appropriate? ++ ++ ++ ++ 
Was allocation concealed? NA NA NR ++ 
Participants or investigators blind to exposure and comparison? NA NA NA NA 
Exposure to intervention appropriate? ++ ++ ++ ++ 
Contamination acceptably low? NA NA ++ ++ 
Other interventions similar in both groups? NA NA ++ ++ 
Participants accounted for at study conclusion? - ++ - ++ 
Did setting reflect usual UK practice? ++ ++ ++ ++ 
Did intervention or control comparison reflect usual UK practice? ++ + + ++ 
SECTION 3 – OUTCOMES 
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Outcome measures reliable? + + ++ + 
All outcome measurements complete? ++ ++ + - 
All important outcomes assessed? ++ ++ ++ ++ 
Outcomes relevant? ++ ++ ++ + 
Similar follow-up times in exposure and comparison groups? NA NA ++ + 
Follow-up time meaningful? + ++ ++ ++ 
SECTION 4 – ANALYSES 
Exposure and comparison groups similar at baseline? If not, were these adjusted? NA NA NR ++ 
Intention-to-treat (ITT) analysis conducted? - - ++ ++ 
Sufficiently powered to detect an intervention effect (if one exists) NR NR NR ++ 
Estimates of effect size given or can be calculated? NR ++ ++ + 
Analytical methods appropriate? + - ++ + 
Precision of intervention effects given or able to be calculated? Were they meaningful? + ++ ++ ++ 
SECTION 5 – SUMMARY 
Study results internally valid? (i.e. unbiased) + + ++ + 
Findings generalisable to the source population? (i.e. externally valid) ++ + ++ + 
++ All of the quality assessment checklist criteria were fulfilled; + Some of the quality assessment checklist criteria have been fulfilled; - Few or 
none of the quality assessment criteria were fulfilled; NR not reported; NA not applicable.
 62 
 
 
3.6.4 Results of individual studies and descriptive data synthesis 
 
Table 12 summarises the multi-component lifestyle behaviour change interventions 
evaluated in the individual studies.  
 
Bazzano and colleagues (2009)163 conducted a single-arm before and after 
intervention in DOUHDG\ RYHUZHLJKW RU REHVH LQGLYLGXDOV %0, NJP2). The 
intervention involved peer-mentoring, one-to-one health education, supervised 
physical activity and clinical support aimed at reducing weight, diet & increasing 
physical activity. 
 
The study by Melville and colleagues (2011)164 also conducted a single-arm study  in 
already obese individuals (BMI  30 kg/m2) who had been referred to a dietician by 
their GP. Nine lessons, every 2–3 weeks, were provided for participants and their 
carers. Lessons were aimed at increasing physical activity and better diet as well as 
weight loss. Interventions also consisted of personalised diet plans with calorie 
restrictions (600 kcals per day). 
 
Bergstrom and colleagues (2013)166 conducted a two-armed trial in community 
residential homes, targeting both people with ID and their carers. The intervention 
offered a ‘study circle’ for carers and an appointed health ambassador at each 
residential home. An educational health course for the residents was also provided. 
The community residences in the control arm received the option to take part in the 
intervention after study completion (wait-list control). The primary outcome for this 
trial was increasing physical activity and the secondary outcomes were decreasing 
weight and BMI.  
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Table 12: Details of the interventions evaluated 
Author & 
year 
Key elements of 
intervention 
Structure of intervention (no. 
sessions & length) 
Who delivered 
intervention 
Where 
interventio
n delivered 
Goal setting Theory 
Bazzano 
(2009)163 
Diet, exercise & behaviour 
modification 
x Interactive health education 
x Supervised physical activity 
x Peer mentoring 
x Clinical support 
 
x Twice weekly, 2 hour sessions (for 7 
months) 
x Each class included 50 mins health 
education and 1 hour supervised 
physical activity 
x Outcomes assessed at baseline and 
at 7 months 
Professionals with ID 
expertise with 
assistance from peer 
mentors 
Community 
organisation 
NR Based on 
Bandura’s social 
cognitive theory 
of health 
behaviour 
change  
Melville 
(2011)164 
Weight loss, diet and exercise 
x Energy-deficit diet 
x Goal setting and self-
monitoring to increase physical 
activity, encourage weight loss 
and improve diet 
x 9 sessions, every 2-3 weeks (40-60 
mins each) 
x 24 week follow up 
Two health 
professionals (dietician 
& sports medicine 
graduate) with 
experience working 
with individuals with ID 
 
Participant’s 
home 
Individual goal 
setting regarding 
weight loss, 
dietary change & 
physical activity 
NR 
McDermott 
(2012)165 
Diet, exercise, & stress 
reduction 
x Health promotion intervention 
focusing on nutrition, exercise, 
stress management, changing 
ways of thinking, communication 
styles, complications of obesity 
& behaviour management 
x 8 weekly sessions (90 mins each) 
x Data collected at baseline, 9 weeks 
after completion, 6 months and 1 year  
Health educator with 
experience working 
with adults with ID 
Community 
venue 
NR Based on 
Bandura’s social 
cognitive theory 
of health 
behaviour 
change  
Bergstrom 
(2013)166 
Diet and exercise modification 
Three components: 
x Health ambassador in each 
residence 
x Study circle for caregivers 
x Health course for residents – 
learn about health issues, try 
healthy foods and physical 
activities 
x 12-16 months to complete programme 
x Health ambassadors: 6 network 
meetings (3 hrs each) 
x Study circle: 10 sessions (90 mins 
each) 
x Health course: 10 sessions 
x Outcomes assessed at baseline and 
at end of intervention (12-16 months 
from baseline) 
x Health ambassador 
x Member of staff from 
residence 
x Course leader from 
national educational 
association for adults 
Community 
residential 
homes 
NR Based on 
Bandura’s social 
cognitive theory 
of health 
behaviour 
change 
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Finally, McDermott and colleagues (2013)165 conducted a two-arm randomised 
control trial. Intervention participants were assigned to eight weekly lessons in 
nutrition, exercise, and changing ways of thinking. The lessons focused on stress 
management, complications of obesity, and behaviour management. The classes 
emphasised moderate to vigorous physical activity (MVPA), healthy eating and BMI 
reduction. The control group was assigned to eight weekly lessons on safety and 
hygiene.  
 
Table 13 summarises the components of the individual behaviour change 
interventions. All of the interventions used both dietary and exercise components.  
 65 
 
Table 13: Individual components of the interventions evaluated 
 Bazzano163 Melville164 McDermott165 Bergstrom166 
DIETARY COMPONENT 
Energy restriction  600 kcal/d   
Weight loss target  5% of initial body weight   
Nutrition advice 9  9  
Try healthy foods in 
session 9  9 9 
National 
recommendations    9 
Healthy dietary habits    9 
Portion sizes  9   
Individualised diet plan  
50% carbs 
<35% fats 
<20% protein 
  
Individualised diet goals  Set one goal per 
week   
EXERCISE COMPONENT 
Individualised exercise 
goals  
- Walking 
targets (using 
pedometer) 
- Set one goal 
per week 
- Minimum 30 
minutes mod, 
intensity 
physical activity 
at least 5 days 
per week 
  
Advice regarding time 
and intensity  
- Advice on 
replacing 
sedentary 
behaviour for 
activities in the 
home, e.g. 
housework 
  
Supervised activity in 
session 
- 1 hour during 
each session 
- Use of local 
parks and fitness 
facilities 
- Exercise video 
created by peer 
mentors 
 
Sessions 
followed by 
optional brisk 
walk 
Physical 
activities in 
sessions 
Information provided 
regarding local leisure 
facilities 
 
9 
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Out of the four included studies, the two single-arm studies with a follow up of seven 
months163 and 24 weeks164 respectively, indicated significantly improved outcomes. 
Reductions in weight, BMI, and waist circumference were demonstrated after the 
implementation of a behaviour change intervention programme aimed at increasing 
physical activity and improving diet. Additionally, both studies demonstrated a 
significant improvement in physical activity outcomes, specifically, for ‘minutes per 
week’ and ‘frequency of sessions’163 and a ‘reduction in sedentary behaviour’.164 
Both cohorts were overweight to obese when they were enrolled into the study. For 
the further two studies165, 166 where the cohort was not recruited based on health 
status, one of the studies showed significant positive improvements in waist 
circumference, BMI, and steps per day in those who received the intervention 
compared with the controls;166 the second study did not show any significant 
differences between control and intervention arms (see Table 14).165 
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Table 14: Reported data for included studies 
Author & year Body mass index 
(Kg/m2) 
Weight (Kg) Waist circumference 
(cm) 
Vegetable intake 
(Servings per day) 
Physical activity/Sedentary 
behaviour 
Bazzano (2009) 
a) Mins per week Ǉ 
b) Sessions per week Ǉ 
Baseline 33.3 (n=44†) 88 (n=44†) 104.9 (n=39) 2 ((n=44) a) 133 b) 3.2 (n=44) 
Follow-up (7 months from 
baseline) 
32.8 (n=44) 86.8 (n=44) 102.6 (n=39) 2.2 (n=44) 
a) 206.4 b) 3.9 (n=44) 
Intervention group change -1.5%* -1.34%* -2.18%** +10% a) +54.89%** b) +21.88%** 
Melville (2011) 
a) Sedentary mins per day 
b) Low PA mins per day 
c) MVPA mins per day 
(accelerometer) 
Baseline 40 [8.03] (n=47) 100.6 [26.8] 
(n=47) 
122.1 [15.7] (n=47) NR a) 623.3 [121.5] b) 73.4 [46.8] 
c) 14.2 [17.5] (n=45) 
Follow-up (24 weeks from 
baseline) 
39.2 [8.2] (n=47) 96.1 [26.9] 
(n=47) 
115.8 [16.7] (n=47) NR a) 581.9 [116.4] b) 81.3 [45.6] 
c) 17.8 [17.3] (n=33) 
Intervention group change -4.45%** -4.55%** -5.15%** NR a) -6.64%* b) +10.76% c) 
+25.42% 
McDermott (2012) 
 
MVPA ratio - minutes 
performed/minutes worn 
(accelerometer) 
Baseline 32.38 [6.85] 
(n=437) 
NR NR NR 3.24 [3.93] (n=401) 
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Follow-up (12 months from 
baseline) 
32.13 [6.59] 
(n=195) 
NR NR NR 4.62 [3.27] (n=118) 
Intervention group change -0.78% NR NR NR -4.18% 
Bergstrom (2013) Steps per day (pedometer) Ǉ 
Baseline 30 [7.6] (n=126) NR 94.5 [16.5] (n=124) 1.4 [0.6] (n=101) 8042 [5524] ((n=99) 
Follow-up (12-16 months 
from baseline) 
29.7 (n=108) NR 92.8 (n=103) 1.6 (n=66) 9650 (n=69) 
Intervention group change Ǉ-1% NR Ǉ-1.8% +14.29% +19.99%* 
Standard deviations in brackets where reported;  
†baseline characteristics of 24 people who did not complete the programme were not reported. 
Ǉself/carer reported data; *significant p<0.05; **significant p<0.01; NR-Not reported; PA-Physical activity; MVPA-Moderate to vigorous physical 
activity;  
 
 
 69 
 
 
3.7 Discussion 
 
3.7.1 Summary of evidence 
 
This review contributes to the existing knowledge on the effectiveness of multi-
component lifestyle behaviour change interventions in adults with ID. Three of the 
interventions included in this review led to some reductions in BMI, weight and waist 
circumference,163, 164, 166 but inferences are limited owing to small sample sizes, 
missing data, selected populations and/or lack of control groups. 
 
3.7.2 Strengths and limitations 
 
To our knowledge, this is the first systematic review and meta-analysis focusing on 
long-term multi-component behaviour change interventions for people with ID in 
order to reduce CVD and/or T2DM risk. We used robust methods and sought 
additional information from authors where relevant. However, only four papers met 
our inclusion criteria. Significant findings were observed only for the single-arm 
studies which are known to over-estimate effect sizes.167 We were unable to test for 
publication bias or to carry out meta-analytical work to explore combined effects, 
particularly as the interventions evaluated were so diverse. Similarly, research has 
shown that improvements in health can be difficult to sustain in the longer term;168 
only two of the included studies had a follow-up period of at least 12-months165, 166 
and even this may not be enough to indicate long-term sustained benefits. 
 
3.7.3 Findings in relation to other studies 
 
In line with previous systematic reviews in this area,153-155  findings from this 
systematic review demonstrate a lack of quality evidence on the effectiveness of 
multi-component behaviour change interventions in people with ID. In 2010, Jinks 
and colleagues153 focused a systematic review on qualitative studies of behavioural 
change approaches in people with ID to aid weight loss and health. The review found 
12 papers, of which only one was qualitative. The authors noted an overall lack of 
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research on behavioural approaches and using qualitative methods. Similarly, in 
2013, Spanos and colleagues reviewed 22 papers assessing interventions for weight 
loss in people with ID.154 They noted that many of the interventions did not meet the 
recommended duration in clinical guidelines and were too specific. Brooker and 
colleagues (2014)155 also reviewed interventions with a primary focus on physical 
activity in people with ID. Again, the review noted small sample sizes and invalid 
measurement tools and recommended further longer term intervention studies. 
 
3.7.4 Implications of findings 
 
This systematic review informed the evidence-base for the development of the STOP 
diabetes educational programme described in Chapter 8 and Chapter 9. The studies 
also revealed a high rate of missing follow-up data for participants who completed 
the multi-component lifestyle behaviour change interventions, which helped to inform 
further development work on feasibility testing (Chapters 10). The wider implications 
for research and practice are discussed in Chapter 13. 
 
3.8 Conclusions 
 
The findings from this systematic review have provided some evidence that multi-
component behaviour change interventions may be beneficial in modifying risk 
factors for T2DM and CVD in people with ID. However, there is a paucity of literature 
on their long-term effects in this population. In keeping with existing 
recommendations,154 we highlight the need for robust randomised controlled trials to 
evaluate the long-term effects of multi-component behaviour change interventions, 
informed by current guideline recommendations, for people with ID. 
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CHAPTER 4.   SERVICE USER INVOLVEMENT 
 
 
4.1 Overview 
 
This chapter details the service user involvement throughout the STOP Diabetes 
research programme. Involvement was integrated into the research from the early 
stages. 
 
4.2 Introduction 
 
The involvement of service users in research is central to UK policies169, 170 and is 
becoming increasingly common both nationally and internationally.171-174 The 
benefits of such involvement in health and social care research are manifold. Service 
users can provide valuable knowledge and insights to research,175-180 encourage 
recruitment through publicity,176, 178, 179 improve quality, relevance and impact of 
research181-185 and potentially help to meet recruitment targets.171 Service users in 
England contribute financially to public-funded research so arguably have a right to 
be involved185, 186 and can personally benefit from their involvement.182, 184, 187 
However, challenges to the successful involvement of service users in research 
include contrasting priorities,182, 188, 189  understanding of research methods,188 use of 
language and jargon188 and lack of time and resources.182, 188 
 
The involvement of people with ID in research can pose additional challenges to 
those outlined above and include the need to plan ahead, allow time for effective 
communication and regular breaks, and ensure that meeting locations are accessible 
to all.190-193 Such challenges can be at odds with researchers’ own demands and 
priorities194 and they often resort to seeking the proxy views of ‘sympathetic others’, 
such as parents or carers,195 which is disappointing, given that people with ID have a 
lot to say and can improve the quality and relevance of research.194 
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4.3 Involvement prior to submitting the research proposal 
 
Before submitting the research proposal, members of the team visited three local ID 
partnership boards to discuss the study, invite feedback, discuss how adults with ID 
could be involved in the research process and advise on reasonable adjustments 
and practical considerations. The boards comprised a mix of professionals and 
public members, including councillors, commissioners, clinicians, charity 
representatives, police officers, family carers, paid carers and people with ID. The 
boards provided useful advice on tailoring information sheets to service users (for 
example, using pictures as well as text, using a larger font and modifying the size 
and colour of the paper for those with visual impairment) and on communication 
issues (for example, using a staged, step-by-step approach to delivering 
information). The team also began forming links with two local self-advocacy groups 
for people with ID: both groups met at least monthly in a central location, and were 
led by an experienced facilitator whose role was to ensure that members understood 
what was being discussed, had every opportunity to give their views and contribute 
to the discussion, and that only one person spoke at a time. 
 
4.4 Involvement during the research programme 
 
4.4.1 Selection of service users for involvement 
 
Service users were approached from different sources to encourage a diverse range 
of views and to minimise burden. Members from the two self-advocacy groups 
approached, the Speaking up for Health Group and the Charnwood Action Group, 
agreed to help the team with the study.  In addition, the manager and residents of a 
communal care establishment were approached through the lead nurse’s contacts 
and agreed to help us with the study. Service users who entered the poster 
competition (see next section) were indirectly involved by providing publicity 
materials for the team (Figure 8). 
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Figure 8: Service users involved in the research programme 
 
 
4.4.2 Service user involvement in the programme management 
 
A common way of involving service users in research is through representation on 
steering group meetings196 and we discussed the potential for this with the service 
users. We considered tailoring these meetings to make them more accessible, but 
past experience suggested that they could be lengthy, involving complex discussions 
about procedures, accelerometer data, health economics and statistical 
methodologies and often used conference call facilities. We were concerned that the 
meetings would be isolating for the service user and their supporters, so instead, we 
agreed to feedback key points from the meetings and that service users could attend 
on an ‘ad hoc’ basis. 
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4.4.3 Service user involvement in promoting the research programme 
 
The study involved a Leicestershire-wide screening programme and it was important 
to promote the research as widely as possible. Among other considerations, the 
study logo and publicity materials needed to be suitable and appropriate for the 
target population. Both of the two service user groups that we approached used 
“word police” cards, which were shown whenever another member of the group or 
visitor used an acronym or abbreviation that they did not understand. Therefore, the 
proposed use of an acronym for the programme was not received favourably and 
instead, the team opted to call the programme, the “STOP Diabetes study”. The 
creative director subsequently devised four corresponding logos (Figure 9) and 
asked the Charnwood Action Group their preference, using a feedback form with a 
scale and pictures. The preferred logo (see option 4, Figure 9) was then shown to 
the Speaking up for Health Group and ways in which the logo and other publicity 
materials, such as posters and fliers, could be used to publicise the programme were 
discussed. The service users recommended printing the STOP Diabetes logo on 
note pads, pens and fridge magnets. When directly asked, they also thought that the 
logo should be printed on the study documentation, such as information leaflets and 
consent forms. Members of the group also suggested holding a poster competition 
as a means of publicising the programme. 
 
All ideas were collated and reported back to the research team for further discussion, 
and to determine if sufficient resources were available to action them. All of the 
suggestions were taken up by the research team. 
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(The fourth picture was the service users’ preferred logo) 
 
Figure 9: Proposed logos for the STOP Diabetes programme 
 
 
Service users were invited to enter the poster competition using brief easy-read 
information distributed by staff at local day centres, health clinics and other 
organisations. People who entered the competition were given a certificate and a 
small award of art and craft materials. Four of the pictures were chosen for the 
promotional materials (Figure 10); this decision was made by both service users and 
members of the research team. 
 
  
 76 
 
 
 
(The four pictures on the left were used for the publicity materials) 
 
Figure 10: Some of the artwork submitted for the poster competition 
 
 
The research programme was publicised via the Leicestershire Diabetes Centre 
website and was also published in the INVOLVE Summer 2013 newsletter,197 both 
as means of raising awareness about the programme and sharing our experiences 
of service user involvement (Figure 11). Similarly, having attended one of the 
programme steering group meetings, one of the co-chairs of the Charnwood Action 
Group contacted the media and was consequently interviewed about the programme 
(radio and newspaper198) which helped with recruitment. 
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Figure 11: Service users’ involvement in promoting the research programme 
(Image of article “Volunteers needed for study” reproduced with permission of Leicester 
Mercury. Copyright © 2016 Local World. All Rights Reserved.);(Image of article “STOP 
Diabetes study” reproduced with permission of INVOLVE. Copyright © INVOLVE all right 
reserved 2015.) 
 
 
4.4.4 Service user involvement in study documentation and process 
development 
 
It was important that information about the programme be available in simple 
language, free from jargon and acronyms, and using pictures and symbols, so that 
potential participants had every opportunity to understand what the research team 
were doing and to reach an informed decision about whether to take part. Prior to 
submission to the research ethics committee, the research team, with support from 
local ID services, drafted an easy-read (symbols and words) information sheet and 
consent form to partnership boards, local ID services and service user groups for 
 78 
 
feedback on the symbols, text and whether additional communication aids might be 
necessary. 
 
The service users that we asked to read the easy-read documents did not report any 
difficulties in understanding them, but recommended additional modes of 
communication, such as flash cards and story cards. A member of the Speaking up 
for Health Group assisted the team by taking photographs to illustrate the 
information leaflet, flash cards and story cards; three service users modelled for the 
photographs (Figure 12). 
 
 
Figure 12: Service users’ involvement in assisting with study documentation 
 
4.4.5 Service user involvement in staff recruitment 
 
Research nurses were integral to successful recruitment to the study, needing to be 
patient, sensitive, responsive to participants’ needs (e.g. seeing participants outside 
typical working hours), as well as able to communicate effectively with people with 
ID. Two members from the Speaking up for Health Group offered to help with the 
interview process for recruiting nurses into the research programme. Supported by 
their group facilitator, they created two questions to assess how good the nurses 
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were at communicating with people with ID, and how they might adapt their style of 
communication if that person did not understand them. On the day that the nurses 
were interviewed, the service users asked these questions in a separate room, with 
the facilitator present. They then rated the nurses’ responses on a 4-point scale 
(Figure 13). Their input helped to reinforce the panel’s decision on who to recruit and 
was particularly valuable in helping the panel to decide between two similar 
applicants. 
 
 
Figure 13: Service users’ rating form for recruitment of nurses 
 
4.4.6 Service user involvement in training staff and assessing 
acceptability of measures 
 
Service users at the participating communal care establishment helped to train staff 
by allowing them to practise communication-based interactions, consent taking and 
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measurement collection. Service users from one of the self-advocacy groups were 
invited to attend a follow-on staff training session so that nurses could put their new 
skills into practice. They gave feedback on nurses’ skills and discussed what they 
liked and what they did not like, enabling staff to gain confidence and develop 
competency in various procedures. The mock clinics also helped the research team 
to determine how long the appointments might take and how many visits may be 
needed. The service users reported that some of the questionnaires were too 
lengthy and complex. The team met to discuss the issues raised and made changes 
to reduce participant burden; these included swapping one of the questionnaires 
(Psychiatric Assessment Schedules for Adults with Developmental Disabilities (PAS-
ADD) mini199 for the PAS-ADD checklist199) and removing two questionnaires 
(Dietary Instrument for Nutrition Education (DINE)200 and International Physical 
Activity Questionnaire (IPAQ)201) entirely.  
 
For the research programme and to help with the design of the anticipated future 
trial, two members of the Speaking up for Health Group and one member of the 
Charnwood Action Group wore the activity monitors (both wrist and waist-worn) and 
provided feedback on their ease of use. 
 
4.5 Service user involvement during final stages of programme 
 
The service user groups were involved in the discussions around disseminating the 
findings and identifying relevant conferences. During the consent process, 
participants were asked if they wished to be informed of the findings. As a means of 
supporting this, and to acknowledge the group homes that had allowed residents to 
take part in the study, two of the research nurses visited 27 homes to present the 
findings in an easy-read format. Other participants received an easy-read report 
posted to them. 
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4.7 Discussion 
 
This chapter discusses the involvement of service users with ID into our research 
programme and draws on our own published work arising from this study.202 In line 
with previous service user initiatives, the impact of involving service users in the 
research study is difficult to quantify.203, 204 We feel that involvement of service users 
improved the quality of, and recruitment for, our study, but we do not know what 
would have happened had we not involved them and there are no similar studies in 
the UK on which to draw comparisons. 
 
We can say with certainty that the team benefited from the involvement, developing 
a greater understanding of the health and personal issues faced by people with ID. 
The team also received positive comments from the service users, particularly in 
relation to being involved in the interview panel process and visiting our study 
offices. In line with previous research,205 we found that people with ID valued the 
opportunity to discuss health issues. Unusually for service user involvement 
initiatives, our service users were also allowed to take part in the research (because 
it was a screening programme); the fact that many also chose to be participants in 
the programme is testament to their commitment. 
 
The service users’ involvement in the research programme was collaborative, and 
not participatory (or ‘emancipatory’), which is favoured by many disability 
academics.206 The agenda was set by the researchers and final decisions were 
always made by the lead investigator. Established self-advocacy groups contributed 
hugely to the success of the involvement, because there was an established group 
dynamic and all of the service users were keen to discuss health issues and voice 
their own opinions. As involvement initiatives expand, there is a danger that self-
advocacy groups will become inundated with requests for support207 so we need to 
ensure that we widen our approach to involvement for future studies. We also 
encountered problems when we discussed paying the service users for their 
contribution, because they were concerned about loss to their benefits, and also 
encountered organisational restrictions. For future work, we aim to consider more 
 82 
 
innovative group payments, such as water coolers or coffee machines, with prior 
organisational approval. 
 
We reiterate the recommendations from INVOLVE that involvement should 
commence at the early stage of the research process when identifying and 
prioritising topics for research.208 We had limited involvement at this stage of the 
programme and further involvement is likely to have improved the quality of our 
application and reduced the need to make changes once the study had started. 
When involving people with ID, it is important to allow extra time for communication 
and consider their physical and/or psychosocial needs, which may include working 
outside normal hours, travelling to different locations, making suitable venue 
arrangements and considering the need for carers, advocates or supporters to be 
present. We also recommend approaching service users through a number of 
sources to minimise the burden of their involvement. 
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CHAPTER 5.   SCREENING PROGRAMME: METHODS 
 
5.1 Overview 
 
This chapter describes the methods used for the screening component of the STOP 
Diabetes research programme included in work package 1. The background and 
rationale are presented in Chapter 1. The methodology for the cost-effectiveness, 
which also formed part of this work package, is described in Chapter 12. An 
additional physical activity sub-study, which was conducted alongside the screening, 
is described in Chapter 7. 
 
5.2 Aims and objectives 
 
The primary aim of the screening component of the research programme was to 
evaluate the feasibility and effectiveness of a diabetes screening programme for 
identifying undiagnosed T2DM and IGR in people with ID.  
 
The specific objectives were: 
x to develop and assess the feasibility of a diabetes screening programme in a 
community setting for adults with ID; 
x to determine the prevalence and demographic risk factors for T2DM, IGR and 
cardiovascular disease in people with mild to profound ID; 
x to validate the Leicester Self-Assessment diabetes risk score in people with 
ID; 
x to establish data linkage to Hospital Episode Statistics and the Office for 
National Statistics. 
 
5.3 Study design 
 
Cross-sectional population-based screening study. 
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5.4 Study setting 
 
The screening study was conducted between February 2013 and September 2015, 
in a variety of community locations within the unitary authorities of Leicester city, 
Leicestershire and Rutland (see Section 1.5.1 on approvals). Based on assumed 
familiarity and acceptability to service users, the locations initially chosen included 
day centres, community hospitals, primary care venues and group residential/nursing 
homes, which were identified through existing service listings. This was 
subsequently widened to include family homes and independent housing, to 
maximise recruitment. 
 
5.5 Participants 
 
5.5.1 Inclusion and exclusion criteria 
 
Inclusion Criteria 
1. Adults with ID 
2. Aged 18 to 74 years inclusive 
3. Registered with a general practice in Leicester city, Leicestershire or Rutland 
4. Participant and/or carer have sufficient English language skills to enable fully 
informed consent to be obtained 
 
Exclusion Criteria 
1. Previous diagnosis of T2DM or T1DM 
2. Disability not confirmed to be ID 
3. Malignancy or life-limiting terminal illness 
4. Severe systemic disease that may interfere with measurement and 
interpretation of HbA1c 
 
5.5.2 Participant recruitment process 
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Eligible participants were invited to take part in the screening programme using a 
four-pronged approach (summarised in Figure 14). 
 
1. Approach via general practice registers 
2. Approach via the Leicestershire Learning Disability Register 
3. Approach via specialist ID psychiatric service clinics 
4. Direct contact with the research team 
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Figure 14: Recruitment pathway to screening programme  
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5.5.2.1 Approach via general practice registers 
 
All general practices in Leicester city, Leicestershire and Rutland who had patients 
with ID on their practice register were sent a letter of invitation about the study. This 
was followed up, if necessary, by a postal reminder and/or telephone call. Practices 
were asked to return a reply slip to the research team to indicate their willingness to 
participate. The research team visited interested practices to explain the study in 
more detail, answer any questions and confirm their willingness to participate. 
General practice staff were then asked to identify people eligible to take part in the 
study from their practice ID register, and to send out a postal invitation. 
 
To adhere to the requirements and underlying principles of the Mental Capacity 
Act,209 information about the research was provided in stages. First, practices sent 
potential participants an easy-read invitation letter and a brief easy-read information 
leaflet, outlining the study. Potential participants were then asked to notify the 
research team of their willingness to participate (assisted by carers) using an easy-
read reply slip and a freepost addressed envelope, or via the telephone. To be 
equitable to people with ID who could not read, lived alone, or lived with carers who 
also had reading difficulties, those who did not respond were followed-up with a 
telephone call. The aim of the call was to check if the invitation had been received, to 
briefly explain what the information was about and to establish if the person or their 
carer wished to find out more about the research programme. The telephone calls 
were initially made by practice staff; however, due to difficulties with practices 
prioritising the time to undertake them, approval was later sought for an ID research 
nurse employed on the study to make these telephone calls from the relevant 
general practice site. See Appendix 7 and 8 and 9 for examples of easy-read 
documentation used in the research programme. 
 
Following this initial approach, a member of the research team telephoned interested 
people to discuss the study further. We anticipated that carers would play an 
important role in supporting the person with ID with their choice about participation; 
individuals were encouraged to talk to someone that they trusted about whether or 
not to participate. Potential participants received verbal explanations about the study, 
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had the opportunity to ask questions and received a preliminary assessment of their 
decision-making capacity to consent to participate in the research. Any indication of 
reluctance or anxiety about taking part was taken as a refusal. Full study information, 
in an appropriate format, was then sent to volunteers and/or an identified consultee 
(see Figure 15). If a personal consultee (i.e. a person interested in the person’s 
welfare but not doing so for remuneration, such as a parent) could not be identified, 
a nominated consultee (e.g. a key worker) was identified and consulted. 
Alternatively, for some people, a face-to-face visit was arranged to facilitate the 
provision of further/full information, supplemented by additional communication 
aids/methods. See Appendix 10 and 11 for example of consultee information leaflets 
used. 
 
5.5.2.2 Approach via the Leicestershire Learning Disability Register 
 
Where general practices declined to take part in the study, potential participants 
were approached via the Leicestershire Learning Disability Register.14 Adults who 
were known to the register were invited to participate following the pathways 
described in Figure 14. 
 
1) The register operates a rolling programme of home interviews210 and those who 
agreed to be contacted for research purposes at their most recent interview were 
contacted by the custodian of the register to confirm that these people were happy to 
be contacted by the research team. Their contact details were passed on directly to 
the research team for invitation. 
 
2) People who did not agree to direct contact for research purposes (either due to 
lack of agreement at previous home interview, or refusal when approached by the 
custodian of the register, as above) were invited by the Principal Investigator in 
Leicestershire Partnership NHS Trust (LPT).   
 
For both methods outlined above, potential participants were approached in the 
same way as for general practices (easy-read invitation letter, brief information 
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leaflet and reply slip to be returned to the research team). Invitations were cross-
checked with those already sent via general practices to avoid duplicate invitations. 
 
Non-responders were also followed-up in a similar manner as previously described 
for general practices; follow-up telephone calls were made by either the custodian of 
the Learning Disability Register or ID research nurses working on the research 
programme. A restricted-access database held on a SQL server was used to record 
and track whether the individual had received the letter of invitation and whether they 
would like any more information about the project.  
 
Capacity assessment and provision of full study information, including involvement of 
carers and/or consultees, also followed the same process as previously described. 
 
The sending of study invitations, via general practices and the Leicestershire 
Learning Disability Register, commenced in December 2012 and January 2013, 
respectively. Approval to utilise two further ways was obtained in February 2014 (see 
Sections 5.5.2.3 and 5.5.2.4 below): 
 
5.5.2.3 Approach via specialist intellectual disability psychiatric service clinics 
 
An additional approach to potential participants was made via specialist ID 
psychiatric service clinics. For patients attending a planned appointment, the 
consulting psychiatrist briefly described the research programme and issued an 
easy-read invitation letter, brief information leaflet and reply slip. Service users were 
given the opportunity to take the information leaflet and reply slip away with them (to 
return in the post) or to have their details passed on to the research team. Those 
who agreed to pass on their details were contacted by a member of the research 
team to provide further information and make an initial assessment of capacity. 
 
Recruitment and capacity assessment then followed the same procedure as for 
general practices and the Leicestershire Learning Disability Register. As before, all 
potential participants were cross-checked against those already invited to ensure 
that they were not invited to take part in the study more than once. 
 90 
 
 
5.5.2.4 Direct contact with the research team 
 
In some cases, direct contact was made by eligible individuals with ID (and/or their 
carers) who had heard about the study via publicity materials or through other people 
who had taken part in the study. The STOP diabetes team provided them with the 
same initial brief written information, as described for the other recruitment sources. 
Recruitment, capacity and cross-checking procedures were similarly undertaken. 
 
5.6 Screening process 
 
Following the invitation stage, volunteers were asked to attend an initial screening 
appointment for consent (see Section 5.6.1) and data collection (see Section 5.6.2). 
Appointments were arranged by the research team at a time and location that was 
convenient to the participants (and carers), often early morning or late 
afternoon/evening in their own homes, but also in day centres, residential homes and 
primary care settings. The number and length of appointments was flexible to allow 
for participants’ individual needs.  
 
5.6.1 Informed consent 
 
At the participant’s first appointment, a final face-to-face capacity assessment was 
undertaken by a trained ID research nurse and informed consent was obtained; 
appropriate mental capacity legislation (see Section 1.5.2) was followed. Consent 
was taken only when it had been established that the person understood the consent 
form and information sheet and that they had been given the opportunity to ask 
questions.  
 
People with capacity to consent were asked to sign a consent form. For those who 
could decide, but were unable to read, the consent form was read to them in the 
presence of an independent witness. For people who did not have capacity to 
consent, an appropriate consultee was identified and consulted about the person’s 
potential participation. The consultee was asked to sign a consultee declaration form 
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confirming that they had been consulted, had their questions answered and had 
considered the study from the participant’s perspective. 
 
The participant and/or personal/nominated consultee (if appropriate) were asked to 
confirm that: 
x they understood the study and were happy with what taking part would mean 
for them; 
x they understood that they could withdraw from the study at any time, without 
giving a reason (and that this would not affect their care); 
x they had been given a chance to discuss their questions with the research 
team; 
x they agreed for their GP to be notified about their participation and of their 
screening results; 
x the research team could access their medical records or records held at their 
residential home or day centre for additional information, if unable to obtain 
from the participant or carer; 
x relevant sections of their medical notes and/or study data could be looked at 
by responsible people/regulatory authorities for purposes of auditing the 
research. 
 
Participants provided their consent for screening to be undertaken (see Section 
5.6.1and Table 15), including a blood test (where the participant was willing). 
Additional optional consent items that participants could chose to agree to or not 
included: 
x to be contacted to take part in further phases of the study if they screened 
positive for IGR or high risk of developing T2DM (based on elevated BMI); 
x to have an additional blood sample taken for storage and future anonymised 
genetic analyses; 
x to allow access to medical records for long-term follow up; 
x for contact details to be stored by the research team so that participants could 
be informed of the study findings and be contacted about future research 
studies. 
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At the end of the appointment, the nurse highlighted the office’s telephone number 
on the participant information sheet to use if the participant decided to withdraw from 
the study or had any queries.  
 
At the start of any subsequent appointments, participants’ retention and 
understanding of the study was re-confirmed.  
 
Following the final study appointment, a photocopy of the signed consent 
form/consultee advice form (as appropriate) was sent to both the participant and the 
general practice; the copy of the form accompanied the screening results, which 
were subsequently sent (see Section 5.6.3). The original consent and advice forms 
were retained at the research offices. See Appendix 12 and 13 and 14 for examples 
of the consent/advice forms. 
 
5.6.2 Data collection 
 
Data collection was usually undertaken over two appointments but could be longer 
(the maximum was five). The data collection process is summarised in Table 15. All 
data were collected in a standardised way by specially trained research nurses, 
following study specific standard operating procedures. Full details of the 
assessment of outcomes are described in Section 5.7.2. 
 
Anthropometric measurements, BP, demographic and lifestyle data were frequently 
obtained at the first appointment, after consent was obtained, and usually took 
between one hour and 90 minutes. Questionnaires were completed via interview 
during the initial screening visit (or at a subsequent appointment), or were given to 
carers to be completed outside of the appointment, as applicable, see Table 15. 
These typically took between 30 to 60 minutes to complete. Venous blood samples 
were usually taken during a separate appointment after deciding with participants 
(and their carers, where relevant) whether a fasting or non-fasting sample would be 
more appropriate; this decision was based on potential behavioural difficulties and/or 
cognitive understanding of participants. This appointment lasted about 30 minutes. 
Medical history and prescribed medication were collected during screening or at a 
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later date from medical records. Other additional information was extracted by a 
researcher from the Leicestershire Learning Disability Register, or records held at 
residential homes or day centres. 
 
5.6.3 Informing of screening results 
 
All participants were informed of their key biomedical screening results in an easy-
read format, supplemented by verbal explanations as appropriate. Anthropometric 
measures and BP readings were presented to participants on the day that they were 
taken. Results of blood tests taken to determine diabetes status were provided within 
seven to 10 days.  
 
Participants with normal results were informed by post, with the option to contact the 
research team and discuss further if they wished. For participants who were screen 
positive for IGR or T2DM, a research nurse telephoned them to explain their results 
and answer any questions, prior to a letter being sent in the post. In some cases, this 
also involved a face-to-face visit by the nurse to support the participant and/or their 
carer. In accordance with consent taken, these participants were then referred to 
their general practice for usual care. 
 
As agreed at the time of consent, participants GPs were provided with full details of 
the screening results, including diabetes status. Additionally, for all participants who 
were identified as meeting the criteria for IGR or T2DM, a member of the research 
team contacted their general practice and informed their GP, prior to any results 
letters being sent. 
 
See Appendix 15 and 16 for example letters used to inform participants and GPs of 
the results. 
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Table 15: Summary of data collected during screening 
 
Biomedical measures   
Bloods Anthropometric 
Plasma glucose (2.7ml fluoride bottle) a Height (cm) 
HbA1c (2.7ml EDTA bottle) Weight (kg) 
Lipids (total cholesterol, LDL, HDL, triglyceridesb) c BMI kg/m2 
Urea and electrolytes (sodium, potassium, creatinine) c Waist and hip circumference (cm) 
Liver function tests (Bili, ALT ALP, GGT) c  
Thyroid function (TSH, free T4) c Blood pressure (mmHg) 
Genetic sample – whole blood (9ml EDTA bottle)d 
 Albumin: creatinine ratio (urine) 
 Questionnaires 
Depression - Glasgow Depression Scale and Carer Supplement   Health related quality of life -  EQ-5D 
Problem behaviour - Aberrant Behaviour Checklist Psychiatric disorders - PAS-ADD checklist 
Demographic details  
Age; Sex  Ethnic background 
Residential circumstances; level of support Deprivation score 
Medical and family history   
Cause of ID; severity of ID Current medication 
Medical history (physical, mental health, ID related) Smoking status 
Family history of diabetes (first degree)  
Lifestyle  
Physical activity  
Brief questions on mobility, walking, sitting and exercise 
Diet & nutrition  
Brief questions on eating, food preparation, 
food groups, portions of fruit and vegetables 
Activity levels  
Activity and sedentary behaviour  
Accelerometer – worn for 7 dayse  
a glucose, fasting (8 hours) or non-fasting; b triglycerides, only requested if fasting; 
c1 bottle (4.9ml serum gel) used for all 4; d only if provided optional consent; eonly for a sub-group. 
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5.7 Outcomes 
 
5.7.1 Primary and secondary outcomes 
 
The primary outcomes for the screening study were the prevalence of T2DM, IGR 
and abnormal (T2DM or IGR) blood glucose level.  
 
Diagnosis of T2DM was made following the most recent WHO criteria,28  more 
specifically +E$F 8 mmol/L or 6.5%. IGR was defined as impaired fasting 
glucose (IFG), WHO criteria, or HbA1c 42-47 mmol/L or 6.0-6.4%, see Figure 15.  
 
Secondary outcomes included: 
x Physical activity levels, including sedentary behaviour, measured by brief 
questions and accelerometer (for a small sub-group); 
x Lipid levels (triglycerides, total cholesterol, high density lipoprotein (HDL) 
cholesterol, low density lipoprotein (LDL) cholesterol); 
x Blood pressure (BP; systolic, diastolic); 
x Cardiovascular risk, as measured by the Framingham risk score;211, 212  
x Health related quality of life, as measured by the EuroQol-5 Dimensions (EQ-
5D)  questionnaire;213 
x Dietary/nutritional intake (food groups and fruit and vegetable intake); 
x Behavioural disorders, as measured by the Aberrant Behaviour Checklist 
(ABC);214, 215 
x Psychiatric disorders, as measured by the PAS-ADD checklist;216 
x Depression, as measured using the Glasgow Depression Scale (GDS) and 
carer supplement.217 
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Figure 15: Flow chart to illustrate diagnosis of type 2 diabetes and impaired glucose regulation for participants in the 
screening programme 
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5.7.2 Assessment of outcomes 
 
All blood and urine samples were analysed at by the University Hospitals of 
Leicester, NHS Trust laboratory services, using stable methodology standardised to 
external quality assurance reference values. HbA1c was measured using an 
ARKRAY ADAMS HA-8180T analyser (ARKRAY Inc, Kyoto, Japan). Plasma glucose 
(fasting and non-fasting); serum total cholesterol, HDL cholesterol and triglycerides; 
and urine albumin and creatinine, were measured using a Siemens Adiva 2400 
analyser (Siemens Healthcare Diagnostics, Camberley, UK). The Friedewald 
equation was used to estimate LDL cholesterol.218  
 
Resting BP was assessed in a seated position on the brachial artery, using an 
Omron M5-I automatic BP monitor (Omron Healthcare UK Ltd); a series of three 
measurements was recorded with a mean value calculated from the final two. Waist 
circumference was measured to the nearest mm over minimal clothing, midway 
between the costal margin and the iliac-crest, and in the mid-axillary line; hip 
circumference was measured to the nearest mm at the widest point over the 
buttocks; a soft tape was used for both anthropometric measures (WM02 Body 
Tape; Chasmors Ltd, UK). Weight was assessed in light clothing and no shoes to the 
nearest 0.1 kg, using a seca 875 digital floor scale (seca United Kingdom); and 
height to the nearest cm, using a Leicester portable height measure and with head 
placed in the Frankfurt plane.  
 
Additional data on health related quality of life (EQ-5D)213 and depression (GDS and 
carer supplement),217 were collected face-to-face via interview administered 
questionnaires at an appointment. To assess problem behaviour (ABC)214, 215 and 
psychiatric disorders (PAS-ADD checklist),216 questionnaires were taken away by 
carers and self-completed following the appointment. The validated questionnaires 
used are described in detail in Appendix 17. Deprivation was assessed according to 
the 2015 Index of Multiple Deprivation (IMD).219 
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Ambulatory activity and sedentary behaviour were measured for a small sub-sample 
of participants; full details of the physical activity sub-study undertaken are presented 
in Chapter 7. 
 
Uptake of screening was measured by recording the: (i) number of invitations sent; 
(ii) number of people responding and refusing at each stage; and (iii) number of 
people attending for screening. 
 
If BP, anthropometric measures and/or bloods were unable to be assessed, details 
of the reason were recorded (refused; physical/behavioural difficulty; equipment 
error; other). For demographic, lifestyle, medical history and prescribed medication, 
additional details were recorded on how the data were obtained; for example, from 
the volunteer, carer/relative or a combination of both, or if personalised records such 
as a health action plan4 were used. 
 
5.8 Sample size 
 
We aimed to screen 1,000 adults with ID, which would measure the overall 
prevalence of T2DM and IGR with 1.49% and 2.01% precision (95% CI) respectively, 
assuming similar prevalence rates of T2DM and IGR in people with ID as in the 
general population (6.2% and 12% respectively).18, 21, 22 
 
5.9 Data analysis 
 
5.9.1 Feasibility of diabetes screening in adults with intellectual 
disabilities  
 
The feasibility of conducting a diabetes screening programme in a community setting 
for adults with ID was assessed using a flow diagram of the screening process and 
summarising the number of drop outs and those for which data were unobtainable at 
each step of the screening process. Particular outcomes of interest in terms of the 
feasibility are (i) the proportion of people invited who complete the screening 
programme (including the blood tests) (ii) the proportion of people who attended the 
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screening session but did not have a blood test. We also assessed the 
completeness of key data items from the CRF and questionnaire to assess the 
feasibility of data collection for future research projects in this group.  
 
5.9.2 Characteristics 
 
The characteristics of those screened were summarised using means (standard 
deviations for continuous variables) and n (%) for categorical. 
 
Additional analyses were conducted to compare the representativeness of the STOP 
Diabetes study cohort to the Leicestershire Learning Disability Register.14 
 
5.9.3 Prevalence of type 2 diabetes and impaired glucose regulation 
 
The overall prevalence of IGR, T2DM and any abnormal glucose regulation was 
calculated with 95% (CI).  
 
5.9.4 Cardiovascular risk 
 
Cardiovascular risk was calculated for participants aged 35-75 years with no 
previous history of CVD. The Framingham CVD risk score211, 212 was used to assess 
risk in White European participants and ETHRISK for South Asians.220 Participants 
with incomplete data for key variables (total and HDL cholesterol, systolic BP, 
smoking status) were unable to be included in analyses. The overall mean risk at 10 
years, and level of risk (high, intermediate, low) based on thresholds determined by 
National Cholesterol Education Program221, were calculated. 
 
5.9.5 Factors associated with abnormal glucose regulation 
 
Logistic regression was used to assess the association between key biomedical and 
anthropometric characteristics and the outcome – abnormal glucose regulation. 
Odds Ratios (OR) and 95% CIs were calculated.  
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5.9.6 Validation of Leicestershire self-assessment risk score 
 
Our initial analysis plan was to update the Leicester Self-Assessment risk score,222 
described in Chapter 1 (see Section 1.6.5), for use in an ID population. This may 
have included adding or removing risk factors and updating the relative weighting 
given to risk factors. However, given the low prevalence of IGR/T2DM we found in 
our screening study (see Section 6.4), this was not considered feasible. There are no 
formal sample size requirements for developing risk scores, although it has been 
suggested that data sets used to develop risk scores should contain between 10-20 
events for each risk factor being assessed.223, 224 Therefore, our data set would be 
very underpowered to develop a risk score.  
 
Hence, it was decided that instead of updating the original Leicester Self-
Assessment risk score, we would alternatively assess the risk score’s performance 
to detect undiagnosed IGR/T2DM. Although this validation would also be 
underpowered (studies suggest that external validation data sets should have at 
least 100 events and 100 non-events),225 this analysis should provide some 
preliminary results to suggest if the score is sensitive and specific in our cohort with 
ID. 
 
The Leicester Self-Assessment risk score contains seven risk factors (age, sex, 
ethnicity, family history of diabetes, waist circumference, BMI and high BP).222 To 
maximise the number of people included in the analysis, the data were analysed in 
two ways: (i) complete case basis (only including those with all seven risk factors 
recorded and the outcome); and (ii) imputing missing data for family history of 
diabetes and high BP. For both a family history of diabetes and high BP, the imputed 
data set assumed a negative response if these items were missing. In both data sets 
the sensitivity, specificity, positive predictive value, and negative predictive value 
were calculated for a cut point of greater than or equal to 16 points. This is the cut 
point used in the general population for invitation to screening.222 
 
All analysis was conducted using Stata version 14 (StataCorp.), statistical 
significance related to p<0.05 and 95% CIs are presented throughout. 
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5.10 Establish data linkage to Hospital Episode Statistics and the 
Office for National Statistics 
 
An additional optional consent item that participants were approached about at their 
initial screening appointment (Section 5.6.1) included consent for follow-up for health 
issues in the longer term.  
 
5.11 Genetic markers 
 
A supplementary component of work package 1 involved collecting blood samples 
for future genetic studies in individuals who had provided consent (optional). For this, 
an extra whole blood sample was taken and stored at -80 degrees centigrade. These 
samples will be analysed in a batch at the end of the study. Future work will involve 
extracting DNA and testing biologically plausible interactions between genetic 
markers and T2DM to determine T2DM susceptibility. The analysis of genetic 
markers does not form part of the work described in this report. 
 
5.12 Concluding remarks 
This chapter has described the methods for the screening component of the STOP 
Diabetes research programme. The following chapter (Chapter 6) presents the 
results of the screening study.  
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CHAPTER 6.   SCREENING PROGRAMME: RESULTS 
 
 
6.1 Overview 
 
This chapter reports the results of the diabetes screening programme undertaken for 
work package 1. The methods for the screening study were reported in the previous 
chapter (see Chapter 5). An additional physical activity sub-study, which was 
conducted alongside the screening, is described in Chapter 7. 
 
6.2 Feasibility of conducting a diabetes screening programme in 
adults with intellectual disability 
 
6.2.1 Participant recruitment 
 
6.2.1.1 Initial approach 
 
Participants were recruited to the STOP Diabetes screening study between February 
2013 and September 2015. In total, 3201 adults with ID were invited to take part via 
the four different routes (see Figure 16).  
 
Fifty one percent (n=73) of all general practices in Leicester city, Leicestershire and 
Rutland (with adults with ID on their practice list) agreed to be involved with the 
study. Subsequently, 1736 potentially eligible people were identified and sent an 
invitation letter by their practice (median n=19, range 3 to 116). People invited via 
this route accounted for the majority of study invitations (54%).   
 
For practices refusing, 1595 people were identified for possible approach via the 
Leicestershire Learning Disability Register. Of these, contact details for 418 people 
(who had previously agreed to be contacted for research purposes) were passed 
directly to the research team to invite (13% of the overall study total). A further 864 
(27%) were invited directly by the principal investigator in LPT. 
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A much smaller proportion of people, were invited via specialist ID psychiatric 
service clinics or after making direct contact with the research team, 2% (n=52) and 
4% (n=131) respectively.  
 
6.2.1.2 Full stage invitation 
 
From the initial invitation, approximately 30% of people refused, 29% were classed 
as non-responders, and 40% expressed an interest to participate in the study (Figure 
17). Following a preliminary assessment of volunteers’ decision-making capacity, 
1209 individuals (38% of those initially invited) were then provided with full study 
information (postal invitation or a face-to-face visit). Subsequently, 984 (31%) 
proceeded to the screening stage. 
 
For people who refused (or agreed) at the initial or full invitation stages, details 
relating to the method of recruitment and reasons for refusal, are presented in Table 
16.  
 
 104 
 
 
 
Figure 16: Invitation flow chart 
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Figure 17: Flow chart of recruitment 
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Table 16: Responses according to recruitment method at initial and full 
invitation stage 
 Initial invitation 
(or chasing  
non-responders) 
Full invitation stage 
(or capacity 1 or 2) 
 Refuse Agree Refuse Agree 
Total number n =918 n=1259 n = 233 n=984 
Male, % 53% a 58% 62% a 58% 
Age mean, years - 43 40 a 44 
Where reside, %            Leicester City  40% a 41% 48% a 40% 
Recruitment method                       GP 50% 47% 67% 41% 
LD Register 33% 18% 12% 19% 
Previous consent to research 15% 19% 17% 20% 
Direct invite 1% 12% 2% 14% 
Psychiatrist clinic 1% 5% 3% 6% 
Refusal/acceptance method    Reply slip 28% 28% 24% 28% 
Telephone call 14% 20% 21% 20% 
Chasing person via tel 55% 33% 55% 28% 
GP notified team 2% 0% 0% 0% 
In person 1% 18% 1% 24% 
Via email 0% 1% 0% 1% 
Reason for refusing           Not Known 77% - 72% - 
Behaviour Issues 7% - 6% - 
Carer would not agree consent 7% - 5% - 
Health issues 3% - 4% - 
Recent Health Check 3% - 6% - 
Too busy 2% - 2% - 
Other 1% - 6% - 
a estimates provided were appropriate for refusals; percentages rounded so may not add up to 100% 
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6.2.3 Screening – consent and data collection  
 
At consent, 930 people (29% of those originally approached) agreed to participate 
and were recruited into the screening study; 54 people either refused (n=19) or were 
ineligible (n=35), see Figure 17. Thirty eight percent of participants (n=350) were 
able to consent for themselves; the other participants required a nominated (39%) or 
personal (23%) consultee. 
 
The availability of data for the key screening outcomes is presented in Table 17. Full 
details regarding the availability of data for all study variables are reported in 
Appendix 18 (Table 65). Anthropometric measures and BP were obtained for most 
participants, approximately 86% and 89% respectively. In the majority of cases, the 
documented reason for not obtaining anthropometric measures was physical or 
behavioural difficulties; for BP, the main reason was participant refusal. 
 
A high proportion of participants agreed to attend for a blood appointment (n=825), 
subsequently 700 (75% of those recruited) proceeded to have a blood test, and 
bloods to allow screening were successfully obtained for 648 (70%). For a few 
additional participants, where a blood test was refused or a sample not obtained, 
recent results were available from their medical records (HbA1c n=27; for other tests 
the amount varies), see Figure 17 and Table 17. For a further five participants, 
HbA1c results were not included due to potential unreliability in assessing diabetes 
status (n=4, due to poor kidney function; n=1, possible Hb variant). Therefore, we 
were able to assess diabetes status for a total of 675 participants. 
  
Validated questionnaires which were administered via interview, were successfully 
completed for a large number of participants (EQ-5D ~94%; GDS or carer 
supplement ~85%). Carer completion of questionnaires outside of the appointment 
(for the ~80% of participants who had an identified carer) was less successful; 
approximately 45% of carers completed the ABC and/or PAS-ADD.  
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Table 17: Data availability for key screening outcomes 
Screening outcomes Outcome measured 
n (%) 
 
Anthropometric                       Height 800 (86.0)  
Weight 799 (86.0)  
Body mass index 782 (84.1)  
Waist circumference 796 (85.6)  
Hip circumference 789 (84.8)  
Blood pressure        Diastolic/Systolic 826 (88.8)  
Blood tests         Agreed to blood test 700 (75%)  
Fasted for test – yes 491 (70%) 
 
Bloods obtained 648 (70%)  
 
Blood results available 
 
Taken for study 
Obtained from 
medical records 
HbA1c  648 (69.7);  27 (2.9) 
Plasma glucose – fasting 417 (44.8); 8 
- non-fasting 223 (24.0); 16 
Total cholesterol 614 (66.0) 39 
HDL cholesterol 615 (66.1) 29 
LDL cholesterol 605 (65.1) 26 
Triglycerides*  404 (43.4) 3 
Diabetes status assessed  
Normal, High risk, Abnormal 
 
675 (72.6) 
 
Validated questionnaires          
EQ-5D score 872 (93.8)  
EQ-5D VAS scale 877 (94.3)  
Glasgow Depression Scale: 
Volunteers with capacity  
 
317 (34.4) 
 
Carer Supplement    464 (50.2)  
Aberrant Behaviour Checklist 341 (36.7)  
PAS-ADD Checklist – Section 2 325 (34.9)  
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6.3 Characteristics of the screened cohort 
 
Key characteristics for the study population are presented in Table 18, Table 19, 
Table 20 and Table 21. Full details for all screening variables are reported in 
Appendix 18 (Table 65). 
 
6.3.1 Demographic characteristics 
The mean age of those screened was 43.3 years (SD 14.2), 58% were male and the 
majority were of white ethnicity (80%), see Table 18.  
 
Most participants lived either with family (36%) or in a residential/nursing home 
(38%), with 6% living alone. A high proportion required 24 hour support (71%) and 
only 7% reported being independent. 
 
The majority of individuals were able to access the community to undertake regular 
daytime activities. Common activities included attending college (18%), voluntary 
work (16%) or involvement in service user/advocacy meetings (13%). Around half 
the participants attended day opportunities/day placements. Only a small number of 
people were in regular paid employment (8%).  
 
6.3.2 Anthropometric and bio-medical measures 
For those screened, the mean waist size was 100.4 cm (SD 16.5), weight 76.4 kg 
(SD 20.8) and BMI 28.7 kg/m2 (SD 7.1), see Table 19. According to their BMI 
category, 31% of participants were classed as overweight and 37% obese. Mean 
values for systolic and diastolic BP were 121.4 mmHg (SD 16.9) and 78.2 (SD 11.1), 
respectively.  
 
For participants where blood results were available, the mean HbA1c was 35.0 (SD 
5.1) mmol/mol (5.3%; SD 1.5), fasting plasma glucose 4.7 mmol/l (SD 0.7) and non-
fasting 5.3 mmol/l (SD 1.5). For lipids, mean total cholesterol was 4.9 mmol/l (SD 
1.0), HDL cholesterol 1.3 mmol/l (SD 0.4), LDL cholesterol 2.9 mmol/l (SD 0.9) and 
triglycerides 1.4 mmol/l (SD 0.9).  
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6.3.3 Current medication and medical history 
Where severity of ID was available (n = 816, 88%), similar proportions of participants 
were classified as mild, moderate or severe (~30% each) and 4% as profound ID, 
see Table 20. Most participants had no confirmed diagnosis or identified cause of 
their ID (~70%); where it was known, the most common causes were Down’s 
syndrome (n=133, 14%) and cerebral palsy (n=58, 6%). 
 
The overall prevalence of existing cardiovascular disease was 2% (n=19).  A history 
of stroke was reported for 12 (1.3%) people, coronary heart disease for 6 (0.6%), 
and one person had a history of both conditions.  
 
Congenital heart disease (2%) and other heart problems (2%) were less frequently 
reported. 
 
Seventy-four participants (8%) had a history of high cholesterol and/or were 
prescribed a lipid lowering medication, 85 (9%) had a history of previously diagnosed 
hypertension and/or were prescribed an anti-hypertensive, and 36 (4%) were 
prescribed an anti-thrombotic.  A minority of participants were either current smokers 
(8%) or ex-smokers (4%).   
 
Where known, approximately one third of participants had a first degree family 
history of diabetes.  Only one participant reported a previous diagnosis of pre-
diabetes and one of polycystic ovary syndrome. Nine percent were currently 
prescribed a steroid medication (the majority were inhaled).  
 
Overall, the most commonly reported diagnosed physical health problems were 
epilepsy 262 (28%), hypothyroidism 93 (10%) and chronic breathing problems 88 
(9%). Thirteen percent of participants had no significant medical history and 19% 
were currently not prescribed any medication. 
 
For mental health related problems, 152 participants (16%) had a history of a mood 
spectrum disorder (ICD-10 codes F30-F39), 35 (4%) a psychotic spectrum disorder 
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(ICD-10 codes F20-F29) and 52 (6%) had a history of both; 143 people (15%) had a 
neurotic, stress-related or somatoform disorders (ICD-10 codes F40-F48). 
Additionally, 28% of participants were prescribed antipsychotic medication and 32% 
depression or anxiety related medication. Other frequently reported problems 
included autistic spectrum disorders (18%) and a recognised behavioural problem 
(14%).  
 
When co-PRUELGLWLHV  GLDJQRVHG KHDOWK SUREOHPV were considered, 121 (13%) 
participants had co-occurring physical health problems, 182 (20%) co-occurring 
mental health problems, and 286 (31%) multiple physical and/or mental health 
problems. 
 
6.3.4 Lifestyle and well being 
Eighty-five percent of those screened were able to walk independently (without 
help/support of another person) but including 6% who required a walking aid, see 
Table 21. Data reported directly by participants and/or carers indicated that most 
people did at least “some” walking on a typical day but only 25% achieved “a lot” of 
walking. Additionally, around half of the participants reported spending “a lot” or 
“most/all” of the day sitting.  
 
Sport/exercise or other physical activities that individuals reported undertaking in a 
typical week included dance (25%), swimming (20%) or walking (21%). Around half 
the participants reported doing housework (such as dusting/hovering) and ~20% 
gardening. A small number of people (7%) did regular chair based exercise. 
 
Problems with eating and drinking were reported for some people, 24% had 
difficulties in chewing or swallowing and 13% needed help to feed themselves (<1% 
were tube fed). For food shopping and preparation, overall, ~35% of participants did 
their own food shopping (either independently or with some support), and a similar 
number were able to prepare at least simple hot and cold food (with or without 
supervision). Reported daily intake of fruit, vegetables or salad indicated that only 
around 30% of participants were eating the recommended five or more portions a 
day. 
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Where questionnaire data were available, the proportion of participants identified 
with possible depression (using a cut point of 13) by the GDS or GDS carer 
supplement was 22% and 16%, respectively.217  For health related quality of life, the 
mean EQ-5D descriptive score was 0.8 (SD 0.3) and for the visual analogue scale 
was 78.1 (SD 19.4). The mean scores for the five problem behaviour sub-scales 
measured by ABC (for participants with carers) were ~4 for irritability, lethargy, and 
hyperactivity, and ~1 for stereotyped behaviour and inappropriate speech. The 
prevalence of mental health problems for organic, affective/neurotic and psychotic 
disorders (as measured by PAS-AD checklist) was 6%, 9% and 5% respectively.  
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Table 18: Key demographic characteristics of cohort screened 
Demographic N      Mean (± SD)  
Unless stated otherwise 
Age (years) 930 43.3 (± 14.2) 
Sex, Male, n (%) 930 537 (57.7) 
Ethnicity, n (%) 930  
White  748 (80.4) 
Asian  147 (15.8) 
Black  14 (1.5) 
Mixed  13 (1.4) 
Other  8 (0.9) 
Residential circumstances, n (%) 929  
Alone  51 (5.5) 
Lives with family  338 (36.4) 
Shared house or supported living  157 (16.9) 
Shared care  16 (1.7) 
Residential home or nursing home  350 (37.7) 
Other   17 (1.8) 
Level of Support, n (%) 929  
Independent  69 (7.4) 
Some Support  205 (22.1) 
24 hour support  655 (70.5) 
Current status a, n (%)   
Paid employment 928 71 (7.7) 
Voluntary work 927 152 (16.4) 
College 
Day opportunities or private day centre 
925 
928 
170 (18.4) 
431 (46.4) 
Shared lives (day placement) 928 19 (2.1) 
Attending meetings 926 122 (13.2) 
Other 924 385 (41.7) 
 a % will not add to 100 as participants can positively answer >1 category  
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Table 19: Key bio-medical measures of cohort screened 
Biomedical Measurements 
 
N 
Total (from medical record) 
Mean (± SD) 
Unless stated otherwise 
Bloods   
Plasma glucose   
    Fasting (mmol/l) 425 (8) 4.7 (± 0.7) 
    Non-fasting (mmol/l) 239 (16) 5.3  (± 1.5) 
   Glycated haemoglobin 675 (27)  
    HbA1c (mmol/mol)  35.0 (± 5.1) 
    Derived HbA1c (%)   5.4 (± 0.5) 
   
Lipids   
    Total cholesterol (mmol/l) 653 4.9 (± 1.0) 
    HDL Cholesterol (mmol/l) 644 1.3 (± 0.4) 
    LDL Cholesterol (mmol/l) 631 2.9 (± 0.9) 
    Triglycerides (mmol/l) a 407 1.4 (± 0.9) 
Anthropometric Measurements   
Height (m) 800 1.6 (± 0.1) 
   Weight ( kg) 799 76.4 (± 20.7) 
   BMI (kg/m2) 782 28.7 (± 7.1) 
BMI Categories, n (%)   
     Underweight   30 (3.8) 
     Normal   223 (28.5) 
     Overweight   241 (30.8) 
     Obese   288 (36.8) 
   
Waist circumference (cm) 796 100.4 (± 16.5) 
Blood Pressure Measurements 826  
Systolic (mmHg)  121.4 (± 16.9) 
Diastolic (mmHg)  78.2 (± 11.1) 
 a only if fasted.     
BMI, body mass index; HbA1c, glycated haemoglobin; HDL, high density lipoprotein; LDL, low density lipoprotein.  
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Table 20: Key medical history and current medication of cohort screened 
Medical history and current medication n (%) 
Severity of ID, n=865  
Not known 49 (5.7) 
Known 816 (84.3) 
Mild 260 (30.1) 
Moderate 244 (28.2) 
Severe 279 (32.3) 
Profound 33 (3.8) 
Cause of ID, n=866  
Not known 581 (67.1) 
Known 285 (32.9) 
Downs syndrome 133 (15.4) 
Fragile X 8 (0.9) 
Cerebral palsy 58 (6.7) 
Hydrocephalus 6 (0.7) 
Phenylketonuria 5 (0.6) 
Prader – Willi syndrome 4 (0.5) 
Medical or Health problems, n=929  
None 117 (12.6) 
Yes 812 (87.4) 
Physical Health 
 
Stroke 13 (1.4) 
Peripheral arterial disease 0 
Coronary heart disease 7 (0.8) 
Congenital heart disease 19 (2.1) 
Other heart problems 15 (1.6) 
High blood pressure 63 (6.8) 
High cholesterol 62 (6.7) 
Hypothyroidism 93 (10.0) 
Polycystic ovary syndrome 1 (0.1) 
Gestational diabetes 0 
Pre-diabetes 1 (0.1) 
Chronic breathing problems  88 (9.5) 
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Sleep apnoea 3 (0.3) 
Epilepsy 262 (28.2) 
Mental Health  
 
Dementia 18 (1.9) 
Schizophrenia, schizotypal and delusional      35 (3.8) 
Mood (affective) disorders 152 (16.4) 
Neurotic, stress-related and somatoform  143 (15.4) 
Personality disorders 13 (1.4) 
Drug / alcohol problems 0 
Attention Deficit Hyperactivity Disorder  8 (0.9) 
Intellectual Disability related 
 
Autistic spectrum disorders 165 (17.8) 
Behavioural problems 128 (13.8) 
Current medication, n (%); n=928  
None 172 (18.5) 
Yes 756 (81.5) 
Anti-psychotic 240 (25.9) 
Depression / Anxiety/  OCD or related 258 (27.8) 
For ADHD 4 (0.4) 
Anti-epileptic 311 (33.5) 
Anti-thrombotic 36 (3.9) 
Lipid lowering 74 (8.0) 
Statin 72 (7.8) 
Fibrate 1 (0.1) 
Statin and Fibrate  1 (0.1) 
Anti-hypertensive 85 (9.2) 
Thyroid medication 93 (10.0) 
Steroids  80 (8.6) 
Oral 5 (0.5) 
Inhaled 62 (6.7) 
Topical 9 (1.0) 
> 1 type of steroid 3 (0.3) 
Not known 1 (0.1) 
Anti-obesity 1 (0.1) 
Other 571 (61.5) 
Smoking status, n=929 
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Current 76 (8.2) 
Ex 38 (4.1) 
Never 815 (87.7) 
Family history of diabetes, n=592 180 (30.4) 
ADHD, Attention deficit hyperactivity disorder ; OCD, Obsessive compulsive disorder 
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Table 21: Key lifestyle and well-being characteristics of cohort screened 
Lifestyle and well being n (%) 
Physical Activity / Exercise 
 
Able to walk, n=927  
No 57 (6.2) 
Yes (with or without walking stick, aid) 787 (84.9) 
Yes, with assistance from person(s) 83 (9.0) 
  
Amount of walking per day, n=927  
None 74 (8.0) 
A short distance 259 (27.9) 
Some 359 (38.7) 
Lots 235 (25.4) 
 
 
Amount of physical activity per week, n=928  
None 184 (19.8) 
1-2 times 360 (38.8) 
3-4 times 259 (27.9) 
5 or more 125 (13.5) 
  
Time spent sitting per day, n=928  
All / most 180 (19.4) 
A lot 252 (27.2) 
Sometimes 475 (51.2) 
Never 21 (2.3) 
Nutrition and diet 
 
Problems relating to eating and drinking, n (%)  
Difficulties with chewing or swallowing, n=929 227 (24.4) 
Needs help or assistance to feed self, n=926 118 (12.7) 
                 Use specialist equipment 95 (10.3) 
                Fed via an nasogastric tube or gastrostomy 7 (0.8) 
  
Food shopping, n=922  
Independently 89 (9.7) 
With support 230 (25.0) 
Relative or carer 297 (32.2) 
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Purchased by residential home 306 (33.2) 
  
Preparing meals, n=921  
Relative or carer 561 (60.9) 
With supervision 117 (12.7) 
Without supervision 145 (15.7) 
Without supervision can prepare variety of meals 98 (10.6) 
  
Daily portions of fruit and vegetables, n=920  
None     33 (3.6) 
1 a day 57 (6.2) 
2 a day 130 (14.1) 
3 a day 230 (25.0) 
4 a day 199 (21.6) 
5 a day 213 (23.2) 
6 a day 36 (3.9) 
7 or more 22 (2.4) 
  
 120 
 
6.3.5 Comparison with the Leicestershire Learning Disability Register 
 
Participant demographic characteristics from this study were compared to adults with 
ID on the Leicester Learning Disability Register. Comparison of age, gender and 
ethnicity suggests that the STOP Diabetes cohort is a representative sample of the 
ID population known to services within the Leicester, Leicestershire and Rutland 
area, see Table 22. 
 
Table 22: Characteristics of cohort screened compared to Leicestershire 
Learning Disability Register  
 
Characteristics STOP Diabetes  
(n=930) 
 
n(%) 
Leicestershire Learning 
Disability Register <80 
years  (n=3867) 
n(%) 
Age (years) 
<30 
30-39 
40-49 
50-59 
60-69 
70-79 
 
207 (22.3) 
195 (21.0) 
211 (22.7) 
185 (19.9) 
107 (11.5) 
25 (2.7)a 
 
1012 (26.2) 
856 (22.1) 
776 (20.1) 
659 (17.0) 
416 (10.8) 
148 (3.8) 
Male  537 (57.7) 2222 (57.5) 
Ethnicity 
White 
S Asian 
Black/Mixed 
Other 
 
748 (80.4) 
147 (15.8) 
27 (2.9)b 
8 (0.9) 
Of n=3571 known 
2893 (81.0) 
553 (15.5) 
80 (2.2) 
45 (1.3) 
STOP Diabetes cohort: aage screened 18-74 years; bethnicity data collected separately 
(Black n=14, 1.5%; Mixed n=13, 1.4%) 
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6.4 Prevalence of type 2 diabetes and impaired glucose regulation 
 
Outcome data to establish prevalence of IGR/T2DM were available for 675 
participants. Screening results indicated that, overall, 44 (6.5%) participants had 
abnormal glucose regulation, prevalence 0.07 (95% CI 0.05, 0.08); 9 participants 
(1.3%) were found to have undiagnosed T2DM, a prevalence of 0.01 (95% CI 0.005, 
0.02); and 35 (5.2%) IGR, a prevalence of 0.05 (95% CI 0.04, 0.07), see Table 23. 
 
Table 23: Prevalence of T2DM, IGR and abnormal glucose regulation 
 
 N (%) Prevalence 95% CI 
Outcome:    
Normal glucose 631 (93.5) 0.93 (0.92, 0.95) 
IGR 35 (5.2) 0.05 (0.04, 0.07) 
T2DM 9 (1.3) 0.01 (0.01, 0.02) 
Abnormal glucose  44 (6.5) 0.07 (0.05, 0.08) 
 
 
6.5 Factors associated with abnormal glucose regulation 
Table 24 shows the association of anthropometric and biomedical characteristics 
with having screen-detected abnormal glucose regulation. Participants of non-white 
ethnicity were almost four times more likely to have abnormal glucose levels 
compared to white European participants (OR 3.93 (95% 2.10 to 7.33)); those with a 
first degree family history of diabetes were over three times more likely (OR 3.35 
(95% 1.64, 6.86)). In addition, abnormal glucose tolerance was associated with 
increasing weight, waist circumference, hip circumference, BMI, diastolic BP and 
triglycerides, and decreasing HDL cholesterol.  
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Table 24: Comparison of anthropometric and biomedical characteristics of 
those with normal and abnormal glucose regulation  
 
 Normal 
Glucose 
(n = 631) 
Abnormal 
Glucose 
(n=44) 
OR 
(95% CI) 
P value 
Age, years 43.0 (±14.3) 45.4 (±13.5) 1.01 (0.99, 1.03) 0.27 
Male 377 (59.8) 28 (63.6) 1.18 (0.63, 2.22) 0.61 
Non-white ethnicity 119 (18.9) 21 (47.7) 3.93 (2.10, 7.33) <0.0001 
Weight, kg 76.6 (±20.2) 91.7 (±27.3) 1.03 (1.01, 1.04) <0.0001 
Waist circumference, cm 100.1 (±16.2) 114.0 (±19.0) 1.04 (1.03, 1.07) <0.0001 
Hip circumference, cm 107.4 (±13.5) 115.6 (±19.1) 1.03 (1.01, 1.06) 0.001 
Body mass index, kg/m2 28.6 (±6.9) 34.1 (±10.2) 1.08 (1.04, 1.13) <0.0001 
Current smoker 56 (8.9) 6 (13.6) 1.62 (0.66, 4.00) 0.30 
FH of diabetes 132 (29.9) 20 (58.8) 3.35 (1.64, 6.86) 0.001 
Systolic BP, mmHg 121.8 (±17.3) 126.5 (±14.4) 1.01 (1.00, 1.03) 0.09 
Diastolic BP, mmHg 78.0 (±11.2) 83.7 (±10.0) 1.04 (1.02, 1.07) 0.002 
Total cholesterol, mmol/l 4.9 (±1.0) 4.7 (±0.9) 0.78 (0.56, 1.10) 0.15 
HDL cholesterol, mmol/l 1.4 (±0.4) 1.2 (±0.3) 0.14 (0.05, 0.43) 0.001 
LDL cholesterol, mmol/l 2.9 (±0.9) 2.7 ±(0.8) 0.71 (0.48, 1.07) 0.10 
Triglycerides, mmol/l 1.4 (±0.9) 1.9 (±1.0) 1.53 (1.11, 2.11) 0.01 
Data given as mean (±SD) for continuous outcomes and n (%) for categorical.  
BP, blood pressure; FH, family history; HDL, high density lipoprotein; LDL, low density lipoprotein. 
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6.7 Validation of the Leicester Self-Assessment risk score  
 
Overall 365 (54%) of the 675 participants with the outcome obtained had complete 
data for the seven risk factors assessed by the Leicester Self-Assessment risk score. 
This was increased to 595 (88.1%) when imputing family history and high BP (Table 
25). Similar percentages of participants fall into the four risk categories based on the 
complete case and imputed data. In the complete case data, 43.1% would be 
referred for screening based on their risk score (>=16 points) and 41.4% based on 
the imputed data.  
 
Table 25: Completeness of the Leicester Self-Assessment risk score variables 
 
Variables All 
(n=675) 
Complete Case 
(n=365) 
Imputed 
(n=675) 
Age (years)    
49 or younger 445 (65.9) 263 (72.1) 445 (65.9) 
50-59 136 (20.2) 69 (18.9) 136 (20.2) 
60-69 75 (11.1) 30 (8.2) 75 (11.1) 
70 or older 19 (2.8) 3 (0.8) 19 (2.8) 
Sex    
Male 405 (60.0) 207 (56.7) 405 (60.0) 
Female 270 (40.0) 158 (43.3) 270 (40.0) 
Ethnicity    
White European 535 (79.3) 278 (76.2) 535 (79.3) 
Other ethnic group 140 (20.7) 87 (23.8) 140 (20.7) 
Family History of T2DM    
No 324 (48.0) 248 (68.0) 523 (77.5) 
Yes 152 (22.5) 117 (32.1) 152 (22.5) 
Unable to assess 199 (29.5) 0 0 
Waist Circumference    
Less than 90 cm 153 (22.7) 90 (24.7) 153 (22.7) 
90-99.9cm 153 (22.7) 92 (25.2) 153 (22.7) 
100-109.9cm 153 (22.7) 83 (22.7) 153 (22.7) 
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110cm or above 157 (23.3) 101 (27.4) 157 (23.3) 
Unable to assess 59 (8.7) 0 59 (8.7) 
Body mass index    
Less than 25 188 (27.9) 111 (30.4) 188 (27.9) 
25-29 182 (27.0) 116 (31.8) 182 (27.0) 
30-34 123 (18.2) 71 (19.5) 123 (18.2) 
35 or above 109 (16.2) 67 (18.4) 109 (16.2) 
Unable to assess 73 (10.8) 0 73 (10.8) 
Antihypertensive medication     
No 525 (77.8) 325 (89.0) 609 (90.2) 
Yes 66 (9.8) 40 (11.0) 66 (9.8) 
Unable to assess 84 (12.4) 0 0 
Total of complete data for  
Leicester Self-Assessment risk score 365 365 595 
Final score    
Low (0-6) - 63 (17.3) 112 (18.8) 
Medium (7-15) - 145 (39.7) 237 (39.8) 
High (16-24) - 121 (33.2) 193 (32.4) 
Very high (25-47) - 36 (9.9) 53 (8.9) 
Data given as n (%) 
T2DM, type 2 diabetes; 
 
 
Table 26 presents the validation of the Leicester Self-Assessment risk score in this 
ID population. The complete case and imputed data have similar results, therefore, 
only the complete case data is interpreted here. Of the 22 participants with abnormal 
glucose regulation and full risk score data, 18 are correctly classified as high or very 
high risk by the risk score. This gives a sensitivity of 81.8%, given the low number of 
events the 95% CI around this estimate is wide 59.7%, 94.8%. Of the 344 
participants with normal glucose regulation, 204 are correctly identified as low or 
medium risk and therefore would not be referred on for further screening. One 
hundred and forty participants would be referred for unnecessary screening, i.e. of 
those with a high or very high risk score only 11.4% have undiagnosed IGR/T2DM. 
The findings suggest that the score may be useful for ruling out disease; 98.1% of 
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those with a low or medium risk score are correctly identified and do not have 
undiagnosed IGR or T2DM.  
 
Table 26: Sensitivity, specificity, PPV, NPV with 95% confidence intervals for 
the cut-RIISRLQWRQWKHLeicester Self-Assessment risk score for predicting 
IGR/T2DM  
 
 
 
  
 Sensitivity Specificity PPV NPV  
Complete 
Case Analysis  
(n=365) 
81.8%  
(59.7%, 94.8%) 
59.5%  
(54.1%, 64.7%) 
11.5%  
(6.9%, 17.5%) 
98.1%  
(95.1%, 99.5%) 
Imputed  
Analysis 
(n=595) 
83.3%  
(67.2%, 93.6%) 
61.4%  
(57.2%, 65.4%) 
12.2%  
(8.4%, 16.9%) 
98.3%  
(96.3%, 99.4%) 
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6.8 Cardiovascular risk 
 
Cardiovascular risk, based on Framingham211, 212 or ETHRISK220 for participants of 
South Asian ethnicity, was able to be calculated for 376 (40.4%) participants. The 
mean risk for CHD in 10 years was 6.1% (SD 5.4%) and for CVD 2.5% (SD 4.4%). 
Most participants were at low future risk for both CHD (81.9%) and CVD (95.2%), 
see Table 27. However, 18% of participants were of intermediate or high risk of 
developing CHD in the next 10 years. 
 
Table 27: Ten year risk of CVD event - Framingham risk score 
 
Risk CHD CVD 
Low (< 10%) 308 (81.9) 358 (95.2) 
Intermediate (10-20%) 59 (15.7) 13 (3.5) 
High (>20%) 9 (2.4) 5 (1.3) 
 
 
6.9 Establish data linkage to Hospital Episode Statistics and the 
Office for National Statistics 
 
Of the 930 people recruited to the main study, 883 participants (95%) gave additional 
consent for the research team to follow-up their health in the longer term. Preliminary 
work to establish data linkage is currently being conducted. 
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6.11 Discussion 
 
6.11.1 Summary of main findings 
 
Utilising a variety of approaches to identify/invite potential volunteers, 930 adults with 
ID (29% of those approached) participated in the screening programme; 38% were 
able to consent for themselves, other participants required a consultee. 
Anthropometric measures (~86%) and BP (89%) were obtained for most participants. 
A high proportion of participants agreed to attend for a blood test and subsequently, 
prevalence of T2DM/IGR was assessed for 675 participants (73%). 
 
The mean age of participants was 43.3 years, 58% were male and the majority of 
white ethnicity (80%). Most lived either with family (36%) or in a residential/nursing 
home (38%); a high proportion required 24 hour support (71%). Most participants 
were either overweight or obese; 2% had a history of existing CVD. 
 
Screening results indicated the overall prevalence of undiagnosed T2DM was 1.3% 
(95% CI 0.5 to 2%) and IGR 5.2% (95% CI 4% to 7%). Participants of non-white 
ethnicity were almost four times more likely to have abnormal glucose levels 
compared to white European participants; those with a first degree family history of 
diabetes were over three times more likely. 
  
6.11.2 Comparison with previous evidence 
 
The prevalence of previously undiagnosed T2DM detected in the screening 
programme is much lower than previously reported.90 Combined evidence from other 
studies, as presented in the meta-analysis in Chapter 2, suggests a prevalence rate 
of 8% for T2DM in adults with ID. Data to enable comparison of rates for T2DM in 
UK ID populations is scarce (a suggested 85-90% of diabetes is T2DM20). Current 
estimated prevalence of diabetes (type not specified) in England, based on 
combined data reported by partnership boards, is 6.8% (range 6.2-8.4%) for people 
with ID of any age.51 Based on current data supplied by 40 (55%) of the general 
practices who took part in the STOP diabetes study, the suggested prevalence of 
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diagnosed diabetes (type not specified) locally is 9.5% (n=148 of 1553 adults 18-74 
years with ID). 
 
The estimates above are based on previously diagnosed diabetes. Our study aimed 
to screen adults with ID to identify undiagnosed T2DM. The rates suggested by data 
supplied by local general practices, alongside the higher recorded uptake of health 
checks locally (57-66% across the three CCGs)226 compared to the national average 
(44%),55 suggests at a local level the lower rate may simply reflect a successful 
annual health checks programme. In the general population, estimated prevalence of 
diabetes rises from 6.2% to 8.0% when including undiagnosed cases.18 However, it 
is acknowledged that the proportion of adults with ID who currently have bloods 
checked, including for diabetes, as part of their annual health check is unclear. 
 
6.11.3 Strengths and limitations 
 
To our knowledge, this is the first diabetes screening study conducted in adults aged 
18-74 years with mild to severe/profound ID. The successful integration of a multi-
disciplinary team, consisting of experienced researchers and ID healthcare 
professionals, enabled the successful development and conduct of the STOP 
Diabetes screening programme. This multi-disciplinary approach allowed for sharing 
of knowledge and best practice, and was complimented by service user involvement, 
particularly in the early stages of developing and trialling study 
procedures/processes. 
   
The screening programme developed utilised robust methods. All data were 
collected by staff who had undertaken study specific training and following standard 
operating procedures. Minimal exclusion criteria were applied for including people in 
the study, and reasonable adjustments to facilitate inclusion, such as staged 
invitation, easy read documents, flexible appointments, and carer involvement, 
maximised participation.  This ensured as many people as possible participated 
rather than being arbitrarily excluded. Additionally, we applied a staged approach to 
invitation and made efforts to contact/chase all people where possible.  
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It is acknowledged that we were unable to establish any contact with approximately 
30% of people, who were non-responders. We therefore do not know if they are 
different in any way to people included in the screening programme; evidence 
suggests that people with mild ID may be at increased risk due to unhealthier 
lifestyles but less likely to access services.11 However, similarities in the 
demographic characteristics (age, gender ethnicity) of participants in this study, 
when compared with adults with ID on the Leicester Learning Disability Register, 
suggests that the STOP Diabetes cohort is a representative sample of the ID 
population known to services within the Leicester, Leicestershire and Rutland area. 
 
The validation of the Leicester Self-Assessment risk score in the ID population was 
successful despite the limited number of events and wide 95% CI. Estimates suggest 
that the Leicester Self-Assessment risk score works as well in ID populations as in 
the general population, sensitivity 81.8%. Based on this 140 participants would be 
referred for unnecessary screening. However, the tool is designed for use in a multi 
stage screening programme and we would rather send more people through the first 
stage than falsely reassure. 
 
6.11.4  Implications for clinical practice and future research 
 
The screening uptake of 29% of those approached was relatively low but favourable 
when compared with two previous screening/prevention studies conducted locally in 
the general population, where 22% and 19% of those invited took part.227 These 
relatively low rates of uptake might reflect that participants were invited to screening 
as part of a research project. If rolled out in clinical practice you would expect to see 
higher rates, for example uptake to the NHS Health Checks Programme,228 which is 
not a research project, has seen uptake rates of double those reported in this and 
other research screening studies. Future research should focus on increasing uptake 
to screening in all groups. 
 
Bloods to enable diabetes screening were successfully obtained for a high proportion 
of participants. However, future research may want to consider allowing for separate 
consent for blood tests so as to not deter people at the initial recruitment stage. Very 
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few people directly expressed “the blood test” as a reason for refusal to participate in 
the screening study; but anecdotal evidence suggests this may have deterred some. 
Alternatively, a staged approach to screening, involving risk stratification as 
recommended by NICE might be considered.27 
 
Our findings suggest that the Leicester Self-Assessment risk score is statistically 
effective at identifying people with ID who are at high risk of undetected IGR/T2DM. 
However, the feasibility of using it in practice with people with ID, given the levels of 
heterogeneity within the ID population, needs to be considered. It may not be 
practical or acceptable for people with ID to calculate their own score, with or without 
added support from carers. Future research could involve developing an easy read 
version (plus a carer supplement) and additional supportive material/communication 
aids, such as digital audio/visual materials; qualitative research would be needed to 
supplement this work. Alternatively, a better way may be to integrate the risk score at 
practice level and incorporate into the Learning Disability Health Check.  
 
6.12 Concluding remarks 
 
This chapter presented the main results of the screening programme for work 
package 1. The methods and results of the physical activity sub-study are presented 
in the following chapter (see Chapter 7). 
 
 131 
 
 
CHAPTER 7.   PHYSICAL ACTIVITY SUB-STUDY 
 
7.1 Overview 
 
This chapter describes the physical activity sub-study, which was conducted 
alongside the screening component in work package 1. The main methods and 
results of the screening stage are described in Chapters 5 and 6, respectively.  
 
7.2 Aims and objectives 
 
The aim of this sub-study was to assess the feasibility of collecting physical activity 
data with the use of a waist worn accelerometer (ActiGraph), see Figure 18. 
However, given the poor uptake to this initial measurement tool, we extended our 
aim to also include the feasibility of collecting physical activity via a wrist worn device 
(GENEactiv). 
 
7.3 Methods 
 
7.3.1 Participants 
 
Participants who met the eligibility criteria, as outlined below, were asked to wear an 
accelerometer as part of the main screening component of work package 1. 
 
7.3.1.1 Inclusion criteria 
 
Inclusion criteria 
1. Consented to take part in the main screening component;  
2. Able to walk without assistance (stick or similar walking aid permissible).  
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Figure 18: Waist worn and wrist worn acclerometers 
(Waist-worn accelerometer, ActiGraph, Pensacolam FL, USA; wrist form 
accelerometer, GENEActiv, Activinsights Ltd., Cambridge, UK) 
 
7.3.2 Participant recruitment process 
 
Initial assessment of eligibility to participate in the physical activity sub-study 
commenced during the capacity assessment process (outline in Chapter 5) and was 
subsequently confirmed once consent to the main screening study had been 
obtained. Eligible participants were then approached about wearing an 
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accelerometer. For most people, this was usually at the end of their first screening 
appointment. 
 
7.3.3 Data collection 
 
Participants were asked to wear an accelerometer for seven continuous days, not 
including the appointment day. The procedure for wearing the accelerometer was 
explained to the participant and/or carer by an ID research nurse.  Participants were 
also provided with a brief accelerometer information leaflet/diary in an easy read 
format, which explained how to use the accelerometer; this diary was also used to 
log when participants had worn the accelerometer, with a page for each of the seven 
days. 
 
After wearing the accelerometer, participants were requested to bring it back to their 
next appointment. If a participant was not having another planned appointment, a 
member of the research team would contact them to arrange a convenient time for 
the accelerometer to be collected. In instances where an accelerometer was not 
returned or unsuccessfully collected, the research team made repeated attempts (at 
least 3) to try and retrieve it. 
 
Two different accelerometers were used to collect data. Initially, physical activity data 
were measured using a waist-worn accelerometer. Later, it was additionally decided 
to trial a wrist-worn accelerometer, given the poor compliance that was emerging 
with the waist worn device (see results, Section 7.4) and following discussion with 
service users (who were assisting with PPI activities). The wrist-worn accelerometer 
was anticipated to encourage greater compliance since it is waterproof and can also 
be worn when sleeping; therefore, participants could wear it continuously over the 
seven day period. 
 
Full details of the assessment of outcomes are described in Section 7.3.6. 
 
7.3.4 Outcomes 
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Physical activity levels were included as one of the secondary outcomes for the main 
screening study (see Chapter 5). Other anthropometric (BMI, waist circumference), 
demographic (ethnicity and social deprivation) and biochemical (fasting blood 
glucose and HbA1c) outcomes assessed are described in Chapter 5. 
 
7.3.5 Sample size 
 
We initially aimed to include at least 50 participants wearing the waist worn 
accelerometer. This was updated to include a comparable number with the wrist 
worn device. 
 
7.3.6 Assessment of physical activity outcomes 
 
Participants attending screening were offered the option of having their physical 
activity levels assessed by a waist-worn accelerometer (ActiGraph, Pensacolam FL, 
USA). Once we had achieved our initial aim of at least 50 individuals with data, the 
remaining cohort were offered an alternative wrist form accelerometer (GENEActiv, 
Activinsights Ltd., Cambridge, UK). Details of the two accelerometers and analytic 
methods used are presented below.  
 
7.3.6.1 Waist worn accelerometer 
 
ActiGraph waist-worn triaxle accelerometers were attached to the trunk (placed on 
the right anterior axillary line) using an elasticated belt. Participants were asked to 
wear the accelerometer during waking hours for seven days, only taking it off at night 
when going to bed, or when partaking in water-based activities such as showering or 
swimming. Participants (and carers) were shown how to re-attach the accelerometer 
after sleep, and carers were asked to provide reminders. Data were set to record at 
100Hz and analysed through a commercially available software package (KineSoft 
version 3.3.76; Kinesoft, New Brunswick, Canada; www.kinesoft.org). Data were 
converted to 60 second epochs and count based format. Time spent sedentary, in 
light-intensity physical activity and in MVPA were gained through applying commonly 
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used thresholds for adults.229 Non-wear time was classified as 60 minutes of 
continuous zero counts. 
 
7.3.6.2 Wrist worn accelerometer 
 
The GENEActiv original wrist-worn triaxle waterproof accelerometer (Activinsights 
Ltd., Cambridge, UK) was worn continuously on the participants’ non-dominant wrist 
for a minimum of seven days. Data were captured in 100 Hz and processed using 
two methods.  
 
Data analysis method 1:  raw acceleration data were converted to 60-s epochs using 
the GENEActiv Post-Processing PC Software (version 2.2, GENEActiv; Activinsights 
Ltd.). Next, the 60-s epoch data files were entered into an open source Excel macro 
(v2; Activinsights Ltd.) in order to classify activity.  Subsequently, time spent in 
sedentary, light-intensity and MVPA activities was calculated for each participant-day 
using validated cut-points.230 Sleep time was estimated using a defined algorithm 
(Activinsights Ltd) and subtracted from total sedentary time, in order to calculate time 
spent sedentary whilst awake. 
 
Data analysis method 2: Given standard definitions for physical activity categories 
are lacking for wrist worn devices, we also included an alternative approach reported 
in the literature using the Euclidian Norm Method.231 Data were proceeded in a freely 
available R-package (GGIR version 1.2-0, http:/cran.r-project.org) using previously 
described methodology to include time spent in sedentary, light-intensity physical 
activity and MVPA.231, 232 In additional, total physical activity levels were reported in 
mg, where g = gravity. 
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7.3.7 Inclusion of physical activity data 
 
Physical activity data were included from each device if there was a minimum of 8 
hours wear per day for at least 3 days. 
 
 
7.3.8 Data analysis 
 
Data are presented as mean (standard deviation). Analysis of covariance models 
were used to compare differences in levels of assessed physical activity between 
monitors, adjusted for age, sex, social deprivation and wear time.  
 
7.4 Results 
 
7.4.1 Feasibility of using accelerometers to assess physical activity in 
adults with intellectual disabilities 
 
Participants were recruited to take part in the physical activity sub-study between 
October 2013 and August 2015 (Figure 19). 
 
Overall, 203 participants were approached to wear the ActiGraph waist-worn 
accelerometer. Subsequently, 97 participants (48%) agreed to wear the ActiGraph 
and valid data ( KRXUVGD\ IRU  GD\V were obtained for 55 participants (57%).  
Reasons for attrition included 14 participants (14%) not returning their accelerometer 
and 28 participants (29%) not having enough valid days of wear for analysis. 
 
A total of 76 participants were asked to wear the GENEActiv wrist-worn 
accelerometer and 47 participants (62%) agreed. Valid data were obtained for 39 
participants (83%). Two individuals (4%) did not return their accelerometer and six 
did not have enough valid days of wear (13%). 
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(Data validity was based on a minimum of 8 hours wear per day for at least 3 days) 
Figure 19: Flow chart collection of accelerometer data 
 
 
7.4.2 Characteristics of participants in physical activity sub-study 
 
The characteristics of those who agreed to wear an accelerometer, either wrist or 
waist worn, and those with valid physical activity data stratified by accelerometer 
type are displayed in Table 28.  Characteristics were similar between those who had 
valid physical activity data and those who did not. Characteristics were also similar 
between those who had valid waist worn and wrist worn accelerometer data. Overall, 
54% of participants were male, mean age was 39.9 (SD13.0) and 85% were of white 
ethnicity. Thirteen per cent lived alone, 42% lived in supported living and 46% lived 
with family; the majority 88% had support from a carer for at least some of the time. 
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Table 28: Characteristics of participants in physical activity sub-study 
Characteristics Total agreed 
(n=144) 
Total valid 
(n=94) 
Waist agreed 
(n=97) 
Waist valid 
(n=55) 
Wrist agreed 
(n=47) 
Wrist valid 
(n=39) 
Gender, Male, n (%) 78 (54.2) 50 (53.2) 53 (54.6) 30 (54.6) 25 (53.2) 20 (51.3) 
Age (years) 39.9 (±13.0) 41.9 (±13.7) 40.8 (±13.6) 43.6 (±14.7) 38.1 (±11.8) 39.3 (±11.8) 
Ethnicity, White, n (%) 122 (84.7) 82 (87.2) 82 (84.5) 48 (87.3) 40 (85.1) 34 (87.2) 
HbA1c (%) 5.3 (±0.4) 5.3 (±0.3) 5.3 (±0.4) 5.3 (±0.3) 5.4 (±0.3) 5.4 (±0.3) 
Fasting plasma glucose (mmol/l) 4.7 (±0.5) 4.6 (±0.5) 4.8 (±0.5) 4.6 (±0.4) 4.6 (±0.5) 4.6 (±0.5) 
Waist circumference (cm) 98.9 (±17.1) 98.4 (±16.6) 98.7 (±17.6) 97.9 (±16.2) 99.4 (±16.3) 99.1 (±17.3) 
BMI (kg/m2) 28.4 (±7.5) 28.3 (±7.1) 28.1 (±7.4) 27.7 (±6.2) 29.1 (±7.7) 29.0 (±8.2) 
IMD 2015 Rank,  
Median (IQR) 
16,280 
(7859.5-24,227.5) 
16,280 
(7734-23,871) 
16,292 
(7546- 24,572) 
16,456 
(7351-24,572) 
16,086 
(8815-23,871) 
15,279 
(7734-21,525) 
Accommodation, n (%)             Alone 
                          Lives with family 
               Supported environment 
18 (12.5) 
66 (45.8) 
60 (41.8) 
10 (10.6) 
46 (48.9) 
38 (40.5) 
13 (13.4) 
44 (45.4) 
40 (41.3) 
6 (10.9) 
27 (49.1) 
22 (40.0) 
5 (10.6) 
22 (46.8) 
20 (42.5) 
4 (10.3) 
19 (48.7) 
16 (41.0) 
Support, n (%)               Independent 
                              Need support 
17 (11.8) 
127 (88.2) 
11 (11.7) 
83 (88.3) 
10 (10.3) 
87 (89.7) 
5 (9.1) 
50 (91.0) 
7 (14.9) 
40 (85.2) 
5 (12.8) 
34 (87.2) 
Severity of ID, n (%)                    Mild 
                                     Moderate 
                         Severe/Profound 
                                   Not known 
62 (46.6) 
39 (29.3) 
23 (17.3) 
9 (6.8) 
39 (44.3) 
27 (30.7) 
16 (18.2) 
6 (6.8) 
38 (42.7) 
29 (32.6) 
17 (19.2) 
5 (5.6) 
17 (34.0) 
19 (38.0) 
11 (22.0) 
3 (6.0) 
24 (54.6) 
10 (22.7) 
6 (13.6) 
4 (9.1) 
22 (57.9) 
8 (21.1) 
5 (13.2) 
3 (7.9) 
  Mean (± SD) unless stated otherwise; Data validity was based on 8 hours wear per day for 3 days; 
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7.4.3 Main findings 
 
Estimates for time spent in MVPA, light-intensity physical activity and sedentary are 
presented across the different monitors and physical methods used (see Table 29). 
Estimates for MVPA and sedentary time were significantly higher with the wrist form 
device, whereas estimates of light-intensity physical activity were lower. Total 
physical activity volume measured by the wrist worn device was 26.7 (8.7) mg. 
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Table 29: Levels of physical activity and sedentary behaviour as assessed by the waist (Actigraph) and wrist worn 
monitors (GENEActiv)  
 
Physical activity 
measures 
 
Waist worn 
 
Wrist worn 
method 1 
Wrist worn 
method 2   
o Wrist method 1 vs 
waist difference 
adjusted for age, sex 
social deprivation 
and wear time or 
estimated waking 
hours 
Wrist method 2 vs 
waist difference 
adjusted for age, sex 
social deprivation and 
wear time or 
estimated waking 
hours 
Time in MVPA 
(mins/day) 33.6 (30.8) 136.9 (79.9) 95.8 (51.8) <0.001 <0.001 
Time in light-intensity 
physical activity 
(mins/day) 
269.1 (72.7) 105.7 (47.1) 195.1 (73.7) <0.001 <0.001 
Time spent sedentary 
(mins/day) 499.2 (96.7) 632.5 (136.4) 790.8 (116.1) <0.001 <0.001 
Ambulatory activity 
(steps/day) 6761 (3483) N/A N/A  
 
Data validity:ULVWPHWKRGEDVHGRQKRXUVZHDUSHUGD\IRUGD\V:ULVWPHWKRGbased on  hours wear per day for 3 days; 
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7.5 Discussion 
 
The key finding from this sub-study was that the objective measurement of physical 
activity is likely to be challenging in adults with ID with high levels of non-compliance; 
however, compliance can be substantially improved and loss of accelerometers 
reduced with wrist worn monitors. Overall, less than 50% of participants agreed to 
wear the waist worn device, with valid data only collected for 57% of the sample. In 
contrast, 62% agreed to wear the wrist worn device with 83% providing valid data.  
 
To our knowledge, this is the first study to access the feasibility of collecting 
objectively assessed physical activity data in those with ID. However, other studies 
have reported high levels of missing data when using objectively measured physical 
activity within their study protocol.164, 233 These results suggest that studies that 
include accelerometers may have poor uptake unless participants are allowed to 
consent separately for this element. These factors will need to be taken into account 
and considered carefully in future physical activity intervention studies within this 
population.  
 
To assist with compliance in our study, participants (and carers) were provided with 
a physical activity diary (instructions) in an easy read format. Service users were 
involved with the development and initial testing of the diary; however; no formal 
assessment was conducted to see if the diary increased compliance for participants 
(and carers). Given the heterogeneity in capacity levels and support needs of 
individuals, further work is needed to explore possible ways to improve compliance 
with accelerometer wear in people with ID. 
 
Based on estimates from the waist worn device, our population engaged in more 
MVPA than several other studies conducted in those with ID. For example, studies 
from Scotland and the United States have reported between 7 to 14 minutes per day 
of MVPA.164, 233 Estimates for MVPA from the waist worn device were also slightly 
higher than levels reported in a primary care cohort from Leicestershire, UK.234 
Similarly, estimates for total physical activity from the wrist worn device were 
consistent with those reported for healthy non-obese adults and higher than those 
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reported for obese or unhealthy populations within the United Kingdom.235 However, 
a previous research study in the United Kingdom in those with ID reported similar 
levels to those found in our study.236 This suggests that in the United Kingdom, those 
with ID are not less active than the general population. This is despite institutional 
barriers that have been hypothesised to inhibit physical activity engagement in those 
with ID.237    
 
An important finding from this sub-study was the difference in activity levels gained 
from wrist and waist worn devices. Whilst waist worn devices have been widely used 
in research over the last decade with established methods of categorising collected 
data which allows for comparisons between studies, wrist worn devices are newer 
and lack standardised approaches to data analysis. Although the underlying raw 
acceleration data between waist and wrist worn monitors are likely to be highly 
correlated, commonly used methods of converting this data into meaningful outputs, 
such as time spent in MVPA, are likely to be monitor and placement specific. This 
has important implication for future trials and suggests that intervention effects, 
standard deviations and population means should be estimated using data gained 
from the same tool that will employed in the study.  
 
7.6 Concluding remarks 
 
This chapter has described a physical activity sub-study, which formed part of work 
package 1. The following chapter (Chapter 8) describes the first phase of the 
education development process that was carried out as part of work package 2, to 
develop an initial curriculum for a lifestyle education programme for adults with ID. 
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CHAPTER 8.   DEVELOPMENT OF INITIAL CURRICULUM FOR 
STRUCTURED EDUCATION PROGRAMME  
 
 
8.1 Chapter overview 
 
This chapter describes the work undertaken for work package 2 to develop an 
educational programme for a population with ID and IGR or high risk of developing 
diabetes and/or CVD (based on increased BMI level). A brief overview of the 
complete development process is presented in Section 8.3. The remainder of this 
chapter details the work conducted to develop an initial curriculum. Further 
development work, including two pilot cycles of testing, evaluation and modification, 
is described in Chapter 9. An additional feasibility phase, which formed part of work 
package 2, is presented in Chapter 10. 
 
8.2 Aims and objectives 
 
The aim of work package 2 was to develop a structured lifestyle education 
programme for prevention of T2DM that is suitable for use in an ID population.  
 
Specific objectives were:  
x First, to develop a lifestyle education programme for a population with ID who 
have IGR or are at a high-risk of developing T2DM and/or CVD based on 
increased BMI level (Chapters 8 and 9); 
x Secondly, to assess the feasibility of collecting outcome measures for 
participants with ID before and 3-months after they attend the education 
programme (Chapter 10). 
 
8.3 Overview of the development process 
 
A multi-disciplinary team with expertise in ID and in the development of nationally 
recognised diabetes and CVD prevention programmes developed the intervention. A 
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systematic approach was employed  (see Figure 20), based on the current Medical 
Research Council framework for developing and evaluating complex interventions238 
and intervention mapping.239 This included reviewing the relevant published 
evidence from existing programmes and the behaviour change literature. The 
curriculum was informed by previous prevention programmes that our research 
group has developed.240-242 Additional qualitative work was undertaken to further 
inform the content, process and style of delivery.  
 
Following development of an initial curriculum, two cycles of testing, evaluation, 
modification and re-testing were conducted during the pilot phase (presented in 
Chapter 9), prior to the programme being used in a third iteration where the 
feasibility of collecting before and after data was explored (presented in Chapter 10). 
This iterative and reflective process, supplemented by qualitative research 
methodology, is an approach that our group has previously used successfully to 
adapt patient education modules for different groups.240, 243, 244 
 
The core multi-disciplinary team, which included ID nurses, education team 
members, a qualitative researcher and the lead study researchers, met monthly 
throughout all stages of the development, supplemented by more frequent meetings 
at key points in the process. The purpose of these meetings was to decide on the 
key elements relating to the content, process and style of the initial curriculum, and 
subsequently reach agreement on any modifications required.  This collaborative 
multi-disciplinary approach allowed the expertise of all members to be used and 
facilitated the iterative and reflective process. 
 
This development work occurred over a period of approximately 27 months, 
commencing in October 2012 and ending in January 2015 when the final 
refinements were made to the curriculum (ready for use in the feasibility phase 
described in Chapter 10). 
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Figure 20:  How phases of the development work fit together 
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8.4 Participants 
People invited to engage in work package 2 (qualitative interview, Chapter 8; pilot 
education sessions, Chapter 9; or feasibility testing, Chapter 10) were service users 
with mild to moderate ID who had taken part in the screening stage (see Chapter 5) 
DQGVFUHHQHGSRVLWLYHIRU,*5RUKDGD%0,DQGDWWKDWWLPHconsented to being 
approached to assist with later phases of the research programme. Carers were also 
approached. An invitation pack, including easy read documents, was sent directly by 
the research team. For people volunteering, capacity assessment and consent 
followed a similar process to previous stages (see Chapter 5). 
 
For people with ID who were invited to assist with the qualitative exploratory 
interviews (see Section 8.5), no further eligibility criteria applied. Additional inclusion 
criteria for invitation to attend the pilot education sessions and give feedback (see 
Chapter 9), or the feasibility phase (see Chapter 10), included: 
x able to stand and walk at least short distances; 
x able to attend group education sessions; 
x not taking part in any other intervention study 
 
ID healthcare professionals (HCPs) were also invited to contribute/assist with 
development of the initial curriculum by agreeing to a qualitative interview. Further 
details are provided in the next section (Section 8.5.1).  
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8.5 Qualitative work to inform development - methods 
 
Semi-structured qualitative exploratory interviews were conducted with service users 
(and carers) and HCPs providing services to adults with ID, to help inform 
development of the initial curriculum. This qualitative work was carried out between 
May 2013 and June 2014. 
 
8.5.1 Recruitment for interviews 
 
A provisional quota was set of conducting up to 25 interviews with the various 
stakeholders (HCPs and service users with ID), to enable a range of views to be 
captured. 
 
Recruitment of HCPs commenced in May 2013. A variety of HCPs were identified 
through ID services at Leicestershire Partnership Trust (LPT). The invited HCPs all 
had previous experience of working with adults with ID. Purposive sampling was 
used to ensure inclusion of HCPs who could offer a range of perspectives based on 
their occupation/professional background. Potential interviewees were sent an 
invitation pack. 
 
For service users (and carers), recruitment began in January 2014. The eligibility 
criteria and method of approach are described previously in Section 8.4. 
 
8.5.2 Data collection and recording 
 
Topic guides were developed to ensure relevant issues were captured (see 
Appendix 19 for service user example). Interviews were semi-structured and based 
on open questioning to elicit issues surrounding knowledge, understanding and 
experience of T2DM and modifiable risk factors, relevance of IGR, perceived barriers 
to behaviour change and support needs for people with ID. Practical aspects in the 
delivery of an education programme were also explored, for example, whether to 
develop separate interventions for carers (family members and/or key workers) and 
people with ID, inclusion of follow-up sessions and length of the programme.  
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Questions were asked appropriately depending on who was being interviewed. 
Additional communication tools were used when interviewing service users, such as 
prompts cards depicting images of various activities (e.g. swimming, bowling, 
walking), to help with eliciting contributions.  
 
Interviews were conducted with HCPs between June and August 2013. All interviews 
were conducted by an experienced qualitative researcher at the HCPs normal place 
of work.  
 
Interviews with service users were conducted from January to June 2014. There was 
an initial delay in finding service users who were either eligible to be invited or willing 
to be approached/interviewed. All interviews were conducted by the same qualitative 
researcher with assistance from an ID research nurse. The researcher had expertise 
in developing and modifying diabetes prevention programmes for different 
populations; prior to commencing the interviews the researcher had undertaken 
additional training within the research team to increase their knowledge and skills in 
the area of ID. The interviews were conducted in a variety of community settings, 
including at a participant’s family home, a residential/care home, an assisted 
independent living flat and a community clinic, to suit the needs and preferences of 
individual participants.  
 
8.5.3 Data analysis 
Audio recordings of interviews were transcribed verbatim and thematic analysis was 
conducted using NVivo version 7, QSR (a qualitative software programme). 
Subsequently, themes relevant to the development of the intervention were 
identified. 
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8.7 Qualitative interviews – findings 
 
8.7.1.1 Characteristics of participants 
Service users 
Eighteen service users were invited to participate. A total of seven service users 
were subsequently interviewed (see Table 30); in two of the interviews carers were 
present (one a family carer, one a care worker).  Three of the service users who 
participated were male, the median age was 47 years (range 28-68), and all were of 
White European ethnicity. Six participants lived in a supported environment with 
family or carers, and one lived independently. One of the participants was in paid 
employment (and did voluntary work), two attended college, two others carried out 
voluntary work, and the remaining participants undertook other activities within the 
community on a regular basis.  
 
Healthcare professionals 
Twenty HCPs were invited to participate. Subsequently, 14 HCPs were interviewed. 
All HCPs currently worked with adults with ID for all or part of their job role. 
Professionals included: ID psychiatrists, nurse related roles (community/primary care 
ID nurse, practice nurse, acute liaison nurse, nursing assistant); allied healthcare 
professionals (clinical psychologist, occupational therapist, speech and language 
therapist), and a day centre manager (Table 31).  
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Table 30: Characteristics of service users who were interviewed 
 Characteristics service users n = 7 
Age 18 – 39 years 
40 – 59 years  
60 – 74 years 
3 
3 
1 
Sex 
 
Male 
Female 
3 
4 
Accommodation Alone 
With family/carers 
Residential home 
1 
3 
3 
Level of support Independent 
Some support 
24 hour support 
2 
2 
3 
 
Table 31: Characteristics of healthcare professionals interviewed 
 Characteristics HCPs n = 14 
Age 
 
20 – 39 years 
40 – 59 years  
unknown 
5 
7 
2 
Sex 
 
Male 
Female 
2 
12 
Profession 
 
ID Psychiatrist 
Allied healthcare professional 
Nurse related 
Other 
2 
5 
6 
1 
Length of time 
working ID 
 
<5 years  
6 - 10 years  
10+ years  
unknown  
1 
2 
9 
2 
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8.7.1.3 Key points from interviews with service users and carers 
 
Interviews conducted with service users ranged between nine to fifteen minutes in 
duration.  
 
In a few of the interviews it was possible to explore awareness of diabetes. Service 
users related this to “sugar”, and also spoke about family members who had 
diabetes and recalled them being on tablets and having injections. When trying to 
gauge service users’ knowledge about healthy lifestyles, some people were able to 
describe basic health messages such as eating vegetables, eating a high fibre diet 
and exercise.  
 
The interviews did yield some useful insights into the lives of service users, for 
example the types of food they enjoyed, and the degree of choice and control 
available in relation to foods consumed; discussions about commonly consumed 
foods ultimately influenced the food images and food models in the dietary sections 
of the curriculum. For a few participants, the additional use of prompt cards enabled 
useful discussion around the types of physical activities undertaken; for those who 
were more independent, walking appeared to be the most preferred and accessible 
form of physical activity.  
 
It was difficult to explore service users’ preferences towards learning as part of a 
group or learning on an individual basis. However, the majority of participants spoke 
about going to some form of group activity sessions, such as sessions held at a local 
day care centre or at a college; activities included arts and crafts, and learning “life 
skills” to facilitate independence. Further discussion around participants preferences 
for photographs or pictorial images (on educational resources), suggested that for 
most participants they preferred photographs. 
 
More general points arising from the interviews included practical considerations to 
be taken into account. First, that education sessions needed to be held locally 
(minimal travelling distance/time for participants), in a setting that was familiar to 
people, and a venue that was easily accessible via public transport or similar. 
 152 
 
Secondly, the importance of including carers within education sessions, to help 
support participants and make them feel at ease during sessions, and to help 
facilitate service users with making changes to their diet and physical activity outside 
of sessions; it was clear from the interviews that both professional and family carers 
currently fulfilled this role in the daily lives of participants.  
 
8.7.1.4 Key points from interviews with health care professionals 
 
All HCPs were enthusiastic to share their knowledge and experience of working with 
people with ID. Most HCPs had previous or current experience of promoting positive 
behaviour change with people with ID, either for behaviour management and/or 
health promotion.  
 
Pre-assessment 
 
The majority of HCPs stressed the importance of undertaking a pre-assessment prior 
to embarking on delivery of an education session. Frequently stated reasons relating 
to carrying out a pre-assessment included: 
x to enable cognition matching, which would involve the assessment of 
preferred communication styles, reading and writing abilities, preferences for 
working with pictures and/ or written sheets/flip charts; 
x to ensure any differences in severity of ID (mild to moderate) between 
individuals in the group are not too wide; 
x to identify and support people who may face challenges or difficulties with 
verbal communication (for example, some people may only be able to say yes 
or no); 
x to prepare people for taking part in a programme and working in a group 
setting; 
x to gain a measure of the level of insight a person may have about their own 
health and the perceived relevance of the programme to themselves; 
x to assess a participant’s ability to identify and engage with their own priorities, 
and reflect on their own skills for undertaking change or wanting to change; 
x to assess how best to support individuals with decision making. 
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 Suggested activities relating to what pre-assessment could involve were: 
1. speaking to the person with ID (and their carer(s) as appropriate) and carrying 
out an assessment via discussion/interview using established tools 
(questionnaires & checklists) or observations; 
2. extracting relevant information from health action plans and core information; 
3. eliciting relevant information and knowledge from staff teams involved with the 
person with ID. 
 
The process and delivery of the programme 
 
1. Preparing the group for learning 
Ensuring that participants are in the right frame of mind or in the “best place to 
learn” (HCP 07) requires some thought and preparation; one HCP described some 
of the strategies they used to promote this during a “healthy living” course. These 
included participants having two to three short breaks over every one hour period, or 
undertaking physical activity or encouraging them to be physically mobile during the 
education sessions. 
 
“Because if you get them in the wrong place or they’re not in at the 
right level of arousal or even in the right mood, this can impact on their 
willingness and their ability to take in information.” (HCP 07) 
 
Other ways in which participants’ receptiveness to learn was developed were 
through watching videos or taking part in practical fun activities.  
 
2. Choosing methods to promote healthy choices  
To deliver knowledge and promote healthy food choices, participants described 
using visual aids including photos and pictures of foods from magazines. They also 
discussed the importance of undertaking practical activities such as preparing 
healthy foods. The rationale for these kinds of sessions was to show alternatives in a 
very literal way. Additionally, to try to convey that too much of a particular food was 
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bad for your health, you would need to show actual or pictorial images from real life, 
not cartoon images. 
 
 “……rather than saying ‘too many biscuits’, which are words.  You 
want to show pictures of biscuits and you want to show one pack, plus 
two pack, plus three pack is this much.  Stuff like that.  So real pictures, 
or even better real objects.” (HCP 04) 
 
In relation to the number and type of messages during a session, the advice from 
HCPs was to keep it simple and not to over load the amount of messages covered in 
one session.  
 
3. Ways of promoting physical activity 
Effective ways to convey messages about increasing levels of physical activity, that 
were suggested by some HCPs, included giving an opportunity for participants to 
experience some of the activities during the education sessions (for example, 
swimming or going for a walk). If this was not possible, another suggestion included 
using pictorial images to stimulate discussion on how physical activity could be 
integrated into someone’s life. This would need to take into account individual needs, 
such as restrictive budgets, physical ability and level of independence. For some 
people, if going for a walk was not possible, alternatives may be skipping or dancing 
to music. 
 
4. The use of open ended questions  
When asked specifically whether the use of open ended questions was appropriate 
for adults with ID, most HCPs went on to describe using this style of questioning with 
service users. However, they emphasised the need to follow up this approach with 
specific and direct questions. The latter helped to ensure questions were not ‘too 
open’ and in danger of being misinterpreted. For example, one HCP explained: 
 
“So sometimes open ended questions can be too open. You have to be 
more specific, like ………… for ground rules -  “What is going to keep 
us all safe amongst ourselves?” - Not talking about slips, trips. Do you 
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see what I mean? That you probably do have to tailor it a little bit…” 
(HCP 03) 
 
Some HCPs also suggested that educators should not assume that commonly used 
words will always be understood by participants. They emphasised the importance of 
eliciting understanding on a frequent basis throughout the session and checking for 
consistency of responses. Other recommended strategies (particularly for those with 
autism) included, giving two options or choices and changing the order of these to 
check their selection is based on an informed understanding. 
 
One suggested disadvantage of asking open ended questions was that it could place 
undue pressure on some individuals, invoking feelings of distress because they may 
not know the answer; educators may need to use pictures to encourage a response.  
 
5. Retention and recall 
To aid retention and recall of messages, the general advice was to use a 
combination of visual and verbal communication, with opportunities to experientially 
learn. The need to cater for differences in attention span, types and levels of abilities, 
and styles of learning, was emphasised. The key message of the interviews was that 
a flexible approach is needed including: 1) educators gauging understanding at 
regular intervals and addressing appropriately; and 2) educators using different 
methods to facilitate delivery to cater for diversity within a group. 
 
6. Health beliefs and behaviours 
When specifically asked, the majority of HCPs felt that exploration of health 
behaviours may be challenging. For adults with ID, their ability to process thoughts 
and associate them with behaviours, or make causal links at a more complex level, 
may be lacking in some individuals. The latter, they believed, may partly be 
influenced by the environment in which people live; service users may have limited 
or restricted opportunities to be in contact with (or be aware of) other people with a 
health condition. There may also be a lack of control about dietary choices and/or 
their association with health conditions. One participant felt, that simple associations 
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could be made such as “too much sugar is not good”, and that these have the 
potential to inform changes in health behaviour. (HCP 04) 
A divergent view was that people with ID are not any different to the general 
population in relation to holding health beliefs. It may just be the communication of 
their beliefs that is different and necessitates educators taking different approaches, 
or that their beliefs may be more unusual/idiosyncratic. 
 
7. Understanding the concept of future health risk of developing diabetes and self-
reflection 
When HCPs were asked whether people with ID are likely to understand the concept 
of risk, there was a variation in the responses. This appeared to be related to views 
on the heterogeneous nature of the ID population and also possible perspectives 
linked to the professional background of HCPs.  
 
One view was that people with mild ID may understand the concept of risk, but 
generally, people with autism may have difficulties. However, it was additionally felt 
that would depend on an individual’s attitude or motivation. 
 
“You’re going to have some people who do understand that things 
change in the future, and things may deteriorate. Then you may have 
other people who wouldn’t have that concept at all. Particularly you 
know if you’ve got somebody with autism and the future doesn’t really 
mean a great deal, because it’s not concrete enough for their 
understanding and perception quite often. So I think it would depend on 
the level of learning disability and many other conditions that the 
individual might have.” (HCP 06) 
 
A few HCPs discussed that people with ID may have difficulty with understanding 
risk, as they may have a cognitive impairment that challenges the ability to 
conceptualise, including projecting into the future.   
“I think those sorts of things are more difficult. A lot of the time we 
probably are used to working in the here and now. So yes, projecting 
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that this might happen to somebody, I think a lot of people find that 
difficult, don’t they, to understand.” (HCP 03) 
 
However, this participant acknowledged that there was also evidence that shows that 
it is: 
 
“…possible for people with a learning disability to be able to handle 
abstract information, reflect on it, appraise it and therefore bring 
change, but that is probably best done by people skilled in offering 
those interventions.” (HCP, 04) 
 
Some HCPs suggested ways to explain the concept of future risk, but in amongst 
these suggestions was a view that it had to be a balancing act between alerting 
people and not scaring people: 
 
“It’s really tricky cos you don’t want to scare people, and people can 
get fixated on something and worry about it, and worry about it. And it 
could become a bit of an obsession, and they could be really worried 
and scared about that.” (HCP 02) 
 
The potential dangers of the above approach were discussed with another HCP who 
suggested anxieties could be allayed by discussing the future with “positive bits.” 
(HCP 06) 
 
One of the suggestions put forward for helping to promote self-reflection included 
using “DVD clips” to show alternative scenarios and facilitate non-threatening 
reflection (i.e. it was not about them). Although, even with this approach, it was 
acknowledged that it would take many weeks of guided discussion and support to 
help facilitate this process.   
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8.8 Drafting of initial curriculum 
 
8.8.1 Key points for initial curriculum from the literature 
 
At the start of the curriculum development process described in this chapter, a 
structured literature review was conducted with a focus on existing lifestyle 
interventions for adults with ID, aimed at primary prevention of T2DM and/or CVD or 
modification of risks factors. This was supplemented by reviewing relevant published 
guidelines, consensus statements, interventions currently in practice and service 
evaluations. 
 
Later, this was formalised by conducting a systematic review considering evidence 
on the effectiveness of multi-component lifestyle behaviour change interventions for 
reducing risk factors for T2DM and/or CVD. The methods and findings of the 
systematic review are presented in Chapter 3.  
 
Key findings from the literature that directly informed the content, theory and process 
of the programme are described below. There were only a small number of studies 
with a focus on people with ID and behaviour change lifestyle interventions. Few of 
these studies163-166 provided a description of their theoretical underpinning, although 
they did recommend the employment of social cognition models such as the Theory 
of Planned Behavior245 and Reasoned Action.246, 247  
 
The Healthy Lifestyle Change Programme, which was developed by Bazzano et 
al,163 was the only published intervention at this initial stage in the development of 
the STOP programme that outlined a conceptual model.  Thus the STOP theoretical 
conceptual framework, as shown in Figure 21, was influenced by this approach.  
 
The STOP framework developed, subsequently informed all aspects of the education 
programme; the framework highlights the importance of an individual’s beliefs about 
health, ill health and its consequences, specifically the impact on them as individuals 
and their life. In terms of ‘attitude’, outcome expectancies were explored, i.e. what 
would happen if I engage in a particular behaviour and how important is the outcome 
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for me.  Methods of learning, specifically vicarious, observational and concrete 
kinesthetic were also highlighted in the literature, as was the importance of social 
support and peer norms.163, 245-248 
 
Self-efficacy is a key component of behaviour change,248 i.e. the person’s belief they 
can perform the behaviour. However, there are many real barriers to behaviour 
change in this population, such as disability and/or a lack of control over their 
physical environment, for instance not being the person who buys or cooks the food. 
Therefore, the concept of actual behavioural control was included in the theoretical 
framework to ensure that these issues were addressed in the programme.  The 
influence of strong intentions and a detailed action plan was also acknowledged. 
Intrinsic motivation and the power of reinforcing feedback loops were also 
highlighted via distal and proximal re-enforcers and the positive impact on quality of 
life and psychological well-being. These specific components of the programme can 
be viewed in Table 32.      
 
Additional key lessons from the literature were: 1) the need to maximize carer 
involvement; 2) that people with ID have extremely heterogeneous needs and any 
intervention would require a multi modal approach; and 3) that pre-group preparation 
is essential.   
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Figure 21: Theoretical framework for the education programme 
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8.8.2 Key points from multi-disciplinary development group  
 
The overarching framework, content, process and learning methods for the 
programme were formed at a large multi-disciplinary meeting following a systematic 
process; this meeting was additional to the regular monthly meetings held throughout 
the development process. The qualitative findings from HCP interviews, relevant 
literature and core theoretical constructs were presented, debated and a consensus 
was formed. This was later supplemented by findings from the qualitative interviews 
with service users (and carers), once available.  
 
The core multi-disciplinary team, which included ID nurses, education team 
members, a qualitative researcher and the lead study researchers, met monthly 
throughout all stages of the development, supplemented by more frequent meetings 
at key points in the process. 
 
Key points agreed included: 
• using  a concrete kinaesthetic learning style; 
• ensuring that resources developed and methods used to convey messages 
allowed for tailoring to different levels of intellectual ability; 
• the development of a specific carer session to engage and promote  involvement; 
• ensuring participants were appropriately prepared prior to attendance and at the 
start of each session; 
• reflection on their own levels of risk; 
• self-monitoring (diaries and pedometers);  
• goal setting and action planning; 
• exploration of barriers and  individualised solutions.  
 
The specific methods employed to ensure that the themes highlighted above were 
operationalised are detailed below.  
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A specific carer session was to be held prior to the participant education sessions. 
 163 
 
 
Curriculum content and activities 
 
The main behavioural goals and content (see Section 8.8.4; Table 32) were to be 
drawn from previous prevention studies.240-242 In addition, abstract concepts like risk 
and future self were to be developed as activities, games or stories using a concrete 
kinaesthetic modality. To promote participant engagement in the programme, the 
educators would use practical and participatory methods such as food models and 
images, visual memory aids and short walks using a pedometer. The educators 
would also use reinforcement methods, including certificates of attendance and 
attendance cards, as a regular activity within the programme. If the participant 
chose, self-monitoring activities/opportunities would be promoted, such as diaries to 
record food and physical activity outside of the session; the opportunity to use a 
pedometer and scales would also be available to monitor weight when attending 
sessions. The curriculum would include action planning and goal setting 
opportunities (in most sessions) around activity, food and other behavioural goals, 
supported by individualised resources. The educators would create opportunities 
through activities to explore barriers and solutions on an individual basis and in 
group activities. 
 
  
 164 
 
8.8.4 Key behavioural goals of the education programme 
 
For the STOP programme, the key behavioural goals and lifestyle messages 
incorporated into the education sessions were based on those of the Let’s Prevent 
programme (nutritional)240 and PREPARE programme (physical activity).241, 242 
Specific goals included: losing weight; reducing consumption of total and saturated 
fat; increasing dietary fibre consumption; and increasing physical activity and/or 
reducing sedentary behaviour (see Table 32). However, the emphasis of the STOP 
programme was on enabling the individual tailoring of goals based on a participant’s 
needs and abilities, including potential mobility restrictions, level of independence 
with food shopping and preparation, potential dietary restrictions, opportunities to 
access the community, cognitive level, and availability and level of carer support 
required. Therefore, more generalised behavioural goals were emphasized, rather 
than setting specified targets (see Table 32).  
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Table 32: Key behavior change goals 
 
Specific nutritional and physical 
activity goals 
STOP Diabetes key behavioural goals 
Weight reduction  
Sustained weight reduction of > 5 % body 
weight 
Choose smaller portions 
Reduce fat intake from all sources 
Reduce sugary drinks and foods 
Choose healthier cooking methods 
Choose healthier snacks and treats 
Increase physical activity/ reducing sedentary 
 
Reduce total fat consumption 
Moderate reduction in total fat to < 30% 
energy intake 
Reduce fat from all sources 
Choose lower fat options 
Reduce processed foods  and ready meals 
Choose healthier snacks and treats 
 
Low saturated fat intake 
Reduce saturated fat intake to < 10% 
energy intake 
Reduce fat from all sources 
Reduce processed and ready meals 
Choosing healthier snacks and treats 
Higher  fibre intake  
Increase fibre intake to  >15g per 1000 
calories  
Increase fruit and vegetable intake to 5 a day 
minimum 
Choose healthier snacks and treats 
Increase physical activity / reduce 
sedentary behaviour 
A minimum recommendation of 30 
minutes of moderate intensity physical 
activity per day 
Increase moderate intensity activity by 
increasing steps or adding extra physical 
activity  
Reduce sitting time 
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8.9 Discussion 
 
This chapter describes the first phase of the development of a lifestyle behaviour 
change programme for adults with ID. We took a pragmatic approach to intervention 
development, using the Medical Research Council framework for developing 
complex interventions238 to combine existing prevention programme,240-242 
intervention mapping,239 evidence reviews, stakeholder interviews and expert advice.  
This systematic process allowed us to make the following underlying assumptions for 
the programme: 
x People with ID have limited knowledge of healthy lifestyle messages. 
x People with ID generally have poorer diet and exercise less often than the 
general population. 
x Health beliefs, knowledge, motivation and social support are key in promoting 
behaviour change among people with ID. 
x People with mild and moderate ID need a specially tailored intervention to 
promote behaviour change. Mainstream interventions are not suitable for this 
population. 
 
Our qualitative findings largely support the literature 47, 48 49 50 in finding that people 
with ID had limited knowledge about healthy lifestyle messages and experienced 
barriers in undertaking physical activity. However, we acknowledge that findings from 
the qualitative exploratory interviews with service users may be limited due to the 
short interview length (average 9-10 minutes); although, this length does not include 
the additional time taken to explain the study, assess capacity, obtain consent and 
allow for breaks. We recognise that people with ID are not a homogenous group; 
some people found it difficult to concentrate and for other people several visits to 
allow trust to be built-up may have been a better approach. Additionally, in some 
circumstances, carers (personal and care workers) were not able to be present 
throughout the whole interview or, if there, they did not agree to participate. It would 
have been beneficial to purposively seek the views of a larger number of carers 
(both personal and care workers) at the development stage. However, we were able 
to obtain valuable feedback from carers during the piloting phases (reported in the 
following chapter, Chapter 9) and modify the programme accordingly. 
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8.10 Concluding remarks 
 
This chapter has described the first phase of the education development process 
that was carried out to develop an initial curriculum for a lifestyle education 
programme for adults with ID. The following chapter (Chapter 9) details a pilot testing 
and evaluation phase. Chapter 10 outlines a feasibility study conducted following 
development of the education programme. Chapter 11 describes development of an 
intervention fidelity process undertaken for work package 3. 
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CHAPTER 9.   PILOT TESTING AND EVALUATION OF AN 
EDUCATIONAL CURRICULUM FOR PREVENTION OF TYPE 2 
DIABETES 
 
9.1 Overview 
 
This chapter describes a pilot testing and evaluation phase, which follows on from 
work conducted to develop an initial education curriculum (presented in Chapter 8). 
An additional feasibility phase, which formed part of work package 2, is presented in 
Chapter 10. 
 
9.2 Aims and objectives 
 
The aim of this further phase of the development work was to conduct two pilot 
cycles of testing, evaluation and modification of the initial education programme. 
 
9.3 Methods 
 
Following development of an initial curriculum, a pilot phase, which involved two 
cycles of testing, evaluation, modification and re-testing, was conducted (see 
Chapter 8, Figure 20) The first pilot cycle was conducted between April to July 2014 
and the second cycle from October to December 2014. 
 
9.3.1 Participants and recruitment 
 
Inclusion/exclusion criteria for work package 2 have previously been described in 
Chapter 8 (Section 8.4).  People invited to engage in the pilot phase were service 
users who had taken part in the screening stage (see Chapter 5), screened positive 
IRU,*5RUKDGD%0,DQGDWWKDWWLPHFRQVHQWHGWREHLQJDSSURDFKHGWRDVVLVW
with later phases of the research programme. Recruitment followed a similar process 
to the earlier development phase (see Section 8.4). An initial telephone call was 
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made to potential participants, followed by further information sent in the post or 
provided at a face-to-face visit.  
 
9.3.2 Delivery of the education 
 
Potential volunteers with ID were approached about attending the education 
programme, approximately four to six weeks prior to the planned programme start 
date. Carers were invited to an initial session, held one week before the delivery of 
the main education sessions. The aim of the carer session was to provide carers 
with an overview of the education programme, and explore their role in supporting 
individuals with ID, both within and between the sessions. 
 
Subsequently, the initial curriculum was delivered to a group of individuals with ID. 
Carers were also invited to attend the sessions to support the service users. 
Following feedback and refinement of the curriculum (see Section 9.3.4), the 
modified curriculum was then delivered to a second separate group, which again 
was followed by feedback and refinement. 
 
Three educators were involved with delivering the programme at each session; a 
registered ID nurse, a diabetes specialist with an education background, and an 
additional ID nurse or health care assistant in a supporting role. The educator 
training process for the study is described in Chapter 11. 
 
9.3.3 Data collection 
 
A range of methods were used to evaluate the education sessions and collect 
feedback. These included observations recorded during the sessions by an 
experienced researcher, reflections from the educators leading the programme and 
qualitative interviews with people who received the programme (those with ID and 
carers). Additionally, subsequent to the first pilot phase, educators were also 
interviewed to explore their views about the content and style of delivery, 
experiences from delivering the programme and perceived practical issues. 
Feedback and reflection on educator training are described in Chapter 11. 
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Participants were approached to take part in a feedback interview prior to the last 
session of the education programme. Interviews were held as soon as possible after 
the final session. Written consent was obtained immediately prior to the interview. 
Participant interviews took place in July 2014 for the first cycle and December 2014 
for the second cycle. 
 
The purpose of these interviews was to explore participant and carer views about the 
education sessions; to identify whether the education sessions resulted in changes 
to participants’ diet and physical activity; and to inform changes to the next iteration 
of education sessions based on participant feedback. 
 
Interviews were conducted and analysed by the same qualitative researcher that 
carried out the previous interviews (see Section 9.5). Key areas and topics that were 
explored included experiences of receiving the education programme, ease of 
understanding, views about the content and style of delivery, usefulness, relevance 
and practical issues (including duration, provision of support, and suggestions for 
improvement).  
 
9.3.4 Refinement 
 
At the end of each pilot cycle modifications were made to the curriculum prior to it 
being used in the next iteration. Modifications and refinements were informed by 
findings from participant and carer interviews, observations made during the 
education sessions, and the ongoing reflection and feedback of the educators.  
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9.4  Findings – first pilot phase 
 
9.4.1 Uptake and attendance at education sessions 
 
The first iteration of the education programme was held in a community resource 
centre. A total of 21 participants were invited to take part in the education 
programme. Five participants (four who had carers) initially agreed to attend the 
programme. Following the carer’s session, one person (and their carer) withdrew 
completely. Subsequently, four participants (and three carers) took part in the main 
education programme. Overall attendance at the education sessions (seven weeks, 
one session per week) was very good, with one participant (and carer) attending all 
seven days and three participants attending six days (see Figure 22).  
 
9.4.2 Characteristics of participants 
 
Of the four participants taking part in the first iteration of the education programme, 
two (50%) were male, the median age was 35 years (range 29-60), three (75%) lived 
in a supported environment with family or carers, and one lived independently. None 
of the participants were in paid employment, one attended college and did voluntary 
work, and all four participated in other activities within the community.  
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Figure 22: Uptake and attendance at first and second testing phases of pilot 
cycle  
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9.4.3 Feedback interviews – first pilot cycle 
 
Following on from the first iteration of the education programme, all participants 
(n=4) and carers (n=3) agreed to be interviewed. One participant was interviewed 
independently. For the remaining three interviews, carers and participants were 
interviewed together; in two of these interviews the carers made major contributions 
to the interviews. 
 
9.4.3.1 Interviews with participants 
 
Key learning and behaviour changes 
 
For one of the participants, who had previous experience of attending health related 
courses/groups, initially during the interview, they suggested that they had not learnt 
anything new. However, through further exploration of the impact of specific 
activities/games it was possible to identify that the programme had reinforced key 
health messages, including types of healthy/unhealthy foods, portion sizes and the 
link between food eaten and body weight.  
 
“Mm, just be careful what…if you do eat any unhealthy [food] not to 
have so much of it.” (Pt2, F) 
 
 “….. yeah, makes you think, doesn’t it, er, if you don’t control what you 
eat, you do put…(weight-interviewer)……. Yeah, because they say this 
country’s, don’t they, obese?” (Pt2, F) 
 
For another participant, the education sessions were cited by the carer as helping 
the participant to become more aware of the changes they needed to make, 
although the participant was also receiving a form of therapy (hypnotherapy) that 
they believed was also helping them to make lifestyle changes. 
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“But since we’ve been on the course and you’ve attended the course 
and they’ve told you this, you’ve become much more aware of it, 
haven’t you? (Carer)  
“I have, yes.” (Pt4, M) 
 
Examples of the dietary changes made by this participant included: reducing the 
portion size of less healthy foods; swapping/replacing some foods for healthier 
alternatives; and moderating the amount of alcohol they drank. 
 
“Um, I’ve also learned that, um, alcohol is, kind of, fattening, but as 
long as you don’t drink it too much…” (Pt 4, M) 
 
Changes to physical activity included doing more walking and going to the gym. 
Consequently this participant (and carer) reported that he had initially lost 10lbs in 
weight, which was maintained at 7lbs (immediately following the intervention). 
However, this participant also reflected that as he grew older he was paying more 
attention to his lifestyle. 
 
“I just didn’t really care so much, to be quite honest, in the past.  But 
now that I’m a lot more older, I’m starting to take things more…more 
wrong, aren’t I, Mumsy? (Pt4, M) 
 
Sustaining changes 
 
The wearing of a pedometer (optional) to measure activity was discussed by one 
participant; it had helped to quantify her existing level of activity, and to her surprise 
it was a lot more than she thought. However, there was a sense of despondency that 
could be observed during the interview about the perceived lack of support or 
encouragement she had to carry out and sustain lifestyle changes to her diet and 
activity levels, outside of the sessions/in the future. This issue, coupled with her 
concerns about her personal safety, featured in the decision not to seek more 
opportunities to go out walking 
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 “but it’s just someone to go with, you know, encouragement. 
………sometimes I give up easy with them sort of things.  But I’ve 
started taking a friend’s dog a walk once a week with my other friend 
and her dog, so round [park], that’s nice.  I go on the walks with the 
church and that.” (Pt2, F) 
 
“..but I’m not walking to [town] or [town] because it’s not safe”. (Pt2, F) 
 
She also questioned her ability to make changes. When probed further she identified 
that if she had encouragement she could make changes. 
 
“But sometimes I can’t believe that I can change it.” (Pt 2, F) 
 
 “I think I could with a bit of encouragement, you know.” (Pt 2, F) 
 
For two of the participants who had expressed a desire and commitment to make 
lifestyle changes, the support and encouragement from carers and other people in 
their lives assisted them with making changes and possibly helping them to sustain 
these changes. In the case of one participant, the people in the place he worked 
were actively trying to help support him to make changes, (specifically changes to 
his diet). He acknowledged that this support helped keep him on track. 
 
“…and so the girls there are trying to help and support you, aren’t 
they… in every way they possibly can.” (Carer for Pt 4) 
 
“It helps a lot, ‘cause then if I do it all by myself, I’ll be ending up having 
burgers or something.”(Pt 4, M) 
 
Asked if he could sustain the changes he had made to his lifestyle, he responded by 
saying he felt he could sustain these changes if he focused. 
 
 “..if I put my mind to it.” (Pt 4, M) 
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In the case of another participant, family and friends had helped them by taking an 
interest in the participant’s take-home activities and resources (completed outside of 
the education sessions), and by buying the participant a bike. These were in addition 
to the dietary and physical activity changes that the family were making. They talked 
about sustaining these changes even when on holiday.  
 
“And she kept going…I says, no we’re walking, and it’s very early, but 
we did it didn’t we, [Name]?  From the beach right up to the hotel?  
Yes?  Yeah, even though you wanted to sit down! (Carer for Pt 3) 
  
Symbols and images used to support learning 
 
For some activities, smiley green faces and red sad faces were used to indicate 
concepts like healthy and less healthy. However, for some participants these 
images/symbols were unhelpful and confusing. They were open to mis-interpretation 
or could mean different things than was originally attended in the curriculum. For two 
of the participants, a red smiley face depicted foods that they did not like as opposed 
to indicating less healthy food. 
 
“Now, if you gave him a bowl of salad and said, does that go in the red 
or the green, he’d put it in the red because he don’t like it.” (Carer for Pt 
1)  
 
Another participant placed an unhealthy food on the green sticker because she liked 
the food. 
 
Reasons for continuing to attend the education sessions 
 
One participant wanted to continue with the education sessions saying that they had 
helped him by giving him freedom from work and enjoyment.  
 
“…to actually carry on with it.  ‘Cause I’ve got that much out of the…out 
of the sessions than I would normally do.” (Pt 4, M) 
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Other reasons given by people for continuing to attend included: meeting other 
people and learning new activities; enjoying the games/activities; and due to a sense 
of achievement upon completion 
 
Only one participant discussed that he would have liked a shorter session, about an 
hour and half, and felt that there was too much information with too much emphasis 
on food. Another participant felt the venue may deter some people from attending, as 
it was a venue that cared for a range of people with ID (including people with 
behavioural difficulties) and they may see people behaving in a challenging way. 
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9.4.3.2 Interviews with carers  
 
Carer’s benefitted from the education sessions in various ways and at different 
levels. For some carers, the sessions reinforced prior learning, and for others they 
motivated and encouraged them to make changes. These are described in more 
detail below: 
 
Support and encouragement 
 
It was evident from contributions made by participants and carers during the 
education sessions, that many of them had prior knowledge and understanding of 
key healthy lifestyle messages. These were gained from their attendance at previous 
health education/promotion courses and from the media.  
 
We were able to explore this issue with one of the carer’s who was asked why 
participation in the education sessions appeared to have made such a difference to 
their life when there were so many health messages in the media that they could 
have acted on (for example, in relation to physical activity). The carer attributed the 
impact of the sessions to the person centered approach, which facilitated their 
understanding of “how” to make and sustain lifestyle changes. 
 
“Well I think how you explained things to us really.  I think that were 
very helpful, it was...…on a level with me…..you know?  And it was as 
though you were speaking to each individual…….. Not just a great 
big party or you got a book.  ……you were telling us and explaining 
more to us how to do it.  Yeah, I think that’s what helped me anyway the 
most.” (Carer for Pt 3) 
 
When specifically asked whether she had heard about the benefits of walking before 
coming to the programme, her response confirmed that she had. However, the 
education sessions contributed by providing encouragement to put into practice her 
knowledge about walking. 
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“Oh yes, yes, but we didn’t do it.  I think you gave us the 
encouragement to do it.” (Carer for Pt 3) 
 
Motivation and focus to make changes 
 
On a different level, another carer felt her levels of knowledge were already raised 
compared to other people, due to previous attendance at other continuing 
development sessions as a consequence of being a paid carer. The STOP education 
sessions had helped to jog and refresh her memory. However, she felt they had little 
impact on her or the participant making further changes largely because the 
participant did not really want to make any changes to their lifestyle. Referring to the 
participant: 
 
“I don’t think you’ve helped [participant], if I’m honest……because 
(referring to participant) you’re a bit stuck in your ways as to what you 
have and what you don’t want, aren’t you. For me, yes, it sort of jogged 
my memory and made me think, oh yeah we’ll do this and we’ll do 
that…….. not just for me with [participant], for me with me other service 
users as well.  But I think, yeah, she can do that and what have you.  
So, although I’m a bit stumped with you (referring to participant).” 
(Carer for Pt 1) 
 
Another Carer described how the experience of attending the education sessions 
motivated and focused her efforts to support the participant to make and sustain 
lifestyle changes.  Underlying this motivation was a sense of fear for the participant’s 
future health, that he may need to go on to medication, and a concern about this if 
she was not around in the future. 
 
“……it’s made us focus.  You’ve showed us the little smiley faces.  
We’ve had to put the smiley faces on the right things and the wrong 
things, and we’ve focussed in with them, you know….  Um, it makes us 
focus in to what he’s doing…” (Carer for Pt 4) 
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..”because I don’t want him to take medication, because I know that 
eventually it’ll be insulin, and if I’m not around, goodness, you know…” 
(Carer for Pt 4) 
 
Additionally, carers identified a number of dietary changes that they had made for 
the whole family as a result of attending the education sessions, which included 
reducing sugary foods and fats, and increasing fruit intake. 
 
Carers session 
 
We tried to ascertain the contribution of the carers session to their understanding of 
what the education sessions would involve prior to them attending. Unfortunately, 
very little information was gleaned as it was difficult for them to remember. One carer 
explained that they appreciated the carer session because it helped prepare her and 
the participant for what the programme would involve. 
 
“So it were a bit, sort of, rather than being just chucked in, I had an idea 
of what we were going to be doing ………. So that I could explain to 
[name] what we were going to be doing.” (Carer for Pt 1) 
 
“You see, I suppose really, the carers’ session is for my side of things, 
and other carers coming in who have to do the meals and have a bit of 
input.” (Carer for Pt 1) 
 
When asked what they would say to a new group of carers to motivate them to 
attend the next round of education sessions, one of the carer’s stated: 
 
“I’d stand up and I’d say go for it because you learn an awful lot that 
you think you know, and you don’t until it’s put down on these.  I really 
would.”(Carer for Pt 3)  
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9.4.3.3 Interviews with educators 
 
Six educators, who were involved with delivering some or all of the education 
sessions for the first iteration, were invited to be interviewed. Subsequently, face-to-
face semi-structured interviews were conducted with five educators. These included 
three registered ID nurses, one diabetes specialist with an education background, 
and one health care assistant. One educator was male. Four of the educators had 
10 years’ experience in their professional area; one had 5 years’ experience. 
 
Overall, educators felt that the education sessions had been positively received by 
people with ID and their carers. The key findings regarding the process, curriculum 
content and delivery of the education sessions, are presented below. 
 
Self and peer reflection 
 
The process of self and peer reflection after delivering the education sessions was 
reported as invaluable for their role as educators. Discussions with educator 
colleagues at the end of each education session helped to identify what worked well 
and areas for improvement in terms of adaptation of resources and identifying any 
sections of the curriculum or facilitation that required adjustment to meet individual 
needs on an ongoing basis. This in turn helped to iteratively refine and modify 
aspects of the curriculum such as, for example, resources and explore different 
strategies to respond to participant group dynamics.  
 
Venue 
 
Overall views were that a “day centre” was a good environment in which to hold the 
education sessions because it was familiar to the participants. 
 
Size of the group 
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Educators felt that the key issue was to balance the need for positive interaction and 
ensure enough support was given to enable participants to learn. The minimum 
number of participants suggested was four and avoiding ‘double’ figures. 
 
Views about resources 
 
Educators highlighted that some of the resources needed to be modified to promote 
greater visibility and accessibility for all participants, as they were often used with the 
group sitting around a table. Suggested solutions included placing posters on a 
frame (so they could be displayed upright or flat) or using larger sizes of all images, 
including photographs. The need to avoid shiny paper/laminating was also 
advocated.   
 
Educators also discussed in detail which participant resources worked well and 
some that would need to be adapted. They highlighted the possibility of reducing 
some resources, so as not to overwhelm participants (and carers). Some key issues 
identified included: 
x attendance certificates, reduce to one card for the whole programme instead of 
individual sheets for each week; 
x the participant folder (handbook of resources) need to be simplified and the 
overall amount of paperwork reduced; 
x sections and inserts need to be differentiated (e.g. by use of colours); 
x to aid the use of stickers in participant resources, need clearer labelling and 
boxes for where to place; 
x food diary worked well for some people but may need to consider alternative 
ways of recording food intake; 
x pedometer worked extremely well for some people but not for others; 
x when discussing “health checks” in the programme, have actual equipment to 
promote discussion/illustrate rather than images. 
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Views about the overall curriculum, style of delivery and group dynamics 
 
Educators contributed a number of things that were perceived to have worked well 
within the group: 
x participants had some prior knowledge which they wanted to apply for 
themselves; the education sessions contributed towards  enabling/supporting 
this; 
x a “happy” and “ keen” group with “characters that complimented each other”; 
x the sessions were perceived to be ‘pitched ‘correctly, although it was 
acknowledged that for group education it may not be possible achieve this for 
everyone; a flexible approach (altering language, using different resources) and 
skilled facilitation helped to address this; 
x a lot of participant (and carer) interest in food and weight reduction;  
x there were visible changes to a participant’s level of confidence over the course 
of seven weeks; 
x the bingo (game/activity) was a useful ‘recap’ tool; 
x allowing time to complete ‘homework’ during the first session was perceived to be 
a better approach; it could have overwhelmed participants if they were required to 
take something away to complete on their first day; 
 
There was a general perception that the short walking activity within sessions 
worked really well on several different levels, it: 
x helped to break up sessions; 
x was energising and helped concentration; 
x sent a “massive message” particularly to carers to show how a short walk can 
result in a lot steps; 
x was a huge motivational tool that sparked off discussion. 
 
Educators felt that carer involvement had contributed to a positive learning 
experience and that “carer” dynamics in the group had worked well. Some of the 
suggested ways that carers had helped included: 
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x identifying difficulties or challenges that participants may have at home and could 
impact affect making lifestyle change; 
x help to support challenging behaviours within the group; 
x playing a crucial role in supporting and motivating participants to undertake 
behavioural changes. 
 
What did not work so well 
 
The primary issue underpinning the education sessions was perceived to be keeping 
the balance between maintaining the motivation of participants to attend each 
session and not overwhelming them. A few educators felt that there were too many 
messages within the curriculum and that these could be reduced, with an emphasis 
in a future iteration on linking and building on messages. Similar views were 
expressed about the amount of resources used and a recommendation to review the 
amount and timing of their introduction at different points within the education 
sessions.  
 
Some specific difficulties raised that related to the second week of the main 
programme included that there was:  
x a lot of repetition (but this may be linked to educators following the curriculum too 
rigidly);  
x too much discussion when pedometers were introduced and participants found it 
difficult to make the connection about their results.  
 
Other points for consideration included: 
x the dominance of one participant highlighted a need to explore different ways of 
addressing this, should it arise in the future; 
x at times there was too much talking, during which some people were lost within 
the discussions; 
x a conceptual exercise/activity called “Big Daddy” did not work well with some 
participants; 
x the pace of sessions was too fast earlier in the programme, although this was 
adjusted in later sessions and subsequently viewed as working better. 
 185 
 
 
Finally, a few educators recognised that it was difficult to convey the concept of 
future risk of developing diabetes and recommended that the next iteration should 
emphasise the importance of providing foundational learning to help motivate and 
understand healthy eating. Educators’ also perceived that future follow-up sessions 
would be an essential part of the education programme and of particular importance 
in this population. Future sessions were seen as helping with: retaining focus; 
reinforcing positive behaviour changes; recap of learning; and identifying progress 
through practical measures (e.g. weighing scales). 
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9.5 Findings – second pilot phase 
 
9.5.1 Uptake and attendance at education sessions 
 
The second iteration of the education programme was held in a residential setting. A 
total of nine participants were invited to take part in the education programme. 
Several staff (care workers) from the residential home attended the initial carers’ 
session and seven participants agreed to take part in the education programme. In 
general, attendance at the education sessions was good, with three participants 
attending all seven days, one attending six and the remainder attending at least four 
days. Care workers from the residential home also attended at various points during 
the seven sessions (see Figure 22). 
 
9.5.2 Characteristics of participants 
 
Of the seven participants who took part in the second iteration, three (43%) were 
male, the median age was 43 years (range 29-50), and all seven lived in a 
residential home supported by carers. One of the participants had paid employment, 
two did voluntary work and all seven participated in other community activities.  
 
9.5.3 Feedback interviews – second pilot cycle 
 
After the final education session, a total of five participants with ID were interviewed 
along with two members of staff (carers) who had attended the education sessions. 
A care support worker who had attended some of the education sessions, provided 
support to one of the participants during the interview, helping her to feel at ease and 
assisting her to recall and discuss some of the lifestyle changes she had made. The 
remaining four participants chose to be interviewed in pairs with their respective 
partners. This arrangement worked well in terms of facilitating participants recall and 
support of each other, although it was challenging to ensure both participants 
contribution to the interview was maximised and balanced.  
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The presentation of quotations to support the summary of findings includes singular 
quotations as well as sections of the discussion with the researcher to help 
contextualise some of the responses to the questions. 
 
9.5.3.1 Interviews with participants 
 
Enjoyable sessions 
 
It was fairly evident that the education sessions had been an enjoyable experience 
for all the participants.  One participant was particularly happy about achieving 
weight loss and being able to share that achievement with their family. 
 
“The steps I’ve done, I’m amazed about the certificates.  I tell my mum 
about it, she is very happy…… They’re pleased about it, and my weight 
has gone down with it.” (Pt 1, M) 
 
Other participants talked about the specific things they had enjoyed, such as being 
part of a team/group, the resources (‘stickies’) they had used, or for one participant 
they were enthusiastic about all aspects of the programme.  
 
“Group activities…..and working well as a team. (Pt 4, M) 
 
“And sticking pictures on the posters, as well.”(Pt 5, F) 
 
“Everything!” (Pt 3, F) 
 
For three participants, when asked further to expand on what they enjoyed the most, 
they described sessions and resources relating to physical activity. Their enjoyment 
appeared to be linked to group walking within sessions, using a pedometer (given to 
them as part of the programme) to record how many steps they were achieving and 
recording steps/activity in their physical activity diary in between the education 
sessions. 
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“That walking around, kept going and going and going…” (Pt 3, F) 
 
“Plus the pedometers. Count how many steps… Shows how many 
steps.” (Pt 4, M) 
 
“Um, actually writing about my miles.”  (Pt 5, F) 
 
Key things learnt 
 
In response to a question about what they had learnt from the education sessions 
two participants cited physical activity and weight loss.  
 
Participant 3, F: “I've learnt a lot.” 
 Researcher:  What kinds of things have you learnt? 
Participant 3, F: “To lose more weight.” 
Participant 4, M: “And exercise.” 
Participant 3, F: “And exercise more.” 
 Researcher:  And you said exercise, what is it about exercise that you 
 learnt? 
Participant 3, F: “It keeps you healthy.” 
Participant 4, M: “And your heart…” 
Participant 3, F: “And your heart beating.” 
 
Establishing if participants associated key dietary and physical activity messages 
with specific parts of the education sessions proved difficult to elicit as recall about 
more detailed aspects of individual sessions was low. Therefore, drawing upon 
observational data that were collected during the seven sessions, the researcher 
took the opportunity to explore two sessions (storytelling and bingo) which had 
noticeably demonstrated a high level of engagement and participation, to identify 
whether participants could link these sessions to specific messages.  
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Both the bingo session and storytelling session were remembered as enjoyable 
sessions. One participant’s comments also conveyed the key message he took from 
the storytelling session.  
 
“And the story books were absolutely fantastic…..Yes, I enjoyed it, 
there’s nobody stopping me reading that, because [Name] was showing 
it, or [name] was showing it, what the whole people were eating, lots of 
cakes. That’s not good, that’s bad you know.” (Pt 1, M) 
 
Behaviour changes 
 
All of the participants who were interviewed had discussed during the education 
sessions that they had lost some weight (ranging from 2-5 kg). A few of the 
participants were motivated to lose weight for personal goals they had set for 
themselves. During the interviews participants (or carers) described some of the 
dietary changes made to help them achieve their goals. These included cutting out 
fizzy (sugary) drinks, reducing alcohol, smaller portions sizes, replacing chips with 
jacket potatoes, cutting down on puddings and eating more salad. 
 
“We used to drink loads of fizzy drinks and we don't now.” (Pt 3, F) 
 
“You’re not having such big portions ………… you have been trying 
hard for quite a while to eat better, haven’t you?  You don’t have chips; 
you have a jacket potato on Friday.” (Care Worker, Pt 5) 
 
 Researcher: You went down by two (Kgs)?  Your weight went down didn’t it? 
Participant 2, F: “Yes.” 
 Researcher: [Name], what did you do to change things? 
Participant 2, F: “Salad.” 
Participant 2, F: “Every Monday I don’t have puddings.” 
 
Feedback also suggested that some participants were consciously focused on 
undertaking physical activity as a consequence of attending the education sessions. 
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Pt 1, M: “Not to too many sweets, go for a walk, try to get some more 
miles down, steps.” 
 Researcher:  “So, that’s something that’s changed for you, you’ve  increased 
your steps?” 
Pt 1, M:  “Yes, I’m proving them right, you see.” 
 
“I've done…so far I'm going on the walking group and making new 
friends.” (Pt 4, M) 
 
“I was starting riding my bike long time ago.…. So I’m starting it again.” 
(Pt 5, F) 
 
 
Sustaining changes 
 
In response to a question about whether making the changes had been easy or 
difficult, two participants acknowledged making healthier choices were challenging 
with respect to reducing portion sizes and to overcome the temptation of sweets 
which are available in the flat shared with other residents. 
 
“Just getting used to the amount you want and stuff” (Pt 3, F) 
 
“It’s hard; it’s tempting to have sweets in the flat all the time, that’s 
what tempting.” (Pt 1, M) 
 
Care workers appeared to play a key role in helping to motivate and support 
participants to make and sustain changes to their diet and physical activity. This was 
illustrated by a participant who had lost a considerable amount of weight and 
described how staff (and his partner) had helped him with making healthy food 
choices and eating smaller portions: 
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“We do (help each other), because my link worker is helping me with 
my diet. She’s got all these healthy eating in my flat, see what I’ve got in 
the cupboard. That’s like salad sandwich and wraps as well, and coffee 
and oranges as well, squash. (Pt 1, M) 
 
When asked for examples of how staff had helped him, he responded by describing 
the following changes: 
 
Participant 1, M: “Eating less, eat salad, eat fresh fruit, coffee, or a 
sandwich, or something.”  
 Researcher: Is there anyone else who can help you to carry on with the 
 changes? 
Participant 1, M: “Link workers” 
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9.5.3.3 Interviews with carers 
 
Sustaining changes 
 
Care staff had already considered ways to sustain the changes made and the 
motivation of residents after the education sessions stopped.  
 
“I've said, it's important we keep it up. So while it's still fresh and you 
can run with it, because the weight loss thing, for their only to be one 
person who hasn't actually lost weight and even though it's a little bit. 
…………….We very often get the talk about how from your little acorns 
grow the big trees.” (Care worker 1) 
 
Things currently being discussed by care workers were a healthy living course and a 
weekly physical activity session. According to staff, following residents’ participation 
in the STOP diabetes study there was a general increased level of interest in 
“healthy living” and a few residents had recently indicated that they would like to do 
more exercise. 
 
 “Yes, it's [putting on a health living course] come about because 
you've come here, because of how the residents have responded, but 
also because I know they've made that request about having more 
exercise. (Care worker 1) 
 
Suggestions to facilitate recall of food messages and sustain changes outside of 
sessions included having images of breakfast alternatives that could be stuck onto a 
fridge door. This is something that is currently being tried with one of the participants 
because he has difficulties remembering. 
 
Amount of information covered in sessions 
 
In response to being asked about how they found the education sessions, and 
specifically about the amount of information, two conflicting views were evident.  
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One carer stated: 
“Well, just right, yeah. That was fine for what they were… And because 
it was the mix of those that could write, could write things, but they 
have their stickers and their pictures.” (Care worker 2) 
 
Another carer felt based on her observation of one of the sessions that there was too 
much information that may not help with retention of information: 
 
“I think in one session I was at there was a lot of information being 
given and maybe just simplify a little bit. Maybe just doing very small 
steps, and even if it's just one piece of information they learn that 
session, at least that might have more chance of sticking.” (Care 
worker 1) 
 
To help with retention this participant felt concentrating on one aspect of diet such as 
drinks for example, may have helped to focus efforts and facilitate discussion about 
alternatives. 
 
Carer involvement 
 
In response to a question about what educators needed to consider for any future 
programmes held in residential homes, the need to allow for variation in care 
workers attendance at sessions to support participants, due to organisational 
pressures (including low staff numbers), was highlighted. 
 
The above discussions also elicited the further suggestions for encouraging carer 
involvement: 
x the need to educate staff about what they will need to consider for people who 
they are responsible for; 
x to enthuse and engage staff to help with practical support such as completing 
the diaries and resetting the pedometer; 
x to provide information about alternative (healthier) food choices/options and 
portion sizes.  
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9.6 Modifications made to curriculum after the pilot cycles 
 
A number of modifications were made to the programme based on feedback from 
participants and carers, observations made during the education sessions, and the 
ongoing reflection and feedback of the educators. Modifications consisted of 
refinement of resources, together with adaptations to educator facilitation within the 
sessions. 
 
9.6.1 Revisions made after the first cycle  
 
The main revisions made after the first cycle included: 
 
Modifications to the carer session  
 
x Reducing the amount of information provided at this session.  
 
Modifications to education sessions 
 
Participant resources 
• Reducing the amount of worksheets given out at any one time. For the first pilot 
phase, all activity sheets developed for the seven week programme were given to 
participants in week one, in a folder format. This caused distraction for some 
participants and impacted on delivery of the session. Subsequently, this was 
changed to allow for the work sheets to be provided directly at the point they were 
required in the programme and for participants‘ to add to their programme folder on 
a weekly basis.  
• Simplifying the physical activity diary to a single sheet of A4, with a table to record 
date, steps/activity and new goal, from a multi-paged booklet. 
• Making the image cards, which are used to facilitate and support learning, 
recognition, recall and summaries, a much larger size. 
• Using realistic images and or photographs in resources. Images were sourced and 
checked with service user groups prior to being changed. 
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Session content 
ವ Reducing/simplifying the content of some sessions. Providing too much information  
led to participants becoming disengaged.  
ವ Changing the symbols used to illustrate healthy and less healthy foods as these 
were not universally understood by participants. Possibly a menu of symbols to 
tailor to individual cognitive needs. Ensure educators explain and check 
understanding when symbols are used.  
  
Maintaining and maximising engagement 
ವ Educators to create opportunities for movement, both within the room to engage in 
different activities and a short walk during each session, to address participants 
becoming disengaged when sitting for longer periods. Additionally, to use the 
walking activity to highlight the number of steps achieved in 5 - 10 minutes of 
walking. 
 
Communication aids 
ವ Using communication cards (with symbols/pictures) as an aid to manage 
discussions in the group and facilitate engagement of people who experience 
difficulty communicating.  
 
9.6.2 Revisions made after the second cycle 
 
Modifications to education sessions 
 
Maintaining and maximising engagement 
x Allowing for educator flexibility to adjust the timetable and breaks to suit the 
needs of individuals, the group dynamic, energy levels and engagement. 
x Educators and supporting staff to be aware of the diversity and dynamics in the 
group, and to arrange the seating and positioning of participants to support 
engagement and one to one support when required. 
x Including more interactive games/activities, such as bingo and board games, to 
promote engagement.  
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Participant resources 
x Including a menu of options to encorage prompts and motivation towards goals. 
For example, fridge magnets may not be useful to those in a residential setting if 
they did not have their own fridge. 
x Incorporating photos of participant‘s on to their “health checklist“,  as a way of 
personalising documents, and helping individuals to relate this information to 
themselves.  
 
 
9.7 Outline of the STOP education programme 
 
An overview of the final education programme developed, prior to using in the 
feasibility phase (Chapter 10), is outlined.  
 
First, the initial carer session, which is held prior to the main education programme, 
is presented (see Table 33). Secondly, in Table 34, the outline structure of a typical 
session in the main programme is outlined. Finally, for each individual session 
(weeks 1-7), the topic areas, the main aims, and the key activities and resources that 
are designed to support learning and behavioural changes, both within and between 
sessions, are also presented (see Table 35, Table 36 and Table 37). 
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Table 33: Outline plan of the initial carer session 
Session name Overview and main aims of activities Time 
Welcome and 
introductions 
To introduce the educators  
To understand the role of any observers 
To be aware of the style and aims of the course 
To ask questions related to the course 
15 mins 
Outline of education 
course 
To be aware of practical aspects (venue, times, number 
of sessions) 
To be aware that carers can attend with participants  
10 mins 
What is different for 
people with ID? 
To have an opportunity to share their thoughts about 
learning needs of the person they care for 
To share their thoughts about supporting people with ID 
to make lifestyle and behavioural changes 
10 minutes 
Course content To be aware of course content and resources 
To be aware of course activities and support participants 
may need between sessions to complete 
60 mins 
What is my role as a 
carer? 
To explore the benefits of attending the course with the 
participant 
To explore the potential health benefits for the person 
they are supporting, and themselves, of attending  
To be aware of their potential role in supporting the 
participant who chooses to make lifestyle and behavioural 
change 
15 mins 
Questions and concerns To have an answer to any questions 
To have concerns explored and addressed 
10 mins 
 
 Total 2 hours 
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Table 34: Outline of the structure of a typical session in the main education 
programme 
Session Aims and activities Time 
Welcome  
Welcome and 
getting to know 
you - week 1 
or 
Welcome back – 
weeks 2-7 
To ground and settle participants  
To outline the aims and style of the course 
To outline the topic areas for the day 
To reflect on actions from previous sessions- celebrate 
achievements and identify/explore barriers 
To develop good working relationship between 
educator and participants 
15 mins 
Topic area 1 Explore a different topic area each week 30 - 45 mins 
Break  15 minute break allocated within the session  
 
Breaks to be taken flexibly according to the expressed 
needs of the group or as indicated by educators 
assessment of engagement in the session 
15 mins 
Topic area 2 New topic area or  may build on/consolidate learning 
from the earlier session  
30 - 45 mins 
Questions and 
preparation for 
next week 
To provide an opportunity to express concerns, ask 
questions relating to the session  
To provide information and prepare participants and 
carers for activities between sessions 
10 mins 
 
 Total 
Minimum 100 mins 
Maximum 130 mins 
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Table 35: Outline plan for the STOP education programme weeks 1 and 2 
Week Overview of main aims  Activities and 
resources 
Theory 
Week 1    
Topic area 1 
What is health? 
Being healthy and 
unhealthy 
To explore what the concept of being healthy means to 
the individual 
To explore the behaviours linked to health 
Develop images that represent healthy and unhealthy 
characters that are used as a learning tool throughout 
the programme 
• Healthy and Unhealthy 
character poster 
• Images to prompt 
recognition and recall 
• Main message summary 
cards 
SRT 
TPB 
 
Topic area 2 
What can go 
wrong with my 
health? 
To explore the health consequences of lifestyle and 
behavioural  choices 
To explore lifestyle and behavioural choices that promote 
health  
To have an opportunity to express their emotional 
response to the different lifestyle choices the characters 
make 
x Images to prompt 
recognition and recall 
SCT 
SRT 
TPB 
 
Week 2   
 
Topic area 1 
This is me and 
Health checks my 
doctor or nurse 
will do 
To create an image that represents the individual, their 
lifestyle and behavioural choices 
To be aware of the health checks a doctor or nurse will 
do and be provided with their own biomedical data and 
risk factors 
To be aware of which results may be a problem to their 
health by placing a sticker on profile 
Plot results on a health profile 
• Personal lifestyle and 
behaviours activity sheet 
• Images to prompt 
recognition and recall 
• Health profile with 
photograph of individual  
• Biomedical data 
• Coloured stickers  
SCT 
SRT 
TPB 
 
Topic area 2 
What can I do to 
stay healthy? 
To explore the impact of the biomedical results and risk 
factors on their own health 
To express any concerns/emotions relating to their 
results 
Recall the consequences of lifestyle and behavioural 
choices 
To explore lifestyle or behavioural choices relating to 
their risk factors 
Have the opportunity to choose and record lifestyle or 
behavioural changes on a personal poster 
Record level of confidence to make this change 
• Images to prompt 
recognition and recall 
• Confidence activity 
sheet 
SCT 
SRT 
TPB 
 
SCT Social Cognition Mode; SRT, Self - regulation Theory; TPB, Theory of Planned Behavior. 
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Table 36: Outline plan for the STOP education programme weeks 3 and 4 
Week Overview of main aims  Activities and 
resources 
Theory 
Week 3    
Topic area 1 
Being active 
To explore what being active means 
To be aware of the consequences to health of being  
inactive 
To explore the benefits to health of being active, moving 
more and sitting less 
To have an experience of using a pedometer to measure 
steps 
• Images to prompt 
recognition and recall 
• Physical activity record  
• Pedometer 
• Walking activity 
SCT 
SRT 
TPB 
Topic area 2 
Me and my 
activity 
To have an experience of a short walk and recording 
steps or activity in a diary 
To identify ways to increase activity by adding an activity, 
increasing step count and/or reducing sitting time 
To record personal confidence to carry out their chosen 
goal 
To create a prompt or reminder for their chosen goal 
To record activity in a diary 
• Images to prompt 
recognition and recall 
• Confidence activity 
sheet 
• Create prompt cards, 
send a postcard or 
create a fridge magnet 
to promote engagement 
with their goal within the 
session and between 
sessions 
II 
SCT 
SRT 
TPB 
 
Week 4   
 
Topic area 1 
How did I do with 
my activity? 
To reflect on current level of activity 
Reflect on feelings related to level of activity 
To explore own and listen to other group members 
barriers to physical activity 
To explore strategies for overcoming barriers 
To experience a short walk to highlight the increase in 
steps from short periods of activity 
To identify a new steps or activity goal for the coming 
week 
• Interactive Dice game to 
explore barriers 
• Physical activity record 
• Walking activity 
(optional) 
SCT 
SRT 
TPB 
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Week Overview of main aims  Activities and 
resources 
Theory 
Topic area 2 
Changes I can 
make to be 
healthy 
Recall the lifestyle and behavioural changes that 
influence risk factors 
To be aware of the impact of unhealthy lifestyle and 
behavioural choices over many years - this is facilitated 
by using a story book 
Recall the personal lifestyle and behavioural choices 
recorded in session 2 
Reflect on progress with these choices 
Participants prepared and facilitated to explore sources 
of support for recording food, drinks and snacks over the 
next week 
• Personal lifestyle and 
behaviours activity sheet 
• Story book 
• Food diary 
II 
SCT 
SRT 
TPB 
II, Implementation Intentions; SCT Social Cognition Mode; SRT, Self - regulation Theory; TPB, Theory 
of Planned Behavior.  
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Table 37: Outline plan for the STOP education programme weeks 5, 6 & 7 
Week Overview of main aims  Activities and resources Theory 
Week 5    
Topic area 1 
How did I do with 
my activity? 
Eating well, 
eating healthy 
To reflect on activity levels over the last week 
Generate ideas for overcoming barriers 
Plan a new activity/step goal 
Walking activity ( optional -decision made collaboratively 
by the group) 
Recall the main messages relating to health 
Identify foods that relate to a healthy lifestyle 
Identify foods that contribute to being unhealthy 
Have an awareness of the consequences of high fat, 
sugar and large portions on health 
Be aware of the consequences of lower fat, sugar and 
smaller portions on health 
Sorting activity with food models and images 
• Physical activity record 
• Walking activity 
(optional) 
• Food models and 
images to support 
recognition and recall  
• Food sort task 
• Stickers 
II 
SCT 
SRT 
TPB 
 
Topic area 2 
Changes I can 
make to eat well 
and eat healthy 
Recall the food messages from the earlier session  
Record personal confidence to make a change to food 
choices 
Identify one or two small changes to make to personal 
food choices based on their food diary 
Create personal prompts to behaviour change  
 
• Food models and 
images 
• Food diary  
• Create prompt cards, 
send a postcard or 
create a fridge magnet 
to promote engagement 
with their goal within the 
session and between 
sessions 
II 
SCT 
SRT 
TPB 
 
Week 6   
 
Topic area 1 
Where am I with 
my activity? 
 
To reflect on activity levels over the last week 
Generate ideas for overcoming barriers 
Plan a new activity/step goal 
Walking activity ( optional -decision made collaboratively 
by the group) 
Recall the main food messages related to health and 
being unhealthy by participating in an interactive game 
Recall the consequences of food choices 
 
• Physical activity record  
• Food diary 
• Food bingo activity 
• Bingo prize for the 
winner 
II 
SCT 
SRT 
TPB 
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Week Overview of main aims  Activities and resources Theory 
Topic area 2 
How am I doing 
with my eating 
well, eating 
healthy? 
Reflect on the food diary 
Identify successes and barriers to making changes to 
food choices 
To explore own and listen to other group members 
barriers to making changes to food choices 
To explore strategies for overcoming barriers with an 
interactive game 
Explore how to reward personal success 
Identify sources of support to reach goals 
Plan a new food goal 
• Food diary 
• Barriers board game  
• Create or amend prompt 
cards, send a postcard 
or create a fridge 
magnet to promote 
engagement with their 
goal within the session 
and between sessions 
II 
SCT 
SRT 
TPB 
 
Week 7 
   
Topic area 1 
What have I 
learnt? 
Reflect on activity levels and the food diary over the last 
week 
Review  the overall programme and raise any 
outstanding concerns or questions 
Recall main points of the programme and revisit 
associated activities 
Identify successes and barriers to making changes 
 
 
• Food diary 
• Activity diary 
• Healthy and unhealthy 
character posters  
• Personal lifestyle and 
behaviours activity 
sheet 
• Images to prompt 
recognition and recall 
II 
SCT 
SRT 
TPB 
 
Topic area 2 
What can help me 
to keep going 
with changes to 
my food and 
activity levels? 
 
Record personal changes on activity worksheet 
Explore possible solutions to barriers 
Explore strategies to support the maintenance of 
changes  
Set new goals and use strategies to help such as writing 
a postcard to themselves to be sent in 3-months’ time or 
creating fridge magnets 
Record personal confidence to carry out their chosen 
goal 
Explore sources of support to help achieve these goals 
Celebrate success 
 
• Worksheet to record 
personal changes that 
have been made 
• Postcards, fridge 
magnets, flashcards and 
stickers 
• Prompt card to give to 
carers to ask for help 
• Confidence activity 
sheet 
• Course attendance 
certificates 
RP 
SCT 
SRT 
TPB 
II, Implementation Intentions; RP Relapse Prevention; SCT Social Cognition Mode; SRT, Self - 
regulation Theory; TPB, Theory of Planned Behavior.  
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9.8 Concluding remarks 
 
This chapter and the previous chapter (Chapter 8) has described the development 
and pilot phases (testing, evaluation, modification and re-testing) that were carried 
out in order to develop a lifestyle education programme for adults with ID.  
 
The STOP programme development benefitted from a systematic process.238, 239 The 
theoretical underpinning was developed and expanded upon from the limited 
evidence in the literature.  This informed the content and style of approach, 
alongside the qualitative findings from people with ID, their carers, and health care 
professionals with expertise in working with people with ID.  The whole programme 
was then tailored further to the specific needs of this group by more user feedback, 
and adaptation by a multi-disciplinary team with expertise in ID and the development 
of education programmes.   
 
From the initial phases the programme has been well received and is acceptable to 
the people it is trying to support.  The initial feedback via qualitative interviews has 
suggested that some of the elements of treatment receipt initially hypothesised may 
have been achieved, via reported changes in beliefs and health behaviours.   
 
The following chapter (Chapter 10) details the feasibility phase. Chapter 11 details 
the intervention fidelity of the education programme 
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CHAPTER 10.   FEASIBILITY STUDY OF STOP DIABETES 
PROGRAMME 
 
 
10.1 Overview 
 
This chapter describes a feasibility phase, which follows on from the education 
development work described in Chapter 8 and Chapter 9, and forms part of work 
package 2. 
 
10.2 Aims and objectives 
 
The aim of this sub-study was to assess the feasibility of collecting outcome 
measures for participants with ID before and 3-months after they attend the lifestyle 
education programme. 
 
10.3 Methods 
 
10.3.1 Study design 
 
Following initial development, testing and refinement of the curriculum (Chapter 8 
and Chapter 9), the education programme was delivered to another group of 
participants to assess the feasibility of collecting pre and post intervention outcome 
measures.  
 
10.3.2 Study setting 
 
The feasibility phase was conducted between January and June 2015 
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10.3.3 Participants 
 
10.3.3.1 Inclusion criteria 
 
Eligibility criteria for the feasibility phase were the same as for the two pilot phases 
described in Chapter 8: 
x service users who had participated in the screening stage (Chapter 5); 
x VFUHHQHGSRVLWLYHIRU,*5RUKDGD%0,; 
x indicated a willingness to assist with later phases of the research programme; 
x mild to moderate ID; 
x able to stand and walk at least short distances; 
x able to attend group education sessions; 
x not taking part in any other intervention study. 
 
 
10.3.3.2  Participant recruitment and consent 
 
Participants were recruited following a similar process to earlier phases (see Section 
8.4). Potential participants received an initial telephone call to gauge their interest, 
and this was followed up by further information sent in the post or provided at a face-
to-face visit.  
 
Volunteers were invited to attend an initial appointment at a convenient time for 
them, where information was provided about the study and informed consent was 
obtained. Consent was obtained following a similar process to that described 
previously (see Section 5.5.1). People were asked to consent to the collection of 
baseline data, attendance at the education programme and collection of 3-month 
follow-up data. 
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10.3.4 Data collection  
 
10.3.4.1 Baseline data collection 
 
Baseline data were collected using the same schedule as in the screening study 
(work package 1, see Chapter 5). If participants had taken part in the screening 
stage within the last three months, and valid measurements had been successfully 
obtained, then these data were used for baseline values. If a participant took part in 
the screening stage >3-months ago, then the measurements were repeated.  
 
Data collected included: 
x weight 
x height 
x BMI 
x waist circumference 
x BP  
x dietary intake (fruit, vegetables and salad).  
 
Physical activity (time spent in light, moderate, vigorous activity) and sedentary 
behaviour (time spent sedentary) were measured using the wrist worn accelerometer 
(GENEActiv, Activinsights Ltd., Cambridge, UK). The process for measuring activity 
using this accelerometer has previously been described in Chapter 7. 
 
10.3.4.2 3-month data collection 
 
At 3-months following the end of the education programme, participants were 
recalled for repeat data collection, as per at baseline. 
 
10.3.5 Outcomes 
 
Particular outcomes of interest in terms of the feasibility included: (i) the proportion of 
people invited who attend the baseline appointment, education programme, 
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individual sessions within the programme, and 3-month follow-up; and (ii) the 
completeness of key data items at baseline and 3-months follow-up. 
 
Problems encountered during data collection appointments and implementing the 
education were also considered. 
 
10.3.6 Delivery of intervention 
 
Following on from the pilot phase of testing, evaluation and modification described in 
Chapter 9, the final modified education programme (see Section 9.7) was delivered 
to another group of adults with ID and their carers, at a local community venue. 
 
10.3.7 Sample size 
 
We aimed to conduct the feasibility study with at least one group of participants (four 
to eight people with ID, plus carers).  
 
10.3.8 Data analysis 
 
The feasibility of recruiting adults with ID to attend for baseline data collection, 
education sessions and 3-month follow-up data collection was assessed using a flow 
diagram to summarise drop outs at each stage. Completeness of outcome data 
collected at each stage was summarised using counts and proportions. 
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10.4 Findings 
 
Study timelines for the feasibility phase enabled us to run one iteration of the 
education programme, with collection of before and after measurements. 
 
10.4.1 Recruitment and consent 
 
A total of 19 participants were invited to take part in the feasibility phase, of which 
five (26%) agreed to attend an initial appointment at the end of February 2015, 
where consent and baseline data were obtained. All participants had the capacity to 
give consent for themselves, without the need to involve a consultee. 
 
10.4.2 Feasibility of collecting baseline data 
 
At baseline, all participants required measurements to be taken as it was >3-months 
since they had originally taken part in the screening study. Baseline data were 
obtained for all five participants, with the exception of physical activity data which 
was only collected for four (80%) participants, as one person refused to wear the 
accelerometer (see Table 38).  
 
Table 38: Availability of data at baseline and 3-months follow-up 
 
Baseline 
n (%) 
3 months follow-up 
n (%) 
Weight, kg  5 (100) 5 (100) 
Height  5 (100) 5 (100) 
BMI, kg/m2  5 (100) 5 (100) 
Waist circumference, cm  5 (100) 5 (100) 
Systolic BP, mmHg  5 (100)            4 (80) 
Diastolic BP, mmHg  5 (100)            4 (80) 
Portions of fruit and vegetables  5 (100) 5 (100) 
Physical activity and sedentary behavior  
(time spent in light, moderate, vigorous 
intensity activity); (time sedentary) 
           4 (80)            3 (60) 
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10.4.3 Uptake and attendance of education programme 
 
Following the baseline appointment, all five participants took part in the education 
programme, which was held from March to April 2015. A total of four carers (two paid 
care workers, two family) attended at least some of the sessions (three regularly). 
Overall attendance at the education sessions was good, 4 (80%) participants 
attended  5 days and 2 participants attended all 7 days (see Figure 23). However, 
one participant only attended 3 days. It is important to note that the most common 
reason for not attending sessions was due to other existing commitments such as 
appointments and holidays.  
 
10.4.4 Feasibility of collecting data at 3-months follow-up 
 
All participants agreed to attend a 3-month follow up appointment at the end of June 
2015, to obtain repeat measures. Four of the participants (80%) attended the 
appointment as arranged; one participant needed a second appointment arranging 
due to non-attendance (this was the same participant who only attended three days 
of the education programme). 
 
Anthropometric measures (weight, BMI, waist circumference) were obtained for all 
participants (see Table 38). BP readings were successfully obtained for four (80%) 
participants. Accelerometer data were obtained for three of the four participants who 
wore one at baseline; four participants initially agreed to wear the accelerometer but 
one participant later telephoned the research team to inform them he had changed 
his mind.  
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Figure 23: Uptake and attendance for data collection and education sessions 
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10.4.5 Characteristics of participants 
 
Key demographic characteristics for the five participants’ are presented in Table 39. 
Four (80%) participants were male, the median age was 40 years (range 20-51) and 
all were of white ethnicity. Two participants lived alone, one lived in supported living 
and two lived in a family setting; the majority (n=4, 80%) had support from a carer for 
at least some of the time. None of the participants were in paid employment, two did 
voluntary work on a regular basis, and two attended college and other community 
related activities,  
 
Table 39: Characteristics of participants 
 
Characteristics n = 5 
Age, years (median, range) 40 (20-51) 
Sex, male n (%) 80 
Ethnicity n (%) 
White 
South Asian 
Other 
 
5 (100) 
0 
0 
Accommodation n (%) 
Alone 
With family/carers 
Residential/supported living 
 
2 (40) 
2 (40) 
1 (20) 
Support from carer n (%) 
Yes, at least some of the time 
No 
 
4 (80) 
1 (20) 
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10.4.6 Baseline data 
Bio-medical and lifestyle characteristics, from data collected at baseline, are 
presented in Table 40. The median values for weight, BMI and waist circumference 
were 110.2 cm, 36.1 kg/m2 and 114.3 cm, respectively. For BP, the median systolic 
value was 123 mmHg and diastolic 85 mmHg. Reported daily intake of fruit, 
vegetables or salad indicated that only two (40%) participants were eating the 
recommended five or more portions a day (median 5). For physical activity, the 
median minutes/day for MVPA and light intensity activity were 107.5 and 93.0, 
respectively; the median time spent sedentary was 555.0 minutes/day. 
 
10.4.7 3-month follow-up data 
 
Data collected at 3-months follow-up are presented in Table 40. The main aim of the 
work conducted was the feasibility of collecting data at two time points, and not 
looking for change.  
 
However, on an individual basis, three participants lost weight (range 1.0 to 4.2 kg 
but two participants gained weight. For one participant who had gained a lot of 
weight (17.6kg), their attendance at the education programme was poor (3 out of 7 
sessions); anecdotal evidence at 3-months follow-up suggested that significant 
changes had occurred in this participants personal circumstances since baseline, 
including moving out of the family home to live independently in their own flat.   
 
Where data were available, participants showed improvements in physical activity 
levels and sedentary behaviour at 3-months follow-up when compared to baseline. 
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Table 40: Baseline and 3 month follow up data – individual level 
Participant  Systolic BP 
(mmHg) 
Diastolic BP 
(mmHg) 
Weight 
(kg) 
BMI (kg/m2) Waist (cm) Fruit & 
vegetables 
(portions) 
Physical 
activity - time 
in MVPA 
(mins/day) 
Time in light-
intensity 
physical 
activity 
(mins/day) 
Sedentary 
behaviour - 
time spent 
sedentary 
(mins/day) 
1 Pre 117 87 133.0 36.1 136.8 7 153.0 126.0 708.0 
 Post 115 80 136.4 37.0 137.0 5 51.0 18.0 150.0 
2 Pre 101 66 84.4 36.1 112.3 3 106.0 102.0 672.0 
 Post 106 68 82.6 35.3 113.5 5 115.0 120.0 708.0 
3 Pre 124 83 110.2 36.4 117.5 1 109.0 84.0 438.0 
 Post 116 84 106.0 35.0 117.0 5 154.0 96.0 402.0 
4 Pre 123 86 112.4 37.6 114.3 6 n/a n/a n/a 
 Post n/a n/a 130.0 43.4 137.4 0 n/a n/a n/a 
5 Pre 146 85 88.6 28.3 108.1 3 91.0 60.0 366.0 
 Post 130 83 87.6 28.0 102.5 3 n/a n/a n/a 
Overall 
median 
(range) 
Pre 
123 
(101-146) 
85 
(66-87) 
110.2 
(84.4-133.0) 
36.1 
(28.3-37.6) 
114.3 
(108.1-136.8) 
3 
(1-7) 
107.5 
(91.0-153.0) 
93.0 
(60.0-126.0) 
555.0 
(366.0-708.0) 
median 
(range) Post 
115.5 
(106-130) 
81.5 
(68-84) 
106.0 
(82.6-136.4) 
35.3 
(28.0-43.4) 
117 
(102.5-137.4) 
5 
(0-5) 
115.0  
(51.0-154.0) 
96.0 
(18.0-120.0 ) 
402.0 
(150.0-708.0) 
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10.5 Discussion 
 
Overall, the findings suggest that it is feasible to collect outcome measures at two 
time points, before and 3-months after attendance at a lifestyle behaviour 
modification intervention. 
 
Twenty-six per cent (n=5) of people who were invited to take part in the feasibility 
phase agreed to participate. At baseline, anthropometric measures and BP were 
obtained for all participants, and accelerometer data for 80%. Attendance at the 
HGXFDWLRQSURJUDPPHZDVRYHUDOOJRRGZLWKRISDUWLFLSDQWVDWWHQGLQJGD\V
(out of seven sessions for the main programme). At 3-months follow-up repeat data 
were successfully collected for a high proportion of participants (anthropometric 
measures 100%; BP 80%; accelerometer data 60%). 
 
It is acknowledged that the feasibility phase only involved a very small number of 
participants (n=5) and carers. Owing to time restrictions we were only able to 
conduct one feasibility cycle (delivery of intervention, plus pre and post intervention 
measures). However, the feasibility phase used robust processes which were 
informed by the preliminary findings from the screening phase and lessons learnt 
from the earlier phases of education development and delivery.  
 
It is recognised that the feasibility phase was not aimed at seeing significant findings 
from baseline to post intervention follow-up. However, at 3-months there were some 
beneficial changes for most participants.  
 
These preliminary findings are positive but we are unable to assess whether it is 
possible to collect longer term data, beyond 3-months post intervention, or at 
repeated time points. The 8-week educational intervention developed as part of work 
package 2 appears to be both feasible and acceptable to people with ID (and their 
carers), who are identified as being at high future risk of T2DM and/or CVD. 
However, the intervention is yet to be tested more robustly via a randomised control 
trial, including possible follow-up maintenance education sessions. Findings from the 
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development and feasibility phases provide valuable data to help inform future 
research.  
 
10.6 Concluding remarks 
 
This chapter has described a feasibility phase that was carried out to assess the 
feasibility of collecting outcome measures for participants with ID before and 3-
months after they attend a lifestyle education programme. Development of the 
education programme was described in Chapter 8 and Chapter 9. The following 
chapter (see Chapter 11) details the intervention fidelity of the education programme. 
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CHAPTER 11.   INTERVENTION FIDELITY PROCESS 
 
 
11.1 Overview 
 
The methods and results of the intervention fidelity process for work package 3 are 
described below. 
 
11.2 Rationale 
 
Intervention fidelity relates to how an intervention is delivered in practice and 
whether the delivery of the intervention varies according to the context. It is now 
recognised as a key  component in the evaluation of complex interventions,238, 249, 250 
enabling the assessment of reliability and validity of an intervention and the process 
factors both advancing the study aims and reducing premature abandonment of 
future interventions.251 
 
The assessment of intervention fidelity is seen as particularly important when 
interventions are evaluated using multi-centre RCTs, because there is risk of 
delivering and/or receiving the intervention differently between sites.250 It was 
anticipated that findings from the current research programme would inform a future 
multi-centre RCT.  
 
The Diabetes Education and Self-Management for Ongoing and New Diagnosed 
(DESMOND) model of structured education,252 which underpins work conducted in 
this chapter, draws on theoretical and philosophical perspectives from both health 
psychology and education;253-255 patient empowerment is at its centre. DESMOND 
programmes meet nationally agreed quality criteria256 for patient education, including 
delivery by trained and accredited educators, and quality assurance.  
 
One of the key components of quality assurance is intervention fidelity. In practice, 
assessment of intervention fidelity involves appraising education delivery, with 
particular emphasis on the assessment of educator behaviours. The DESMOND 
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education approach purports that individuals in the main are responsible for making 
their own choices around self-management. Barriers outside of  the persons control 
are acknowledged, but the role of the facilitator or educator is to encourage the 
participant to explore their motivations for self-management or engaging in health 
promoting behaviours, rather than telling them what to do; the former set of 
behaviours can be attributed to being ‘DESMOND’ and the later are non-DESMOND. 
Further details of the methods used to assess educator behaviour and the 
DESMOND and non-DESMOND approach, are outlined in Section 11.5.3 and Table 
42. 
 
The original programme of work included a pilot RCT to assess the effectiveness of 
the lifestyle education programme (intervention) developed. However, amendments 
to the programme of research requested by the NIHR, determined that a feasibility 
phase was conducted (described in Chapter 10) rather than an RCT. Thus data 
collection from multiple iterations of the programme and across different educators 
was not practicable. The amended aims and objectives, as outlined in the next 
section (Section 12.3), take the above into account. 
 
11.3 Aims and objectives 
 
The primary aim of this component of the research programme was to conduct 
preliminary work towards developing an intervention fidelity process and tool 
specifically tailored to this population.  
 
Specific objectives were to: 
x develop an outline educator training programme;  
x conduct a preliminary assessment of educator behaviour using an existing quality 
development tool; 
x identify key important adaptations to the existing tool for use in a programme 
developed for the ID population in the future. 
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11.5 Methods 
 
11.5.1  Educator training 
 
The educators for delivery of the intervention (outlined in Chapter 10) comprised a 
registered ID nurse and a diabetes specialist with an education background, with 
support from an ID nurse or health care assistant. 
 
The process of training the educators, first, involved professional development 
around the DESMOND education programme. This stage took place between 
January and March 2014, and included observations of DESMOND based 
programmes and attendance at a Core DESMOND training day. This provided an 
introduction to the theoretical basis, philosophy and core skills of DESMOND. 252 
 
Secondly, the educators attended an initial study-specific training day in April 2014, 
where they were introduced to the  theoretical component, content, structure and 
delivery of the STOP Diabetes education programme (Table 41). This was followed 
by a second study-specific day in June 2014. A staged approach was used for 
delivering the educator training to take into account any necessary changes to the 
programme (curriculum content, delivery and structure) based on the delivery of the 
early sessions. 
 
The training was delivered by two members of the development team, a consultant 
clinical health psychologist and diabetes specialist nurse with an education 
background. Training included detailed information on the content, structure and 
delivery of the programme, and incorporated additional support and considerations 
around working with people with ID. Guidance around indirect approaches for 
educating participants (e.g. role-playing behaviour change techniques) and direct 
approaches (e.g. presentations), were included.  
 
Educators used a specific training curriculum to equip them to support the delivery of 
education sessions and were encouraged to use personal reflection and peer review 
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tools to reflect on their delivery. They were also supported with mentorship from 
trainers attached to the research team. 
 
An outline of the training programme is presented in Table 41. The first training day 
covered the first five sessions of the education programme (the carers’ session and 
weeks 1-4).  
 
Day 2 educator training, which covered the curriculum and resources for the final 
three sessions (weeks 5 – 7), followed a similar format to the first training day, taking 
into account feedback relating to the initial training. In addition, educators were able 
to feedback their experiences on delivery of the first 4 sessions, and to reflect on 
their own self-monitoring and behaviour change experiences. 
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Table 41: Outline of the education training programme – Day 1 
Session name Overview and aims Time 
Welcome and 
introductions 
Explore expectations and concerns about training  
Outline the style and aims of the training 
15 mins 
What is different about 
group self-management 
education for people with 
ID 
Exploring participants experience of delivering education to 
people with ID 
Exploring how working with a group may be different to 1:1 
Methods to promote learning in this programme 
30 mins 
Prevention and health 
messages 
Exploring the key messages for CVD and diabetes prevention 
Explore the key messages for the education programme  
30 mins 
Key messages for each 
session 
Provide an opportunity to review the curriculum and identify 
the key messages and activities for each session 
30 mins 
Development and 
theoretical underpinning 
Recap on the theories that underpin this programme 
Providing an opportunity to explore their own health 
behaviours and making a plan. 
60 mins 
Lunch   
Carer session Review curriculum and aims of session 
Explore how to engage carers 
45 mins 
Sessions: Weeks  1-3 Review curriculum and resources for sessions 1-3 
Identify any challenges to delivering these sessions 
60 mins 
Session: Week 4 and 
resources 
Review curriculum and resources for week 4Be aware of 
other resources available for use with the programme 
Identify any challenges to delivering the session and using the 
resources 
40 mins 
Overcoming challenges 
to delivering the sessions 
Recall the challenges identified 
Explore options for overcoming the challenges 
50 mins 
Reflection and feedback 
tools 
Explore the purpose of the reflection and feedback tools 
Explore strategies to increase confidence to deliver the 
programme 
15 mins 
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Session name Overview and aims Time 
Next Steps Give out food diaries, pedometers and activity diaries to 
provide experience of self monitoring and behaviour change. 
Explore the benefits of experiencing using the tools and self 
monitoring that participants will use. 
15 mins 
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11.5.2 Evaluation of educator training 
 
Subsequent to completion of their training, educators completed an evaluation form 
(see Appendix 20) for the STOP diabetes training sessions. Following their first 
delivery of the education programme, educators involved in delivering the sessions 
were interviewed by a qualitative researcher, to explore their views about the content 
and style of delivery, experiences from delivering the programme and perceived 
practical issues; feedback from these interviews is presented as part of the first pilot 
phase (see Chapter 9).  
 
11.5.3  Preliminary assessment of educator behaviour 
 
The quality development tool used to conduct preliminary assessment of educator 
behaviour was based on current assessment tools developed by the DESMOND 
collaborative;252 which recognises that training health professionals to deliver 
education programmes does not always result in appropriate or consistent delivery of 
the programmes.257 
 
The tool was developed in 2015 and consists of 5 ‘global’ categories, each 
containing specific items to evaluate programme delivery; it is a revision of a 
previous DESMOND tool.258 The tool is designed to be used by a separate observer 
who assesses the educator’s behaviours when they teach/deliver education. Each 
item in the tool represents a discrete DESMOND behaviour which is paired with an 
‘opposite’ item (labelled as a non-DESMOND behaviour), that are coded when 
observed. The observer is asked to rate which behaviour (i.e. DESMOND or non-
DESMOND) is most commonly seen during the training session. For example, the 
first item requires the observer to assess whether the educator uses open body 
language to support engagement of participants (Table 42). DESMOND behaviours 
for this item include nodding and smiling at the participants and non-DESMOND 
behaviours include avoiding eye contact and the educator turning their back on the 
participants when asking a question. By noting down these behaviours when they 
occur, the observer can determine which behaviour was most common during the 
training session. 
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Prior to using the tool to assess educator behavior for the STOP programme, three 
members of the education development team reviewed the existing quality 
development tool, and its application in the STOP diabetes programme. As a result 
only one of the items in the reflective learning category was changed (see Table 42), 
because it is recognised that people with ID are more amenable to concrete 
concepts and visual imagery than to more abstract concepts, such as analogies,165 
(see also Chapter 8 and Chapter 9). 
 
Between March and April 2015, a member of the research team attended the final 
iteration of the education programme employing the tool. The researcher was an 
experienced member of the research team, had attended specific STOP educator 
training and was involved in the development of the education programme. The tool 
was used to describe how the educators interacted with the group, identify 
differences between educators’ behaviours and to assess appropriateness to this 
client group. The researcher used the quality development tool to conduct 
assessments during six out of seven of the education sessions. During these 
sessions the researcher positioned themselves outside of the group and completed 
the tool separately for each educator.   
 
In addition to noting educator behavior, assessment of participant-educator 
interaction was undertaken during one observation visit, using a 10 second   event 
coding to estimate the amount of time educators were speaking. When the beep 
sounded, the coder indicated on a response sheet who was talking at that point in 
time (whether an educator or a participant), with other activity classed as 
‘miscellaneous’ (indicating silence, laughter or multiple conversations during learning 
activities).  The 10-second event coding is an objective measure and an established 
method of measuring talk time educator ratio.259, 260  
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Table 42: Assessment items in educator behavior assessment tool 
DESMOND behaviour Non-DESMOND behaviour 
Facilitating non-judgemental engagement of all participants 
Uses a range of open body language to support 
engagement of participants 
Tends to use more closed body language 
behaviours 
Uses non-judgemental statements regarding 
participant verbal utterances  
Uses judgemental statements in response to 
participant verbal utterances 
Seeks answers from a number of participants 
before discussing further, including right and 
wrong answers 
Accepts the first (right) answer and/or immediately 
providers correct or up-to-date information 
Seeks clarification of participants’ contribution 
Rarely seeks clarification of participants’ 
contribution 
Avoids giving general healthy messages Provides general healthy messages 
Avoids giving their own opinion Gives their own opinion 
Eliciting and responding to emotions/feelings (empathetic responding) 
Prompts participants to express and explore their 
feelings about diabetes 
Avoids actively engaging participants in emotional 
discussion 
Acknowledges and/or prompts exploration of 
participant emotional response 
Retreats from/ignores/denied participant emotional 
response 
Facilitating reflective learning 
Uses analogies* Avoids the use of analogies* 
Uses visual tools and resources Does not use visual tools and resources 
Uses and refers to participants’ comments and 
quotes 
Uses his/her own words when working through 
session content 
Encourages group to discuss/answer their own 
questions 
Answers most questions asked by the group 
Prompts participants to explore misconceptions 
and gaps in knowledge 
Immediately provides correct information to fill 
apparent gaps in knowledge 
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DESMOND behaviour Non-DESMOND behaviour 
Notices and prompts discussion of personal 
health beliefs 
Avoids discussion of health beliefs within the group 
Prompts all participants to ask questions about 
issues discussed 
Rarely invites (more than once) participants to ask 
questions 
Prompts group to summarise key messages Tends to summarise key messages 
Prompts group to summarise their own 
understanding 
Tends to summarise what she/he thinks is the 
group’s understanding 
Prompts ‘self talk’ about how the key messages 
from the session applies to them 
Does not ask participants to reflect on how the key 
messages apply to them 
Only provides new information after group 
discussion 
Regularly provides new information without group 
discussion  
Behavioural change, planning and goal setting  
Acknowledges when participants decide not to 
make any future changes to self-care behaviours 
or beliefs 
Expects participants to make necessary changes 
Prompts participants to discuss their thoughts 
about possible changes 
Avoids generating discussion about possible 
changes 
Prompts participants to review the impact of 
possible choices on their future health 
Avoids generating discussion about range of 
options/impact 
Prompts participants to talk about what they are 
going to do as a result of the session 
Rarely asks participants what they are going to do 
as a result of the session 
Prompts problem solving of possible barriers to 
change 
Avoids ‘active’ problem solving support 
Prompts participants to reflect on their 
goals/plans 
Avoids reflective discussion regarding goals/plans 
Facilitates sharing of stories about positive 
attempts to manage their health 
Avoids use of participant stories of positive 
success 
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DESMOND behaviour Non-DESMOND behaviour 
Supports participants to plot their results on the 
health profile/action plan 
Provides little support to assist participants with the 
completion of their health profile/action plan 
Prompts reflection of changes already made Does not prompt reflection of changes made 
Overall group management  
Uses strategies to manage time Avoids using strategies to manage time 
Notices tone/dynamics within the group and uses 
these to manage the group 
Tends to ignore issues within the group 
Prompts engagement of quieter participants 
Avoids seeking engagement of quieter members of 
the group 
Uses co-educator to support delivery 
Appears to work alone despite opportunities that 
may be assisted by co-educator 
Manages group to provide time and space to 
complete tasks 
Avoids managing group to allow time and space 
Provides overviews of the sessions/day Does not provide overviews of the sessions/day 
Outlines the style of the sessions Does not outline style of sessions 
Facilitates full engagement in interactive tasks 
Tends to facilitate interactive tasks with only a few 
participants 
Engages participants using rapport building skills Avoids using rapport building skills 
* The DESMOND behaviour was modified to “Does not use analogies” and non-DESMOND behaviour 
to “Does use analogies” for the STOP Diabetes education programme. 
 
11.5.4  Identifying key important educator behaviours 
 
Once the preliminary assessment had been conducted, members of the research 
team met to explore the items within the tool, primarily to distinguish between 
educator behaviors’ that were seen to be important versus those that appeared less 
core or essential when facilitating adult learners with ID.   
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11.6 Results 
 
11.6.1  Educator training 
 
The STOP Diabetes specific training was attended by two diabetes education 
specialists, four ID health care professionals and other members of the research 
team. It is important to note that not all of these members of the team went on to 
deliver the education programme.  
 
Based on evaluation forms completed by six of the educators following the two 
training days, the training was universally well evaluated. Using a standard 
evaluation self-report measure, all of the educators agreed with the statement that 
they had learned new skills and believed they could apply these skills in practice. 
The most helpful aspects of training cited by educators included: going through the 
curriculum and resources; learning about the development and theoretical 
underpinning of the programme; and group discussions and learning from 
colleagues. 
  
11.6.2  Preliminary assessment of educator behaviour 
 
Based on findings from one observation visit conducted to assess participant-
educator interaction. In general, the observer noted that the diabetes specialist (who 
was the trained educator) generally displayed more of the facilitation of learning 
behaviours, such as using open body language, seeking clarification of participants’ 
contributions and providing overviews of the sessions; the ID nurse displayed more 
engagement behaviours, prompting exploration of feelings, involvement of quieter 
participants and facilitating full engagement in interactive tasks. The DESMOND 
behaviour of prompting the group to summarise the key messages was rarely 
observed. 
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11.7 Discussion  
 
Based on initial feedback educator training was universally well evaluated. Educators 
believed they had learnt new skills and could apply them in practice. However, we 
acknowledge only trained one group of educators. 
 
The preliminary assessment of educator behaviours has identified that different 
behaviours may be delivered depending on the educator. The small number of noted 
differences between educators in terms of behaviours may be due to professional 
background and training.  The ID nurse may have had more specialist expertise in 
engaging people with greater communication and engagement needs.  However this 
difference may have also been due to differing roles in the delivery of the programme 
as the diabetes educator had been the original developer of the programme and may 
have been focused on exploring the delivery and the content of the programme 
further. This work has identified what needs to be focused on for future training in 
this area.  
 
This work has been a useful first step in the development of a tool that could usefully 
be employed in this area.  Further work is required as the tool thus far has only been 
used on one programme by one observer. The first two iterations of the development 
of the STOP diabetes programme could not be assessed using the tool as the 
programme was still in development. However, despite this the tool allowed for 
preliminary assessment, it provided a structure for the and even at this early stage 
found variance between educators and will provide a benchmark for future work.  
 
11.8 Recommendations 
 
The findings from this chapter have provided a positive starting point and highlighted 
a number of recommendations for future work in this area. The tool is now ready for 
further adaptation to optimise its relevance for the target population. Possible 
adaptions include: 1) shortening the tool for simplicity; 2) omission of some items 
that are not relevant or appropriate for this client group, such as items that relate to 
abstract concepts and that require participants to remember or summarise the 
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training points. Items essential to this group have also been identified such as 
teaching at the group’s pace and being flexible. In any future work the tool would 
also be specifically tailored to follow the structure of the STOP programme. The tool 
would then need to be tested with a wider group of educators across the delivery of a 
larger number of programmes.  
 
The health care assistant and the nurses who supported the STOP programme were 
not included in the intervention fidelity observations.  It is suggested they be included 
in future assessments as they are also key to the delivery of the programme and 
need to be demonstrating the same set of behaviours. In addition, it is recommended 
that in the future more than one researcher completes the intervention fidelity tool to 
increase the reliability of the findings.  
 
Furthermore, the findings from this work can also feed in to recommendations for 
future educator training, particularly the importance of being aware of quieter 
participants and encouraging engagement to avoid participants feeling isolated. 
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CHAPTER 12.   ECONOMIC ANALYSIS 
 
 
12.1 Overview 
 
In this chapter, we describe the economic work undertaken as part of work package 
1, in order to estimate the cost-effectiveness of the STOP Diabetes lifestyle 
intervention. Development of the lifestyle intervention is described in Chapter 8 and 
Chapter 9. 
 
12.2 Rationale and aims 
 
The overall aim of the economic work undertaken was to estimate the cost-
effectiveness of the STOP Diabetes lifestyle intervention, compared with current 
care, in reducing cardio-metabolic co-morbidities amongst individuals with ID. 
 
The objectives of the economic analysis reflect the revised protocol for the STOP 
Diabetes study. The economic analysis focused on the purpose of the intervention; 
that is, to increase physical activity (and to a lesser extent change in dietary 
behaviours) amongst overweight or obese individuals with ID. The context of the 
analysis reflects the likely real-world implementation of the intervention, including a 
screening phase, which could be appended to the established health checks for 
people with ID which carried out annually within current NHS practice, in order to 
identify individuals during to identify individuals suitable for the intervention. This 
screening can therefore be viewed as a potential additional component of the 
Learning Disability Health Check (see below for more details of the Learning 
Disability Health Check). If the STOP Diabetes intervention were to be rolled out, it 
would target only those with mild or moderate ID as the intervention is not suitable 
for those with severe or profound ID. We therefore restrict the economic evaluation 
to the subset of individuals in STOP Diabetes with mild/moderate ID. 
 
The economic analysis does not attempt to estimate the cost-effectiveness of 
screening individuals for IGR and T2DM due to a lack of evidence and poor clarity of 
Prevention of T2DM in adults with ID                                                              12.Economic analysis 
 
232 
  
context within current clinical care and the proposed STOP Diabetes intervention. 
This is explained more fully in Appendix 21. 
 
12.2.1 Context of proposed screening with existing intellectual disability 
care pathways 
 
12.2.1.1 Learning Disability Health Check  
 
Royal College of General Practitioners’ guidelines state that NHS general practices 
should identify individuals that are a high priority for health checks, stating that mild 
cases of ID are a lesser priority.261 However, the current 2015/2016 NHS General 
Medical Services contract states that all individuals with ID over 14 years of age 
should be offered a Learning Disability Health Check and we therefore do not 
exclude those with mild ID from the analysis. 
 
It was assumed that the model starts at the point following attendance of a Learning 
Disability Health Check by all baseline individuals.  
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Figure 24: Logic diagram showing how screening for suitability for intervention fits 
within Learning Disability Health Checks  shows how the screening and intervention 
elements the STOP Diabetes study would fit into the Learning Disability Health 
Check and the scope of the economic evaluation. 
 
There is no need to explicitly model the Learning Disability Health Check process as 
the baseline characteristics from the STOP Diabetes study are assumed to reflect 
characteristics post health check and the resulting baseline risks of CVD and T2DM. 
 
Attending a Learning Disability Health Check obviates the need to participate in the 
general population “NHS Health Checks” program for those over 40 years of age. 
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Figure 24: Logic diagram showing how screening for suitability for 
intervention fits within Learning Disability Health Checks  
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In 2013/14, nationally 44% of those on an ID register attended a Learning Disability 
Health Check; this varies greatly by geographical area, ranging from 10% to 60%. 
Specifically, 29% missed a check, implying an offer rate of 73% and an uptake rate 
(amongst those offered) of 44%/73% = 60%.262 
 
Within the Learning Disability Health Check, BP, weight and height are measured263 
unless not possible because of physical disability (meaning the patient is unable to 
stand for height and/or weight measurement) or behavioural difficulties, so their BMI 
should be calculated. Some blood tests may also be carried out during a Learning 
Disability Health Check (or in advance of their Health Check, or as a follow-up test 
recommended by patients in their Health Action Plan). There is also scope to screen 
for hyperglycaemia (and dyslipidaemia) and assess cardiovascular risk as part of 
routine care, although there is much variation in practice as to whether such blood 
tests are deemed to be necessary or a priority within a Learning Disability Health 
Check, or indeed uptake of blood tests by individuals. For the purpose of the 
modelling, we assume these blood tests would fall within the Learning Disability 
Health Check.  
 
The model starting point is an individual having been offered and attending for their 
Learning Disability Health Check; that is, one of the 44% noted above. 
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12.3 Methods 
 
12.3.1 Overview of approach 
 
This section provides an overview of the economic work before more details are 
described in subsequent sections. 
 
The first phase of work involved obtaining all necessary parameter inputs and 
assumptions for the economic model, specifically: 
1) Data from the STOP Diabetes study to provide the baseline patient 
characteristics. 
2) Data collected and quotes and input from the study team to provide the details 
required to calculate the cost per participant of the STOP Diabetes lifestyle 
intervention. 
3) Assumptions on uncertain inputs such as rate of uptake of the intervention and 
the durability of the benefits of the intervention through discussion with the clinical 
team. 
 
The modelling itself comprised: 
1) Model development - an existing economic model of cardiovascular and diabetes 
risk, driven by characteristics such as BMI, total cholesterol, HDL cholesterol and 
HbA1c was adapted to incorporate the relationship between changes in physical 
activity (steps) and changes in the above risk factors. 
2) Modelling the screening process – determining those individuals from the STOP 
Diabetes study that are suitable for, and take up the intervention. The modelling 
takes account of individuals’ BMI, capacity to participate in the intervention and 
rates of uptake of the intervention.   
 
Modelling the screening process involved an adaptation of the prevention Sheffield 
School for Public Health Research (SPHR) Type 2 Diabetes Model. The model is 
used to simulate the lifetime patient clinical pathways, incidence of complications 
and associated cost and health utility impacts arising from an intervention compared 
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to routine care. The assumptions for the modelling are described in detail later in the 
report, but the key ones are listed here: 
1) The STOP Diabetes intervention was estimated to cost £ 1,097 for the initial 
intervention and eight maintenance sessions, delivered within a one-year timeframe. 
2) The benefits of increases in physical activity could be mapped to changes in BMI, 
systolic BP, total and HDL cholesterol using a relationship identified in the literature. 
3) The durability of the intervention effects was uncertain so, for the modelling, two 
scenarios were adopted with the effects lasting (but decreasing linearly) for three 
and five years (from the start of the intervention) respectively. 
 
The usual approach to economic evaluation is to estimate the incremental lifetime 
discounted costs and quality-adjusted life-years (QALYs) of an intervention 
compared with usual (routine) care. From this, the incremental cost-effectiveness 
ratio (ICER) can be calculated and compared with usual acceptability thresholds (£ 
20,000 - £ 30,000 per QALY). However, because the clinical effectiveness of the 
STOP Diabetes intervention is not known, the economic modelling was primarily 
based on threshold analysis. Under this approach, the requisite clinical effect size 
needed for the intervention to be just cost-effective (given the cost of the 
intervention) was estimated. Because the STOP Diabetes intervention promotes 
physical activity and dietary change, the output of the threshold analyses was not a 
single effect size but various permutations of these that would be adequate to make 
the intervention cost-effective. 
 
Uncertainty around the results was analysed primarily using one-way sensitivity 
analysis. Due to the computational demands of undertaking threshold analyses, 
probabilistic sensitivity analysis was restricted to one scenario to give an indication of 
the degree of uncertainty around such an intervention. 
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12.3.2 Data sources – STOP Diabetes 
 
12.3.2.1 Baseline Population 
 
The baseline population in the model reflected as far as possible the patient-level 
baseline data from the STOP Diabetes study during which data from 930 individuals 
with ID from the Leicester area were gathered. Other risk factors (left ventricular 
hypertrophy, heart rate, and valve disease) were based on general population 
prevalence as data were not available from the STOP Diabetes study.  
 
Only individuals with mild/moderate ID would be be targeted with the STOP Diabetes 
intervention; thus those recorded as having severe/profound ID were removed from 
the sample, leaving a total of 618 individuals in the modelled cohort. Summary 
statistics of these individuals are shown in Table 43. 
 
The initial Learning Disability Health Check itself is not simulated to prevent 
modification of baseline characteristics (such as diabetes diagnosis or statin 
treatment) before initiation of the intervention. 
 
12.3.2.2 Data Imputation 
Many individuals were lacking responses to some questions in the baseline 
questionnaire but had data for others. The SPHR Diabetes Prevention Model uses 
imputation models based upon Health Survey for England (HSE) 2011 data264 to 
impute missing anthropometric and metabolic measures. Full details of imputation 
models can be found elsewhere in an online discussion document.265  
 
12.3.2.3 Clinical effectiveness 
The feasibility study was intended to assess the practicality of implementing the 
intervention in the target group. Sample sizes were, however, too small to 
quantitatively assess the effectiveness of the intervention (n=4 with before and after 
accelerometer data reporting step count); therefore, there were no estimates of 
clinical effectiveness available (see later Section 12.3.15.1 on Threshold analysis). 
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Table 43: Baseline characteristics of individuals with mild or moderate 
intellectual disabilities in the STOP Diabetes study 
Parameter Number 
(Total n=618) 
Percentage  
Male 337 54.5%  
White 537 86.9%  
IMD 1 (least deprived) 109 17.6%  
IMD 2  107 17.3%  
IMD 3 125 20.2%  
IMD 4 142 23.0%  
IMD 5 (most deprived) 135 21.8%  
Non-smoker 512 82.8%  
Anti-hypertensive treatment 62 10.0%  
Statin treatment 55 8.9%  
Cardiovascular disease 12 1.9%  
Depression/anxiety 171 27.7%  
Congenital heart disease 12 1.9%  
Capable of taking up intervention 484 78.3%  
Eligible for intervention by BMI 
 
458 74.1%  
Eligible for and capable of 
intervention 
384 62.1%  
Parameter Mean Standard 
deviation 
Median  
Age (years) 43.07 14.15 42.32 
BMI (kg/m2) 29.25 7.36 28.10 
Total Cholesterol (mmol/L) 4.91 1.02 4.80 
HDL Cholesterol (mmol/L) 1.35 0.49 1.30 
HbA1c (%) 5.37 0.49 5.35 
Systolic BP (mm Hg) 121.60 17.67 120.00 
Diastolic BP (mm Hg) 78.10 11.07 78.00 
EQ-5D  0.838 0.219 0.850 
Baseline physical activity in mean 
steps per day (N=46) 
6,892 3,556 6,453 
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IMD,  Index of Multiple Deprivation; BP, Blood Pressure; BMI, Body Mass Index; HDL, High Density 
Lipoprotein; EQ-5D, EuroQol-5 Dimensions; a BMI>25 or BMI>23 and Black or Asian ethnicity  
 
12.3.3 Assessing suitability for intervention 
 
Process: 
All individuals at the start of the model were assumed to be attending the Learning 
Disability Health Check in the first year and therefore potentially eligible for the 
intervention. However, not all individuals were deemed to be at sufficient high risk or 
capable of receiving a lifestyle intervention. Therefore, in the intervention arm of the 
model, suitable individuals needed to be identified as part of the Health Check 
process using pragmatic selection and capacity criteria. The selection criteria for 
clinical need for the intervention was being overweight or obese; that is, BMI>25 
(BMI>23 for individuals from black or minority ethnic groups). It was assumed that 
individuals were capable of taking part in the intervention if they could walk (without 
aids), if they did not have behaviour problems and if their ID was mild, moderate or 
unknown. The capabilities assessment itself was assumed to occur in all baseline 
individuals at the start of the model. 
 
These criteria resulted in 62.1% of individuals with mild or moderate disability being 
eligible for intervention. 
 
The proportion of individuals receiving the intervention was further reduced by taking 
account of the willingness of suitable individuals’ to participate in the programme of 
intervention sessions, so the model also incorporates this rate of uptake. 
 
12.3.4 Screening cost 
 
In order to assess the real-world impact of the intervention if it were rolled out at 
scale, we assume that the above assessments would be carried out at the same 
time as their routine Learning Disability Health Check, as opposed to a separate 
appointment that occurred for the screening component of the programme. 
Therefore, the additional screening-related costs attributable to STOP Diabetes were 
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simply those to assess: i) an individual’s need for the intervention; and ii) an 
individual’s capacity to undertake the intervention (whenever increased activity is 
recommended). Recruitment costs from the STOP-DM study were excluded as these 
would be covered by the existing recruitment activity for the Learning Disability 
Health Check.  
 
It was estimated that the BMI calculation, capabilities assessment, and time taken to 
explain and potentially gain consent for the intervention would take on average an 
extra 15 minutes of healthcare assistant time during the NHS Health Check 
compared with current care (£5.10). This cost is incurred by all individuals in the 
intervention arm of the model. 
 
The process of risk assessment and any associated screening for diabetes or IGR, 
and any overall assessment of CVD risk is assumed to fall within the existing remit of 
their annual Health Check and therefore outside the scope of this economic 
evaluation. 
 
12.3.5 Intervention form, cost, clinical effectiveness and uptake 
 
12.3.5.1 Form 
 
The costs of the intervention were divided into three phases: 
A) Development phase – the costs of setting up the intervention for example the up-
front costs of training the educators and equipping them to deliver the 
intervention 
B) Delivering the initial intervention - the key components are: 
 - Seven sessions for patients plus an additional one for their carers 
 - Each session lasting 2.5 hours, plus 30 minutes set-up/pack-up time  
 - Three educators per group, one band 8a, one band 7 and one band 3 
C) Maintenance sessions – eight monthly sessions starting after the initial 
intervention, as it is recognised that for lifestyle interventions to have sustained 
benefits, some ongoing education is needed to re-enforce behaviour change. 
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12.3.5.2 Cost 
 
A micro-costing exercise was undertaken by colleagues at Leicester, assisted by the 
economics team, in order to obtain a cost-per-patient of receiving the intervention. 
As STOP Diabetes was a feasibility study, not all elements of the full cost of its 
delivery are known with precision. Furthermore, some cost would be different if 
incurred in a real-world setting. As the economic analysis is essentially a threshold 
analysis to inform any further study of the STOP Diabetes intervention within a trial 
setting, it was decided there was little point in separate costings of the intervention 
so a single costing was undertaken based on actual resources incurred during the 
study where available, but modified where appropriate to reflect the costs that would 
be incurred in a real-world setting and using price quotes obtained by the clinical 
team for some aspects of the intervention’s development.  
 
Within the STOP Diabetes research study, the average number of patients per group 
was six but for the costing an average number of 8 people per group was assumed 
as this would be an acceptable maximum number in the ‘real world’. 
 
'Research costs', such as recruiting patients to the study and initial development of 
the intervention, were excluded because the intervention had already been 
developed and it was assumed that recruitment costs were part of the existing 
annual health checks process for ID patients.  
 
Costs of the components of the intervention were obtained from several sources. 
Unit costs of some nurse grades are available from Curtis 2014.266 Costs for other 
nurse bands were obtained by combining salary costs provided by the study team 
with overhead adjustment in line with Curtis 2014. The costs of non-staff items were 
provided by the study team. 
 
The individual cost elements of the STOP Diabetes intervention are shown in Table 
44. 
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Table 44: Cost of the STOP Diabetes intervention 
A. One-off costs of intervention Costs 
Details Costs apportioned to Cost 
Trainer costs for educator training (one-off) 
– initial DESMOND + intervention specific 
Band 7 x 6 days @ £ 353 
Band 8a x 4 days @ £438 
 
In theory, up  to max 15 educators possible per group 
training session 
Apportion to ‘Educator 
team set-up’ 
 
£ 2,118  + 
        £ 1,752 
 
 
Trainer time for Quality Development intervention fidelity  
(i.e. sit in on educator delivering session) - Band 7 trainer 
1.5 Days needed per educator x 3 educators @ 
£ 353 /day 
‘Educator team set-up’        £ 1,588 
Educator costs - attendance at training (time and travel)  
– initial DESMOND + intervention specific 
Band 3 x 3 days @ £ 173 
Band 7 x 3 days @ £ 353 
Band 8a x 3 days @ £ 438 
(This mix reflects a group of educators that can deliver a 
course together) 
‘Educator team set-up’ 
£ 519      + 
£ 1,059   + 
       £ 1,314    
Educator costs - prep time to deliver curriculum – each 
educator time to prepare before deliver their few courses 
Band 3 x 2 days @ £ 173 
Band 7 x 2 days @ £ 353 
Band 8a x 2 days @ £ 438 
(This mix reflects a group of educators that can deliver a 
course together) 
‘Educator team set-up’ 
£ 346   + 
£ 706   + 
        £ 876 
Educator time for QD intervention fidelity - QD and 
mentorship visits (1.5 days per educator) 
Band 3 x 1.5 days @ £ 173 
Band 7 x 1.5 days @ £ 353 
Band 8a x 1.5 days @ £ 438 
 
‘Educator team set-up’ 
Assume this is required 
over a cycle of 3 years (as 
in DESMOND)  
£ 260 
£ 530 
£ 657 
Developing training package, resources and Intervention 
Fidelity tools 
What trainers needed to train up educators.  
Some elements could be re-used but some could be 
consumed, e.g.  food during training 
Apportion to ‘Trainer team 
one-off’ 
 
£1,000 
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Assume 50% of the estimated total £ 2,000 costs could 
be attributable to a single team of educators (there may 
be a few training providers around the country so cannot 
spread the cost over lots and lots of educator teams) 
Delivery materials - education curriculum  
3 educators x £ 100 
‘Educator team set-up’ £300 
Delivery materials - education resources and 
resources/food models per set (initial set £100, more 
substantive set up to £2,000) 
Per team of educators – assume non-re-usable 
Apportion to ‘Educator 
team set-up’ 
£1,000 
Venue costs for educator training (one-off) 
- initial DESMOND + intervention specific 
-£100 per day x 3 days 
 
In theory, up  to max 15 educators possible per group 
training session 
Apportion to ‘Educator 
team set-up’ 
£300 
B. Initial educational intervention Costs 
 
Costs apportioned to Costs 
Administrative time and coordinator time (combined) 
 
 – phone calls to confirm suitability and willingness - 15 
mins per person but would not be needed in real world 
as would be part of nurse assessment;  
  arrange appointments, send confirmation and follow-
up reminder phone call(s): 15 mins per person @ £ 21 
per hour (estimated on average £18 per hour 
administrator, £24 per hour coordinator).  
 
 booking/confirming venue (30 mins per group) 
 coordinating educators and resources (60 mins per 
session x 8).  
 
Assuming £21 per hour average salary costs  
 
 
 
 
 
per participant 
 
 
per 8-session course 
per 8-session course 
 
 
 
 
 
£ 5.25 
 
 
£ 10.50 
£ 168 
Delivery   
 
7 sessions to patients + 1 carer session = 8 sessions 
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Each session = 2.5 hours delivery + 0.5 hour set-
up/pack-up time per session = 3 hours per sessiona 
 
Each session run by 2 educators + 1 healthcare 
assistant (1 x Band 3 + 1 x band 7 + 1 x band 8a).  
Band 3 x 3 hours @ £ 23 x 8 sessions 
Band 7 x 3 hours @ £ 47 x 8 sessions 
Band 8a x 3 hours @ £ 58 x 8 sessions 
 
per 8-session course 
 
 
 
£ 552 
£ 1,128 
£ 1,392 
Participant Handbook Included under cost of 
course materials below 
 
Pedometer (1 per person +50% for carers, at £8 each, 
assume need 10 per group + 20% for loss)  
Total per group if 7, allow 13 pedometers  
per 8-session course £ 104 
Refreshments  
£1 per person, plus 50% for carers, for 8 weeks 
Total per group if 7  
 
per 8-session course 
 
£ 84 
Postage/phone calls 
 
Total per group = £10 
per 8-session course £ 10 
Stationary and reprographics 
 
 – letters/information/course materials £ 10 per person 
Total per group  
per 8-session course £ 70 
Venue Hire Cost  
 
Could be NHS premises (in which case costs absorbed 
into Curtis  rates) 
Could be non-NHS community (Local Authority) - some 
would charge 
Assume 50% of venues not in NHS & incur a charge 
3 hours x 8 weeks, £10-20 per hour (assume £15) 
per 8-session course £ 360 
Travel costs - staff (45p per mile for 3 educators x 8 
sessions, return mileage estimated at 10 to 30 miles 
depending on distance from base)  
per 8-session course £36.00 
Travel costs –  
In STOP Diabetes, participants (taxi travel or re-
imbursement of bus -fare, assuming 50% of people (3-4 
per group) need travel costs paying, estimated £10-20 
taxi & £2.00-3.00 bus fare per journey)  
 £ 0 
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In real world, however, it can be assumed that such 
travel costs me all be accounted for with the patient’s 
free bus pass and/or mobility allowance  
C. Monthly ongoing support sessions Costs 
 
8 monthly sessions 
 
The cost of delivering these sessions is uncertain. They 
could be delivered one-to-one or in a group. Although 
group-based delivery would normally be cheaper for 
lifestyle interventions, for individuals with ID this might 
not be the case. Delivering maintenance might be 
achievable though a single educator visiting the patient’s 
home (thereby avoiding venue costs), and provision of a 
shorter hour long one-to-one session might be sufficient. 
 
It was therefore judged to be a conservative approach to 
allow for maximum potential costs by costing on the 
assumption of group-based delivery and cost of a 
maintenance session was assumed to be the same as 
an initial session  
 
As per section B. 
above 
‘Educator team set-up’ in the ‘Costs apportioned to’ column refers to costs to train up a team of 3 
educators 
a No staff time for travel to courses included as could be on-site or if straight from home, would not be 
reimbursed if no further than to workplace) 
 
 
To obtain an overall cost per patient, a sequential process of apportioning ‘Educator 
team set-up’ to educators, then educator costs to a cost per course, then to course 
costs to patients was undertaken, giving a cost per patient of £ 1,097 (combined cost 
for the initial and maintenance intervention). 
 
Potentially, there might be some scope for either reducing the cost of the intervention 
or actual costs incurred being lower than estimated above. For example, the mode or 
frequency of delivery of maintenance sessions could be re-visited, a different mix of 
grades of educators may be possible in the real world, some individuals that attend 
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the initial course may not continue to the maintenance sessions, and the method of 
apportioning overhead costs within Curtis is somewhat arbitrary (appears to load 
greater overhead costs to more senior staff). Through a cost-specific threshold 
analysis, we explored to what degree the cost of the intervention would need to be 
reduced in order to make it cost-effective. 
 
12.3.5.3 Clinical Effectiveness 
 
Due to the small number of individuals in the feasibility study with data on physical 
activity (as measured using an accelerometer) before and after the programme 
(n=4), effectiveness estimates were not available from the  STOP Diabetes 
programme itself. Therefore, a threshold analysis approach (see Section 12.3.15.1) 
was used to estimate the threshold for the effect size needed to make the 
intervention marginally cost-effective in the £20,000-£ 30,000 cost per QALY range 
as recommended by NICE.267 As the intervention includes dietary advice as well as 
the physical activity element, we report the threshold in terms of possible 
permutations of the number of steps and the additional diet-attributable BMI and 
systolic BP changes that would be needed to be able to demonstrate that the 
intervention is cost-effective. 
 
12.3.5.4 Durability of effect 
 
The initial intervention-related changes in BMI, systolic BP and HDL cholesterol 
within the year of intervention were subsequently assumed to wear off linearly such 
that, after three years from the start of the intervention, individuals have returned to 
the BMI, systolic BP and HDL cholesterol trajectories that they would have followed 
in the absence of intervention. Alongside the above base case assumption, an 
additional scenario analysis was carried out to test the response of the results to 
five-year duration of effect. 
 
12.3.5.5 Intervention uptake 
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Of individuals that are both eligible for and capable of taking up the intervention, we 
assumed that 55% do so and thereby incur the full costs of the intervention based on 
advice for a previous lifestyle intervention evaluation.268  
 
12.3.6 Modelling the benefits of changes in physical activity (steps) 
 
The economic model chosen for the modelling (the SPHR Diabetes Prevention 
model described later) does not include physical activity as a risk factor for CVD or 
diabetes. However, the primary measure of interest, in terms of informing any future 
follow-on trial from the STOP Diabetes study, is change in steps per day (and this is 
a key output of the threshold-based economic analyses, see Section 12.3.15.1, and 
any subsequent full trial would be based around change in physical activity 
measured in steps using a pedometer). It was therefore necessary to identify a 
mechanism to map changes in physical activity to changes in the above risk factors 
that already exist in the model (BMI, systolic BP, total and HDL cholesterol and 
glucose-related risk factors), and vice versa. 
 
12.3.6.1 Rationale for surrogate-based model 
 
A surrogate-based approach was chosen because: 
1) The SPHR Diabetes Prevention model uses metabolic trajectories to model long-
term progression of risk factors and incidence of co-morbidities 
2) A meta-analysis was identified which linked changes in physical activity to 
changes in systolic BP, total and HDL cholesterol 
3) We are unaware of any meta-analyses of hazard ratios for the effect of changes 
in physical activity on incidence of CVD and diabetes 
4) Although we were made aware of a study linking physical activity to CVD (Yates 
2014; NAVIGATOR Trial269), the analysis was undertaken assuming a constant 
change in steps over a six-year period, whereas the effect of the STOP Diabetes 
intervention would decline over time. So any hazard-ratio adjustments to the risks 
of CVD and diabetes would need to have been analysed in a time-dependent 
way. The behavioural changes in this study were also based on dietary advice 
but it is unknown how intensive this was compared to the STOP Diabetes 
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intervention (which contained some dietary advice but no weight loss target). The 
reported hazard ratio may therefore include significant risk reduction attributable 
to dietary changes. Additionally, this study recruited a cohort of individuals with 
IGR at baseline and only reported CVD (not diabetes). 
 
We did, however, believe that it would be useful to compare the predictions of the 
model (modified to reflect a constant changes in risk factors for six years) with the 
six-year results reported in Yates 2014. For an increase in activity of 2,000 steps, 
Yates et al reported a hazard ratio of experiencing a cardiovascular event over the 
following 6 years of 0.92 (95% CI = 0.86-0.99), that is a risk reduction of 8%. The 
hazard ratio from our adapted model was 0.95 (5% risk reduction). The details of the 
method behind this comparison are provided in Appendix 22. 
 
There are various reasons why a slightly lower reduction in risk might be expected 
from the model compared to that observed in the NAVIGATOR trial. First, patients in 
the NAVIGATOR trial had IGR but were not necessary overweight, whereas the 
baseline population in the model were mostly normal glucose tolerant but with BMI 
above defined thresholds. BMI and diabetes both input into cardiovascular risk, but 
the relative effect this population difference might have on cardiovascular outcomes 
is unclear. Secondly, the trial participants received both exercise and dietary advice, 
but potential differences in diet between individuals with different step counts was 
not accounted for in the trial analysis. It is possible that individuals who follow 
exercise advice are more likely to follow dietary advice too and so may show a 
greater effect on metabolic trajectories than accounted for in our analysis based on 
steps alone. This would result in the model underestimating the results of the trial as 
is indeed observed. Thirdly, there are some differences in the events picked up in 
the trial and those accounted for in the model (e.g. transient ischaemic attack and 
stable angina are in the model but not the trial), although it is unclear what effect 
restricting outcomes to those used in the trial would have on the hazard ratio. Finally, 
it cannot be ruled out that exercise may impact positively upon factors not included in 
the model, which in turn result in reduced cardiovascular risk. 
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It should be noted that since the Yates 2014 study reports hard outcomes in terms of 
cardiovascular events but not changes in biomarkers of risk, the results could not be 
used to parameterise the SPHR model (which estimates a range of outcomes, 
including CVD, based on cardio-metabolic risk factors and their projected trajectory 
over time). 
 
12.3.6.2 Review of Relationship between physical activity (steps) and  risk 
factors for cardiovascular disease and diabetes in the model 
 
To identify a suitable mapping between steps and model risk factors, a targeted 
review of the published literature was carried out using a search of the on-line 
PubMed database, a subsequent citation search, and advice from clinicians. This 
evolved into a 3-step process as described below. 
 
Step 1: Search strategy for physical activity studies reporting step as an outcome 
 
The search strategy using the PubMed publications database is detailed in Appendix 
23 (Table 66). The search yielded 153 results, from which 54 abstracts were 
selected based on titles. Of these, 19 were relevant, of which full text was available 
for 14. One of these studies, Stuckey 2011,270 discussed a meta-analysis undertaken 
by Bravata and colleagues,271 which is discussed below. 
 
Step 2: Citation search for review papers citing Bravata 2007 
 
This search identified 22 abstracts for review. Abstract/title sifting led to 7 full text 
papers being checked. Of these 7, 4 were excluded as narrative reviews only, 1 was 
a review of reviews but focussed on diet only or diet and physical activity 
interventions and therefore was not relevant, 1 was excluded because it was a 
primary trial not a review or meta-analysis. 1 was excluded because it reported only 
weight and no metabolic outcomes. This search identified two relevant studies of 
potential use for the modelling, Murphy272 and Qui 2014,273 which were reviewed in 
full text and are discussed below. 
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Step 3: Conversation with clinical advisors  
 
In discussion with clinicians it was determined that cholesterol changes were also 
very likely to be observed as a result of the intervention. In this respect, we were 
referred to a study by Camhi and colleagues274 which is described below. This 
conversation also highlighted the Yates 2014 study269 already discussed earlier. 
 
Description of key studies 
 
Bravata 2007 reviewed and combined the results of studies which used a pedometer 
to measure physical activity and reported health outcomes (mean duration of studies 
= 18 weeks). The overall step change induced by intervention studies was 2,491 
additional steps per day. Significant reductions were reported in BMI (-0.38 kg/m2) 
when 18 studies (n=562) were combined and in systolic BP (-3.8mmHg) when 12 
studies (n=468) were combined. There were also non-significant reductions in lipids 
with, a reduction in total cholesterol of 0.09mmol/l and an increase in HDL 
cholesterol of 0.06mmol/l. 
 
Murphy 2007272 was a review of walking interventions on metabolic risk factors, 
based on minutes per week rather than steps. It reported very similar outcomes to 
Bravata et al. (188 additional minutes per week was associated with 0.95kg weight 
loss, 0.28 BMI reduction and 1.54mmHg Diastolic BP reduction). 
 
Qui 2014 was a recent meta-analysis of step-counting and its effects on HbA1c 
control.273 Although it found evidence of significant increases in steps it found no 
strong evidence for changes in HbA1c. This backs up the results of the previous 
Bravata review which only found significant changes in BMI and BP. 
 
Camhi 2011274 was a cross-sectional study based on the US NHANES survey 
(National Health and Nutrition Examination Survey). This study assessed the 
relationship between activity (steps per day) and cardio-metabolic risk factors, 
including cholesterol. Data for 1,371 adults were analysed and significant changes 
were observed in triglycerides, HDL cholesterol and waist circumference for each 
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1,000 additional steps achieved, but does not report BMI changes or BP.  The study 
reported results as an odds ratio of 0.91 (95% CI 0.81 – 0.96) of having HDL 
cholesterol above the cut-off of 1.03 mmol/L (men) or 1.2mmol/L (women).  
 
For the purpose of parameterising the model, this study was not preferred over the 
evidence from the Bravata study because it is only a single study and is cross-
sectional whereas Bravata is a meta-analysis of intervention studies. 
 
12.3.6.3 Implementation of mapping steps to risk factors 
 
Physical activity and the mapping are not contained within the simulation model 
itself. The estimation of the number of steps needed is calculated manually after the 
model has been run several times and a threshold analysis has identified the degree 
of BMI change needed for the intervention to be marginally cost-effective (see 
section 12.3.15.1 on ‘Threshold analysis’ for more details). 
  
Table 45 shows the mapping between physical activity and risk factors obtained from 
Bravata. 
 
 
Table 45: Effectiveness outcomes from Bravata for the mean increase of 2,491 
steps per day 
Risk factor Mean change 95% C.I. 
BMI (kg/m2) -0.38  - 0.05 to - 0.72 
Systolic BP (mmHg) -3.8  - 1.7 to - 5.9 
Total cholesterol -0.09 - 0.32 to 0.15 
HDL cholesterol 0.06 - 0.012 to 0.14 
 
 
12.3.7 Model - Overview and Structure 
 
The SPHR Diabetes Prevention Model is an individual patient simulation model, 
written in the programming language R, which was built to enable evaluation of a 
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wide range of different diabetes prevention and weight loss interventions in the 
general population. The model was originally developed using a new conceptual 
modelling framework for complex public health models,275 in collaboration with a 
project stakeholder group comprising health economists, public health specialists, 
research collaborators from other SPHR groups, diabetologists, local commissioners 
and lay members. A review of existing diabetes prevention models was undertaken 
to inform conceptual model development,276 resulting in the model including multiple 
diabetes risk factors (in particular both BMI and IFG) and complications of diabetes 
and obesity. 
 
The model has been adapted to evaluate the outcomes of an intervention to promote 
physical activity in high risk subgroups of an ID population. Due to limited data about 
care pathways, disease risk and utility values in ID populations, much of the model is 
based on general population data; however, where possible data from ID populations 
has been used.  
 
The model is based upon individual longitudinal trajectories of metabolic risk factors 
(BMI, systolic BP, cholesterol and HbA1c). For each individual, yearly changes in 
these risk factors occur, dependent upon the individuals’ baseline characteristics.  
 
Illustrated (see Figure 25) is the sequence of updating clinical characteristics and 
clinical events that are estimated within a cycle of the model. This sequence is 
repeated for every annual cycle of the model. The first stage of the sequence 
updates the age of the individual. The second stage estimates how many times the 
individual attends the GP. The third stage estimates the change in BMI of the 
individual from the previous period. In the fourth stage, the change in glycaemia is 
estimated using different statistical models depending upon whether or not they have 
been diagnosed with diabetes (see below). In stages five and six the individual’s BP 
and cholesterol are updated. In stage seven, the individual may undergo assessment 
for diabetes, hypertension and dyslipidaemia during a GP consultation. From stage 
eight onwards the individual may experience cardiovascular outcomes, diabetes 
related complications, cancer, osteoarthritis or depression.  If the individual has a 
history of cardiovascular disease, they follow a different pathway in stage eight to 
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those without a history of cardiovascular disease. Individuals with HbA1c greater 
than 6.5% are assumed to be at risk of diabetes related complications. Individuals 
who do not have a history of cancer are at risk of cancer diagnosis, whereas those 
with a diagnosis of cancer are at risk of mortality due to cancer. Individuals without a 
history of osteoarthritis or depression may develop these conditions. Finally, all 
individuals are at risk of dying due to causes other than cardiovascular or cancer 
mortality. Death from renal disease is included in the estimate of other-cause 
mortality. The time horizon of the model is the lifetime of all baseline individuals. 
 
Cardiovascular events are modelled using the QRISK2 algorithm, more details are 
provided in Appendix 24 (Table 67 and Table 68). The model uses risk equations 
from the UK Prospective Diabetes Study (UKPDS) Outcomes model to estimate the 
occurrence of major events relating to microvascular complications, including renal 
failure, amputation, foot ulcer, and blindness.277, 278   
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Figure 25: Model Schematic of risk of co-morbidities 
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12.3.8 Routine care – components of cardiovascular risk reduction 
 
Both intervention and comparator arms of the model need to include any screening 
for hyperglycaemia and high CVD risk that is carried out routinely in clinical practice. 
This may be through the Learning Disability Health Check or opportunistic screening. 
 
12.3.8.1 Learning Disability Health Checks  
 
Individuals with ID should be invited to an annual health check where they undergo 
screening for hypertension, high cardiovascular risk and diabetes amongst other 
conditions. Although uptake of health checks amongst people with ID is only 44%, it 
was assumed that at baseline, all individuals had been identified through attending a 
Learning Disability Health Check and would therefore be very likely to attend future 
health checks. It was therefore assumed that all eligible individuals would attend 
annual Health Checks. Individuals that have been diagnosed with diabetes, CVD or if 
they are taking statins or anti-hypertensives do not continue to receive health 
checks, as they receive extra GP care specific to their diagnosis.  
 
Not all individuals consent to blood tests as part of their Learning Disability Health 
Check. It was assumed that 33% of individuals would never consent to blood tests 
during a health check (based on uptake of blood tests and availability of results for 
the screening programme, presented in Chapter 5); therefore, they could not be 
screened for CVD risk or diabetes by this method. However, it was assumed that if 
such individuals met the criteria for opportunistic diagnosis (see below), they would 
consent to blood tests and so could be diagnosed through this means. A different 
cost for a Learning Disability Health Check was used for individuals who do or do not 
consent to blood tests (see Costs section). 
 
12.3.8.2 General practitioner attendance and opportunistic screening  
 
Frequency of GP visits (separate from NHS health checks) was simulated in the 
dataset for two reasons; first, to estimate the healthcare utilisation for the ID 
population without diabetes and CVD and secondly, to predict the likelihood that 
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individuals participate in opportunistic screening for diabetes and elevated risk 
factors for CVD. This is important as many individuals in the model cannot be 
diagnosed through annual health checks, either due to ineligibility or because they 
do not consent to blood tests as part of their Learning Disability Health Check. 
 
It was assumed that GP attendance in the ID population occurs at the same 
frequency as in the general population. However, for cost purposes, consultations 
were assumed to take 40% longer than the general population average (see Costs 
section). A model of GP attendance conditional on age, sex, BMI, ethnicity, and 
health outcomes was derived from analysis of wave 1 of the Yorkshire Health Study 
and is described elsewhere.265 
 
12.3.9 Long-term longitudinal trajectories of metabolic factors 
 
The SPHR Diabetes Prevention model265 is based upon individual longitudinal 
trajectories of metabolic risk factors (BMI, latent blood glucose, total cholesterol, 
HDL cholesterol and systolic BP), derived from statistical modelling of the dataset 
from the Whitehall II cohort study.279 The statistical modelling uses parallel latent 
growth modelling to incorporate correlations and associations between risk factors 
that impact upon long term risk profiles. An advantage of the parallel growth analysis 
is that it is possible to estimate the effect of growth in BMI on the other metabolic risk 
factors so, for example, a change in an individual’s BMI will result in an indirect 
change in their HbA1c trajectory. Growth factors are also conditional on several 
individual characteristics including age, sex, ethnicity, smoking, family history of 
CVD, and family history of type 2 diabetes. It is also possible to estimate correlation 
between changes in underlying glycaemia (measured by HbA1c), systolic BP, total 
cholesterol and HDL cholesterol. Full details of this analysis are currently described 
in an on-line Discussion Paper265 with journal publication expected soon. 
 
The characteristics of the Whitehall II cohort (civil servants living in London) are likely 
to differ significantly from that of the STOP Diabetes ID population. However, there 
are, to our knowledge, no available longitudinal surveys of ID populations on which 
to base a similar analysis, and no other analysis of metabolic trajectories takes into 
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account the correlations between risk factors that make the Whitehall model so 
powerful. Importantly, the baseline values for the metabolic risk factors do come from 
the STOP Diabetes ID population, with the Whitehall-based trajectories being used 
simply to describe the expected changes in metabolic values over time.  
 
If an individual in the model is diagnosed with diabetes, or starts treatment with anti-
hypertensives or statins, trajectories alter to reflect the expected changes due to 
treatment. The criteria for opportunistic screening and diagnosis of diabetes, 
hypertension and high CVD risk can be found in Appendix 25 (Table 69), together 
with details of changes in metabolic trajectories. 
 
12.3.10 Risks of mortality - raised risk in individuals with intellectual 
disabilities 
 
In every model cycle individuals within the model are evaluated to determine whether 
they experience a fatal event or mortality. The evidence for risk of mortality in 
individuals with ID compared to the general population is described below, analysed 
by cause, that is, CVD, cancer and other-causes. 
 
Cardiovascular mortality: 
CVD mortality is included as an event within the estimated CVD risks calculated by 
the QRISK2 score as described in the cardiovascular disease section below. There 
is some evidence for an increased risk of CVD mortality in individuals with ID,280 but 
other studies report no difference or even reduced risk compared to the general 
population (see results of meta-analysis presented in Chapter 2). It is also unclear 
whether these differences in mortality risk are due to differences in risk factors 
included in the QRISK or due to other factors. It was assumed for the purposes of 
the model that any differences in cardiovascular mortality between individuals with ID 
and individuals in the general population occur simply due to differences in risk 
factors. 
 
Cancer mortality: 
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It was assumed that risk of cancer and subsequently cancer mortality would be the 
same in an ID population as in the general population, taking into account individual 
differences in risk factors. This is supported by several studies looking at mortality 
rates from various causes in ID populations.280, 281 
 
Other cause mortality: 
This describes the risk of death from any cause except cardiovascular disease and 
cancer. This was derived from all-cause mortality rates by age and sex; extracted 
from the Office of National Statistics (ONS).282 The mortality statistics report the 
number of deaths by ICD codes for 5-year age groups. To obtain other cause 
mortality, the number of cardiovascular disease, breast and colorectal cancer related 
deaths were subtracted from the all-cause mortality total. 
 
There is good evidence from various sources that the rate of all-cause mortality is 
higher in individuals with ID,280, 283, 284 particularly due to excess deaths from 
respiratory disorders, neurological diseases, congenital abnormalities and accidents. 
Standardised mortality ratios (SMR) of 2.28 (95% CI 2.02-2.56) for ID men and 3.24 
(95% CI 2.83-3.69) for ID women compared to the general population, reported in a 
14 year study of individuals from the Leicester area,280 were applied to the other 
cause mortality rates derived from the ONS data. The SMRs were not adjusted 
upwards to take into account the minimal increase and decrease in cancer and CVD 
mortality respectively in ID populations as it was unclear how large this adjustment 
should be and it was expected to make little difference to the outcomes. 
 
The rate of other cause mortality by age and sex was treated as the baseline hazard. 
An increased risk of mortality was assigned to individuals with diabetes using data 
from a published meta-analysis.285 This study used data from 820,900 people from 
97 prospective studies to calculate hazard ratios for cause-specific death, according 
to baseline diabetes status.285 Cause of death was separated into vascular disease, 
cancer and other cause mortality. From this study it was estimated that individuals 
with a diagnosis of diabetes have a fixed increased risk of other cause mortality 
(Hazard ratio 1.8 (95% CI 1.71-1.9)). The estimates reported in the meta-analysis 
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include increased risk of death from renal disease; therefore mortality from renal 
disease was not simulated separately to avoid double counting of benefits. 
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12.3.11 Comorbid outcomes with no excess risk in individuals with 
intellectual disabilities 
 
In every model cycle individuals within the model are evaluated to determine whether 
they have a clinical event. In each case within the simulation, risk equations estimate 
the probability that an individual has an event, and a random number is drawn to 
determine whether the event occurred. 
 
12.3.11.1 Cardiovascular Disease 
 
The QRISK2 model was chosen to estimate cardiovascular risk and incidence as it is 
a validated model based on a UK population.286 Probability of a first cardiovascular 
event in the next year (including cardiovascular mortality) is calculated conditional on 
ethnicity, smoking status, age, BMI, ratio of total/HDL cholesterol, deprivation score, 
atrial fibrillation, rheumatoid arthritis, renal disease, hypertension, diabetes, and 
family history of cardiovascular disease. Coefficients for the QRISK2 model can be 
found in Appendix 24 (Table 67 and Table 68). The QRISK2 assumptions regarding 
the relationship between diabetes and CVD were modified to reflect observations 
from the UKPDS and the European Prospective Investigation into Cancer and 
Nutrition (EPIC) that HbA1c (rather than diabetes) increases the risk of MI and 
Stroke in a linear manner.277, 287 
 
The STOP Diabetes baseline data had no information about atrial fibrillation; 
however it did have a category representing unspecified other heart conditions, 
which was recorded for 10 individuals (1.6% of total population). A diagnosis of atrial 
fibrillation was randomly assigned to 7 of these individuals in line with an audit of 
patients with ID in North Essex, which found that 1.1% of individuals had atrial 
fibrillation.288 The STOP Diabetes baseline data also had no specific questions about 
rheumatoid arthritis or renal disease. However, one individual was noted to suffer 
from rheumatoid arthritis using the other health problems variables and no 
individuals were noted to suffer from renal disease so we assumed no renal disease 
at baseline. 
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There is conflicting evidence about whether individuals with ID have a greater risk of 
CVD than is seen in the general population, and if so, whether this can be accounted 
for through the risk factors already incorporated into the QRISK2 model. Whilst some 
studies have found an increase in prevalence of CVD,83 or CVD mortality280 in ID 
individuals, other studies report no difference or reduced risk compared to the 
general population. (see results of meta-analysis presented in Chapter 2). Lower 
CVD mortality compared to the general population could partially be explained 
through competing risks, given that individuals with ID have higher mortality due to 
other causes, particularly respiratory illnesses, congenital abnormalities, neurological 
disorders and accidental injury.280, 281 
 
The model estimates that individuals recruited into the STOP Diabetes study have a 
much lower incidence of CVD than unmatched (for age) individuals from the HSE 
2011 due to their baseline characteristics (see Table 46). This cannot be explained 
solely by the five year lower mean age of the ID cohort (for example, compare year 
10 in the ID cohort with year 5 in the general population cohort). Given the lack of a 
clear consensus over CVD risk in individuals with ID, it was assumed that the 
QRISK2 equations were suitable for use in the ID population, and that any 
differences in CVD risk compared to the general population would be accounted for 
through the differences in baseline risk factors. 
 
All CVD events modelled using QRISK2 are assigned to a specific diagnosis 
according to age and sex specific distributions of cardiovascular events reported in a 
previous Health Technology Assessment (HTA) for statins.289 Events are also split 
into fatal versus non-fatal ones.  
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Table 46: Modelled within-year cardiovascular disease incidence: STOP 
Diabetes cohort vs. Health Survey for England 2011 (general population) 
cohort 
CVD Incidence 
(per 10,000) 
Year 
1 
Year 
5 
Year 
10 
Year 
15 
Year 
20 
Year 
25 
Year 
30 
Year 
35 
ID cohort 37 56 63 83 113 124 146 162 
General population 
cohort 
77 91 101 123 144 158 169 195 
Relative risk with ID 0.48 0.61 0.62 0.68 0.78 0.78 0.86 0.83 
Relationships between risk factors and different types of CVD (e.g. hypertension 
being more of a risk for stroke) are not incorporated into the model. 
 
 
12.3.11.2 Congestive Heart Disease 
 
Congestive heart failure was coded as a separate cardiovascular event using the 
Framingham risk equation290 because it is not included as an outcome of the 
QRISK2. The Framingham equation is not ideal as it is based on a US population 
from the 1990s and there is no evidence for its accuracy in representing risk in an ID 
population. However, it was thought to be the best option in the absence of data 
specific to an ID population. The equation includes age, diabetes diagnosis (either 
formal diagnosis or a HbA1c>6.5), BMI, systolic BP, congenital heart disease, left 
ventricular hypertrophy, heart rate and valve disease to adjust risk based on 
individual characteristics. Full details of the equation coefficients can be found in an 
on-line Discussion paper.265 
 
No baseline information was available about three of these risk factors (left 
ventricular hypertrophy, resting heart rate and valve disease) therefore they could 
not be included in the model to predict congestive heart disease. The baseline odds 
of congestive heart disease were adjusted to reflect the expected prevalence of 
these symptoms; this was done using general population data as data specific to 
individuals with ID could not be identified. The heart rate for men was assumed to be 
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63.0bpm and for women 65.6bpm based on data from previous Whitehall II cohort 
analyses.291 The proportion of the UK population with left ventricular hypertrophy 
was assumed to be 5% in line with previous analyses of the Whitehall II cohort.292 
The prevalence of valve disease was estimated from the Echocardiographic Heart of 
England Screening study.293 Twelve baseline individuals from the STOP Diabetes 
study suffered from congenital heart disease (1.9%). This is higher than the 
prevalence of congenital heart disease in the general population (0.80% of live 
births),294 and is unsurprising given the high proportion of individuals with Down’s 
and Williams syndrome who are known to suffer from congenital heart defects.295 
This means that the risk of congestive heart failure is higher in individuals with 
learning difficulties than in the general population. 
 
12.3.11.3 Microvascular complications of diabetes 
 
UKPDS data, derived from a UK diabetic population,277, 278 was used to estimate the 
incidence of major microvascular complications including ulcer, amputation, renal 
IDLOXUH DQG EOLQGQHVV LQ LQGLYLGXDOV ZLWK +E$F  6.5, whether or not they are 
diagnosed with diabetes. Earlier stages of microvascular complication were not 
included in the model as they have less of an impact on costs and utilities. It was 
assumed that risk of microvascular complications would be the same in an ID 
population as in the general population, taking into account individual differences in 
risk factors.  
 
The UKPDS outcomes model v2 includes four statistical models to predict foot 
ulcers, amputation with no prior ulcer, amputation with prior ulcer and a second 
amputation277. In order to simplify the simulation of neuropathy outcomes, the 
models for first amputation with and without prior ulcer were consolidated into a 
single equation. UKPDS outcomes model v2 was also used to estimate the 
incidence of blindness, whereas the UKPDS outcomes model v1 was used to 
estimate the incidence of renal failure.278 Early validation analyses identified that the 
UKPDS v2 model implemented in the SPHR model substantially overestimated the 
incidence of renal failure. Details of the models used are reported elsewhere in an 
on-line Discussion Paper.265 
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All equations incorporate a coefficient for age at diabetes diagnosis. This was 
multiplied by age in the current year if the individual had not been diagnosed with 
diabetes or by the age at diagnosis if the individual had received a diagnosis. The 
expected values for the risk factors not included in the SPHR model (heart rate, 
white blood count, micro-/macroalbuminurea, peripheral vascular disease and atrial 
fibrillation) were taken from figure 3 of the UKPDS publication in which these are 
described,277 with the exception of peripheral vascular disease, which was assumed 
to affect 2% of the population. The baseline risk was modified to take account of 
these mean values. 
 
12.3.11.4 Cancer 
 
Breast cancer and colorectal cancer risk are related to BMI and so were included in 
the SPHR model.  
 
Incidence rates for breast and colorectal cancer in the UK were estimated from the 
EPIC cohort. This is a large multi-centre cohort study looking at diet and cancer. In 
2004 the UK incidence of breast cancer by menopausal status was reported in a 
paper from this study investigating the relationship between body size and breast 
cancer.296 A second paper from EPIC reported the UK incidence of colorectal cancer 
by gender.297 Incidence rates in the model for breast and colorectal cancer are 
shown in Table 47. 
 
A large meta-analysis that included 221 prospective observational studies has 
reported relative risks of cancers per unit increase in BMI, including breast cancer 
and colorectal cancer.298 A risk adjustment was included in the model so that 
individuals with higher BMI have a higher probability of pre-and post-menopausal 
breast cancer or colon cancer (see Table 47). In the simulation, the incidence of 
breast and colorectal cancer was adjusted by multiplying the linear relative risk by 
the difference in the individual’s BMI and the average BMI reported in the EPIC 
cohort.  
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Table 47: UK colorectal/breast cancer incidence  
Cancer Type and 
sub-group 
Number 
of Cases 
Person 
Years 
Mean 
Age 
Mean 
BMI 
Incidence rate 
per person-year 
Breast Cancer 
    UK pre- 102 103,115 NA 24 0.00099 
    UK post- 238 842,15 NA 24 0.00283 
Colon Cancer 
    Male 125 118,468 53.1 25.4 0.00106 
    Female 145 277,133 47.7 24.5 0.00052 
 
 
Evidence suggests that mortality from breast and colon cancer occurs at a similar 
rate in ID populations as in the general population.280, 281 Cancer mortality rates were 
obtained from the ONS.299 The ONS report one and five year net survival rates for 
various cancer types, by age group and gender. Net survival was an estimate of the 
probability of survival from the cancer alone. It can be interpreted as the survival of 
cancer patients after taking into account the background mortality that the patients 
would have experienced if they had not had cancer.  
 
 
Table 48: Relative risk of colon/breast cancer per unit increase in body mass 
index 
Cancer Type and sub-group Mean relative risk 2.5th C.I. 97.5 C.I. 
Breast Cancer 
    UK pre-menopause 0.89 0.84 0.94 
    UK post-menopause 1.09 1.04 1.14 
Colon Cancer 
    UK pre-menopause 1.21 1.18 1.24 
    UK post-menopause 1.04 1 1.07 
CI, Confidence Interval 
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The age-adjusted 5-year survival rate for breast cancer and colorectal cancer were 
used to estimate an annual risk of mortality assuming a constant rate of mortality. It 
was assumed that the mortality rate does not increase due to cancer beyond five 
years after cancer diagnosis. The five year survival rate for breast cancer is 84.3%, 
which translated into a 3.37% annual probability of death from breast cancer. The 
five year survival rate for persons with colorectal cancer is 55.3%, which translated 
into an 11.16% annual probability of death from colorectal cancer. 
 
12.3.11.5 Osteoarthritis 
 
Osteoarthritis is related to BMI and diabetes, and so was included in the SPHR 
model. It was assumed that risk of osteoarthritis would be the same in an ID 
population as in the general population, taking into account individual differences in 
risk factors. The Bruneck cohort, a longitudinal study of inhabitants of a town in Italy 
reported diabetes and BMI as independent risk factors for osteoarthritis.300 The data 
used to estimate the incidence of osteoarthritis is reported in Table 49. 
 
 
Table 49: Incidence of osteoarthritis and estimated risk factors 
Risk factor Hazard ratio 2.5th C.I. 97.5th C.I. 
Diabetes 2.06 1.11 3.84 
BMI 1.076 1.023 1.133 
73 cases of diabetes, mean BMI 24.8; 13835 person 
years; incidence rate 0.00053 
 
 
12.3.11.6 Depression 
 
The SPHR Diabetes model includes depression as a health state due to its 
relationship with diabetes, but does not model its severity. Further details are 
available on-line.265 
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12.3.12 Economic Impact: Utilities 
 
12.3.12.1 Baseline Utility 
 
Baseline utilities for all individuals in the model were extracted from the STOP 
Diabetes study. The tariffs for the responses to the 3 level EQ-5D were derived from 
a UK population study.301 Baseline utility was assumed to decline due to ageing as 
has been found in general population studies. An absolute decrement of 0.004 per 
year is applied in the model; this is based on previous HTA modelling in 
cardiovascular disease.289 
 
12.3.12.2 Body mass index and utility 
 
It was assumed that changes in BMI will impact on the utility of an individual with ID 
in the same way as for an individual in the general population. In a previous 
modelling of diabetes prevention, weight loss from education interventions was 
associated with an increase in utility of 0.0025 per kg change in weight.302 This 
estimate was derived from weight loss trial data in which all participants were 
overweight or obese. In the ID population a large proportion of individuals are normal 
or underweight so it would not be appropriate to extrapolate the effects of weight loss 
on utility to these individuals. A change in utility due to a change in BMI was added 
to an individual’s EQ-5D if they had a BMI greater than 25. As a consequence, 
obese individuals who reduce their BMI as a result of the intervention will experience 
an increase in EQ-5D. 
 
12.3.12.3 Utility Decrements 
 
Utility decrements for long term chronic conditions were applied to the age and BMI 
adjusted EQ-5D score. It was assumed that a diagnosis of diabetes was not 
associated with a reduction in EQ-5D independent of the utility decrements 
associated with complications, comorbidities or depression. Cardiovascular disease, 
renal failure, amputation, foot ulcers, blindness, cancer, osteoarthritis and 
depression were all assumed to result in utility decrements. The utility decrements 
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are measured as a factor which is applied to the individual’s age and BMI adjusted 
baseline. If individuals have multiple chronic conditions the utility decrements are 
multiplied together to give the individual’s overall utility decrement from comorbidities 
and complications, in line with current NICE guidelines for combining 
comorbidities.303   
 
Due to the number of health states it was not practical to conduct a systematic 
review to identify utility decrements for all health states. Furthermore, there is very 
little or no data to inform utility decrements for comorbid conditions specifically in 
individuals with ID. A pragmatic approach was taken to search for health states 
within existing HTA for the relevant disease area in the general population or by 
considering studies used in previous economic models for diabetes prevention. 
Discussions with experts in health economic modelling were also used to identify 
prominent sources of data for health state utilities.  
 
Two sources of data were identified for diabetes related complications. A recent 
study from the UKPDS estimated the impact of changes in health states from a 
longitudinal cohort.304 This data was used to estimate the utility decrement for 
amputation and congestive heart failure. The absolute decrement for amputation was 
converted into utility decrement factors that could be multiplied by the individuals’ 
current EQ-5D to estimate the relative effect of the complication. Utility decrements 
for renal failure and foot ulcers were not available from the UKPDS study described 
above, so were obtained from a different study of 2,048 subjects with T1DM and 
T2DM.305  
 
Utility decrements for the variety of cardiovascular events were taken from an HTA 
assessing statins to reflect the utility decrements in the general population.289 A 
burden of illness study with a broad utility decrement for cancer was identified and 
used to define utility decrements for breast and colon cancer.306 A utility decrement 
for osteoarthritis was taken from a HTA,307 and a utility decrement for depression 
was calculated from a trial that had used EQ-5D.308 
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The multiplicative utility factors that are used in the model to describe health utility 
decrements from comorbid complications are shown in Table 50. The mean absolute 
decrement estimated in each study is reported alongside the baseline utility for each 
study. The utility factor was estimated by dividing the implied health utility with the 
comorbidity by the baseline utility. 
 
Economic Impact: Costs 
 
At any given time period of the model individuals can have multiple health 
complications that incur direct healthcare costs. Some of the health states are 
mutually exclusive; however an individual can accrue multiple complications within 
the model. Each health state is associated with an average cost, which is accrued by 
all individuals for every time period for which the state is indicated. Resource use for 
each comorbidity is added together and no savings are assumed to be made from 
the use of the same resources for two or more comorbidities for an individual. An 
exception to this is an assumed adjustment to the utilisation of GP services for 
individuals with chronic diseases. In the majority of cases it is assumed that the unit 
costs of healthcare for someone with ID would be the same as the unit costs for an 
individual in the general population.  
 
  
Prevention of T2DM in adults with ID                                                              12.Economic analysis 
 
272 
  
Table 50: Utility decrement factors 
Event / Co-
morbidity 
Mean 
Absolute 
decrement 
Standard 
error for 
absolute 
decrement 
Baseline 
Utility 
Multiplicative 
Utility Factor 
Source 
Foot ulcer -0.099 0.013 0.689 0.856 Coffey305 
Amputation -0.172 0.045 0.807 0.787 UKPDS304 
Blind 0.033 0.027 0.807 1.041 UKPDS304 
Renal failure -0.078 0.026 0.689 0.887 Coffey305 
Stable Angina    0.801 Ward HTA289 
Unstable 
Angina y1 
   0.770 Ward HTA289 
Unstable 
Angina y2 
   0.770 Ward HTA289 
Myocardial 
Infarction y1 
   0.760 Ward HTA289 
Myocardial 
Infarction y2 
   0.760 Ward HTA289 
Transient 
Ischaemic 
Attack  
   1.000 Ward HTA289 
Stroke y1    0.629 Ward HTA289 
Stroke y2    0.629 Ward HTA289 
Breast Cancer -0.060  0.800 0.913 Yabroff306 
Colorectal 
Cancer 
-0.060  0.800 0.913 Yabroff306 
Osteoarthritis -0.101    Black HTA307 
Depression -0.116  0.7905 0.875 Benedict308 
Congestive 
Heart Failure 
-0.101 0.032  0.875 UKPDS304 
UKPDS baseline utility 0.807; HSE baseline 0.7905 
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12.3.13 Economic Impact: Costs 
 
At any given time period of the model individuals can have multiple health 
complications that incur direct healthcare costs. Some of the health states are 
mutually exclusive; however an individual can accrue multiple complications within 
the model. Each health state is associated with an average cost, which is accrued by 
all individuals for every time period for which the state is indicated. Resource use for 
each comorbidity is added together and no savings are assumed to be made from 
the use of the same resources for two or more comorbidities for an individual. An 
exception to this is an assumed adjustment to the utilisation of GP services for 
individuals with chronic diseases. In the majority of cases it is assumed that the unit 
costs of healthcare for someone with ID would be the same as the unit costs for an 
individual in the general population.  
 
The exception was cost for a GP appointment, which was expected to be 40% higher 
than in the general population due to increased length of consultation. All costs were 
inflated to 2014/15 values using the retail price index where necessary, from the 
Personal Social Services Research Unit (PSSRU) sources of information266.  
 
Currently the following costs are incorporated are: 
x Costs of GP appointments; 
x Costs of hypertension/dyslipidaemia/diabetes diagnosis and treatment with 
statins and anti-hypertensives. Statins have a 65% uptake rate; 
x Diabetes costs (three stage treatment regimen incorporating Metformin 
monotherapy (HbA1c>6.5%), Metformin plus a dipeptidyl peptidase 4 inhibitor 
(DPP-IV), (when HbA1c>7.4%), and insulin plus antidiabetics (HbA1c>8.5%), 
together with associated costs such as blood tests, extra GP visits); 
x CVD and Heart Failure Costs (including hospital and primary care costs, 
medications and ongoing care costs for people with Stroke); 
x Microvascular Costs (including renal dialysis and transplant, treatment costs 
for amputation, ulcer and blindness); 
x Cancer Costs (including screening and treatment by cancer stage); 
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x Osteoarthritis costs (including extra primary care, medications and joint 
replacement); 
x Depression costs (including nurse costs, medication and emergency care). 
 
A summary of all the unit costs used in the model and their sources is shown in 
Table 51.266, 309-328 
 
12.3.13.1 Diabetes costs 
 
A three stage diabetes treatment regimen is applied in the model as a trade-off 
between model simplicity and capturing key cost differences between the 
interventions. At diagnosis all patients are prescribed low cost treatments, 
represented by metformin (weighted average of standard and modified release) to 
describe the average cost of these medications. If HbA1c increases above a 
threshold the individual is prescribed one of the more expensive DPP-IV inhibitors in 
addition to metformin. The individual continues to receive metformin plus DPP-IV 
inhibitor for a period of time until they require insulin. The cost of diabetes in the year 
of diagnosis is assumed to be greater than subsequent years because the individual 
will receive more contact time whilst their diabetes is being controlled. 
 
Simulated individuals experience an annual increase in HbA1c. It is assumed that 
individuals switch to dual treatment in the first annual cycle in which HbA1c 
increases above 7.4%, based on a recent HTA.329 For costing purposes the second 
drug to be added to metformin was assumed to be Sitagliptin. The second major 
treatment change is assumed to be initiation of insulin. Within the model the 
individual is switched to insulin in the first annual cycle at which HbA1c exceeds 
8.5%.329 The insulin Glargine was chosen to represent insulin treatment in the UK. 
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Table 51: Summary of all drug, treatment, care and resource costs included in 
the model 
Drug, Treatment, Care and Resource Costs Cost per year/ 
incident in 2014/15 
prices 
Source 
STOP Diabetes intervention per person £ 1,097 
Micro-
costing 
Screening and Intervention costs   
 Standard Learning Disability Health Check £43.48 
Dept. of 
Health316 
 
 
Learning Disability Health Check without Blood 
Tests 
£18.67  
 
Health Check capabilities assessment and 
explanation of intervention (10 mins Health Care 
assistant time) 
£3.40 PSSRU266 
First line diabetes treatment - low cost diabetes 
monotherapy  
  
 
Ongoing costs of diabetes monotherapy – made 
up of… 
£79.06 
 
 
 
Metformin 500 mg bid standard (85% of patients) 
or modified release (15%) tablets £18.83 BNF
315
 
 Nurse at GP (consultation) £25.52 PSSRU266 
 Health care assistant (10 mins) £3.40 PSSRU266 
 Urine sample £1.00 326 
 Eye screening £24.31 320 
 Lab tests – made up of… £6.00  
  HbA1c test £3.00 326 
  Lipids test £1.00 326 
  Liver function test £1.00 326 
  B12 test £1.00 326 
 
Additional first year costs of diabetes monotherapy 
– made up of… 
£103  
 Nurse at GP (2 x consultations) £51.03 PSSRU266 
 Health care assistant (2 x 10 mins) £6.80 PSSRU266 
 Urine sample (x2) £2.00 326 
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 Lab tests as above (x2) £12.00 326 
 
Smoking cessation (central estimate of cost of 
nicotine replacement therapy) taken up by 50% of 
the assumed 20% of population who smoke 
£30.90 PSSRU266 
Second line diabetes treatment - Metformin and a DPP-IV 
inhibitor – made up of… 
£529  
 Sitagliptin 100 mg daily £434 BNF315 
 
Metformin 500 mg bid standard (85% of patients) 
or modified release (15%) tablets £85 BNF
315
 
 Self-monitoring strips (82 per annum) 322 £16.36 BNF315 
 Nurse at GP (consultation) £25.52 266 
 Health care assistant (10 mins) £3.40 266 
 Urine sample £1.00 326 
 Eye screening £24.31 320 
 Lab tests as for first line treatment £6.00 326 
Third line diabetes treatment - Insulin and oral anti-
diabetics – made up of… 
£1,503  
 Nurse at GP (3 x consultations) £76.55 PSSRU266 
 Health care assistant (3 x 10 mins) £10.21 PSSRU266 
 Urine sample (x3) £3.00 326 
 Eye screening £24.31 320 
 Lab tests as for first line treatment (x3) £18.00 326 
 Insulin treatment costs – made up of… £1,376  
  Glargine £830.83 312 
  Oral anti-diabetics £57.75 312 
  Reagent test strips £292.74 312 
  Hypoglycaemic rescue £30.98 312 
  Pen delivery devices £72.44 312 
  Sharps £90.98 312 
Other primary care costs   
 GP visit (17 minutes) £68.38 PSSRU266 
 
Diagnosis of hypertension (including ambulatory 
BP monitoring) £56.51 
327
 
 
Annual treatment with statins (simvastatin 20 mg 
bid) £26.59 BNF
315
 
 Annual treatment with anti-hypertensives £195.94 321 
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Cardiovascular disease costs   
 
Unstable Angina year 1: 
Secondary care costs: 100% hospitalisation, 50% 
revascularisation procedure, three outpatient 
appointments). 
Primary care costs (three GP visits) and 
medications 
£4,674 324 
 
Myocardial infarction year 1 
Secondary care costs: 100% hospitalisation, 
50% revascularisation procedure, three outpatient 
appointments) 
Primary care costs (three GP visits) and 
medications. 
£4,813 324 
 
Subsequent ACS care costs 
Secondary care costs (one outpatient 
appointment). 
Primary care costs (three GP visits) and 
medications. 
£410 324 
 
Stroke year 1 (NHS costs) 
Costs of acute events reported in Youman et al. 57 
weighted by the distribution of severity of stroke 21. 
£9,716 309 
 
Social care costs of stroke in subsequent years 
The costs of ongoing care at home or in an 
institution weighted by the distribution of severity of 
stroke and discharge locations. 
£2,730 324 
 
Fatal coronary heart disease 
Assumed that 50% of fatalities incurred cost. 
£713 313 
 
Fatal non cardiac vascular event 
Assumed that 50% of fatalities incurred cost. 
£4,443 309 
 Congestive heart failure £3,091 UKPDS318 
Other complications of diabetes costs   
 Renal failure – weighted composite of… £25,046  
  Haemodialysis with overheads £42,049 323 
  Automated peritoneal dialysis  £27,217 323 
  Continuous ambulatory peritoneal dialysis  £19,742 323 
  Transplant (year 1) £23,660 310 
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  Immunosuppressant (10 years) £6,959 310 
 Foot ulcers £216 317 
 Amputation first year £10,101 UKPDS325 
 Amputation subsequent years  £1,896 UKPDS325 
 Blindness first year £1,434 UKPDS325 
 Blindness subsequent years  £479 UKPDS325 
 Breast cancer £13,818 314 
 Colorectal cancer £18,729 311 
 Osteoarthritis £962 328 
 Depression - made up of… £137 319 
  Practice nurse at surgery £13.70  
  Practice nurse at home visit £0.54  
  Practice nurse telephone £0.99  
  Health visitor £1.94  
  District nurse £0.38  
  Other nurse £1.17  
  HCA phlebotomist £1.05  
  Other primary care £4.85  
  Out of hours £6.18  
  NHS direct £2.28  
  Walk-in centre £8.15  
  Prescribed medications £74  
  Secondary care £21  
Assumed 20% smoking prevalence and 50%  uptake of smoking cessation services 
SANG Stable angina; UANG unstable angina; MI myocardial infarction; TIA transient 
ischemic attack; CHD congestive heart failure; ACS acute Coronary Syndrome; UKPDS 
United Kingdom prospective Diabetes Study; BNF British National Formulary; DPP-IV, 
dipeptidyl peptidase 4 inhibitor  
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12.3.13.2 Health checks 
 
The cost of a health check in the ID population was derived from the Department of 
Health Economic modelling for vascular checks.316 This study estimated the cost of a 
health check in the general population to be £23.70 in 2009 including blood tests, 
healthcare professional time, follow up and administration costs. For individuals with 
ID, it was assumed that all staff costs would double as the health check would take 
twice as long to perform (based on personal communication from Dr Kamlesh 
Khunti). All other costs were assumed to stay the same. Costs were inflated to 
2014/15 values prices, giving a final value of £43.48 for a full Learning Disability 
Health Check. 
 
Some individuals refuse to have blood taken as part of the health check. For these 
individuals a modified health check cost was derived, removing the cost of blood 
tests (consumables and laboratory costs) and the cost of nurse follow-up from the 
total. After inflation this came to £18.67. 
 
12.3.13.3 Other primary care costs 
 
Individuals with ID are assumed to visit their GP with the same frequency as 
individuals in the general population; however, each consultation is estimated to take 
40% longer than the average (based on personal communication from Prof K Khunti, 
Diabetes Research Centre, University of Leicester, UK; October 2015). PSSRU unit 
costs were used to estimate the cost of a 17.2 minute consultation at £67,266 which 
was then inflated to 2014/15 prices. Individuals who are prescribed statins receive a 
daily dose of 40mg of generic Simvastatin. The individual remains on statins for the 
rest of their life. A unit cost of anti-hypertensives was obtained from a 2004 study321 
and inflated to 2014/15 prices. Due to the number of different anti-hypertensive 
treatments available and possibilities for combination therapies, using the cost from 
this study of prescriptions was preferred to using costs directly from the BNF.  
 
12.3.13.4 Cardiovascular costs 
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Costs for cardiovascular disease were obtained from a 2009 HTA for high dose lipid-
lowering therapy.324  The costs included are shown in Table 51. The costs of fatal 
stroke and MI were obtained from two separate studies,309, 313 and it was assumed 
that 50% of individuals would incur these costs. The costs of congestive heart failure 
were estimated from the UKPDS costing study for complications related to 
diabetes.318  
 
12.3.13.5 Costs of other comorbidities 
 
More details of the costs of microvascular complications of diabetes, cancers, 
osteoarthritis and depression are available on-line.265 
 
12.3.14 Other model inputs  
 
x Perspective: the model adopts an NHS and social care perspective. Societal 
costs are not included.  
x Horizon: The time horizon of the model is the lifetime of all baseline individuals. 
x Discount Rates: Costs and QALYs are discounted at 1.5% per annum in line with 
NICE guidance for economic evaluation of public health interventions158. 
 
12.3.15 Reporting outcomes of the economic modelling 
 
The model compares the outcomes of an identical baseline population undergoing 
the screening (and possible intervention) with those if current care were followed. 
The model allows a variety of different clinical outcomes to be gathered, as well as 
costs and QALYs. The model also allows a range of other incremental outcomes to 
be collected including life years saved and diabetes and cardiovascular cases 
prevented. 
 
12.3.15.1 Use of threshold analysis  
 
The usual output of an economic evaluation, for a pre-specified intervention with 
known clinical effectiveness and cost per patient, is the incremental cost-
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effectiveness ratio, the ICER (see below for formulae) which can then be compared 
with the £ 20,000 to £ 30,000 cost per QALY acceptability threshold set out by NICE.  
 
However, as the clinical effectiveness of the STOP Diabetes intervention was not 
tested as part of the current programme of research (only its feasibility), a different 
approach for this analysis was needed. The output was the change in effectiveness 
needed for the intervention to be marginally cost-effective; that is, the ICER equals 
the cost per QALY acceptability threshold. As the primary clinical outcome of interest 
to the STOP Diabetes study investigators is change in steps per day, the economic 
analysis deals with the change in physical activity (steps) and associated risk factors 
(BMI, SBP, total and HDL cholesterol) needed for the intervention to be marginally 
cost-effective. The STOP Diabetes intervention also contains dietary advice (but no 
specific weight goal) so the threshold analysis needs to take account of benefits 
attributable to physical activity and diet. The results tables for the threshold analyses 
therefore show alternative permutations of step changes together with the additional 
benefit from dietary change that would be necessary for the intervention to be cost-
effective overall.  
  
12.3.16 Analyses, scenarios and sensitivity analyses undertaken 
 
All statements herein about an increase in the number of steps refer to the increase 
in steps per day. 
 
12.3.16.1 Exploratory analysis 
 
An initial analysis was undertaken to assess how cost-effective the STOP Diabetes 
intervention would be if it achieved the average 2,491 change in daily steps reported 
in the Bravata meta-analysis. Initially, it was assumed that the intervention would 
increase mean daily step count by 2,491 steps as detailed in Bravata et al, leading 
to: 
x mean reduction in BMI of 0.38 
x mean reduction in systolic BP of 3.8mmHg 
x mean reduction in total cholesterol of 0.09mmol/L 
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x mean increase in HDL cholesterol of 0.06 mmol/L 
 
The intervention effect was assumed to decline linearly such that by three years 
(from the start of the intervention), the risk factors have reverted back to their 
trajectory had there been no intervention.  
 
The ICER is obtained using the incremental costs and QALYs gained from 
implementing the intervention rather than current care, calculated using the following 
formulae: 
Incremental costs (£) = Total costs Intervention (£) – Total costs Comparator (£) 
Incremental QALYs = Total QALYs Intervention (£) – Total QALYs Comparator (£) 
ICER (£/QALY) = Incremental Costs (£) / Incremental QALYs 
 
Although total costs and QALYs can be assessed at any year in the model, allowing 
estimation of both short-term and long-term cost-effectiveness, we report the long-
term cost-effectiveness as this is what regulatory bodies are primarily interested in. 
 
In addition, a simple budget impact was calculated, as follows: 
1. The number of adults in England with moderate to critical needs using social 
care was taken from 2015 estimates by PHE’s learning disabilities 
observatory for adults (546,489)330 
2. The percentage of the above that have IGR was based on the percentage in 
the STOP screening study found to be IGR after screening, recruitment and 
blood testing (5%) 
3.  The percentage likely to take up an intervention was based on the 
percentage of those in the feasibility study invited to take part on the STOP 
programme who actually attended sessions (26%) 
4. The resulting number of likely STOP users for the whole of England (7,104) 
was multiplied by the intervention cost per user to give the total budget impact 
of implementing the STOP programme. 
 
12.3.16.2 Scenarios for duration of effect 
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For all analyses undertaken, we model two fundamental alternative scenarios to test 
the sensitivity of the cost-effectiveness to two alternative durations of effect of the 
intervention, that is, after starting to reduce after year 1, by which time-point have the 
benefits of intervention worn off. The first scenario, assuming a three-year duration, 
is considered most likely given that the proposed maintenance sessions finish at the 
end of the first year and the alternative five-year scenario is presented as a what-if 
scenario.  
 
12.3.16.3 Deterministic one-way sensitivity analysis 
 
Previous analyses using the model and of economic evaluations of lifestyle 
interventions suggested which parameters are likely to have the largest effect on 
model results, so the following were considered for one-way sensitivity analysis: 
i) Increased clinical effects 
There is significant uncertainty around the relationship reported in Bravata, so we 
explored the impact of a more beneficial impact by taking the 65th percentile for the 
possible magnitude of beneficial change in BMI, systolic BP, total cholesterol and 
HDL cholesterol from the CIs reported in Bravata (assuming the distributions are 
normally distributed). In this case, an increase in mean daily step count of 2,491 
steps as detailed in Bravata is estimated to lead to: 
x mean reduction in BMI of 0.45 kg/m2 
x mean reduction in systolic BP of 4.21 mmHg 
x mean reduction in total cholesterol of 0.14 mmol/L 
x mean increase in HDL cholesterol of 0.07 mmol/L 
 
This alternative mapping was explored in the context of both the three and five-year 
duration of effect scenarios above. 
ii) Uptake rates: 
These were considered not to be a key driver because individuals that do not uptake 
the intervention incur no costs other than the very small cost of screening relative to 
the cost of the intervention. 
 
iii) Discount rates: 
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Alternative rates were considered but testing out lower rates than 1.5% seems 
implausible and higher rates would not have altered the conclusions. 
 
12.3.17 Subgroup analyses 
 
As initial analyses suggested that the intervention would be unlikely to be cost-
effective in the overall ID population, further work was set out in order to identify the 
most beneficial subgroups. Three sub-groups were identified to explore if the cost-
effectiveness of the intervention might be improved if screening were more targeted: 
 
1) By age band 
Based on the distribution of age in the STOP Diabetes study, the age bands were 
FKRVHQDQGDQGDQG6HOHFWLQJ LQGLYLGXDOV
aged 35+ would include 65% of the STOP Diabetes cohort; aged 40+ 45+ and 50+ 
would include 55%, 45% and 35% respectively. Age cut-offs of 55+ and 60+ would 
have only covered 24% and 14% of the cohort only respectively. 
 
2) BMI 
We carried out a subgroup analysis in which everyone was screened but only obese 
individuals were eligible for intervention. 
 
3) Baseline cardiovascular risk 
We calculated the baseline 10-year CVD risk using the QRISK score and excluded 
any individuals with a risk <5%. This is a low cut-off but using a higher cut-off would 
have meant fewer than 25% of the cohort being screened, and a very low proportion 
actually receiving and benefiting from intervention. 
 
12.3.18 Probabilistic sensitivity analysis  
 
Due to the exploratory nature of the analysis (described in Section 12.3.16.1), full 
probabilistic sensitivity analysis (PSA) was carried out on only one of the threshold 
scenarios, with the aim of illustrating the extent of non-linearity in the model (i.e. by 
comparing the results of the PSA with the corresponding deterministic results). PSA, 
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which describes the uncertainty in model parameter inputs, is not suitable for 
describing the decision uncertainty in this analysis i.e. the current research was 
leading to the stage at which the intervention could be considered for implementation 
into clinical practice. Instead, analyses were more exploratory to inform potential 
future research and intervention refinement.  
 
In addition, the true uncertainty around the effectiveness estimates is much wider 
than that around the parameters available from the Bravata-based relationship. 
There is also uncertainty around the effectiveness of the planned intervention in 
increasing physical activity and uncertainty around whether increasing the number of 
steps increases metabolic benefits in a linear way. This uncertainty cannot be 
accurately quantified (although it could potentially be estimated through a time-
consuming expert elicitation, which is outside the scope of this investigation), but 
PSA analysis without it would vastly underestimate the uncertainty in the cost-
effectiveness estimates. 
 
For the single PSA completed, a suitable distribution was selected for each 
parameter, based upon its mean and standard error, and within the simulations, 
random sampling across all input parameter distributions was undertaken. 2000 
different random samples of parameter values were selected, and each was applied 
to a different random cohort of 5,000 individuals randomly sampled with replacement 
from the baseline STOP Diabetes population. For each probabilistic sensitivity 
analysis sample, the model was run and results compiled. 
 
More details of the distributions around key model parameters are shown in 
Appendix 26 (Table 70 and Table 71).  
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12.4 Results 
 
This section presents a series of results for the scenarios and sensitivity analyses 
described earlier. First is an analysis of how cost-effective the STOP Diabetes 
intervention would be if it achieved the average change for a physical activity 
intervention, 2,491 steps, as reported in the Bravata meta-analysis. Next, results of 
the threshold analyses for the necessary risk factor changes needed to achieve cost-
effectiveness are presented under a variety of scenarios and sub-groups. Lastly, an 
alternative threshold analysis explores what the maximum budget for the intervention 
would be given certain changes in risk factors. 
 
Whenever results are stated as the ‘base case’, these reflect the base case 
assumption for the effects a change in steps has on risk factors for CVD (BMI, 
systolic BP, total and HDL cholesterol). Most analyses present results for both 3 and 
5 years durations of intervention effect, but if not specified, the base case of 3 years 
applies.  
 
It should be noted that effects lasting to year 3 means that they have worn off 2 
years from the end of year 1 (which is close to when the last monthly maintenance 
session occurs). Similarly, effects that have worn off by year 5 effectively last for 4 
years from the end of the maintenance sessions. 
 
12.4.1 Cost-per-QALY results based on Bravata step count 
 
Before the threshold analyses were undertaken, an exploratory analysis was 
undertaken to see how cost-effective the STOP Diabetes intervention would be, 
assuming an increase in steps in line with that calculated in the meta-analysis by 
Bravata. This analysis assumes no dietary intervention. 
 
The estimated incremental cost-effectiveness ratio (cost per QALY gained) under the 
base case is £275,000 compared to a usual acceptability threshold (what funders are 
willing to pay) in the range £ 20,000 to £ 30,000 per QALY. Savings in lifetime costs 
of CVD and primary care, and savings in treating diabetes and its complications are 
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far outweighed by the £ 1,097 intervention cost per person. A much greater 
intervention effect in terms of either physical activity, diet or both, or a reduction in 
intervention cost would be required to make the intervention cost effective. 
 
The estimated budget impact for delivering the STOP programme to 7,104 adults 
with ID and IGR across England was estimated at £7.8m. If the programme were 
taken up by all ID adults with IGR in England (over 27,000) then the total cost could 
be as high as £30.0m. There is uncertainty around the true prevalence of IGR 
amongst adults with ID. If this is actually 10% (rather than 5%), the above budget 
impacts would rise to £15.6m and £60.0m respectively. 
 
12.4.1.1 Probabilistic sensitivity analysis  
 
Probabilistic sensitivity analysis was carried out for the above Bravata-based 
analysis (an increase of 2,491 steps), giving a probabilistic central estimate of the 
ICER of £253,000 which is lower than the deterministic estimate by about 6%, 
demonstrating a small degree of non-linearity in the model. Given how high the 
deterministic ICER was compared with the acceptability threshold of £ 30,000/QALY, 
this is clearly a negligible difference for the overall conclusion about the intervention. 
 
The probability that such an intervention is cost-effective compared to current care at 
a threshold of £ 30,000 per QALY is almost zero at 0.15%. However, as described in 
the methods section, the uncertainty around intervention effectiveness is much 
higher than the uncertainty described in the Bravata study and used in the PSA, 
meaning that the PSA will underestimate the total uncertainty. 
 
The cost-effectiveness plane for the intervention compared to current care at £ 
30,000 per QALY is shown in Appendix 27 (Figure 30).  
 
12.4.2 Threshold analyses for effect sizes needed 
 
A series of model simulations were performed in order to determine the thresholds 
required for the intervention to be cost-effective at acceptability thresholds of 
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£20,000 and £ 30,000 per QALY. The presented thresholds are rounded to the 
nearest 500 steps. 
 
At the calculated thresholds, the ICER for the intervention is £20,000 (or £ 30,000) 
per QALY, and, the greater savings from CVD and diabetes treatment and primary 
care costs, together with the value of the health gain (QALYs) are just enough to 
outweigh the additional cost of the intervention.  
 
Ascertainment of the thresholds relies upon the assumption of a linear relationship 
between change in steps and risk factors (that observed in Bravata) being 
maintained over the wide range of steps inherent within the calculation of the 
thresholds. 
 
It is recognised that under many, if not most scenarios, the magnitude of the 
additional diet-related changes in BMI and systolic BP (that are necessary to attain 
cost-effectiveness) are implausible in terms of their achievability. They are 
nevertheless genuine estimates from the threshold approach fundamental to this 
economic analysis. 
 
12.4.2.1 Summary of key results from threshold analyses 
 
In subsequent Section 12.4.2.5, detailed results are presented for a number of 
alternative levels of increase in steps per day, up to 15,000. There are however 
many tables, each containing many permutations of the magnitude of physical 
activity-related and dietary related BMI change that could achieve cost-effectiveness 
as illustrated in Table 56. To aid digestion of the results, in this section, the results 
are summarised for some mid-range levels of change in steps, 3000, 5000 and 7000 
per day. 
 
In 
Table 52, the necessary diet-related effects that would need to be achieved, in 
addition to the effects arising from an increase of 5000 steps, are shown across 
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various scenarios and sub-groups (see Section 12.3.15.1. for the rationale of the 
threshold analyses as presented). 
 
As an example, consider the base case row of  
Table 52, assuming an acceptability threshold of £30,000 per QALY and 3 year 
duration of effects. BMI and systolic BP reductions of 2.9kg/m2 and 29mmHg 
respectively would be needed, in addition to the BMI and systolic BP benefits of 
5000 additional steps, in order for the intervention to be cost-effective. An increase of 
5000 steps corresponds to a BMI reduction of 0.76kgm2, an systolic BP reduction of 
7.6mmHg and a reduction in the lipid ratio of 0.22 (all purely through physical activity 
without diet). So the overall (steps plus dietary) BMI and systolic BP reductions 
needed for a cost-effective intervention would be 3.66kg/m2 and 36.6mmHg, which 
are clearly unachievable in practice. 
 
Table 52: Summary of dietary effects needed in addition to 5000 steps 
 Population group £20,000 per QALY £30,000 per QALY 
  
3 year 5 year 3 year 5 year 
Dietary contributions only 
BMI 
(systolic BP) 
BMI 
(systolic BP) 
BMI  
(systolic BP) 
BMI  
(systolic BP) 
Base case -4.2 (-42) -2.6 (-26) -2.9 (-29) -1.5 (-15) 
Increased 
effectiveness 
intervention 
-4.0 (-40) -2.0 (-20) -2.4 (-24) -1.2 (-12) 
Obese subgroup -4.0 (-40) -2.0 (-20) -2.6 (-26) -1.3 (-13) 
45 to 49-year-old 
subgroup 
-1.8 (-18) -1.1 (-11) -1.4 (-14) -0.9 (-9) 
50+ age group -3.4 (-34) -2.0 (-20) -1.8 (-18) -0.9  (-9) 
High CVD risk group  
-year risk)  -2.7 (-27) 
      -1.4 (-
14) -1.5 (-15) -0.8 (-8) 
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Table 53 and Table 54 present similar analyses for a change in steps of 3000 and 
7000 respectively.  
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Table 53: Summary for 3000 steps 
 Population group £20,000 per QALY £30,000 per QALY 
  
3 year 5 year 3 year 5 year 
Dietary contributions only 
BMI 
(systolic BP) 
BMI 
(systolic BP) 
BMI  
(systolic BP) 
BMI  
(systolic BP) 
Base case -4.5 (-45) -2.9 (-29) -3.2 (-32) -1.8 (-18) 
Increased 
effectiveness 
intervention 
-4.3 (-43) -2.3 (-23) -2.7 (-27) -1.5 (-15) 
Obese subgroup -4.3 (-43) -2.3 (-23) -2.9 (-29) -1.6 (-16) 
45 to 49-year-old 
subgroup 
-2.1 (-21) -1.4 (-14) -1.7 (-17) -1.2 (-12) 
50+ age group -3.7 (-37) -2.3 (-23) -2.1 (-21) -1.2 (-12) 
High CVD risk group  
-year risk) -3.1 (-31) -1.7 (-17) -1.8 (-18) -1.1 (-11) 
 
Table 54: Summary for 7000 steps 
 Population group £20,000 per QALY £30,000 per QALY 
  
3 year 5 year 3 year 5 year 
Dietary contributions only 
BMI 
(systolic BP) 
BMI 
(systolic BP) 
BMI 
(systolic BP) 
BMI 
(systolic BP) 
Base case -3.9 (-39) -2.3 (-23) -2.6 (-26) -1.2 (-12) 
Increased 
effectiveness 
intervention 
-3.7 (-37) -1.7 (-17) -2.1 (-21) -0.9 (-9) 
Obese subgroup -3.7 (-37) -1.7 (-17) -2.3 (-23) -1.0 (-10) 
45 to 49-year-old 
subgroup 
-1.5 (-15) -0.8 (-8) -1.1 (-11) -0.6 (-6) 
50+ age group -3.1 (-31) -1.7 (-17) -1.5 (-15) -0.6 (-6) 
High CVD risk group  -2.4 (-24) -1.1 (-11) -1.2 (-12) -0.5 (-5) 
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-year risk) 
 
12.4.2.2 Intervention cost threshold analysis 
 
As an alternative type of threshold analysis, we explored the maximum intervention 
cost that could be afforded for a given increase in steps per day. At a value of 
£30,000 per QALY, for the subgroup of individuals aged over 50, with an assumed 
duration of effect of 3 years, the maximum intervention budget (combined initial plus 
maintenance cost) to achieve cost-effectiveness is around £280 for a 4,000 step per 
day increase (0.61 BMI reduction and 6mmHg systolic BP reduction) and around 
£420 for a 6,000 step per day increase (0.91 BMI reduction and 9mmHg systolic BP 
reduction). For the subgroup of individuals with increased CVD risk, the maximum 
budget for a cost-effective intervention is around £500 for a 4,000 step per day 
increase and around £700 for a 6,000 step per day increase. 
 
12.4.2.3 Interpretation of threshold analysis results 
 
First, we summarise the implications of aiming to achieve cost-effectiveness through 
step changes alone. For the overall STOP Diabetes cohort, to achieve cost-
effectiveness at a value of £20,000 per QALY, the results suggest that in excess of 
30,000 additional steps per day would be required (around 5 kg/m2 reduction in BMI 
and 50mmHg reduction in systolic BP), which is biologically implausible. At £30,000 
per QALY the threshold was around 24,000 additional steps per day (3.7 kg/m2 -
reduction in BMI and 37mmHG reduction in systolic BP). If the intervention effect is 
assumed to last (decreasing linearly) until year 5, the threshold reduces to around 
22,000 steps (2.4 kg/m2 reduction in BMI and 34mmHG reduction in systolic BP) at 
£20,000 per QALY and 15,000 steps (2.3 kg/m2 reduction in BMI and 23mmHG 
reduction in systolic BP) at £30,000 per QALY. Note that as all these values 
represent effect sizes more than five times that achieved in the source study 
(Bravata et al.) and as such they are reliant on extrapolations of the Bravata 
relationship well outside the range in which it can be reliably done so. 
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Cost-effective effect sizes could alternatively be achieved through a combination of 
risk factor changes through physical activity and risk factor changes through dietary 
intervention. Clearly there are many permutations of the magnitude of physical 
activity-related and dietary related changes that could achieve cost-effectiveness. A 
necessary increase of 13,000 steps under an assumption of increased effectiveness 
and 5 years duration (at £30k per QALY) equates to a BMI change of -2.75kg/m2 
based on Bravata et al. This overall BMI change could be achieved, for example, 
through the effect of an additional 7,000 steps per day together with further BMI 
reduction achieved through dietary intervention of -1.68kg /m2.  
 
12.4.2.4 Alternative body mass index and systolic blood pressure 
equivalents 
 
A limitation of the threshold results presented above is that the necessary BMI and 
systolic BP changes attributed to diet exclusively use the Bravata study in their 
calculation. This results in the small combined (steps plus diet) BMI changes relative 
to the systolic BP changes reflecting the ratio of benefits that could be expected from 
a physical activity rather than a dietary intervention.  
 
To aim to address this, as an exploratory analysis, the table below shows an 
alternative set of permutations, the difference being that the diet-related BMI and 
systolic BP changes are now ‘re-aligned’ to reflect more realistically the relative ratio 
of BMI and systolic BP changes likely through dietary change. The calculations are 
underpinned by the BMI and systolic BP hazard ratios in the QRISK score for CVD, 
and thereby the analysis relies on the assumption that most of the economic benefits 
of intervention accrue through CVD risk reduction. We estimated that a 1mmHg 
systolic BP reduction gives approximately the same benefit as 0.6kg/m2 BMI 
reduction. 
 
The analysis was undertaken just in the context of a change of 5000 steps, that is, a 
re-working of results presented earlier in  
Table 52. 
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For the high CVD risk groups, if the effects could be maintained such that the effect 
is not completely lost until year 5, then the effect sizes needed are becoming closer 
to those achievable in practice. 
 
 
Table 55: Body mass index/systolic blood pressure equivalents for the diet-
attributable benefits needed to be cost-effective 
 Population group £20k per QALY £30k per QALY 
  
3 year 5 year 3 year 5 year 
BMI 
(systolic BP) 
BMI 
(systolic BP) 
BMI 
(systolic BP) 
BMI 
(systolic BP) 
Base case -11.8 (-29) -7.3 (-18) -8.1 (-20) -4.2 (-11) 
Increased effectiveness 
intervention 
-11.2 (-28) -5.6 (-14) -6.7 (-17) -3.4 (-8) 
Obese subgroup -11.2 (-28) -5.6 (-14) -7.3 (-18) -3.6 (-9) 
45 to 49-year-old 
subgroup 
-5 (-13) -3.1 (-8) -3.9 (-10) -2.5 (-6) 
50+ age group -9.5 (-24) -5.6 (-14) -5 (-13) -2.5 (-6) 
High CVD risk group  
-year risk) -7.6 (-19) -3.9 (-10) -4.2 (-11) -2.2 (-6) 
 
 
12.4.2.5 Full threshold analysis results tables  
 
Here we present the full set of model results for a wide range of change in step 
count. For disadvantaged groups, there is a higher likelihood than normal of NICE 
recommending a treatment at the upper end of the usual £ 20,000 - £ 30,000 per 
QALY bracket so the results presented here are for a willingness to pay of £30,000 
per QALY. The diet-related improvements in BMI, systolic BP and cholesterol that 
would be needed at £ 20,000 per QALY would be even more challenging (or 
implausible) than those presented here so the results for £20,000 per QALY are 
presented in Appendix 28 (Table 72, Table 73, Table 74, Table 75, Table 76, Table 
77). 
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Base case results 
 
The systolic BP and cholesterol ratio effects shown in the third and fourth columns of 
the tables are the total (step-related) effects for these parameters, that is, effects 
mediated indirectly through BMI reduction and direct effects of physical activity. 
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Table 56: Combinations of daily step increases and additional dietary changes required to achieve a cost-effective 
outcome for base case intervention effects, at £30,000 per QALY assuming all risk factors change together. 
Initial 
increase 
in steps 
needed 
Change attributable to the 
increase in steps 
Additional change needed to be 
generated through diet 
Additional change needed to 
be generated through diet 
Base case (3 year durability) 5 year durability 
BMI 
(kg/m2) 
Systolic 
BP 
(mmHg) 
Total:HDL 
cholesterol 
ratio 
BMI 
(kg/m2) 
Systolic
BP 
(mmHg) 
Total:HDL 
cholesterol 
ratio 
BMI 
(kg/m2) 
Systolic
BP 
(mmHg) 
Total:HDL 
cholesterol 
ratio 
0 0.0 0 0.00 -3.7 -37 -1.54 -2.3 -23 -1.08 
1000 -0.2 -2 -0.09 -3.5 -35 -1.49 -2.1 -21 -1.03 
3000 -0.5 -5 -0.26 -3.2 -32 -1.40 -1.8 -18 -0.90 
5000 -0.8 -8 -0.42 -2.9 -29 -1.30 -1.5 -15 -0.78 
7000 -1.1 -11 -0.57 -2.6 -26 -1.19 -1.2 -12 -0.64 
9000 -1.4 -14 -0.71 -2.3 -23 -1.08 -0.9 -9 -0.50 
11000 -1.7 -17 -0.84 -2.0 -20 -0.97 -0.6 -6 -0.34 
13000 -2.0 -20 -0.97 -1.7 -17 -0.84 -0.3 -3 -0.18 
15000 -2.3 -23 -1.08 -1.4 -14 -0.71 0.0 0 0.00 
a obtained from model runs 
b obtained from manual calculation after model runs 
 
Prevention of T2DM in adults with ID                                                              12.Economic analysis 
 
297 
  
 
A more detailed breakdown of the base case events, costs and QALYs is shown in  
Table 57. The mean QALY gain per person screened equates to an average of less 
than 1 day of additional life (in full health). 
 
Table 57: Detailed breakdown of results for 2,491 steps  
Incremental Outcomes 
per person 
Base Case effectiveness Increased effectiveness 
3 year duration 
5 year 
duration 
3 year duration 
5 year 
duration 
Total costs £329 £326 £328 £322 
Total QALYs 0.0012 0.0018 0.0014 0.0021 
ICER £273,000 £ 183,000 £ 231,000 £ 154,000 
Cardiovascular cases 
(per 1m) -130 -187 -153 -239 
STOP Diabetes 
Intervention cost 
£336 £336 £336 £336 
Diabetes Treatment 
Costs 
£ 0 £ 1 £0 £0 
Cardiovascular Costs -£5 -£6 -£5 -£7 
Costs other Diabetes 
Complications 
-£6 -£8 -£7 -£10 
 
 
Sensitivity Analyses – increased clinical effects 
 
In this analysis, it was assumed that effects on BMI, systolic BP and the lipid ratio of 
a given increase in steps would be greater than the base case, as described in the 
methods section.  
 
Under this modified assumption and assuming 3-year duration of effects, the 
estimated incremental cost per QALY gained for an increase of 2,491 steps (with no 
dietary intervention) was £228,000.  
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To achieve cost-effectiveness at a value of £20,000 per QALY, threshold analysis 
suggests that in excess of 30,000 additional steps per day would be required (some 
4.7 kg/m2 reduction in BMI and 47 mmHg reduction in systolic BP), which is still 
biologically implausible. At £30,000 per QALY the threshold is around 21,000 
additional steps per day (3.2 kg/m2 reduction in BMI and 32mmHG reduction in 
systolic BP). If the intervention effect is assumed to last (decreasing linearly) until 
year 5, the threshold reduces to around 18,000 steps (2.8 kg/m2 reduction in BMI 
and 27mmHG reduction in systolic BP) at £20,000 per QALY and 13,000 steps (2.0 
kg/m2 reduction in BMI and 20mmHG reduction in systolic BP) at £30,000 per QALY. 
The combination of step change and additional dietary change needed to reach cost-
effectiveness (assuming all risk factors change together) is shown in Table 58 (see 
Appendix 28, Table 73 for £ 20,000 per QALY acceptability) 
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Table 58: Combinations of daily step increases and additional dietary changes required to achieve a cost-effective 
outcome for an increased effectiveness intervention at £30,000 per QALY assuming all risk factors change together. 
 
Initial 
increase 
in steps 
needed 
Change attributable to the 
increase in steps 
Additional change needed to be 
generated through diet 
Additional change needed to 
be generated through diet 
Base case (3 year durability) 5 year durability 
BMI 
(kg/m2) 
Systolic
BP 
(mmHg) 
Total:HDL 
cholesterol 
ratio 
BMI 
(kg/m2) 
Systolic
BP 
(mmHg) 
Total:HDL 
cholesterol 
ratio 
BMI 
(kg/m2) 
Systolic
BP 
(mmHg) 
Total:HDL 
cholesterol 
ratio 
0 0.0 0 0.00 -3.2 -32 -1.40 -2.0 -20 -0.97 
1000 -0.2 -2 -0.09 -3.1 -31 -1.35 -1.8 -18 -0.90 
3000 -0.5 -5 -0.26 -2.7 -27 -1.25 -1.5 -15 -0.78 
5000 -0.8 -8 -0.42 -2.4 -24 -1.14 -1.2 -12 -0.64 
7000 -1.1 -11 -0.57 -2.1 -21 -1.03 -0.9 -9 -0.50 
9000 -1.4 -14 -0.71 -1.8 -18 -0.90 -0.6 -6 -0.34 
11000 -1.7 -17 -0.84 -1.5 -15 -0.78 -0.3 -3 -0.18 
13000 -2.0 -20 -0.97 -1.2 -12 -0.64 0.0 0 0.00 
15000 -2.3 -23 -1.08 -0.9 -9 -0.50 0.0 0 0.00 
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Sub-group analysis: obese 
 
Separate results are reported for a subgroup of the population only (using the base 
case clinical effects) who were defined as obese.  
 
The estimated incremental cost per QALY gained for a 2,491 increase in steps under 
this scenario was £276,000.  
 
To achieve cost-effectiveness at a value of £20,000 per QALY, threshold analyses 
suggest that in excess of 30,000 additional steps per day would be required and at 
£30,000 per QALY the threshold is around 22,000 additional steps per day. If the 
intervention effect is assumed to last (decreasing linearly) until year 5, the threshold 
reduces to around 18,000 steps at £20,000 per QALY and 13,500 steps at £30,000 
per QALY.  These values are very similar to the whole population results. 
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Table 59: Combinations of daily step increases and additional dietary changes required to achieve a cost-effective 
outcome for an obese subgroup in a base case intervention at £30,000 per QALY assuming all risk factors change 
together. 
Initial 
increase 
in steps 
needed 
Change attributable to the 
increase in steps 
Additional change needed to be 
generated through diet 
Additional change needed to 
be generated through diet 
Base case (3 year durability) 5 year durability 
BMI 
(kg/m2) 
Systolic
BP 
(mmHg) 
Total:HDL 
cholesterol 
ratio 
BMI 
(kg/m2) 
Systolic
BP 
(mmHg) 
Total:HDL 
cholesterol 
ratio 
BMI 
(kg/m2) 
Systolic
BP 
(mmHg) 
Total:HDL 
cholesterol 
ratio 
0 0.0 0 0.00 -3.4 -34 -1.45 -2.1 -21 -1.00 
1000 -0.2 -2 -0.09 -3.2 -32 -1.40 -1.9 -19 -0.94 
3000 -0.5 -5 -0.26 -2.9 -29 -1.30 -1.6 -16 -0.81 
5000 -0.8 -8 -0.42 -2.6 -26 -1.19 -1.3 -13 -0.68 
7000 -1.1 -11 -0.57 -2.3 -23 -1.08 -1.0 -10 -0.53 
9000 -1.4 -14 -0.71 -2.0 -20 -0.97 -0.7 -7 -0.38 
11000 -1.7 -17 -0.84 -1.7 -17 -0.84 -0.4 -4 -0.22 
13000 -2.0 -20 -0.97 -1.4 -14 -0.71 -0.1 -1 -0.05 
15000 -2.3 -23 -1.08 -1.1 -11 -0.57 0.0 0 0.00 
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Subgroup analysis: age subgroups 
 
The results in Table 60 show the effect sizes needed for subgroups by age (for both 
the base case clinical effects and increased effects sensitivity assumption). 
The estimated incremental cost-effectiveness ratio (cost per QALY gained) in the 
base case across the whole baseline population was £276,000. For age-based sub-
groups, this ICER varied from £172,000 (ages 50+) to £482,000 (ages 35-39). In the 
base case with 5 year durability, the ICER varied from £107,000 (ages 50+) to 
£301,000 (aged less than 35). In the increased effectiveness scenario with 5 year 
durability, the ICER ranged from £92,000 (ages 50+) to £262,000 (aged less than 
35). 
 
Prevention of T2DM in adults with ID                                                              12.Economic analysis 
 
303 
  
 
Table 60: Change in body mass index / systolic blood pressure required to achieve a cost-effective outcome for individual 
age bands 
  
  
Population 
group 
Base case clinical effects Increased clinical effects 
£20k per QALY £30k per QALY £20k per QALY £30k per QALY 
Base case 
(3 yrs) 
5 yrs Base 
case (3 
yrs) 
5 yrs Base 
case (3 
yrs) 
5 yrs Base 
case (3 
yrs) 
5 yrs 
All ages -5.8 / -58 -3.4 / -
34 
-3.8 / -
38 
-2.3 / -
23 
-5.6 / -56 -2.9 / -
29 
-3.5 / -
35 
-1.9 / -
19 
Age <35 -18.3 / -
183 
-4.7 / -
47 
-7.9 / -
79 
-3.4 / -
34 
-13 / -130 -4 / -40 -6.7 / -
67 
-2.8 / -
28 
Age 35-39 -4.3 / -43 -2.7 / -
27 
-3.6 / -
36 
-2.2 / -
22 
-2.8 / -28 -2.4 / -
24 
-2.4 / -
24 
-2 / -20 
Age 40-44 -5.3 / -53 -3.1 / -
31 
-3.7 / -
37 
-2.2 / -
22 
-5.2 / -52 -2.7 / -
27 
-3.4 / -
34 
-1.9 / -
19 
Age 45-49 -2.6 / -26 -1.9 / -
19 
-2.1 / -
21 
-1.7 / -
17 
-2.8 / -28 -2.1 / -
21 
-2.2 / -
22 
-1.6 / -
16 
Age 50+ -4.1 / -41 -2.7 / -
27 
-2.6 / -
26 
-1.7 / -
17 
-4.6 / -46 -2.1 / -
21 
-2.5 / -
25 
-1.3 / -
13 
Only BMI and Systolic BP effects are shown but corresponding changes in the lipid ratio in line with 
Bravata would also be needed 
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To achieve cost-effectiveness at a value of £30,000 per QALY in the overall ID 
cohort, threshold analyses suggest that 25,000 additional steps per day would be 
required. For age sub-groups, this threshold varied from 14,000 additional steps per 
day (ages 45-49) to 52,000 (ages less than 35). If the durability were extended to 5 
years the threshold ranges from 11,000 additional steps (ages 45+) to 22,000 
additional steps (ages less than 35) and if effectiveness is increased the threshold 
ranges from 8,500 additional steps (ages 50+) to 18,500 steps (ages less than 35). 
The combinations of steps and additional dietary changes needed to reach cost 
effectiveness for people aged 45-49 and aged more than 50 at £30,000 (£20,000) 
per QALY are shown in Table 61 and Table 62 (and Appendix 28, Table 75 and 
Table 76). 
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Table 61: Combinations of daily step increases and additional dietary changes required to achieve a cost-effective 
outcome for a 45 to 49-year-old subgroup in a base case intervention at £30,000 per QALY assuming all risk factors 
change together 
 
Initial 
increase 
in steps 
needed 
Change attributable to the 
increase in steps 
Additional change needed to be 
generated through diet 
Additional change needed to 
be generated through diet 
Base case (3 year durability) 5 year durability 
BMI 
(kg/m2) 
Systolic
BP 
(mmHg) 
Total:HDL 
cholesterol 
ratio 
BMI 
(kg/m2) 
Systolic
BP 
(mmHg) 
Total:HDL 
cholesterol 
ratio 
BMI 
(kg/m2) 
Systolic
BP 
(mmHg) 
Total:HDL 
cholesterol 
ratio 
0 0.0 0 0.00 -2.1 -21 -1.03 -1.7 -16.8 -0.8 
1000 -0.2 -2 -0.09 -2.0 -20 -0.97 -1.5 -15.3 -0.8 
3000 -0.5 -5 -0.26 -1.7 -17 -0.84 -1.2 -12.2 -0.6 
5000 -0.8 -8 -0.42 -1.4 -14 -0.71 -0.9 -9.2 -0.5 
7000 -1.1 -11 -0.57 -1.1 -11 -0.57 -0.6 -6.1 -0.3 
9000 -1.4 -14 -0.71 -0.8 -8 -0.42 -0.3 -3.1 -0.2 
11000 -1.7 -17 -0.84 -0.5 -5 -0.26 0.0 0.0 0.0 
13000 -2.0 -20 -0.97 -0.2 -2 -0.09 0.0 0 0.00 
15000 -2.3 -23 -1.08 0.0 0 0.00 0.0 0 0.00 
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Table 62: Combinations of daily step increases and additional dietary changes required to achieve a cost-effective 
outcome for a greater-than-50-year-old subgroup in a base case intervention at £30,000 per QALY assuming all risk 
factors change together 
Initial 
increase 
in steps 
needed 
Change attributable to the 
increase in steps 
Additional change needed to be 
generated through diet 
Additional change needed to 
be generated through diet 
Base case (3 year durability) 5 year durability 
BMI 
(kg/m2) 
Systolic
BP 
(mmHg) 
Total:HDL 
cholesterol 
ratio 
BMI 
(kg/m2) 
Systolic
BP 
(mmHg) 
Total:HDL 
cholesterol 
ratio 
BMI 
(kg/m2) 
Systolic
BP 
(mmHg) 
Total:HDL 
cholesterol 
ratio 
0 0.0 0 0.00 -2.6 -26 -1.19 -1.7 -16.8 -0.8 
1000 -0.2 -2 -0.09 -2.4 -24 -1.14 -1.5 -15.3 -0.8 
3000 -0.5 -5 -0.26 -2.1 -21 -1.03 -1.2 -12.2 -0.6 
5000 -0.8 -8 -0.42 -1.8 -18 -0.90 -0.9 -9.2 -0.5 
7000 -1.1 -11 -0.57 -1.5 -15 -0.78 -0.6 -6.1 -0.3 
9000 -1.4 -14 -0.71 -1.2 -12 -0.64 -0.3 -3.1 -0.2 
11000 -1.7 -17 -0.84 -0.9 -9 -0.50 0.0 0.0 0.0 
13000 -2.0 -20 -0.97 -0.6 -6 -0.34 0.0 0.0 0.0 
15000 -2.3 -23 -1.08 -0.3 -3 -0.18 0.0 0.0 0.0 
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Subgroup analysis: high cardiovascular risk subgroup 
We ran an additional analysis looking at effectiveness of intervening in a subgroup of 
the population with 10-year CVD risk of at least 5% using the base case 
assumptions about clinical effects. A 5% cut-off was chosen because if the cut-off 
KDG EHHQ   WKLV ZRXOG KDYH UHVXOWHG LQ DURXQG RQO\  RI WKH SRSXODWLRQ
being screened (before factoring in eligibility, suitability and willingness so probably 
less than 5% would have actually received the intervention). 
 
The estimated incremental cost effectiveness ratio (cost per QALY gained in the 
base case across the whole baseline population was £177,000. With 5 year 
durability of effects, the ICER falls to £133,000.   
 
To achieve cost-effectiveness in the base case at a value of £30,000 per QALY, 
threshold analyses suggest that 15,000 additional steps per day would be required 
with 3 year durability and 10,000 if the durability were extended to 5 years. The 
combinations of steps and additional dietary changes needed to reach cost 
effectiveness for people with high CVD risk at £30,000 per QALY are shown in Table 
63 (see Appendix 28, Table 77 for £20,000 per QALY). 
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Table 63: Combinations of daily step increases and additional dietary changes required to achieve a cost-effective 
outcome for a high cardiovascular risk subgroup in a base case intervention at £30,000 per QALY assuming all risk 
factors change together. 
 
Initial 
increase 
in steps 
needed 
Change attributable to the 
increase in steps 
Additional change needed to be 
generated through diet* 
Additional change needed to 
be generated through diet 
Base case (3 year durability) 5 year durability 
BMI 
(kg/m2) 
Systolic
BP 
(mmHg) 
Total:HDL 
cholesterol 
ratio 
BMI 
(kg/m2) 
Systolic
BP 
(mmHg) 
Total:HDL 
cholesterol 
ratio 
BMI 
(kg/m2) 
Systolic
BP 
(mmHg) 
Total:HDL 
cholesterol 
ratio 
0 0.0 0 0.00 -2.3 -23 -1.08 -1.5 -15 -0.78 
1000 -0.2 -2 -0.09 -2.1 -21 -1.03 -1.4 -14 -0.71 
3000 -0.5 -5 -0.26 -1.8 -18 -0.90 -1.1 -11 -0.57 
5000 -0.8 -8 -0.42 -1.5 -15 -0.78 -0.8 -8 -0.42 
7000 -1.1 -11 -0.57 -1.2 -12 -0.64 -0.5 -5 -0.26 
9000 -1.4 -14 -0.71 -0.9 -9 -0.50 -0.2 -2 -0.09 
11000 -1.7 -17 -0.84 -0.6 -6 -0.34 0.0 0 0.00 
13000 -2.0 -20 -0.97 -0.3 -3 -0.18 0.0 0 0.00 
15000 -2.3 -23 -1.08 0.0 0 0.00 0.0 0 0.00 
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12.5 DISCUSSION 
 
12.5.1 Statement of principal findings 
 
Using a threshold analysis approach, the base case results indicate that the STOP 
Diabetes intervention that we have evaluated, costing £ 1,097 per patient, would 
need to result in a very large overall increase in steps, systolic BP, BMI and 
cholesterol for it to be cost-effective at a threshold in the £ 20,000 to £ 30,000 cost 
per QALY range usually adopted by NICE. These increases are much more than 
could be expected to be achievable in practice, even for the general population. 
Specifically for steps, an increase of 3,000 to 5,000 per day appears to be much 
more commonly reported for an intervention. 
 
If we adopt two very favourable assumptions: 1) that the benefits of the intervention 
would not be fully lost until 4 years after the intervention (5 years from the start); and 
2) that commissioners/payers would be willing to fund the intervention up to a 
threshold of £ 30,000 per QALY, then some of the scenarios begin to show more 
favorable results to some extent.  
 
Targeting screening at either individuals over age 45, or at those obese, or those at 
relatively high baseline risk of CVD improves the cost-effectiveness of the 
intervention but it is still not cost-effective at an readily achievable combinations of 
steps and diet-attributable changes in risk factors (unless the cost of the intervention 
could be reduced). 
 
12.5.2 Strengths and limitations 
 
A strength of the analysis is that it was based on a relatively large set of baseline 
data for an ID cohort, so the baseline risks of the cohort were well-evidenced. 
However, there are large uncertainties around the intervention cost, and the precise 
relationship between changes in physical activity and cardiovascular risk factors. 
‘Number of steps’ per day was the primary outcome of interest from the modelling 
based on the fact that it is the primary measure of interest to the STOP-DM study 
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investigators. The available evidence linking steps to biomarkers is somewhat 
limited, and comes from very diverse studies. Each intervention is unique and 
therefore estimates of effectiveness are unlikely to predict exactly the outcomes of 
the intervention in question. In addition, identified studies were undertaken in the 
general population not an ID population, and it is unknown whether differences in 
either behavioural or physiological response to intervention vary in the ID 
community. 
 
Despite the fact that most diabetes prevention interventions combine dietary and 
physical activity elements, in order to model the threshold level of the primary 
measure of interest (steps) we therefore had to use steps as the key variable in our 
estimates, with its effects mediated through changes in BMI, systolic BP and 
cholesterol. This complicates interpretation because it then becomes necessary to 
show what permutations of combined diet and activity intervention may achieve the 
necessary magnitude of changes to BMI, systolic BP and cholesterol. The fact that 
the intervention is not cost-effective with 2,491 additional steps (in line with the effect 
size observed by Bravata)271 means that, in order to determine the cost-effective 
threshold, extrapolation is required. The extrapolation makes an assumption of a 
linear relationship between step increase and change in biomarkers, however, the 
true relationship may be non-linear. 
 
The Bravata study was considered to provide the most suitable data for the mapping 
between steps and risk factors. This study reported a seemingly large change in 
systolic BP (-3.8 mmHg) relative to the change in BMI (-0.38) for an increase of 
2,491 steps. Further evidence confirming this relationship is desirable.  If this ratio of 
systolic BP change relative to BMI is overstated, then the true results may be less 
favourable than presented.  A further limitation is the inevitable disparity between the 
STOP Diabetes intervention and the heterogeneous mix of interventions (in terms of 
number of sessions, delivery period, end-point timing) that were pooled in the 
Bravata meta-analysis. The effects of uncertainty around the effectiveness and other 
parameter estimates were assessed using an illustrative PSA, however, it is not 
possible to incorporate the full uncertainty around the applicability of pooled 
estimates from Bravata et al. to this specific intervention in the target population. 
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Further uncertainty analysis would be required once the clinical effectiveness of the 
STOP programme has been quantitatively assessed. 
 
There is a lack of good evidence on the durability of effects of an intervention such 
as STOP Diabetes especially when the maintenance sessions all take place within 
the same year as the initial intervention. Additionally, the STOP Diabetes cohort 
does not overall appear to be a particularly unhealthy one at baseline, perhaps due 
to recruitment criteria or self-selection, or just purely due to the average age of 
individuals recruited. There may be some obscure mechanisms that are not capture 
within the model structure and that drive the reported reduced life-expectancy for 
individuals with ID. If such mechanisms exist and can be modified by lifestyle 
intervention, then the results will not capture the economic impact of such benefits. 
 
12.5.3 Comparison with related studies 
 
There are several factors concerning the form of the intervention that lead to a high 
intervention cost per patient compared to other preventive lifestyle interventions: 
1) Relative small group size of eight that the clinical team considered most 
appropriate for educating those with LD 
2) Longer sessions for those with ID compared to the general population – 2 hours 
versus 1 hour 15 minutes for the NICE prevention modelling302 
3) The need for 3 educators rather than two, and more advanced at a higher grade 
4) The need for maintenance sessions to be spaced fairly close together, such as 
monthly, for information to be retained by individuals with ID. This compares with 
less frequent sessions, every four months in years two to four in the case of the 
modelling undertaken for the NICE diabetes prevention guidance.302 
 
12.5.4 Implications 
 
The purpose of the economic analysis was to provide a reasonable estimate of the 
cost-effectiveness of the STOP Diabetes intervention with a view to a subsequent full 
trial to assess effectiveness. The results of the current analysis suggest that, in the 
likely range of effectiveness achievable, the STOP Diabetes intervention in its 
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current form would not be cost-effective at a £ 20,000 to £ 30,000 cost/QALY 
threshold.  
 
Risk profile of STOP Diabetes and ID population in general: 
The large effect sizes needed for the intervention to be cost-effective are partly a 
result of the low risk profile of the STOP Diabetes cohort, in particular the average 
age at being 43. 
 
The intervention primarily reduces risks of CVD and cancer. The evidence suggests 
that excess risks in ID cohorts compared to the general population are attributable 
primarily due to respiratory disorders, neurological diseases, congenital 
abnormalities and accidents. These risks are unlikely to be reduced through an 
intervention such as STOP Diabetes. The mortality aspects of this risks may be 
captured through the increased other-cause mortality for individuals with ID (see 
methods chapter), but other-cause mortality is not linked to the risk factors modified 
by the STOP Diabetes intervention (BMI, systolic BP, total and HDL cholesterol). It is 
therefore rational that an intervention targeting CVD risks, costing £ 1,097 (3-4 times 
the cost of diabetes prevention lifestyle interventions), will necessitate our reported 
very large reductions in risk factors in order to fall within usual NICE thresholds for 
cost-effectiveness. 
 
The low risk profile is reflected in the mean QALY gain per person screened (with a 
subsequent increase in steps of 2,491 for suitable individuals) equating to an 
average of less than 1 day of additional life (in full health). 
 
Equity is a factor that decision-makers take into account when deciding whether or 
not to recommend an intervention. Given that the ID population is a disadvantaged 
group, decision-makers might be prepared to pay more per QALY than for the 
general population 267 In practice this means that there is a greater likelihood of 
recommending an intervention at the upper end of the usual £ 20,000 to £ 30,000 
per QALY range than for the general population. £30,000 per QALY tends to be the 
upper limit except in the context of end of life. 
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Although the average person with ID is overweight (and nearly obese), the 10-year 
CVD risk using cohort averages (mild/moderate severity only) is around only 2%. 
This is because risk factors seem to be well controlled in STOP Diabetes – average 
systolic BP was 121mmHg, and the lipid ratio was a healthy 3.63 – and it was a 
relatively young cohort. 
 
A limitation of the STOP Diabetes intervention is that the reduction in CVD risk is 
likely to be confined to a few years following intervention. Combined with the 
average baseline age of 43 and associated low average CVD risk, this explains why 
the intervention has such as high cost per QALY for the overall group. An alternative 
more cost-effective structuring of the intervention sessions may be possible such 
that a smaller initial benefit is achieved but sustained for more years, possibly 
through additional maintenance sessions beyond the first year.  
 
A minority, though significant, proportion of individuals identified as suitable for 
intervention may not make the desired progress towards reducing their risk factors 
for CVD. This could be due either to an individual’s physiological response to the 
intervention or the numbers of intervention sessions that they actually attend, or a 
combination of both factors. For such patients, continuing with the maintenance 
session may be reducing the overall effectiveness of the intervention that might be 
more cost-effective, potentially at favourable cost-per-QALY levels, in those who 
achieve a good initial response.  
 
12.5.5 Unanswered questions and further research 
 
Further subgroup analyses could be undertaken in groups at 10%, 15% or 20% 10-
year risk of CVD (diabetes risk could also be factored in), although such sub-groups 
would result in a very small proportion of the STOP Diabetes cohort actually 
receiving the intervention. 
  
Further research is needed to identify the optimal mix of initial and maintenance 
sessions for physical activity programs, together with a better understanding of how 
long benefits are likely to last. Modelling may also help to inform primary research 
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into the optimal trade-off between investment in initial intervention and maintenance 
sessions. 
 
Weight loss can be difficult to maintain even with ongoing maintenance as seen in 
the Finnish DPS. However, physical activity can help to maintain weight loss so it is 
unknown if benefits of physical activity can be sustained for longer than dietary-
induced weight loss (hence why we explored 3 and 5 years as scenarios for 
durability of effect). 
 
Further analysis may help to identify optimal permutations of the magnitude/intensity 
of the physical activity and dietary advice components to maximise the cost-
effectiveness
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CHAPTER 13.   DISCUSSION AND CONCLUSIONS 
 
 
13.1 Overview 
 
In this chapter, we summarise and discuss the research programme’s findings 
against each of its objectives. We also summarise the findings in terms of outputs, 
implications for practice, make research recommendations and discuss 
dissemination activities and plans for the research programme. 
 
13.2 Development and assessment of the feasibility of a diabetes 
screening programme in adults with intellectual disabilities 
 
13.2.1 Main findings 
 
Adults with ID for the screening programme were identified through general 
practices, specialist ID services (through the Leicestershire Learning Disability 
Register), specialist ID clinics and through direct contact with the research team. In 
total, 930 (29% of those originally approached) took part in the screening 
programme; 38% were able to consent for themselves, other participants required a 
consultee. There were slightly more men than women in those screened (58%), 
participants were relatively young (mean age 43.3 years), mainly of white ethnicity 
(80%) and most were overweight (31%) or obese (37%). We were able to collect 
data on anthropometric measures for most participants (~86%), BP for (89%), and 
outcome data for 675 participants (73%) to assess the prevalence of IGR/T2DM. 
 
13.2.2 Physical activity sub-study 
 
We found that the objective measurement of physical activity is likely to be 
challenging in adults with ID, given that there are high levels of non-compliance. 
However, compliance could be substantially improved using wrist-worn monitors. Of 
203 people approached, less than half (n=97; 48%) consented to wear the waist-
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worn device, compared with 62% (47 of 76 approached) of those consenting to wear 
the wrist-worn device. Similarly, valid data were obtained from 57% (n=55) of the 
sample who wore the waist-worn devices, compared with 83% (n=39) of those 
wearing the wrist-worn devices. 
 
Other studies among adults with ID have found a high proportion of missing data 
when using objectively measured physical activity data.164, 233 However, to our 
knowledge, this is the first time the feasibility of collecting objectively measured 
physical activity data in those with ID has been formally assessed.  The results 
suggest that poor compliance needs to be considered when conducting studies of 
physical activity interventions in this population. Researchers may also need to 
explore the potential for allowing separate consent in their study design for proposed 
accelerometer components.  
 
Another somewhat unexpected finding was the high level of physical activity 
observed in our study population. We found that adults with ID engaged in similar 
amounts of physical activity as the general population, whereas most,164, 233 but not 
all,236 studies have found that people with ID generally engage less. This might 
reflect current policy drives to improve health and fitness in this population but may 
also indicate selection bias (i.e. active people preferentially choosing to wear the 
monitors) or behaviour change as a result of accelerometer wear. 
 
13.3 Prevalence and demographic risk factors for type 2 diabetes 
and impaired glucose regulation in people with intellectual 
disabilities 
 
The overall prevalence of screen detected (previously undiagnosed) T2DM was 
1.3% (95% CI 0.5% to 2%) and IGR was 5% (95% CI 4% to 7%) among people with 
ID, which is lower than previously reported. Our systematic review (Chapter 2), found 
that the prevalence of diagnosed T2DM was approximately 8% (95% CI 5% to 11%), 
similar to that found in the general population. None of the studies in the review 
reported on screen-detected T2DM (they included prevalent known cases, we 
excluded) so it is not possible to make direct comparisons. Our lower than expected 
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rates of T2DM may simply reflect a successful annual health check programme, at 
least in the study’s geographical location, and the younger age of participants. 
 
Abnormal glucose levels were associated with non-white ethnicity (OR=3.93; 95% CI 
2.10 to 7.33), a first degree family history of diabetes (OR=3.35; 95% CI 1.64 to 
6.86), increasing weight, waist circumference, BMI, diastolic BP, triglycerides and 
decreasing HDL cholesterol. 
 
13.4 Validation of the Leicester self-assessment diabetes risk 
score in people with intellectual disabilities 
 
When the seven risk factors in the Leicester Self-Assessment risk score were used 
to explore risk of having undiagnosed  IGR/T2DM among people with ID (with data 
available), the risk score achieved a sensitivity of 82% in identifying those with 
abnormal glucose regulation. High sensitivity is generally considered most important 
for screening tools because the priority is to ‘rule out’ the disease without missing 
true cases. Ninety-eight per cent of participants with a low/medium risk score were 
correctly identified as being at low risk. Our findings suggest that the Leicester Self-
Assessment risk score is statistically effective at identifying people with ID who are at 
risk of undiagnosed IGR/T2DM and does not require modification, if it was integrated 
at practice level. However, it may not be practical or acceptable for people with ID to 
calculate their own score; development of an easy read version (plus a carer 
supplement) and additional supportive material would need to be explored. 
 
13.5 Cost-effectiveness 
 
Findings from the health economic analysis showed that, in its current form, the 
STOP diabetes multi-component intervention would need to result in a very large 
overall increase in steps, systolic BP, BMI and lipids, for it to be cost-effective at a 
threshold in the £ 20,000 to £ 30,000 cost per QALY range usually adopted by NICE. 
 
The results would be favourable under the assumptions that: 
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1) the benefits of the intervention would not be fully lost until 4 years after the 
intervention (5 years from the start); 
2) commissioners/payers would be willing to fund the intervention up to a 
threshold of £ 30,000 per QALY. 
 
The cost-effectiveness of the intervention would be improved by targeting screening 
at the following groups, either: 
x individuals aged over 45 years; 
x individuals with BMI in the obese range; 
x individuals with relatively high baseline risk of CVD. 
 
However, it is still not cost-effective at readily achievable levels of change in steps 
and diet-attributable risk factors, unless the cost of the intervention could be 
reduced. 
 
The relatively high cost of the STOP diabetes intervention compared with other 
similar multi-component behaviour change interventions is due to a number of 
factors: 
x small samples needed for each group session; 
x longer sessions; 
x the need for three educators rather than two;  
x the need for more experienced educators; and 
x the need for regular, monthly refresher sessions. 
 
Many of these factors were identified in advance as being important for the 
interventions to be appropriate and relevant for people with ID. It is known that the 
high support needs of this population, including co-existing challenging behaviour,64 
psychiatric disorders,331 physical health problems32 and communication difficulties 
make this a challenging group for behavioural interventions. We aim to explore other 
ways in which the intervention may be adapted to minimise resources, such as the 
potential to target carers under certain circumstances. 
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Finally, the findings also revealed a lack of good quality evidence for the durability of 
effects of multi-component behaviour change interventions, such as that developed 
for the STOP diabetes programme.  
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13.6 Data linkage to Hospital Episode Statistics and the Office for 
National Statistics 
 
In total, 883 (95%) participants gave consent for the research team to follow-up their 
health in the longer term via data linkage. 
 
13.7 Development of a lifestyle education programme for people 
with intellectual disabilities and impaired glucose regulation 
 
The research involved the development of a structured lifestyle education 
programme for a population with ID with IGR or at high-risk of developing T2DM 
and/or CVD based on a high BMI. This was a complex process encompassing initial 
curriculum development, two cycles of testing, evaluation, modification and re-
testing, prior to final refinement of the programme. 
 
The STOP programme development benefitted from a systematic process.238, 239 The 
theoretical underpinning was developed and expanded upon from the limited 
evidence in the literature. This informed the content and style of approach, alongside 
the qualitative findings from people with ID, their carers, and health care 
professionals with expertise in working with people with ID.  The whole programme 
was then tailored further to the specific needs of this group by more user feedback, 
and adaptation by a multi-disciplinary team with expertise in ID and the development 
of education programmes (with psychological underpinning).   
 
From the initial phases the programme has been well received and is acceptable to 
the people it is trying to support.  The initial feedback via qualitative interviews has 
suggested that some of the elements of treatment receipt initially hypothesised may 
have been achieved, via reported changes in beliefs and health behaviours.   
 
The research also involved an assessment of feasibility of collecting outcome 
measures from participants with ID before and 3-months after delivering the 
intervention programme. For this component, our findings suggest that it is both 
acceptable and feasible to collect outcome measures for weight, height, BMI, waist 
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circumference, BP and dietary intake (portions of fruit and vegetables), and objective 
measures for physical activity and sedentary behaviour, using wrist-worn 
accelerometers, both before and after (3-months) attending the programme. At 
baseline, anthropometric measures and BP were obtained for all participants, and 
accelerometer data for 80%. Attendance at the education programme was overall 
JRRGZLWKRISDUWLFLSDQWVDWWHQGLQJGD\VRXWRIVHYHQVHVVLRQVIRUWKHPDLQ
programme). At 3-months follow-up repeat data were successfully collected for a 
high proportion of participants (anthropometric measures 100%; BP 80%; 
accelerometer data 60%). Owing to time restrictions, we were only able to conduct 
one feasibility cycle and were also unable to assess whether it is possible to collect 
longer term data, but these preliminary findings are overall positive.  
 
Only four of the five participants who took part in the intervention agreed to wear the 
wrist-worn accelerometers at baseline, and this suggests that an assessment of 
willingness to wear the accelerometer is an important component of any future 
evaluation work. Furthermore, the feasibility component of our work suggested that 
lifestyle circumstances could play an important role in adhering to the education 
programme and this needs to be considered for future work. 
 
13.8 Development of an intervention fidelity process for the 
assessment of educators delivering the intervention 
 
As part of this research, we successfully completed the first step in developing a tool 
for assessing intervention fidelity of the STOP diabetes educational programme. 
Preliminary findings using the tool already suggest some variance between 
educators, which will provide a benchmark for future work. One of the key 
considerations for this component of the research involved reconsidering existing 
learning methods that are known to be effective in the general population to meet the 
needs of people with ID. This included removing abstract concepts, avoiding 
abbreviations and jargon, teaching at the group’s pace and, above all, avoiding 
isolating the learners by ‘putting them on the spot’ to summarise key messages,  
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13.9 Main findings and outputs 
 
The main findings and outputs arising from this extensive research programme are 
summarised below: 
 
x We developed and assessed the feasibility of a diabetes screening 
programme for adults with ID. 
x In total, 930 (29% of those originally approached) people with ID took part in 
the screening programme; 58% were men and the average (mean) age of 
participants was 43 years old. 
x Most people who took part in the screening programme (68%) were 
overweight or obese. 
x We were able to collect blood samples from 73% of participants and 
anthropometric measures on more than 85% of participants. 
x We found that wrist-worn accelerometers were more acceptable to 
participants with ID than waist-worn accelerometers to measure physical 
activity. 
x We found that 1.3% of people with ID had undiagnosed T2DM and 5% of 
people with ID had IGR (screen detected). 
x We found that abnormal glucose tolerance was associated with non-white 
ethnicity, first degree family history of diabetes, increasing weight, waist 
circumference, hip circumference, BMI, diastolic BP, triglycerides and lower 
HDL cholesterol. 
x We developed a lifestyle intervention programme for a population with ID with 
IGR or at high-risk of developing T2DM and/or CVD based on a high BMI. 
x Using concrete messages and visual aids facilitated learning in this group; 
abstract and conceptual examples tended to be less well received. 
x We found that the collection of outcome measures prior to and after (3-
months) delivering the intervention was both acceptable and feasible. 
x We identified that for the intervention to be cost-effective (£20,000 to £ 30,000 
cost per QALY range), the required change in steps and diet-attributable risk 
factors may be more than is achievable in practice 
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x We found that if commissioners were willing to fund the intervention up to a 
higher threshold, cost-effectiveness may improve by targeting specific 
individuals (>45 years; obese, high CVD risk). 
x We developed a preliminary quality development tool to assess intervention 
fidelity of the educational programme for people with ID. 
 
13.10 Limitations 
 
We have found that conducting a programme of research to enhance the knowledge 
and understanding of IGR and T2DM in people with ID, including development of a 
lifestyle education programme, is feasible but not without challenges. We 
acknowledge the following limitations: 
x With regard to the systematic review of the evidence in relation to prevalence 
of T2DM and IGR, we acknowledge that limited data were available on T2DM 
in people with ID and that reported outcomes were sometimes poorly defined 
or unclear. We would also have benefited from more general population data 
for comparison. 
x Similarly, for the systematic review of long-term multicomponent behaviour 
change interventions for the prevention of CVD and T2DM in people with ID, 
we acknowledge that only four papers met our inclusion criteria which limited 
our ability to draw meaningful conclusions. However, our findings do highlight 
the lack of work in this area and the need for robust interventions, such as 
that developed for this programme of work. 
x Despite highlighting a number of achievements in involving service users in 
our research programme, we acknowledge that we could have done more to 
involve them in the design and dissemination phases of our programme. 
x We acknowledge that the recruitment approach utilised for the screening 
study may not be transferable to other geographical areas in England. 
Recruitment was facilitated by the Leicestershire Learning Disability 
Register14 (either via direct invitation from the register, or for people previously 
agreeing to be approached about future research) which accounted for 40% 
of people invited (~39% of participants). The register is only one of three adult 
ID case registers in England and has a strong research tradition. However, we 
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only approached people via this route for general practices that declined to 
take part in the study and we feel that approaches such as direct invitation 
and invitation via ID psychiatric service clinics could be replicated in other 
areas. 
x We acknowledge some difficulties in recruiting services users to the 
development phase (work package 2) despite using a direct approach to 
people who had already participated in the screening phase. For the 
qualitative development interviews low recruitment was largely due to an initial 
lack of people who were either ineligible (based on severity of ID, and/or BMI 
RU,*5RUunwilling. Additionally, for the later phases, where participation 
involved attending a course of education sessions held over several weeks 
(with little flexibility in scheduling), reported barriers were largely linked to the 
regular daytime commitments (social activities/work/education) of service 
users which they were either unwilling or unable to change. The “busy 
schedules” of potential participants has previously been identified as a barrier 
to recruitment for people with ID.332 Unfortunately, within the constraints of 
this research study there was no flexibility to offer alternative dates to attend 
the programme. However, for the second pilot education cycle, which was 
held in a residential setting, the day and timing of sessions were arranged as 
much as possible to suit the needs of both service users and care workers, 
and recruitment levels were much higher. 
x For the economic evaluation, we acknowledge the exploratory nature of the 
work, given that data on clinical effectiveness for the STOP Diabetes 
programme were not available. In particular, the analysis involved 
extrapolating data outcomes, which assumed a linear relationship between 
step increase and changes in biomarkers (BMI, systolic BP and cholesterol), 
which may not reflect their true relationship. 
x We further acknowledge limitations with using the EQ-5D for the economic 
evaluation since this has not been validated in people with ID. We look 
forward to the outputs from current work to validate the EQ-5D in this 
population.159 
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13.11 Implications for practice 
 
We have found that, at least in Leicester/Leicestershire, there is a low prevalence of 
previously undiagnosed (screen detected) IGR/T2DM. However, we also found that 
a significant proportion of people with ID are overweight or obese and are likely to be 
at risk of developing T2DM and/or CVD in the future. Our non-invasive risk score 
might also help to identify people at risk of undiagnosed IGR/T2DM. The 
development of the STOP diabetes educational programme is the first stage in 
identifying preventative strategies for future research. 
 
13.12 Research recommendations 
 
We make the following recommendations for further research: 
x The recruitment rate for the screening study was relatively low (29%). In some 
cases the use of gatekeepers, including general practitioners, residential 
home managers and family carers presented a barrier to recruitment. We 
recommend utilising a multi-pronged/multi-layered approach, actively 
engaging with both intermediaries and service users, and following up all 
potential participants to ensure people are given an equitable chance to 
participate.  
x In order to be truly inclusive, we highlight the importance of making 
reasonable adjustments, including offering appointments whenever and 
wherever is most appropriate for the person, minimising disruption to their 
routine and ensuring that appropriate support is in place. Given limited 
resources, it is likely that researchers and funders need to lower the threshold 
for an ‘acceptable’ response in this population, so that adults with ID are not 
excluded altogether from taking part in research.   
x We recommend a staggered consent process when recruiting people with ID 
into research to enable them to opt out of some components, such as having 
blood tests or wearing accelerometers. 
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x We have demonstrated that adults with ID can be meaningfully involved in the 
research process; we recommend exploring further ways in which people with 
ID can be involved in research and be recompensed for their time. 
x We recommend further work to explore ways in which compliance with 
accelerometer wear can be improved in people with ID.  
x We recommend ongoing monitoring of the participants in our study to identify 
longer term health and mortality outcomes. 
x Finally, we have found preliminary evidence that the STOP Diabetes 
education programme is acceptable and feasible. We recommend further 
work to evaluate its clinical and cost effectiveness in a randomised controlled 
trial informed by the Medical Research Council framework for evaluating 
complex interventions,238 with a view to integrating the programme into 
national preventive strategies and reducing health inequalities among people 
with ID. 
 
13.13 Dissemination activities and plans 
 
During the consent process, participants were asked if they wished to be informed of 
the findings. Between September and December 2015 we disseminated the results 
to participants (and carers). Two of the ID research nurses visited 57 homes (group 
homes, supported living, residential and nursing homes) to present the findings to 
participants in easy-read format supplemented by verbal explanations/presentations. 
Other participants received a brief easy-read report sent in the post. We have begun  
to disseminate the findings to healthcare professionals locally, both in primary care 
and within ID services. 
 
The work from the service user involvement component of this research has been 
published in one of the NIHR INVOLVE newsletters197 and in the academic literature. 
202
 The initial education development work has previously been presented at the 
Diabetes UK Professional Conference in March 2015.333 Similarly, the two 
systematic reviews for this programme and the screening study were presented at 
the 2016 Diabetes UK Professional Conference.334-336 
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The next steps will involve writing up and submitting academic articles in relation to 
the individual components of the research programme. This will include the 
screening study, risk score validation, cost-effectiveness component, intervention 
development and updated versions of the two systematic reviews. We will continue 
to present the findings both locally, through existing collaborations with NIHR 
CLAHRC East Midlands and the East Midlands Academic Health Services Network 
(AHSN), and nationally. We have been invited to present our work at a meeting of 
the Royal Society for Medicine Intellectual Disability Forum (Managing diabetes in 
people with intellectual disabilities: recent advances) in November 2016. 
 
13.14 Summary 
 
Results from this programme of work have significantly enhanced existing 
knowledge and understanding of T2DM and IGR in people with ID, and have 
enabled us to test strategies for early identification of IGR and T2DM in people with 
ID. This is the first large diabetes screening study in people with ID in the UK and to 
our knowledge the largest screening study globally. We have also developed a 
lifestyle education programme and educator training protocol to promote behaviour 
change in a population with ID at risk of developing T2DM. Further work is now 
needed to evaluate the intervention we have developed and to identify cost-effective 
strategies for its implementation.  
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Appendix 1:  Assessment of capacity and consent 
 
 
 
Figure 26: Diagram showing how capacity and consent were assessed in the study 
(flowchart adapted from Dixon-Woods and Angell)337
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Appendix 2:  Example from Leicester Self-Assessment Risk Score 
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Appendix 3:  Outcome definitions for T2DM and CVD prevalence and risk factors 
 
(see main report for reference list) 
 
Table 64: Outcome definitions for articles included in the systematic review of T2DM and CVD prevalence and risk factors 
 
Author/year CVD outcomes Diabetes/blood 
sugar outcomes 
Obesity/Overweig
ht outcomes 
Blood pressure 
outcomes 
Lipid outcomes Metabolic 
syndrome 
Split by ID 
severity 
Molteno (2000)   Obese 
BMI >30 
Overweight 
BMI 25–<30 
   MILD 0.3% 
MOD 18.7% 
SEV 37.7% 
PROF 33.5% 
MISSING DATA 
Robertson 
(2000) 
  
Obese 
BMI  >30 
Overweight 
BMI 25.1–30 
   
 
Janicki (2002) Cardiovascular 
disease Ǉ 
NR 
Diabetes Ǉ 
Adult onset 
 
Obese Ǉ 
BMI >27 
OverweightǇ 
BMI 22–27 
Hypertension Ǉ 
NR 
Hyperlipidaemia
Ǉ
 
NR 
 MILD 1.3% 
MOD 50.3% 
SEV/PROF 
47% 
Lewis (2002)   Obese 
%0, 
Overweight 
BMI  25–29.9 
Elevated BP 
SBP >140mmHg or 
DBP >90mmHg 
Hypercholestero
lemia 
Total cholesterol 
PPRO/ 
 MILD 37.1% 
MOD 16.4% 
SEV 14.7% 
PROF 15.3% 
Marshall (2003)   Obese Hypertension Elevated   
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Author/year CVD outcomes Diabetes/blood 
sugar outcomes 
Obesity/Overweig
ht outcomes 
Blood pressure 
outcomes 
Lipid outcomes Metabolic 
syndrome 
Split by ID 
severity 
%0, 
Overweight 
BMI 26–30 
SBP >140mmHg Cholesterol 
Definition NR 
Havercamp 
(2004) 
Cardiovascular 
disease Ǉ 
Definition NR 
 
Diabetes Ǉ 
Definition NR 
 
Obese  
definition NR – BMI 
data were collected 
Overweight 
definition NR – BMI 
data were collected 
Elevated BPǇ 
Definition NR 
  
MILD 39.4% 
MOD 26.6% 
SEV 14.7% 
PROF 10.6 % 
Hove (2004)   Obese 
%0, 
Overweight 
BMI 25–29.9 
   
MILD 39.2%  
MOD 42.1% 
SEV 15.5% 
Merrick (2004) Heart disease Ǉ 
Definition NR 
Type 2 diabetes Ǉ 
Definition NR 
Overweight and 
above Ǉ 
BMI >27 
Hypertension Ǉ 
Definition NR 
Hyperlipidaemia 
Ǉ 
Definition NR 
 
 
Moore (2004)   Obese 
%0, 
Overweight 
BMI 25 –<30 
   
 
Emerson (2004)   Obese * 
BMI > 30 
Overweight * 
BMI 25.1–30 
   
 
Yen (2005)   ObeseǇ 
%0, 
  
 MILD 22.2% 
MOD 34.9% 
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Author/year CVD outcomes Diabetes/blood 
sugar outcomes 
Obesity/Overweig
ht outcomes 
Blood pressure 
outcomes 
Lipid outcomes Metabolic 
syndrome 
Split by ID 
severity 
OverweightǇ 
BMI 24–<27 
SEV 28.1% 
PROF 14.8% 
Ito (2006)   Obese 
BMI >30 
Overweight 
BMI 25–30 
   
 
Lennox (2006)   Obese 
BMI >30 
Overweight 
BMI 25–30 
Elevated BP 
SBP>140mmHg 
  
 
Levy (2006)  Diabetes* 
Definition NR 
Obese * 
%0, 
Overweight 
BMI  25–29.9 
Obese/overweight 
 
Elevated BP* 
Definition NR 
Hypercholestero
lemia* 
Definition NR 
 MILD 47.6% 
MOD 31.1% 
SEV 14.6% 
PROF 6.8% 
McDermott 
(2006) 
Coronary artery 
disease* 
ICD-9-codes 
Transient ischemic 
attack* 
ICD-9- codes 
Type 1 & Type 2 
Diabetes* 
ICD-9- codes 
 
Obese* 
 NR 
Hypertension & 
Elevated BP* 
ICD-9- codes 
  
 
Rurangirwa 
(2006) 
  
Overweight/obese 
Ǉ
 
  
   
 
Shah (2006)  Diabetes Ǉ      
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Author/year CVD outcomes Diabetes/blood 
sugar outcomes 
Obesity/Overweig
ht outcomes 
Blood pressure 
outcomes 
Lipid outcomes Metabolic 
syndrome 
Split by ID 
severity 
Definition NR 
Van Den Akker 
(2006) 
Coronary heart 
disease* 
ICD-10-codes 
Cerebrovascular 
disease*  
ICD-10-codes 
  
Hypertension*  
ICD-10-codes 
  
MILD 11% 
MOD 53% 
SEV 28% 
PROF 8% 
Levy (2007)  Diabetes* 
Definition NR 
Overweight and 
above 
BMI  
Elevated BP* 
Definition NR 
Hypercholestero
lemia* 
Definition NR 
 
SEV 65.4% 
PROF 34.6% 
McDermott 
(2007) 
 Diabetes* 
Although a detailed 
description is given, it 
is not possible to 
define the type of 
diabetes is used as 
an outcome. 
  
  
 
McGuire (2007)   Obese Ǉ 
BMI >30  
Overweight Ǉ 
BMI >25  
   MILD 14.1% 
MOD 63.5% 
SEV 12.8% 
PROF 9% 
Wang (2007) Heart diseaseǇ 
ICD-9-codes 
Specific codes in manual 
for the Rochester health 
status survey (includes 
 Overweight and 
aboveǇ 
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Author/year CVD outcomes Diabetes/blood 
sugar outcomes 
Obesity/Overweig
ht outcomes 
Blood pressure 
outcomes 
Lipid outcomes Metabolic 
syndrome 
Split by ID 
severity 
some non-CVD codes) 
Bhaumik (2008)   Obese * 
%0, 
Overweight 
BMI 25.1– <30 
Hypertension * 
6%3PP+J
DQGRU'%3
90mmHg 
  
 
Henderson 
(2008) 
 Type 2 diabetes* 
Derived from medical 
problem lists 
Obese* 
BMI >30 
Overweight* 
BMI > 25 < 30 
Hypertension* 
Derived from 
medical problem lists 
Dyslipidaemia* 
Derived from 
medical problem 
lists 
 
 
Melville (2008)   Obese  
%0, 
Overweight  
BMI 25–<30 
   MILD 40.9% 
MOD 25.1% 
SEV 18.2% 
PROF 15.8% 
Wallace (2008) Cardiovascular 
disease  * 
History of: Peripheral 
vascular disease, stroke, 
or coronary heart 
disease. 
Elevated glucose * 
>6.1mmol/L 
(fasting and non-
fasting tests grouped 
together in results) 
Type 1 & 2 diabetes 
Obese * 
BMI > 30 
Overweight 
BMI 25-29.9 
Hypertension * 
SBP >140mmHg 
Elevated 
cholesterol * 
>5.5mmol/L 
(fasting and non-
fasting tests 
grouped together 
in results)  
 
 
De Winter  
(2009) 
Cerebrovascular 
disease*  
Diagnosed by CT scan 
 
Myocardial infarction*  
Diagnosed by ECG  
Diabetes 
JOXFRVHPPRO/
or use of anti-diabetic 
drugs. 
 
Obese 
BMI > 30 
 
Hypertension 
SBP > 140mmHg or 
use of drugs 
Hypercholestero
lemia 
Total cholesterol 
>5.1mmol/L to 
PPRO/
(depending on 
 MILD 12.1% 
MOD 33.2% 
SEV 34.3% 
PROF 20.4% 
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Author/year CVD outcomes Diabetes/blood 
sugar outcomes 
Obesity/Overweig
ht outcomes 
Blood pressure 
outcomes 
Lipid outcomes Metabolic 
syndrome 
Split by ID 
severity 
changes 
 
laboratory 
reference values) 
or use of 
cholesterol 
lowering drugs 
Elevated LDL 
PPRO/ 
 
Gale (2009)   Obese 
BMI 30–<40 
Severely Obese 
 
Overweight 
BMI 25–<30 
   
 
Henderson 
(2009) 
  
Overweight or 
above Ǉ 
%0, 
   MILD/MOD 53% 
SEV/PROF 
47% 
Maaskant (2009)   Obese 
%0, 
Overweight 
BMI 25–<30 
   
 
Moss (2009)  Elevated glucose 
Non-fasting test – 
definition NR 
Overweight and 
above 
BMI >25 
Hypertension 
Definition NR 
Elevated total 
cholesterol 
Non-fasting test – 
definition NR 
 
 
Sohler (2009)  Diabetes* Obese* Hypertension* Hypercholestero   
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Author/year CVD outcomes Diabetes/blood 
sugar outcomes 
Obesity/Overweig
ht outcomes 
Blood pressure 
outcomes 
Lipid outcomes Metabolic 
syndrome 
Split by ID 
severity 
Definition NR BMI > 30 
Overweight* 
BMI 25–29.9 
Definition NR lemia* 
Total cholesterol 
>13.3mmol/L 
Van De Louw 
(2009) 
   
Hypertension 
SBP >140mmHg 
  MILD 10% 
MOD 38% 
SEV/PROF 52% 
Shireman (2010)  Diabetes* 
ICD-9-codes 
 
   
 
Stedman (2010)   Obese* 
%0, 
Overweight* 
BMI 25–29.9 
   
 
Tyler (2010) Coronary heart 
disease* 
ICD-9-codes 
Diabetes* 
ICD-9-codes 
Obese* 
ICD-9-codes 
Hypertension* 
ICD-9-codes 
Hyperlipidaemia
* 
ICD-9-codes 
 
 
Chen (2011) Heart disease 
Such as cardiac 
arrhythmias and 
coronary 
atherosclerosis. 
Diagnoses based on 
clinical manifestations or 
ECG findings. 
 
Elevated blood 
glucose 
exceeding normal 
range 3.9–6.1 mmol/L  
Diabetes  
)3*PPRO/RUK
SODVPDJOXFRVH
11.1 mmol/L or OGTT  
2h >11.1mmol/L 
 
 
Hypertension 
6%3PP+JRU 
'%3PP+J 
Elevated total 
cholesterol 
PPRO/ 
Elevated 
triglycerides 
PPRO/ 
 
 
Frighi (2011)  Type 2 diabetes Overweight or    MILD 48% 
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Author/year CVD outcomes Diabetes/blood 
sugar outcomes 
Obesity/Overweig
ht outcomes 
Blood pressure 
outcomes 
Lipid outcomes Metabolic 
syndrome 
Split by ID 
severity 
NR 
 
 
above 
definition NR – BMI 
data & WC were 
collected 
MOD 30.2% 
SEV/PROF 21.8% 
POMONA II 
study 
Haveman (2011) 
 
+ Martinez-Leal 
(2011) 
(Obesity data) 
Heart attack Ǉ 
Definition NR 
Cerebrovascular 
disease Ǉ 
Definition NR 
 
DiabetesǇ 
Definition NR 
 
Obese  
definition NR – BMI 
data were collected 
Overweight 
definition NR – BMI 
data were collected 
Hypertension Ǉ 
Definition NR 
  Haveman 
MILD 22.7% 
MOD 28.2% 
SEV 20.7% 
PROF 11.8% 
 
Martinez-leal 
MILD 21.8% 
MOD 27.7% 
SEV 19.7% 
PROF 11.4% 
Hsu (2011)   Overweight or 
above * 
%0, 
  3/5 criteria 
NCEP-ATPII  
MILD/MOD 
47% 
SEV/PROF 
53% 
Lee (2011) Cardiac illness* History 
of coronary heart 
disease or congestive 
cardiac failure 
Diabetes*  
implied by 
prescription of 
hypoglycaemic drugs 
Obese* 
%0, 
Overweight* 
BMI 26–30 
Hypertension* 
Definition NR 
  MILD 33% 
MOD 22% 
SEV 23% 
PROF 21% 
Stancliffe (2011)   Obese 
BMI > 30 
Overweight 
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Author/year CVD outcomes Diabetes/blood 
sugar outcomes 
Obesity/Overweig
ht outcomes 
Blood pressure 
outcomes 
Lipid outcomes Metabolic 
syndrome 
Split by ID 
severity 
BMI > 25–<30 
Overweight and 
above 
%0, 
Wong (2011) Heart diseaseǇ 
Definition NR 
Cerebrovascular 
diseaseǇ 
Definition NR 
DiabetesǇ 
Definition NR 
Overweight and 
aboveǇ 
BMI >23 
HypertensionǇ 
Definition NR 
Hypercholestero
lemiaǇ 
Definition NR 
 
MILD 4.9% 
MOD 41.8% 
SEV/PROF 51.9% 
Chang (2012)  Elevated blood 
sugar 
)3*PPRO/RU
use of drugs 
Obesity 
BMI (definition NR) 
Overweight 
BMI (definition NR) 
Central 
overweight 
FWC > 80cm/MWC 
> 90cm 
Hypertensive SBP 
PP+JRU 
use of drugs 
 
Hypertensive DBP 
PP+JRU 
use of drugs 
Elevated 
triglycerides 
PPRO/RU
use of drug) 
 
Reduced HDL 
HDL Male < 2.2 
mmol/L, Female 
< 2.8mmol/L (or 
use of drugs) 
3/5 criteria 
NCEP-ATPIII 
and MetS criteria 
for Taiwanese 
people 
MILD 65% 
MOD 16% 
SEV 9% 
PROF 10% 
De Winter 
(2012)_1 
HA-ID study 
  
Obesity 
BMI > 30 
Overweight 
BMI > 25 
Central obese 
FWHR > 
88cm/MWHR > 
   
MILD 24.8% 
MOD 48% 
SEV 16% 
PROF8.9% 
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Author/year CVD outcomes Diabetes/blood 
sugar outcomes 
Obesity/Overweig
ht outcomes 
Blood pressure 
outcomes 
Lipid outcomes Metabolic 
syndrome 
Split by ID 
severity 
102cm 
Central 
overweight 
FWHR > 
80cm/MWHR > 
94cm 
De Winter 
(2012)_2 
HA-ID study 
 
Diabetes 
)6*PPRO/RU
use of drugs 
 
 
Hypertension 
SBP > 140mmHg 
Or DBP > 90mmHg 
and/or medication 
Hypercholestero
lemia 
Fasting serum 
total cholesterol  
>6.5 mmol/L or 
use of drugs 
Defined 
separately by:  
3/5 criteria (joint 
interim 
statement) 
and 
3/5 criteria 
NCEP-ATPIII 
MILD  24.5% 
MOD  48.6% 
SEV  16% 
PROF 8.7% 
Gazizova (2012)   Obese 
BMI >30 
Overweight 
BMI  25.1–30 
   
MILD 61% 
MOD 24% 
SEV 15% 
Lin, L.P. (2012)    Hypertension 
6%3PP+JRU
'%3PP+J 
  
 
Morin (2012) Heart disease  Ǉ 
ICD-10-codes 
Diabetes Ǉ 
ICD-10-codes 
 
   MILD 32.9% 
MOD 46.4% 
SEV 11.2% 
PROF 5.2% 
Begarie (2013)   Obese     
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Author/year CVD outcomes Diabetes/blood 
sugar outcomes 
Obesity/Overweig
ht outcomes 
Blood pressure 
outcomes 
Lipid outcomes Metabolic 
syndrome 
Split by ID 
severity 
%0, 
Overweight 
%0,–<30 
De Winter 
(2013) 
HA-ID study 
Peripheral arterial 
disease  
Ankle-Brachial-Index  < 
0.9 (measured only in 
subjects with >1 CVD 
risk) 
     
MILD 24.9% 
MOD 53% 
SEV 13.4% 
PROF 4.6% 
Haider (2013) Heart disease Ǉ 
ever diagnosed by a 
doctor/relevant 
healthcare professional 
Stroke Ǉ 
ever diagnosed by a 
doctor/relevant 
healthcare professional 
Type 2 diabetes Ǉ 
In the paper it groups 
type 1 and 2 together, 
but in a separate 
report outcomes are 
available separately, 
it also says if been 
told by doctor 
Obese Ǉ 
BMI >30 
Overweight Ǉ 
25–<30 
   
 
Jansen (2013) Cerebrovascular 
accident*  
acute disruption of 
cerebral circulation with 
focal neurological 
V\PSWRPVKU 
Myocardial infarction*  
clinical signs & ECG 
diagnosis and/or lab 
     
MILD 6.9% 
MOD 37.8% 
SEV 29% 
PROF 26.3% 
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Author/year CVD outcomes Diabetes/blood 
sugar outcomes 
Obesity/Overweig
ht outcomes 
Blood pressure 
outcomes 
Lipid outcomes Metabolic 
syndrome 
Split by ID 
severity 
results 
Lin, J.D. (2013)  Hyperglycaemia * 
)3*PPRO/ 
 
Hypertension * 
SBP > 140mmHg or 
DBP > 90mmHg or 
use of drugs 
Hyperlipidaemia 
* 
Triglyceride > 
11.1mmol/L or 
Total cholesterol 
> 13.3mmol/L 
 
 
McCarron (2013) Heart disease Ǉ 
History of Angina, heart 
attack, coronary heart 
failure, open heart 
surgery (ever diagnosed 
by a doctor/relevant 
healthcare professional) 
Stroke/TIA Ǉ 
ever diagnosed by a 
doctor/relevant 
healthcare professional 
 
 Hypertension Ǉ 
ever diagnosed by a 
doctor/relevant 
healthcare 
professional 
 
  
 
Vacek (2013)    Hypertension* 
ICD-9-codes 
 
 
 
Hsieh (2014)   Obese Ǉ 
%0, 
Overweight 
BMI 25 – <30 
   
MILD 44.9% 
MOD 23.7% 
SEV/PROF 8.4% 
Mikulovic (2014)   Obese 
BM I>30 
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Author/year CVD outcomes Diabetes/blood 
sugar outcomes 
Obesity/Overweig
ht outcomes 
Blood pressure 
outcomes 
Lipid outcomes Metabolic 
syndrome 
Split by ID 
severity 
Overweight 
%0, 
De Winter 
(2015) 
 
 
T1DM 
T2DM 
Diabetes 
)6*PPRO/RU
use of drugs 
 
Central obese 
FWHR > 
88cm/MWHR > 
102cm 
Central 
overweight 
FWHR > 
80cm/MWHR > 
94cm 
Hypertension 
SBP > 140mmHg 
Or DBP > 90mmHg 
and/or medication 
Hypercholestero
lemia 
Fasting serum 
total cholesterol  
>6.5 mmol/L or 
use of drugs 
Defined 
separately by:  
3/5 criteria (joint 
interim 
statement) 
and 
3/5 criteria 
NCEP-ATPIII 
MILD  24.5% 
MOD  48.6% 
SEV  16% 
PROF 8.7% 
Lin, L.P. (2015)   Obese 
%0, 
Overweight 
BMI 24–26.9 
   MILD 6.5% 
MOD 32.6% 
SEV 34.8% 
PROF 26.1% 
Zaal-Schuller 
(2015) 
Peripheral arterial 
disease 
Ankle-Brachial-Index 
<0.9 
     MILD/MOD 
51.1% 
SEV/PROF 
48.9% 
*retrospective data extracted from database/medical records, or, Ǉdata self-reported or reported by carer; NR (not reported); SBP 
(systolic blood pressure); DBP (diastolic blood pressure); HDL (high density lipoprotein); LDL (low density lipoprotein); BMI (body 
mass index); FPG (fasting plasma glucose); MWC (male waist circumference); FWC (female waist circumference); MWHP (male 
waist-to-hip ratio); WWHP (female waist-to-hip ratio). 
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Definitions 
 
Ischaemic heart disease: defined as ischaemic heart disease, myocardial infarction, heart attack, coronary atherosclerosis and/or 
coronary artery disease. 
Cerebrovascular disease: defined as cerebrovascular disease, stroke and/or transient ischaemic attacks 
Undefined CVD: defined as undefined heart disease, undefined CVD, or a combined CVD outcome where the majority is 
undefined.  
T2DM: defined as T2DM only 
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Appendix 4:  Funnel plot for T2DM 
 
 
 
Figure 27: Funnel plot with pseudo 95% confidence limits for T2DM 
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Appendix 5:  Funnel plot for ischaemic heart disease 
 
 
 
Figure 28: Funnel plot with pseudo 95% confidence limits for ischaemic 
heart disease 
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Appendix 6:  Funnel plot for cerebrovascular disease 
 
 
Figure 29: Funnel plot with pseudo 95% confidence limits for 
cerebrovascular disease 
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Appendix 7:  Example easy-read invitation letter 
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Appendix 8:  Full easy-read information sheet 
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Appendix 9:  Full easy-read reply form 
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Appendix 10:  Personal consultee information leaflet 
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 402 
 
 
  
 403 
 
 
  
 404 
 
  
 405 
 
Appendix 11:  Nominated consultee information leaflet 
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Appendix 12:  Easy-read consent form 
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 412 
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Appendix 13:  Personal consultee advice form 
 
 
  
 414 
 
Appendix 14:  Nominated consultee advice form 
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Appendix 15:  Example of letter to inform participants of results 
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Appendix 16:  Example letter to inform general practice of results  
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Appendix 17:  Questionnaires used in the research programme 
 
EQ-5D:  a generic instrument for the measurement of health related quality of 
life.213 It provides a simple descriptive profile in five dimensions (mobility, self-
care, usual activities, pain/discomfort and anxiety/depression), each with three 
levels. This instrument can be used in the clinical and economic evaluation of 
health care and can be used to analyse changes in the health status of 
individuals or groups of individuals over time.  
 
Aberrant Behaviour Checklist: an informant-based problem behaviour rating 
scale which assesses a wide range of behavioural disorders and has been 
shown to be a reliable and valid behaviour rating instrument.215 The 
questionnaire consists of 58 items, scored on a 4-point scale.214 The sub-
categories are: (i) irritability, agitation, crying; (ii) lethargy, social withdrawal; 
(iii) stereotypic behaviour; (iv) hyperactivity, noncompliance; and (v) 
inappropriate speech.  
 
PAS-ADD Checklist: a 25-item questionnaire and can be used to make an 
initial assessment for mental illness/psychiatric disorders in people with ID.216 
The instrument generates threshold scores which are then used as a measure 
to indicate the likely absence or presence of possible psychiatric problems. 
The scores produced relate to: i) affective or neurotic disorder; ii) possible 
organic condition (including dementia); iii) psychotic disorder. 
 
Glasgow Depression Scale: an established measure of depression among 
people with ID.217 The Glasgow Depression Scale for people with learning 
disability (GDS-LD) differentiates depression and non-depression groups, 
correlates with the Beck Depression Inventory II (r=0.88), has good test-retest 
reliability (r=0.97) and internal consistency (Cronbach’s a=0.90), and a cut-off 
score of 13 yielded 96% sensitivity and 90% specificity. The Carer 
Supplement is also reliable (r=0.98; a=0.88), correlating with the GDS-LD 
(r=0.93).  
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Appendix 18:  Summary of baseline characteristics 
 
Table 65: Baseline characteristics of participants in the screening study 
 
 
Characteristic 
 
N (medical 
record) 
 
     Mean (± SD) Unless 
stated otherwise 
 
  
Biomedical Measurements 
  
   
Plasma glucose 
  
    Fasting (mmol/l) 425 (mr: 8) 4.7 (± 0.7) 
    Non-fasting (mmol/l) 239 (mr: 16) 5.3  (± 1.5) 
   
Glycated haemoglobin 675 (mr: 27)  
    HbA1c (mmol/mol)  35.0 (± 5.1) 
    Derived HbA1c (%)   5.4 (± 0.5) 
   
Lipids 
  
    Total cholesterol (mmol/l) 653 4.9 (± 1.0) 
    HDL Cholesterol (mmol/l) 644 1.3 (± 0.4) 
    LDL Cholesterol (mmol/l) 631 2.9 (± 0.9) 
    Triglycerides (only if fasted) (mmol/l) 407 1.4 (± 0.9) 
   
Urea and electrolytes 
  
    Sodium (mmol/l) 713 (mr: 84) 139.6 (± 3.1) 
    Potassium (mmol/l) 701 (mr: 80) 4.3 (± 0.5) 
    Urea (mmol/l) 712 (mr: 83) 5.4 (± 1.9) 
    Creatinine (mmol/l) 714 (mr: 84) 69.0 (± 22.7) 
    eGFR (mL/min), n (%) 603 (mr: 80)  
            476 (78.9) 
        60-89  110 (18.2) 
        45-59  10 (1.7) 
        30-44  4 (0.7) 
            3 (0.5) 
 
  
Liver function tests 
  
    Bilirubin (umol/l) 683 (mr: 52) 9.6 (± 5.9) 
    Alanine transaminase (iu/l) 691 (mr: 61) 24.8 (± 15.8) 
    Alkaline phosphatise (iu/l) 694 (mr: 67) 86.8 (± 27.6) 
    Gamma GT (iu/l) 621 (mr: 3) 32.5 (± 32.2) 
   
Thyroid function 
  
    Thyroid stimulating hormone (mui/l) 637 (mr: 22) 2.6 (± 2.1) 
    Free thyroxine (T4) (pmol/l) 621 (mr: 10)  14.0 (± 2.4) 
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Characteristic 
 
N (medical 
record) 
 
     Mean (± SD) Unless 
stated otherwise 
Urine ACR 
  
Urine albumin creatinine ratio (mg/mmol) 569 (mr: 1) 2.5 (± 12.5) 
 
 
  
Anthropometric Measurements 
  
Height (m) 800 1.6 (± 0.1) 
Weight ( kg) 799 76.4 (± 20.7) 
BMI (kg/m2) 782 28.7 (± 7.1) 
BMI Categories, n (%)   
     Underweight   30 (3.8) 
     Normal   223 (28.5) 
     Overweight   241 (30.8) 
     Obese   288 (36.8) 
Waist circumference (cm) 796 100.4 (± 16.5) 
Hip circumference (cm) 789 107.6 (± 14.0) 
   
 
  
Blood Pressure Measurements 826  
Systolic (mmHg)  121.4 (± 16.9) 
Diastolic (mmHg)  78.2 (± 11.1) 
  
    
 
  
Demographic and Lifestyle 
  
Age (years) 930 43.3 (± 14.2) 
   
Sex, Male, n (%) 930 537 (57.7) 
   
Ethnicity, n (%) 
   White 
    Asian 
    Black 
930 748 (80.4) 
147 (15.8) 
14 (1.5) 
    Mixed 
    Other 
 
 13 (1.4) 
8 (0.9) 
Residential circumstances, n (%) 929  
    Alone  51 (5.5) 
    Lives with family  338 (36.4) 
    Shared house or supported living  157 (16.9) 
    Shared care  16 (1.7) 
    Residential home or nursing home  350 (37.7) 
    Other   17 (1.8) 
   
Level of Support, n (%) 929  
    Independent  69 (7.4) 
    Some Support  205 (22.1) 
    24 hour support  655 (70.5) 
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Characteristic 
 
N (medical 
record) 
 
     Mean (± SD) Unless 
stated otherwise 
   
Current status*, n (%) 
  
    Paid employment 928 71 (7.7) 
    Voluntary work 927 152 (16.4) 
    College 
    Day opportunities or private day centre 
925 
928 
170 (18.4) 
431 (46.4) 
    Shared lives (day placement) 928 19 (2.1) 
    Attending meetings 926 122 (13.2) 
    Other 924 385 (41.7) 
 
  
Deprivation (IMD 2015)**, Median (IQR) 930 16,353 (7351-23,606) 
  
    
 
  
Medical History  
  
Severity of ID, n (%) 865  
    Not known   49 (5.7) 
    Known  816 (84.3) 
       Mild  260 (30.1) 
       Moderate  244 (28.2) 
       Severe  279 (32.3) 
       Profound  33 (3.8) 
   
Cause of ID, n (%) 866  
    Not known   581 (67.1) 
    Known  285 (32.9) 
       Downs syndrome  133 (15.4) 
       Fragile X  8 (0.9) 
       Cerebral palsy  58 (6.7) 
       Angelman syndrome  4 (0.5) 
       Cytomegalovirus  1 (0.1) 
       Foetal Alcohol syndrome  0 
       Homocystinuria  0 
       Hydrocephalus  6 (0.7) 
       Hurler syndrome  0 
       Klinefelter’s syndrome  3 (0.4) 
       Lesch – Nyan syndrome  0 
       Neurofibromatosis  2 (0.2) 
       Phenylketonuria  5 (0.6) 
       Prader – Willi syndrome  4 (0.5) 
       Rett syndrome  1 (0.1) 
       Sturge – Weber syndrome  1 (0.1) 
       Tay – Sachs disease  0 
       Triple X syndrome  0 
       Trisomy 13  0 
       Trisomy 18  0 
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Characteristic 
 
N (medical 
record) 
 
     Mean (± SD) Unless 
stated otherwise 
       Tuberous sclerosis  2 (0.2) 
       Turner syndrome  0 
       Other cause  57 (6.6) 
Medical or Health problems, n (%) 929  
    None 
 117 (12.6) 
    Yes 
 812 (87.4) 
       Physical Health 
           Stroke 
           Peripheral arterial disease 
 13 (1.4) 
0 
           Coronary heart disease  7 (0.8) 
           Congenital heart disease  19 (2.1) 
           Other heart problems  15 (1.6) 
           High blood pressure  63 (6.8) 
           High cholesterol  62 (6.7) 
           Hypothyroidism  93 (10.0) 
           Polycystic ovary syndrome  1 (0.1) 
           Gestational diabetes  0 
           Pre-diabetes  1 (0.1) 
           Chronic breathing problems   88 (9.5) 
           Sleep apnoea  3 (0.3) 
           Epilepsy  262 (28.2) 
      Mental Health  
  
           Dementia  18 (1.9) 
           Schizophrenia, schizotypal and delusional            35 (3.8) 
           Mood (affective) disorders  152 (16.4) 
           Neurotic, stress-related and somatoform  143 (15.4) 
           GLVRUGHUV  52 (5.6) 
           Personality disorders  13 (1.4) 
           Drug / alcohol problems  0 
           Attention Deficit Hyperactivity Disorder  8 (0.9) 
     Intellectual Disability 
  
           Autistic spectrum disorders  165 (17.8) 
           Behavioural problems  128 (13.8) 
 
  
Current medication, n (%) 928  
    None 
 172 (18.5) 
    Yes 
 756 (81.5) 
      Anti-psychotic 
 240 (25.9) 
           PHGLFDWLRQ  24 (2.6) 
      Depression/Anxiety/OCD 
      or related 
  
258 (27.8) 
           PHGLFDWLRQ  43 (4.6) 
      For ADHD 
 4 (0.4) 
      Anti-epileptic 
 311 (33.5) 
      Anti-thrombotic 
 36 (3.9) 
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Characteristic 
 
N (medical 
record) 
 
     Mean (± SD) Unless 
stated otherwise 
      Lipid lowering 
 74 (8.0) 
           Statin  72 (7.8) 
           Fibrate  1 (0.1) 
           Statin and Fibrate   1 (0.1) 
     Anti-hypertensive 
 85 (9.2) 
     Thyroid medication 
 93 (10.0) 
     Steroids  
 80 (8.6) 
          Oral  5 (0.5) 
          Inhaled 
          Topical 
          More than 1 type of steroid medication 
          Not known 
62 (6.7) 
9 (1.0) 
3 (0.3) 
1 (0.1) 
    Anti-obesity 
    Other 
 1 (0.1) 
571 (61.5) 
 
Smoking status, n (%) 
 
929 
 
    Current  76 (8.2) 
    Ex  38 (4.1) 
    Never  815 (87.7) 
 
  
Family history of diabetes, n (%) 592 180 (30.4) 
 
  
 
  
Physical Activity / Exercise 
  
Able to stand, n (%) 929  
    No  58 (6.2) 
    Yes  871 (93.8) 
 
  
Able to walk, n (%) 927  
    No  57 (6.2) 
    Yes (with or without walking stick,  
    aid) 
    Yes, with assistance from person(s) 
  
787 (84.9) 
83 (9.0) 
Mobility aids, n (%) 928  
    No 
 703 (75.8) 
    Yes 
 225 (24.3) 
         Uses a walking aid  52 (5.6) 
         Uses a wheelchair, all or most  81 (8.7) 
         Uses a wheelchair, some  78 (8.4) 
         Other  12 (1.3) 
         Not known  2 (0.2) 
 
  
Amount of walking per day, n (%) 927  
    None  74 (8.0) 
    A short distance  259 (27.9) 
    Some  359 (38.7) 
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Characteristic 
 
N (medical 
record) 
 
     Mean (± SD) Unless 
stated otherwise 
    Lots  235 (25.4) 
 
  
Speed of normal walking (if can 
walk), n (%) 
850  
    Slow  301 (35.4) 
    Steady  373 (43.9) 
    Brisk or fast  176 (20.7) 
 
  
Activities*, n (%) 
  
    Keep fit/aerobics 928 83 (8.9) 
    Walking  197 (21.2) 
    Running/jogging 
    Swimming 
    Dance 
929 39 (4.2) 
190 (20.5) 
233 (25.1) 
    Bowling  155 (16.7) 
    Gym  92 (9.9) 
    Horse riding 
    Cycling 
 32 (3.4) 
62 (6.7) 
    Gardening  179 (19.3) 
    Housework 927 489 (52.8) 
    Chair based exercise 863 68 (7.9) 
    Other 925 131 (14.2) 
   
Amount of physical activity per 
week, n (%) 
 
928 
 
    None  184 (19.8) 
    1-2 times  360 (38.8) 
    3-4 times  259 (27.9) 
    5 or more   125 (13.5) 
 
  
Time spent sitting per day, n (%) 928  
    All / most  180 (19.4) 
    A lot  252 (27.2) 
    Sometimes  475 (51.2) 
    Never  21 (2.3) 
 
  
 
  
Nutrition and diet 
  
Problems relating to eating and drinking, n (%) 
 
    Difficulties with chewing or  
    swallowing 
 
929 
 
227 (24.4) 
    Needs help or assistance to feed    
    self 
 
926 
 
118 (12.7) 
    Use specialist equipment  95 (10.3) 
    Fed via an ng-tube or a gastrostomy  7 (0.8) 
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Characteristic 
 
N (medical 
record) 
 
     Mean (± SD) Unless 
stated otherwise 
Only included if not fed via tube  922  
   Food shopping, n (%) 
  
      Independently  89 (9.7) 
      With support  230 (25.0) 
      Relative or carer  297 (32.2) 
      Purchased by residential home  306 (33.2) 
 
  
   Prepare meals, n (%) 921  
      Relative or carer  561 (60.9) 
      With supervision  117 (12.7) 
      Without supervision  145 (15.7) 
      Without supervision & prepare variety of meals 98 (10.6) 
   
   Types of food daily eaten, n (%) 
  
      Starch 
      Fruit / vegetables 
919 
921 
916 (99.7) 
864 (93.8) 
      Milk / yoghurt 
      Meat, fish, eggs/ other vegetarian     
      alternative 
920 
919 
896 (97.4) 
898 (97.7) 
   
Daily proportion of fruit, vegetable, 
n (%) 
 
 
920 
 
      None 
      1 a day 
      2 a day 
 33 (3.6) 
57 (6.2) 
130 (14.1) 
      3 a day  230 (25.0) 
      4 a day  199 (21.6) 
      5 a day  213 (23.2) 
      6 a day  36 (3.9) 
      7 or more  22 (2.4) 
 
  
 
  
Questionnaires 
  
Administered Via Interview 930  
    Health Related Quality of Life 
  
      EQ-5D Score 872 0.8 (± 0.3) 
      EQ-5D Scale 877 78.1 (± 19.4) 
 
  
    Depression  
  
      GDS-LD 317 7.5  (± 6.7) 
         Number Depressed, n (%)  67 (21.1) 
      GDS-LD Carer Supplement 464 5.5  (± 5.8) 
        Number Depressed, n (%)  71 (15.3) 
   
Carer Completed Outside 
Appointment 
930  
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Characteristic 
 
N (medical 
record) 
 
     Mean (± SD) Unless 
stated otherwise 
    Behaviour Problem 
  
       Aberrant Behaviour Checklist 341  
        1) Irritability, Agitation, Crying  4.3 (± 6.7) 
        2) Lethargy, Social Withdrawal  3.5 (± 5.5) 
        3) Stereotypic Behaviour  1.2 (± 2.6) 
        4) Hyperactivity, Noncompliance  3.9 (± 6.0) 
        5) Inappropriate Speech  1.3 (± 2.2) 
        Total score  14.0 (± 19.5) 
 
  
    Psychiatric Disorders 
  
          PAS-ADD Checklist Section 1                    930  
          No events  207 (22.3) 
          Death  of a first degree relative  34 (3.7) 
          Death of a close friend, carer or relative 36 (3.9) 
          Serious illness or injury  21 (2.3) 
          Retirement form work  1 (0.1) 
          Serious illness of relative, carer or friend  28 (3.0) 
          Move of house or residence 
          Break up of steady relationship 
 45 (4.8) 
10 (1.1) 
          Separation or divorce  1 (0.1) 
          Alcohol problem 
          Drug problem 
 1 (0.1) 
1 (0.1) 
          Serious problem with relative, carer/friend 11 (1.2) 
          Unemployed/seeking work  4 (0.4) 
          Breakdown of relationship with parent(s) 4 (0.4) 
          Laid off or sacked from work  0 
          Something valuable lost or stolen  4 (0.4) 
          Problems with police or other authority 7 (0.8) 
          Major financial crisis  1 (0.1) 
          Sexual problem  2 (0.2) 
          Other event  38 (4.1) 
 
  
    PAS-ADD Checklist Section 2 325  
         Possible organic condition  1.0 (± 1.7) 
                7KUHVKROGVFRUHQ  20 (6.2) 
         Affective or neurotic disorder  1.4 (± 3.2) 
               7KUHVKROGVFRUHQ  28 (8.6) 
         Psychotic disorder  0.2 (± 0.6) 
              7KUHVKROGVFRUHQ  16 (4.9) 
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Appendix 19:  Example topic guide for service users interviews  education 
development stage 
 
 
  
 427 
 
 
 
 
 428 
 
Appendix 20:  Example form for educator training 
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Appendix 21:  Scope of the economic evaluation 
 
The reasons for not attempting to estimate the cost-effectiveness of screening 
people with ID for diabetres (including T2DM)/IGR and overweight/obese are 
listed below: 
 
1. Lack of evidence 
There is a dearth of good quality evidence in relation to the costs and effects 
of diabetes prevention interventions in people with ID. 
 
2. Number of pathways/screening strategies 
The economic model needs to take account of all permutations of screening 
for diabetes only, screening for diabetes and IGR, and screening for 
overweight/obese. Since screening cannot be considered in isolation (i.e. it 
depends upon interventions), the economic model would need to take into 
account of how standard prevention interventions and the STOP diabetes 
education programme would be implemented for people with ID. It is also 
unclear how such screening would fit into existing policy in relation to Learning 
Disabiltiy Health Checks. 
 
3. Evaluation of screening outside of the UK 
Evaluating screening outside the UK in people with ID would lead to unreliable 
conclusions because: 
 we do not have estimates for the prevalence of undiagnosed diabetes and 
IGR, and the rates are likely to be different in other countries (even those 
within Europe); 
 there are different thresholds for HbA1C for diagnosing IGR; 
 we do not know how effective prevention interventions would be; and 
 we would need to model different countries’ diagnostic and care 
pathways, use country-specific costs, and different thresholds for 
‘willingness-to-pay’. 
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Appendix 22:  Comparison of surrogate-based physical activity approach 
against Yates et al. 2014 
 
When using biomarkers (e.g. changes in physical activity through BMI and SBP) 
to predict clinical events, it is important where possible to undertake validation 
against a study reporting hard clinical outcomes. Potentially surrogate-based 
modelling could overlook some other mechanism of reduction in risk of CVD. To 
the extent that any such other mechanisms are correlated with changes in BMI 
and systolic blood pressure, these mechanisms would be captured within our 
mapping. It was decided to compare the models predicted impact on CVD 
outcomes with another study. 
 
In consultation with clinical experts we were directed to the NAVIGATOR trial 
results (Yates et al. 2014269), which could be used for the validation. In this study, 
all groups participated in a lifestyle modification programme that was designed 
to help them achieve and maintain a 5% weight loss, reduce the amount of 
saturated and total fats in their diet and increase physical activity to 150 minutes 
per week. The study reported the relationship between activity (steps) and CVD 
outcomes (events) in a cohort of 9,306 people. The analysis controlled for 
changes in BMI. 
 
For the validation, a model adaptation was created which mimicked the 
NAVIGATOR trial by assuming changes in daily step counts continued without 
declining for a period of 6 years (the study followed participants for 6 years, but 
was not an intervention trial so we assumed that steps/day was stationary 
rather than declining). For an increase in activity of 2,000 steps, Yates and 
colleagues reported a hazard ratio of experiencing a cardiovascular event over 
the following 6 years of 0.92 (95% CI = 0.86-0.99); that is, a risk reduction of 8%. 
The hazard ratio from our adapted model was 0.95 (5% risk reduction). 
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Appendix 23:  Database search terms for health economic analysis 
 
Table 66: PubMed database search terms for physical activity studies 
 
 
("activity"[title] OR "sedentary"[title] OR "exercise"[title]) 
AND 
("weight"[title] OR "diabetes"[title] OR "BMI"[title] or "cardio-metabolic"[title] 
or "glucose"[title]) 
AND 
("steps"[All Fields] OR "step-counter"[All Fields] OR "accelerometer"[All Fields]) 
AND ("weight"[All Fields] OR "diabetes"[All Fields] OR "BMI"[All Fields]) 
AND ("blood glucose"[All Fields] OR "hba1c"[All Fields] OR "cholesterol"[All 
Fields] OR "BMI"[All Fields] OR "weight"[All Fields] OR "waist"[All Fields] OR 
"hip"[All Fields] OR "blood pressure"[All Fields] OR "glycated haemoglobin"[All 
Fields] OR "blood sugar"[All Fields])  
NOT ("school"[title] OR "child"[title] OR "children"[title] OR "childhood"[title])  
 
(Date of search: 23/10/2015) 
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Appendix 24:  Modelling cardiovascular events 
 
The QRISK2 risk equation can be used to calculate the probability of a 
cardiovascular event, including coronary heart disease (angina or myocardial 
infarction), stroke, transient ischaemic attacks and fatality due to CVD.  
 
The QRISK assumptions regarding the relationship between IGR, diabetes and 
cardiovascular disease were modified for the model and are outlined below: 
1) It was assumed that individuals with HbA1c>6.5 have an increased risk of 
cardiovascular disease even if they have not received a formal diagnosis. 
2) Risk of cardiovascular disease was assumed to increase with HbA1c for 
test results greater than 6.5 to reflect observations from the UK 
Prospective Diabetes Study (UKPDS) that HbA1c increases the risk of 
myocardial infarction and stroke.277 
3) Prior to T2DM (HbA1c>6.5), HbA1c was assumed to be linearly associated 
with CVD. A study from the EPIC Cohort found that a unit increase in 
HbA1c increases the risk of coronary heart disease by a hazard ratio of 
1.25, after adjustment for other risk factors287 Individuals with an HbA1c 
greater than the mean HbA1c observed in the Health Survey for England 
(HSE) 2011 cohort were at greater risk of CVD than those with an HbA1c 
lower than the HSE mean.264 
 
The QRISK algorithm identifies which individuals experience a cardiovascular 
event but does not specify the nature of that event. The nature of the 
cardiovascular event was determined independently. A targeted search of recent 
Health Technology appraisals of cardiovascular disease was performed to 
identify a model for the progression of cardiovascular disease following a first 
event (Table 67). 
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Table 67: Coefficients from the 2012 QRISK2 risk equation and estimated standard errors 
 
 
 
Covariates 
Estimated coefficients adjusting for individual characteristics 
Women Men  Women Men 
Mean Standard 
error 
Mean Standard 
error 
Interaction terms Mean Standard 
error 
Mean Standard 
error 
White 0.0000 0.0000 0.0000 0.0000 Age1*former smoker 0.1774 0.035 -3.881 0.776 
Indian 0.2163 0.0537 0.3163 0.0425 Age1*light smoker -0.3277 0.066 -16.703 3.341 
Pakistani 0.6905 0.0698 0.6092 0.0547 Age1*moderate smoker -1.1533 0.231 -15.374 3.075 
Bangladeshi 0.3423 0.1073 0.5958 0.0727 Age1*Heavy smoker -1.5397 0.308 -17.645 3.529 
Other Asian 0.0731 0.1071 0.1142 0.0845 Age1*AF -4.6084 0.922 -7.028 1.406 
Caribbean -0.0989 0.0619 -0.3489 0.0641 Age1*renal disease -2.6401 0.528 -17.015 3.403 
Black African -0.2352 0.1275 -0.3604 0.1094 Age1*hypertension -2.2480 0.450 33.963 6.793 
Chinese -0.2956 0.1721 -0.2666 0.1538 Age1*Diabetes -1.8452 0.369 12.789 2.558 
Other -0.1010 0.0793 -0.1208 0.0734 Age1*BMI -3.0851 0.617 3.268 0.654 
Non-smoker 0.0000 0.0000 0.0000 0.0000 Age1*family history CVD -0.2481 0.050 -17.922 3.584 
Former smoker 0.2033 0.0152 0.2684 0.0108 Age1*SBP -0.0132 0.003 -0.151 0.030 
Light smoker 0.4820 0.0220 0.5005 0.0166 Age1*Townsend -0.0369 0.007 -2.550 0.510 
Moderate smoker 0.6126 0.0178 0.6375 0.0148 Age2*former smoker -0.0051 0.001 7.971 1.594 
Heavy smoker 0.7481 0.0194 0.7424 0.0143 Age2*light smoker -0.0005 0.000 23.686 4.737 
Age 1a 5.0327  47.3164  Age2*moderate smoker 0.0105 0.002 23.137 4.627 
Age 2a -0.0108  -101.2362  Age2*Heavy smoker 0.0155 0.003 26.867 5.373 
BMIa -0.4724 0.0423 0.5425 0.0299 Age2*AF 0.0507 0.010 14.452 2.890 
Ratio Total /HDL 
cholesterol 
0.1326 0.0044 0.1443 0.0022 Age2*renal disease 0.0343 0.007 28.270 5.654 
SBP 0.0106 0.0045 0.0081 0.0046 Age2*hypertension 0.0258 0.005 -18.817 3.763 
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Townsend 0.0597 0.0068 0.0365 0.0048 Age2*Diabetes 0.0180 0.004 0.963 0.193 
AF 1.3261 0.0310 0.7547 0.1018 Age2*BMI 0.0345 0.007 10.551 2.110 
Rheumatoid 
arthritis 
0.3626 0.0319 0.3089 0.0445 Age2*family history CVD -0.0062 0.001 26.605 
5.321 
Renal disease 0.7636 0.0639 0.7441 0.0702 Age2*SBP 0.0000 0.000 0.291 0.058 
Hypertension 0.5421 0.0115 0.4978 0.0112 Age2*Townsend -0.0011 0.000 3.007 0.601 
Diabetes 0.8940 0.0199 0.7776 0.0175      
Family history of 
CVD 
0.5997 0.0122 0.6965 0.0111      
AF: Atrial Fibrillation; CVD: Cardiovascular disease; SBP: systolic blood pressure 
a
 covariates transformed with fractional polynomials 
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All QRISK events are assigned to a specific diagnosis according to age- and sex- specific 
distributions of cardiovascular events used in a previous Health Technology Assessment 
(HTA).289 The probability of cardiovascular outcomes by age and gender is shown in 
Table 68. 
 
Table 68: The probability distribution of cardiovascular events by age and 
gender 
Sex Age Stable 
angina 
Unstable 
angina 
MI rate Fatal 
CHD 
TIA Stroke Fatal 
CVD 
Men 45-54 0.307 0.107 0.295 0.071 0.060 0.129 0.030 
55-64 0.328 0.071 0.172 0.086 0.089 0.206 0.048 
65-74 0.214 0.083 0.173 0.097 0.100 0.270 0.063 
75-84 0.191 0.081 0.161 0.063 0.080 0.343 0.080 
85+ 0.214 0.096 0.186 0.055 0.016 0.351 0.082 
Women 45-54 0.325 0.117 0.080 0.037 0.160 0.229 0.054 
55-64 0.346 0.073 0.092 0.039 0.095 0.288 0.067 
65-74 0.202 0.052 0.121 0.081 0.073 0.382 0.090 
75-84 0.149 0.034 0.102 0.043 0.098 0.464 0.109 
85+ 0.136 0.029 0.100 0.030 0.087 0.501 0.117 
MI: myocardial infarction; CHD: coronary heart disease; TIA: transient ischaemic attack; CVD: 
cardiovascular disease 
 
After an individual has experienced a cardiovascular event, it is not possible to predict 
the transition to subsequent cardiovascular events using QRISK2. Instead, as with 
assigning first CVD events, the statin HTA reports the probability of future events, 
conditional on the nature of the previous event.289 More details on the probabilities 
within a year of transitioning from stable angina, unstable angina, myocardial infarction 
(MI), transient ischemic attack (TIA) or stroke for individuals in different age groups 
can be found in an on-line Discussion Paper.265 
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Appendix 25:  Assumptions made for diagnosis and treatment of diabetes, hypertension and CVD risk for health economic 
analysis 
 
Table 69: Assumptions made for diagnosis and treatment of diabetes hypertension and high CVD risk 
Diabetes Hypertension High CVD risk 
DIAGNOSIS 
- At baseline, individuals are assigned an HbA1C 
threshold above which diabetes is detected 
opportunistically. 
- Individuals with HbA1C levels above their 
individual threshold will attend the GP to be 
diagnosed with diabetes. 
- Assumed that people eligible for anti-hypertensive 
treatment will be identified through opportunistic 
screening if they meet certain criteria and see the GP 
at least once during the simulation period. 
- Assumed that people eligible for statins will 
be identified through opportunistic screening 
if they meet certain criteria and see the GP at 
least once during the simulation period. 
TREATMENT 
Assumed that there are three, non-mutually exclusive outcomes from the vascular checks and opportunistic screening 
Patient’s blood glucose test  indicates T2DM as 
measured by HbA1c > 6.5mmol/L  
(assumed that FPG and 2-hr glucose test not 
used for diabetes diagnosis, but future 
adaptations of the model could include these 
criteria). 
 
A 3-stage treatment regime assumed (as a trade-
Patient has high blood pressure and should be treated 
with anti-hypertensive medication: 
- Anti-hypertensive treatment initiated if systolic 
BP>160. 
- Anti-hypertensive treatment initiated if systolic 
BP>140 and individual also has a history of CVD, 
diabetes, or CVD risk >20%.338 
Patient receives statins to reduce 
cardiovascular risk: 
- Statins initiated if >20% 10-year CVD risk 
estimated from the QRISK286 2012 
algorithm.339 
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off between model simplicity and capturing key 
cost differences between interventions): 
(a) At diagnosis patients are prescribed low 
cost treatments, represented by Metformin 
500mg/day. 
(b) If HbA1c level rises above 7.4%, individual 
is prescribed more expensive DPP-IV inhibitor 
+ Metformin. 
(c) Individual is assumed to continue DPP-IV 
inhibitor + Metformin until HbA1c level rises 
above 8.5% whereby they are assumed to 
require insulin. 
 
More details are available on-line.265 
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Appendix 26:  Distributions for key parameters within the probabilistic 
sensitivity analysis 
 
Given the very large numbers of parameters in the model, many of which belong to 
complex forms of statistical modelling, it would not be helpful to present all of them in 
this report. Below (Table 70) we present distributions for parameters related to the 
intervention, the relationship between physical activity (steps)271 and BMI and other 
risk factors. Details of distributions for the other model parameters are reported 
elsewhere.265 
 
Table 70: Uncertainty around Bravata-based intervention effect size (assuming 
2,491 steps) 
Parameter 
Description 
Distribution Parameter 1 Parameter 2 Central 
estimate 
Source 
BMI Normal -0.38 0.171 -0.38 Bravata  
SBP Normal -3.8 1.071 -3.8 Bravata  
Total Cholesterol  Normal -0.09 0.120 -0.09 Bravata  
HDL Cholesterol  Normal 0.06 0.039 0.06 Bravata  
 
No uncertainty is included around uptake rates. As duration of effect is explored 
through scenario analyses, no uncertainty is included around this parameter. 
 
Mortality 
Mortality rates from other causes by age were assumed to be constant in the 
probabilistic sensitivity analysis (PSA).
282
 The parameter distributions for the hazard 
ratio for other cause mortality with diabetes and for the standardised mortality ratios 
for other cause mortality in males and females with ID are reported in Table 71. The 
table shows the probability distribution for each model parameter and the mean value 
(central estimate). Parameter 1 and parameter 2 are arguments for the specific forms of 
statistical model, such as lognormal. 
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Table 71: Input parameters for mortality hazard ratio for diabetes and 
standardised mortality ratios (SMR) for intellectual disability 
Parameter Description Distribution Distribution 
Parameter 1 
Distribution 
Parameter 2 
Central 
estimate 
Mortality hazard ratio for diabetes Lognormal 0.588 0.186 1.80 
SMR for intellectual disability in 
males 
Normal 3.24 0.219 3.24 
SMR for intellectual disability in 
females 
Normal 2.28 0.138 2.28 
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Appendix 27:  Results  Cost-effectiveness plane 
 
 
 
Figure 30: Cost-effectiveness plane for an increase of 2,491 steps at £30,000 
per QALY 
QALY: Quality-adjusted life year 
 
In Figure 30, each black dot represents a result from a sample run of the PSA. The red 
line represents the cost-effectiveness frontier; points below this line represent sample 
results from the PSA that lie in the cost-effective region. The spread of the points gives 
an indication, for this type of intervention, of how much uncertainty there is around the 
reported mean incremental costs and QALYs (quality-adjusted life years). 
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Appendix 28:  Detailed threshold analysis results tables at £20,000 per QALY 
 
Table 72: Combinations of daily step increases and additional dietary changes required to achieve a cost-effective 
outcome (base case intervention £20,000 per QALY assuming all risk factors change together) 
 
 
Initial increase in 
steps needed 
Change attributable to the 
increase in steps 
Additional change needed to be generated 
through diet 
Additional change needed to be generated 
through diet 
Base case (3 year durability) 5 year durability 
BMI 
(kg/m2) SBP (mmHg) 
Total:HDL 
cholesterol 
ratio 
BMI (kg/m2) SBP (mmHg) 
Total:HDL 
cholesterol ratio 
BMI (kg/m2) SBP (mmHg) 
Total:HDL 
cholesterol ratio 
0 0.0 0 0.00 -5.0 -50 -1.88 -3.4 -34 -1.45 
1000 -0.2 -2 -0.09 -4.8 -48 -1.85 -3.2 -32 -1.40 
3000 -0.5 -5 -0.26 -4.5 -45 -1.77 -2.9 -29 -1.30 
5000 -0.8 -8 -0.42 -4.2 -42 -1.69 -2.6 -26 -1.19 
7000 -1.1 -11 -0.57 -3.9 -39 -1.60 -2.3 -23 -1.08 
9000 -1.4 -14 -0.71 -3.6 -36 -1.52 -2.0 -20 -0.97 
11000 -1.7 -17 -0.84 -3.3 -33 -1.42 -1.7 -17 -0.84 
13000 -2.0 -20 -0.97 -3.0 -30 -1.32 -1.4 -14 -0.71 
15000 -2.3 -23 -1.08 -2.7 -27 -1.22 -1.1 -11 -0.57 
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Table 73: Combinations of daily step increases and additional dietary changes required to achieve a cost-effective 
outcome (increased effectiveness intervention at £20,000 per QALY assuming all risk factors change together) 
 
 
 
Initial increase in 
steps needed 
Change attributable to the 
increase in steps 
Additional change needed to be generated 
through diet 
Additional change needed to be generated 
through diet 
Base case (3 year durability) 5 year durability 
BMI 
(kg/m2) SBP (mmHg) 
Total:HDL 
cholesterol 
ratio 
BMI (kg/m2) SBP (mmHg) 
Total:HDL 
cholesterol ratio 
BMI (kg/m2) SBP (mmHg) 
Total:HDL 
cholesterol ratio 
0 0.0 0 0.00 -4.7 -47 -1.83 -2.7 -27 -1.25 
1000 -0.2 -2 -0.09 -4.6 -46 -1.79 -2.6 -26 -1.19 
3000 -0.5 -5 -0.26 -4.3 -43 -1.71 -2.3 -23 -1.08 
5000 -0.8 -8 -0.42 -4.0 -40 -1.63 -2.0 -20 -0.97 
7000 -1.1 -11 -0.57 -3.7 -37 -1.54 -1.7 -17 -0.84 
9000 -1.4 -14 -0.71 -3.4 -34 -1.45 -1.4 -14 -0.71 
11000 -1.7 -17 -0.84 -3.1 -31 -1.35 -1.1 -11 -0.57 
13000 -2.0 -20 -0.97 -2.7 -27 -1.25 -0.8 -8 -0.42 
15000 -2.3 -23 -1.08 -2.4 -24 -1.14 -0.5 -5 -0.26 
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Table 74: Combinations of daily step increases and additional dietary changes required to achieve a cost-effective 
outcome for an obese subgroup (base case intervention at £20,000 per QALY assuming all risk factors change together) 
 
 
Initial increase in 
steps needed 
Change attributable to the 
increase in steps 
Additional change needed to be generated 
through diet 
Additional change needed to be generated 
through diet 
Base case (3 year durability) 5 year durability 
BMI 
(kg/m2) SBP (mmHg) 
Total:HDL 
cholesterol 
ratio 
BMI (kg/m2) SBP (mmHg) 
Total:HDL 
cholesterol ratio 
BMI (kg/m2) SBP (mmHg) 
Total:HDL 
cholesterol ratio 
0 0.0 0 0.00 -4.7 -47 -1.83 -2.7 -27 -1.25 
1000 -0.2 -2 -0.09 -4.6 -46 -1.79 -2.6 -26 -1.19 
3000 -0.5 -5 -0.26 -4.3 -43 -1.71 -2.3 -23 -1.08 
5000 -0.8 -8 -0.42 -4.0 -40 -1.63 -2.0 -20 -0.97 
7000 -1.1 -11 -0.57 -3.7 -37 -1.54 -1.7 -17 -0.84 
9000 -1.4 -14 -0.71 -3.4 -34 -1.45 -1.4 -14 -0.71 
11000 -1.7 -17 -0.84 -3.1 -31 -1.35 -1.1 -11 -0.57 
13000 -2.0 -20 -0.97 -2.7 -27 -1.25 -0.8 -8 -0.42 
15000 -2.3 -23 -1.08 -2.4 -24 -1.14 -0.5 -5 -0.26 
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Table 75: Combinations of daily step increases and additional dietary changes required to achieve a cost-effective 
outcome for a 45 to 49-year-old subgroup (base case intervention at £20,000 per QALY assuming all risk factors change 
together) 
 
 
 
Initial increase in 
steps needed 
Change attributable to the 
increase in steps 
Additional change needed to be generated 
through diet 
Additional change needed to be generated 
through diet 
Base case (3 year durability) 5 year durability 
BMI 
(kg/m2) SBP (mmHg) 
Total:HDL 
cholesterol 
ratio 
BMI (kg/m2) SBP (mmHg) 
Total:HDL 
cholesterol ratio 
BMI (kg/m2) SBP (mmHg) 
Total:HDL 
cholesterol ratio 
0 0.0 0 0.00 -2.6 -26 -1.19 -1.9 -19 -0.94 
1000 -0.2 -2 -0.09 -2.4 -24 -1.14 -1.8 -18 -0.87 
3000 -0.5 -5 -0.26 -2.1 -21 -1.03 -1.4 -14 -0.74 
5000 -0.8 -8 -0.42 -1.8 -18 -0.90 -1.1 -11 -0.61 
7000 -1.1 -11 -0.57 -1.5 -15 -0.78 -0.8 -8 -0.46 
9000 -1.4 -14 -0.71 -1.2 -12 -0.64 -0.5 -5 -0.30 
11000 -1.7 -17 -0.84 -0.9 -9 -0.50 -0.2 -2 -0.13 
13000 -2.0 -20 -0.97 -0.6 -6 -0.34 0.0 0 0.00 
15000 -2.3 -23 -1.08 -0.3 -3 -0.18 0.0 0 0.00 
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Table 76: Combinations of daily step increases and additional dietary changes required to achieve a cost-effective 
outcome for a 50-year-old subgroup (base case intervention at £20,000 per QALY assuming all risk factors change 
together) 
 
 
Initial increase in 
steps needed 
Change attributable to the 
increase in steps 
Additional change needed to be generated 
through diet 
Additional change needed to be generated 
through diet 
Base case (3 year durability) 5 year durability 
BMI 
(kg/m2) SBP (mmHg) 
Total:HDL 
cholesterol 
ratio 
BMI (kg/m2) SBP (mmHg) 
Total:HDL 
cholesterol ratio 
BMI (kg/m2) SBP (mmHg) 
Total:HDL 
cholesterol ratio 
0 0.0 0 0.00 -4.1 -41 -1.67 -2.7 -27.5 -1.2 
1000 -0.2 -2 -0.09 -4.0 -40 -1.63 -2.6 -25.9 -1.2 
3000 -0.5 -5 -0.26 -3.7 -37 -1.54 -2.3 -22.9 -1.1 
5000 -0.8 -8 -0.42 -3.4 -34 -1.45 -2.0 -19.8 -1.0 
7000 -1.1 -11 -0.57 -3.1 -31 -1.35 -1.7 -16.8 -0.8 
9000 -1.4 -14 -0.71 -2.7 -27 -1.25 -1.4 -13.7 -0.7 
11000 -1.7 -17 -0.84 -2.4 -24 -1.14 -1.1 -10.7 -0.6 
13000 -2.0 -20 -0.97 -2.1 -21 -1.03 -0.8 -7.6 -0.4 
15000 -2.3 -23 -1.08 -1.8 -18 -0.90 -0.5 -4.6 -0.3 
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Table 77: Combinations of daily step increases and additional dietary changes required to achieve a cost-effective 
outcome for a high CVD risk subgroup (base case intervention at £20,000 per QALY assuming all risk factors change 
together) 
 
 
 
Initial increase in 
steps needed 
Change attributable to the 
increase in steps 
Additional change needed to be generated 
through diet 
Additional change needed to be generated 
through diet 
Base case (3 year durability) 5 year durability 
BMI 
(kg/m2) SBP (mmHg) 
Total:HDL 
cholesterol 
ratio 
BMI (kg/m2) SBP (mmHg) 
Total:HDL 
cholesterol ratio 
BMI (kg/m2) SBP (mmHg) 
Total:HDL 
cholesterol ratio 
0 0.0 0 0.00 -3.5 -35 -1.49 -2.1 -21 -1.03 
1000 -0.2 -2 -0.09 -3.4 -34 -1.45 -2.0 -20 -0.97 
3000 -0.5 -5 -0.26 -3.1 -31 -1.35 -1.7 -17 -0.84 
5000 -0.8 -8 -0.42 -2.7 -27 -1.25 -1.4 -14 -0.71 
7000 -1.1 -11 -0.57 -2.4 -24 -1.14 -1.1 -11 -0.57 
9000 -1.4 -14 -0.71 -2.1 -21 -1.03 -0.8 -8 -0.42 
11000 -1.7 -17 -0.84 -1.8 -18 -0.90 -0.5 -5 -0.26 
13000 -2.0 -20 -0.97 -1.5 -15 -0.78 -0.2 -2 -0.09 
15000 -2.3 -23 -1.08 -1.2 -12 -0.64 0.0 0 0.00 
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Copyright credits for Appendices 
 
Images and symbols used in the easy read study information examples are reproduced with 
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